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Abstract	  
Plasma	  cells,	  the	  effector	  stage	  of	  the	  B	  cell	  compartment,	  secrete	  large	  amounts	  
of	  antibody.	  These	  cells	  arise	  in	  two	  waves	  during	  T-­‐dependent	  immune	  
responses;	  an	  early	  wave	  (extrafollicular	  plasma	  cells)	  generate	  low-­‐affinity	  
antibodies	  that	  provide	  a	  first	  line	  of	  defence	  against	  invading	  pathogens.	  Later,	  
plasma	  cells	  emerge	  from	  the	  germinal	  centre	  reaction	  and	  secrete	  high-­‐affinity	  
antibodies.	  These	  plasma	  cells	  have	  the	  capacity	  to	  migrate	  to	  the	  bone	  marrow,	  
where	  they	  become	  established	  as	  long-­‐lived,	  non-­‐dividing	  plasma	  cells.	  
Here,	  I	  show	  that	  plasma	  cells	  found	  in	  the	  bone	  marrow	  of	  young	  (5-­‐week-­‐old)	  
mice	  had	  a	  turnover	  comparable	  to	  that	  seen	  in	  the	  spleen.	  Long-­‐lived	  plasma	  
cells	  accumulated	  over	  the	  ensuing	  weeks	  until	  they	  came	  to	  dominate	  the	  bone	  
marrow	  plasma	  cell	  compartment	  by	  30-­‐weeks	  of	  age.	  This	  accumulation	  
required	  MHC	  II,	  CD40	  and	  a	  normal	  B	  cell	  receptor	  repertoire,	  implying	  that	  
these	  cells	  are	  generated	  during	  T-­‐dependent	  immune	  responses.	  
Secondly,	  I	  determine	  the	  signalling	  pathways	  required	  to	  generate	  splenic	  
extrafollicular	  plasma	  cell	  responses	  in	  the	  T-­‐dependent	  response	  to	  sheep	  red	  
blood	  cells	  (SRBC)	  and	  in	  bacterial	  infection	  with	  Salmonella.	  While	  T	  cell	  help,	  
antigen	  recognition	  through	  the	  B	  cell	  receptor	  (BCR)	  and	  TLR	  signalling	  were	  
required	  for	  maximal	  plasma	  cell	  responses	  to	  SRBC,	  in	  Salmonella	  infection	  
TLR	  signalling	  was	  required	  for	  day	  4	  IgM	  plasma	  cell	  responses,	  whereas	  class-­‐
switched	  responses	  at	  day	  8	  required	  T	  cell	  help.	  The	  extrafollicular	  responses	  
generated	  in	  Salmonella	  persisted	  for	  around	  35	  days,	  far	  greater	  than	  the	  2-­‐3	  
days	  seen	  following	  SRBC	  immunisation.	  This	  was	  likely	  due	  to	  both	  antigen	  
persistence	  causing	  the	  generation	  of	  new	  plasma	  cells,	  and	  the	  induction	  of	  
cellular	  populations	  that	  produced	  the	  plasma	  cell	  survival	  factor	  APRIL.	  
Thirdly,	  I	  document	  the	  failure	  of	  chronic	  immune	  responses	  to	  generate	  long-­‐
lived	  bone	  marrow	  plasma	  cells.	  This	  was	  accomplished	  by	  measuring	  the	  
generation	  and	  survival	  of	  bone	  marrow	  plasma	  cells	  in	  models	  of	  rheumatoid	  
arthritis	  (K/BxN	  mice),	  long-­‐term	  infection	  with	  Salmonella,	  and	  a	  direct	  
comparison	  between	  acute	  and	  chronic	  delivery	  of	  the	  T-­‐dependent	  protein	  
	  
	   xii	  
antigen	  NP-­‐KLH.	  In	  all	  cases,	  chronic	  immune	  responses	  generated	  few	  bone	  
marrow	  plasma	  cells,	  ostensibly	  due	  to	  a	  failure	  to	  migrate	  to	  the	  organ.	  
Finally,	  I	  show	  the	  depletion	  of	  bone	  marrow	  plasma	  cell	  populations	  caused	  by	  
inflammatory	  episodes.	  This	  was	  observed	  in	  Salmonella	  infection,	  Schistosoma	  
mansoni	  infection	  and	  immunisation	  with	  protein	  antigen	  plus	  adjuvants.	  This	  
depletion	  mediated	  a	  reduction	  of	  antigen-­‐specific	  bone	  marrow	  plasma	  cell	  
populations	  and	  serum	  antibody	  previously	  established	  by	  the	  secondary	  
response	  to	  NP-­‐KLH.	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  growth	  factor-­‐beta	  	  
Th	  cell	  –	  T	  helper	  cell	  
TI	  –	  T-­‐independent	  
TIRAP	  –	  Toll-­‐interleukin	  1	  receptor	  domain	  containing	  adaptor	  protein	  
TLR	  –	  Toll-­‐like	  receptor	  	  
TNF-­‐α	  –	  Tumour	  necrosis	  factor-­‐alpha	  	  
TRAM	  –	  TRIF-­‐related	  adaptor	  molecule	  
TRIF	  –	  TIR-­‐domain-­‐containing	  adaptor-­‐inducing	  interferon-­‐β	  
Treg	  cell	  –	  Regulatory	  T	  cells	  	  
VCAM-­‐1	  –	  Vascular	  cell	  adhesion	  protein	  1	  
VLA-­‐4	  –	  Very	  late	  antigen	  4	  
WT	  –	  Wild	  type	  
XBP-­‐1	  -­‐	  X-­‐box	  binding	  protein	  1	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Chapter	  1	  -­‐	  Introduction	  
The	  immune	  response	  
The	  immune	  response	  defends	  organisms	  from	  invading	  pathogens	  that	  would	  
otherwise	  overrun	  the	  body.	  Many	  immune	  cell	  types	  exist,	  all	  with	  their	  own	  
distinct	  roles	  in	  dealing	  with	  the	  multitude	  of	  infections	  that	  may	  be	  
encountered	  by	  an	  organism	  in	  its	  environment.	  However,	  the	  interplay	  
between	  these	  immune	  cells	  creates	  an	  extremely	  complex	  scenario	  that	  
continues	  to	  challenge	  immunologists.	  	  
The	  immune	  system	  has	  two	  branches,	  originally	  thought	  of	  as	  distinct,	  but	  now	  
known	  to	  be	  interrelated1,2.	  Innate	  immunity	  is	  the	  first	  arm	  to	  respond	  and	  
contains	  many	  of	  the	  effector	  mechanisms	  required	  for	  clearing	  infections.	  
Innate	  cells	  such	  as	  macrophages	  and	  granulocytes	  are	  able	  to	  phagocytose	  
extracellular	  pathogens	  and	  kill	  infected	  cells	  through	  reactive	  nitrogen	  
species3,4.	  Adaptive	  immunity	  takes	  longer	  to	  establish,	  but	  is	  critical	  for	  
generating	  long-­‐lasting,	  highly-­‐specific	  immunity.	  This	  branch	  is	  able	  to	  enhance	  
the	  efficiency	  of	  innate	  immune	  mechanisms	  through	  the	  production	  of	  
antibodies	  that	  are	  of	  high	  affinity	  for	  a	  specific	  target,	  and	  the	  production	  of	  
targeted	  cytokines	  that	  are	  able	  to	  further	  activate	  innate	  immune	  cells5.	  The	  
end	  goal	  of	  the	  adaptive	  response	  is	  long-­‐lasting,	  protective	  immunological	  
memory	  that	  is	  able	  to	  rapidly	  produce	  a	  targeted,	  highly	  efficient	  response	  on	  
subsequent	  encounters	  with	  a	  pathogen5,6.	  
One	  of	  the	  aims	  of	  immunological	  research	  is	  to	  produce	  vaccines	  that	  provide	  
long-­‐lasting,	  highly	  specific	  immunity	  against	  a	  particular	  pathogen,	  or	  to	  
provide	  therapies	  or	  medication	  that	  can	  restore	  control	  to	  a	  dysregulated	  or	  
misdirected	  immune	  response.	  This	  requires	  a	  thorough	  understanding	  of	  how	  
the	  many	  aspects	  of	  the	  immune	  response	  function	  independently,	  and	  how	  
they	  collaborate	  in	  vivo.	  This	  chapter	  aims	  to	  provide	  a	  detailed	  background	  to	  
the	  data	  presented	  in	  this	  thesis,	  concerning	  a	  number	  of	  aspects	  of	  plasma	  cell	  
biology.	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Splenic	  structure	  
The	  spleen,	  the	  largest	  secondary	  lymphoid	  organ	  in	  mammals,	  is	  composed	  of	  
the	  red	  and	  white	  pulp	  (fig	  1.3).	  The	  red	  pulp	  is	  an	  area	  in	  which	  blood	  flows	  
from	  terminal	  arterioles	  into	  open	  sinusoids7.	  Here,	  where	  blood	  flow	  is	  slower,	  
macrophages	  scavenge	  and	  remove	  any	  dead	  or	  dying	  erythrocytes	  (or	  other	  
particles	  found	  in	  the	  blood),	  which	  become	  entangled	  in	  fibres	  that	  filter	  the	  
blood.	  CXCL12	  is	  secreted	  by	  many	  stromal	  cells	  in	  the	  red	  pulp,	  and	  cells	  which	  
reside	  there	  express	  the	  receptor	  CXCR48.	  Following	  filtration,	  blood	  exits	  the	  
spleen	  via	  the	  collecting	  vein7.	  
The	  white	  pulp,	  which	  is	  clustered	  around	  the	  central	  arteriole,	  is	  made	  up	  of	  T	  
cell	  zones	  and	  B	  cell	  follicles7.	  B	  and	  T	  cells,	  which	  are	  produced	  in	  the	  bone	  
marrow	  and	  thymus	  respectively,	  migrate	  out	  of	  these	  organs	  early	  after	  
formation	  and	  travel	  to	  secondary	  lymphoid	  organs	  including	  the	  spleen9.	  Here	  
CCR7	  expressing	  T	  cells	  migrate	  to	  T	  zones,	  attracted	  by	  the	  CCR7-­‐ligands	  
CCL19	  and	  CCL21,	  secreted	  by	  networks	  of	  fibroblast	  reticular	  cells10.	  CXCR5	  
expressing	  ‘follicular’	  B	  cells	  are	  attracted	  by	  CXCL13,	  secreted	  by	  networks	  of	  
follicular	  dendritic	  cells	  (FDC)10.	  The	  defined	  structure	  of	  the	  white	  pulp	  allows	  
for	  the	  efficient	  meeting	  of	  rare	  activated	  antigen-­‐specific	  clones	  of	  B	  and	  T	  cells,	  
as	  well	  as	  the	  rapid	  activation	  of	  T	  cells	  by	  antigen	  presenting	  dendritic	  cells7.	  
Surrounding	  the	  white	  pulp	  is	  the	  marginal	  zone,	  where	  blood	  leaves	  the	  
arterioles	  and	  enters	  the	  open	  sinuses.	  This	  is	  also	  the	  access	  point	  for	  cells	  and	  
blood	  borne	  particulate	  antigen	  entering	  the	  spleen7.	  Certain	  cell	  types	  reside	  in	  
this	  area	  including	  two	  types	  of	  macrophage,	  marginal	  metallophilic	  
macrophages	  and	  marginal	  zone	  macrophages11.	  Marginal	  zone	  macrophages	  
are	  located	  in	  the	  very	  outer	  ring	  of	  the	  marginal	  zone,	  closest	  to	  the	  red	  pulp.	  
They	  are	  vital	  for	  the	  uptake	  of	  antigen	  as	  it	  enters	  the	  spleen,	  and	  express	  a	  
number	  of	  receptors	  that	  allow	  this	  to	  be	  performed	  efficiently,	  such	  as	  SIGN-­‐R1	  
(C-­‐type	  lectin-­‐specific	  intracellular	  adhesion	  molecule-­‐grabbing	  non-­‐integrin	  
receptor)	  and	  the	  scavenger	  receptor	  MARCO	  (macrophage	  receptor	  with	  a	  
collagenous	  structure)12.	  Marginal	  metallophilic	  macrophages	  reside	  in	  the	  
inner	  ring	  of	  the	  marginal	  zone,	  adjacent	  to	  the	  white	  pulp.	  Their	  exact	  function	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is	  unknown,	  although	  they	  may	  be	  important	  for	  type	  I	  interferon	  production	  
during	  viral	  infections11.	  
These	  two	  macrophage	  populations	  sandwich	  a	  subset	  of	  B	  cells	  (marginal	  zone	  
B	  cells),	  which	  express	  low	  amounts	  of	  IgD	  and	  high	  amounts	  of	  IgM	  on	  their	  
surface13-­‐15.	  	  
Through	  splenic	  architecture,	  the	  blood	  is	  constantly	  monitored	  for	  blood	  borne	  
pathogens,	  and	  once	  encountered,	  adaptive	  immunity	  can	  be	  triggered	  in	  an	  
efficient	  way	  despite	  the	  rarity	  of	  individual	  clones	  of	  T	  and	  B	  cells.	  
Innate	  immune	  receptors	  
Pattern	  recognition	  receptors	  (PRR)	  recognise	  conserved	  ‘pathogen	  associated	  
molecular	  patterns’	  or	  PAMPs	  that	  are	  generally	  evolutionarily	  ancient	  and	  
therefore	  present	  on	  many	  species	  of	  pathogen3,16.	  	  
Toll-­‐like	  receptors	  (TLRs)	  are	  a	  major	  class	  of	  PRR,	  and	  are	  widely	  expressed	  in	  
mammalian	  cells.	  Toll,	  a	  receptor	  identified	  in	  Drosophila,	  was	  found	  to	  
recognise	  a	  cleaved	  form	  of	  the	  cytokine	  spaetzle,	  generated	  during	  fungal	  
infection,	  and	  initiates	  inflammatory	  pathways17,18.	  TLRs	  are	  the	  mammalian	  
homologue	  and	  serve	  a	  similar	  function,	  although	  through	  the	  direct	  recognition	  
of	  PAMPs1.	  There	  are	  11	  known	  TLRs,	  many	  recognising	  different	  PAMPs,	  
however	  all	  have	  related	  structures;	  a	  leucine-­‐rich	  repeat	  extracellular	  domain	  
and	  a	  toll-­‐IL-­‐1	  receptor	  (TIR)	  intracellular	  domain19	  (fig	  1.2).	  TLR4,	  the	  first	  to	  
be	  identified,	  binds	  bacterial	  lipopolysaccharide	  (LPS)20,21,	  while	  TLR9	  binds	  
CpG	  motif-­‐rich	  DNA	  sequences	  (found	  mainly	  in	  microbial	  DNA)22,	  and	  TLR5	  
binds	  flagellin23.	  On	  binding	  of	  ligands,	  the	  TIR	  domain	  associates	  with	  various	  
adaptor	  proteins	  (exactly	  which	  depends	  on	  the	  receptor	  involved)	  such	  as	  
MyD88	  (myeloid	  differentiation	  primary	  response	  gene	  88),	  TIRAP	  (TIR	  domain	  
containing	  adaptor	  protein),	  TRAM	  (TRIF-­‐related	  adaptor	  molecule)	  and	  TRIF	  
(toll-­‐like	  receptor	  adaptor	  molecule	  1)24.	  This	  begins	  signalling	  cascades,	  
through	  the	  Iκκ	  (inhibitor	  of	  κB	  kinase),	  MAP	  kinase	  (mitogen	  activated	  protein	  
kinases)	  or	  IRF	  (interferon	  regulatory	  factor	  4)	  pathways	  leading	  to	  activation	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of	  transcription	  factors	  such	  as	  NFκB1	  and	  2	  (nuclear	  factor-­‐κB)	  and	  AP-­‐1	  
(activator	  protein	  1)24.	  	  
Signalling	  cascades	  are	  complex;	  adaptor	  molecules	  often	  collaborate	  to	  induce	  
many	  differential	  effects	  through	  the	  recruitment	  of	  distinct	  downstream	  
signalling	  molecules	  (for	  a	  basic	  summary,	  see	  fig	  1.2).	  For	  example,	  in	  TLR4	  
signalling,	  MyD88	  and	  TIRAP	  signalling	  induces	  NFκB	  activation.	  This	  leads	  to	  
the	  production	  of	  inflammatory	  cytokines	  such	  as	  IL-­‐1,	  IL-­‐6	  and	  TNF-­‐α,	  which	  
produce	  inflammation19,24.	  In	  addition,	  stimulated	  cells	  are	  activated,	  gaining	  
enhanced	  phagocytic	  abilities,	  production	  of	  inducible	  nitric	  oxide	  species	  and	  
the	  up-­‐regulation	  of	  cell	  signalling	  molecules	  such	  as	  MHC	  II	  and	  CD80/864,19,25.	  
TLR4	  also	  signals	  through	  TRAM	  and	  TRIF,	  which	  leads	  to	  the	  production	  of	  
type	  I	  interferons;	  potent	  stimulators	  of	  antiviral	  responses	  amongst	  other	  
effects	  (discussed	  later)26.	  However,	  it	  can	  be	  noted	  that,	  with	  the	  exception	  of	  
TLR3	  (which	  causes	  the	  production	  of	  type	  I	  interferons	  in	  response	  to	  double	  
stranded	  RNA	  by	  signalling	  through	  TRIF	  alone)	  and	  TLR4,	  all	  other	  TLRs	  
require	  MyD88	  to	  signal19,24. 
TLRs	  are	  positioned	  in	  locations	  that	  enhance	  the	  likelihood	  of	  detecting	  their	  
respective	  ligands.	  TLRs	  that	  detect	  extracellular	  ligands	  are	  present	  on	  the	  
surface	  of	  cells,	  such	  as	  TLR4	  (LPS),	  TLR5	  (flagellin),	  and	  TLR1,	  2	  and	  6	  
(bacterial	  lipopeptides)3,24,27.	  Those	  that	  detect	  viral	  ligands,	  and	  bacterial	  
ligands	  that	  are	  only	  exposed	  once	  a	  pathogenic	  cell	  is	  broken	  down,	  are	  located	  
on	  the	  membranes	  of	  endosomal	  compartments	  such	  as	  TLR3	  (double	  stranded	  
RNA),	  TLR7,	  8	  (single	  stranded	  RNA)	  and	  TLR9	  (CpG	  rich	  DNA)28.	  This	  also	  
sequesters	  these	  receptors	  away	  from	  any	  possible	  contact	  with	  self-­‐DNA	  and	  
RNA,	  which	  could	  potentially	  bind	  (despite	  preferentially	  binding	  of	  microbial	  
DNA	  and	  RNA,	  mammalian	  nucleic	  acids	  are	  capable	  of	  binding	  to,	  and	  
activating,	  these	  receptors)19,29.	  	  
TLRs	  are	  tightly	  regulated,	  especially	  in	  the	  gut	  where	  commensal	  bacteria	  are	  
common.	  Regulatory	  signalling	  molecules	  such	  as	  IRF4	  and	  SHP	  (small	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heterodimer	  partner)	  compete	  with	  inflammatory	  signalling	  molecules	  (such	  as	  
IRF5	  and	  IRF7)	  for	  access	  to	  the	  adaptor	  molecules	  associated	  with	  TLRs24,26,30.	   
Expression	  of	  TLRs	  
TLRs	  are	  widely	  expressed	  in	  mammals;	  both	  in	  immune	  and	  non-­‐immune	  cell	  
types.	  Often,	  signalling	  in	  non-­‐immune	  cells	  leads	  to	  the	  recruitment	  of	  innate	  
immune	  cells	  through	  altered	  cytokine,	  chemokine	  and	  adhesion	  molecule	  
expression19,28.	  In	  mice,	  many	  antigen	  presenting	  cells	  (APC)	  as	  well	  as	  B	  cells	  
express	  all	  known	  TLRs.	  Expression	  patterns	  vary	  in	  different	  subsets	  of	  cells;	  
for	  example,	  marginal	  zone	  and	  B1	  cells	  express	  more	  TLR2,	  6	  and	  7	  than	  
follicular	  B	  cells31.	  Dendritic	  cells	  express	  all	  TLRs,	  while	  plasmacytoid	  dendritic	  
cells	  do	  not	  express	  TLR2,	  3,	  4	  or	  5	  but	  signal	  through	  TLR7	  and	  932.	  	  
Other	  PRRs	  and	  innate	  receptors	  
Numerous	  other	  PRRs	  exist	  and	  are	  abundant,	  especially	  in	  APC.	  NOD-­‐like	  
receptors	  (NLRs)	  are	  a	  family	  of	  PRRs	  similar	  to	  TLRs.	  Some	  NLRs	  activate	  
inflammatory	  signals	  through	  the	  NFκB	  and	  MAP	  kinase	  pathways	  much	  like	  
TLRs	  (although	  signalling	  through	  RIP2	  (receptor	  interacting	  protein	  2)	  rather	  
than	  MyD88	  etc);	  others	  generate	  inflammasomes,	  leading	  to	  caspase-­‐1	  
activation	  and	  the	  production	  of	  IL-­‐1β and	  IL-­‐1833.	  These	  receptors	  are	  present	  
in	  the	  cytoplasm	  and	  are	  important	  for	  recognising	  intracellular	  bacteria	  and	  
viruses.	  Similar	  to	  NOD-­‐like	  receptors	  are	  RIG-­‐like	  receptors	  (RLR)	  and	  RNA-­‐
helicases,	  which	  are	  cytoplasmic	  PRRs	  able	  to	  trigger	  innate	  immune	  
responses33.	  	  
In	  addition	  to	  these,	  other	  surface	  receptors	  exist.	  Mannose	  receptors	  (present	  
mainly	  on	  macrophages	  and	  dendritic	  cells)	  recognise	  repeated	  mannose	  units	  
on	  the	  surface	  of	  bacteria,	  and	  through	  the	  activation	  of	  the	  complement	  
cascade,	  form	  the	  membrane	  attack	  complex	  that	  is	  able	  to	  form	  
transmembrane	  channels	  through	  the	  lipid	  bilayer	  of	  pathogenic	  cells34.	  
Scavenger	  receptors	  are	  a	  family	  of	  PRRs	  that	  are	  expressed	  mainly	  on	  
macrophages.	  Although	  diverse	  in	  their	  specificities,	  the	  best	  studied	  (SR	  A-­‐I	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and	  SR	  A-­‐II)	  recognise	  negatively	  charged	  low-­‐density	  lipoproteins	  on	  the	  
surface	  of	  bacterial	  cells.	  They	  also	  mediate	  the	  clearance	  of	  apoptotic	  cells35.	  	  
Fc	  receptors	  
Other	  mechanisms	  exist	  for	  activating	  innate	  cells,	  which	  do	  not	  rely	  on	  the	  
recognition	  of	  molecular	  patterns.	  An	  example	  of	  such	  is	  Fc	  receptors	  that	  bind	  
to	  the	  Fc	  region	  of	  antibody	  molecules.	  These	  are	  expressed	  on	  the	  surface	  of	  
many	  innate	  cell	  types,	  and	  must	  be	  cross-­‐linked	  before	  signalling	  is	  induced36.	  
This	  requires	  that	  multiple	  antibody	  molecules	  have	  bound	  to	  a	  single	  pathogen	  
or	  antigen	  molecule	  to	  form	  an	  immune	  complex.	  Generally,	  Fc	  receptors	  
recognise	  class-­‐switched	  IgG	  or	  IgE	  antibodies.	  As	  pre-­‐existing	  natural	  antibody	  
is	  non-­‐class-­‐switched	  IgM,	  an	  active	  B	  cell	  response	  against	  a	  pathogen	  is	  
required	  for	  efficient	  activation	  through	  Fc	  receptors37.	  Effects	  of	  cross-­‐linking	  
Fc	  receptors	  depend	  on	  the	  class	  of	  receptor,	  and	  the	  cell	  type	  it	  is	  expressed	  on.	  
There	  are	  4	  classes	  of	  Fcγ	  receptor	  alone,	  three	  providing	  activating	  signals	  
(FcγRI,	  FcγRIII	  and	  FcγRIV)	  that	  associate	  with	  activatory	  ITAM	  
(immunoreceptor	  tyrosine-­‐based	  activation	  motif)	  motifs	  and	  signal	  through	  
the	  ERK	  (extracellular	  signal-­‐related	  kinase),	  p38	  MAP	  kinase,	  Jnk	  (c-­‐JUN	  NH2-­‐
terminal	  kinase)	  pathway37.	  One	  receptor	  provides	  inhibitory	  signals	  (FcγRIIb)	  
by	  association	  with	  an	  inhibitory	  ITIM	  (immunoreceptor	  tyrosine-­‐based	  
inhibitory	  motif)	  motif37.	  	  
Activatory	  Fc	  receptors	  on	  phagocytic	  cells	  initiate	  phagocytosis	  and	  the	  
secretion	  of	  inflammatory	  cytokines,	  as	  well	  as	  the	  release	  of	  reactive	  oxygen	  
species37.	  Neutrophils,	  eosinophils	  and	  NK	  cells	  can	  also	  lyse	  antibody-­‐bound	  
cells	  through	  antibody-­‐dependent	  cell-­‐mediated	  cytotoxicity.	  On	  dendritic	  cells,	  
Fc	  receptor	  cross-­‐linking	  causes	  the	  presentation	  of	  phagocytosed	  particles	  to	  T	  
cells	  on	  MHC	  II37.	  Meanwhile,	  inhibitory	  receptors	  tend	  to	  cause	  a	  modulation	  of	  
these	  effects;	  the	  activation	  state	  of	  these	  cells	  depends	  on	  the	  balance	  of	  
inhibitory	  and	  activatory	  signals	  they	  receive.	  Interestingly,	  B	  cells	  express	  
inhibitory	  Fc	  receptors,	  and	  if	  cross-­‐linked	  with	  the	  BCR,	  this	  acts	  to	  inhibit	  
proliferation	  and	  activation,	  whereas	  cross-­‐linking	  of	  Fc	  receptors	  alone	  causes	  
apoptosis	  (this	  effect	  is	  also	  seen	  in	  plasma	  cells,	  which	  express	  FcγRIIb)37,38.	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PRR	  signalling	  initiates	  adaptive	  immunity	  
As	  stated	  above,	  PRR	  signalling	  leads	  to	  many	  pro-­‐inflammatory	  effects.	  
However,	  the	  extent	  to	  which	  signalling	  through	  innate	  PRRs	  controls	  adaptive	  
immunity	  has	  only	  become	  apparent	  relatively	  recently2.	  While	  it	  may	  seem	  
counterintuitive	  that	  a	  primitive	  system	  with	  little	  specificity	  is	  required	  to	  
direct	  one	  with	  fine	  specificity,	  it	  is	  now	  clear	  that	  the	  innate	  system	  controls	  
the	  type	  of	  adaptive	  response	  that	  is	  generated2,39.	  This	  is	  achieved	  both	  by	  
signalling	  through	  different	  TLRs,	  leading	  to	  differential	  inflammatory	  cytokine	  
production	  from	  APC,	  but	  also	  through	  intrinsic	  signalling	  in	  B	  cells,	  which	  
directs	  antibody	  class-­‐switching,	  germinal	  centre	  formation	  and	  plasma	  cell	  
formation.	  The	  effects	  of	  TLR	  signalling	  on	  B	  cells	  will	  be	  covered	  in	  detail	  later,	  
what	  follows	  is	  a	  description	  of	  the	  effects	  of	  innate	  signals	  on	  innate	  cells,	  and	  
how	  innate	  signals	  cause	  the	  priming	  of	  the	  adaptive	  immune	  response.	  
Dendritic	  cells	  are	  ‘professional’	  APC;	  their	  primary	  function	  is	  to	  survey	  the	  
peripheral	  tissues	  for	  pathogens	  and	  present	  these	  to	  CD4	  T	  cells,	  which	  express	  
an	  antigen-­‐specific	  receptor	  that	  must	  recognise	  antigen	  presented	  to	  it	  on	  an	  
MHC	  II	  molecule40.	  	  
It	  should	  be	  noted	  that	  while	  dendritic	  cells	  are	  the	  only	  professional	  APC,	  other	  
cells	  exist	  that	  are	  capable	  of	  presenting	  antigen	  to	  CD4	  T	  cells,	  notably	  
macrophages	  and	  B	  cells41-­‐43.	  Immature	  dendritic	  cells	  in	  the	  periphery	  express	  
many	  PRRs	  and	  other	  innate	  receptors	  and	  are	  primed	  to	  recognise	  pathogens.	  
When	  they	  encounter	  such	  a	  pathogen,	  signals	  through	  PRRs	  or	  other	  receptors	  
such	  as	  Fc	  and	  scavenger	  receptors	  lead	  to	  the	  ingestion	  of	  the	  invader	  into	  
endosomal	  compartments40.	  Here	  it	  is	  broken	  down	  and	  delivered	  to	  the	  
endoplasmic	  reticulum	  where	  it	  is	  loaded	  onto	  MHC	  II	  molecules	  and	  presented	  
to	  CD4	  T	  cells.	  Co-­‐stimulatory	  molecules	  such	  as	  CD80,	  CD86	  and	  CD40	  are	  up	  
regulated	  and	  the	  dendritic	  cell	  migrates	  to	  the	  T	  cell	  zone	  of	  secondary	  
lymphoid	  organs40.	  	  
This	  is	  similar	  to	  the	  activation	  of	  T	  cells	  by	  macrophages,	  which	  are	  also	  able	  to	  
phagocytose	  and	  present	  antigen43.	  B	  cells	  however,	  are	  not	  capable	  of	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internalising	  antigen	  via	  innate	  receptors,	  and	  PRR	  stimulation	  does	  not	  cause	  
the	  uptake	  of	  antigen.	  Instead,	  antigens	  must	  be	  specifically	  recognised	  by	  the	  
BCR,	  (discussed	  below)	  before	  endocytosis	  occurs41.	  This	  means	  that,	  early	  in	  
the	  response	  to	  T-­‐dependent	  (TD)	  antigens	  (when	  antigen-­‐specific	  B	  cells	  are	  at	  
low	  frequency),	  B	  cells	  are	  not	  a	  major	  contributor	  to	  T	  cell	  priming.	  However,	  
they	  have	  been	  shown	  to	  be	  important	  at	  later	  phases,	  especially	  during	  the	  
generation	  of	  memory	  T	  cells,	  and	  likely	  play	  a	  larger	  role	  in	  recall	  responses44.	  
T	  cell	  polarisation	  by	  cytokines	  
Depending	  on	  the	  type	  of	  pathogen	  encountered,	  APCs	  will	  secrete	  different	  
inflammatory	  cytokines	  that	  polarize	  naïve	  CD4	  T	  cells	  in	  different	  ways.	  For	  
example,	  IL-­‐12	  is	  secreted	  when	  APCs	  encounter	  pathogens	  such	  as	  intracellular	  
bacteria	  and	  viruses,	  and	  induces	  CD4	  T	  cells	  to	  adopt	  a	  Th1	  phenotype45-­‐48.	  
This	  leads	  to	  T	  cells	  expressing	  the	  transcription	  factor	  Tbet	  (T	  box	  expressed	  in	  
T	  cells)	  and	  secreting	  IFN-­‐γ,	  a	  potent	  activator	  of	  many	  innate	  immune	  cells	  
such	  as	  macrophages	  and	  dendritic	  cells	  themselves47.	  For	  Th2	  pathogens,	  such	  
as	  helminths	  infections,	  IL-­‐4	  from	  several	  cellular	  sources	  is	  the	  main	  driving	  
cytokine	  for	  T	  cell	  polarisation,	  although	  the	  cognate	  interactions	  with	  APC	  are	  
still	  vital45-­‐47.	  This	  leads	  to	  the	  expression	  of	  the	  transcription	  factor	  GATA3	  
(GATA	  binding	  protein	  3)	  and	  the	  secretion	  of	  IL-­‐4,	  5	  and	  13	  from	  T	  cells,	  which	  
causes	  alternate	  activation	  of	  macrophages	  and	  the	  activation	  of	  basophils,	  mast	  
cells	  and	  eosinophils47.	  	  
Additional	  T	  cell	  subsets	  have	  been	  discovered	  in	  more	  recent	  years.	  Th17	  cells	  
can	  be	  generated	  through	  a	  combination	  of	  TGF-­‐β	  (from	  many	  sources)	  and	  IL-­‐6	  
or	  IL-­‐21	  (from	  APCs).	  These	  cells	  are	  generated	  in	  response	  to	  extracellular	  
bacteria,	  express	  the	  transcription	  factor	  RORγT	  (retinoic	  acid	  receptor-­‐related	  
orphan	  receptor	  gamma	  T),	  and	  produce	  the	  highly	  inflammatory	  cytokine	  IL-­‐
17,	  as	  well	  as	  IL-­‐2147,49.	  IL-­‐17	  functions	  to	  attract	  neutrophils	  (which	  kill	  
pathogens	  through	  phagocytosis	  and	  the	  release	  of	  anti-­‐microbial	  molecules	  
such	  as	  cathepsins	  and	  defensins	  in	  granules)	  and	  also	  to	  activate	  many	  cell	  
types	  to	  produce	  inflammatory	  cytokines	  such	  as	  TNF-­‐α	  and	  IL-­‐649.	   
Chapter	  1	  -­‐	  Introduction	  
	   9	  
Th9	  cells	  may	  arise	  from	  unpolarised	  T	  cells	  responding	  to	  TGF-­‐β	  and	  IL-­‐4,	  or	  
differentiate	  from	  Th2	  polarised	  cells	  stimulated	  with	  TGF-­‐β.	  These	  cells	  secrete	  
IL-­‐9	  and	  are	  involved	  in	  pathogen	  clearance,	  although	  it	  is	  not	  known	  whether	  
they	  are	  a	  truly	  distinct	  lineage47.	  	  
CD4	  T	  cells	  are	  capable	  of	  enhancing	  innate	  immune	  cell	  function,	  and	  also	  play	  
a	  role	  in	  directing	  TD	  B	  cell	  responses,	  as	  the	  cytokines	  they	  secrete	  during	  
interactions	  with	  B	  cells	  control	  the	  outcome	  of	  B	  cell	  activation,	  as	  will	  be	  
discussed	  below.	  
B	  cell	  responses	  
B	  cell	  receptors	  
B	  cells	  express	  both	  a	  B	  cell	  receptor	  (BCR),	  and	  PRR31.	  The	  BCR	  is	  a	  membrane-­‐
bound	  immunoglobulin	  molecule	  expressed	  on	  the	  surface	  of	  B	  cells,	  which	  is	  
able	  to	  signal	  through	  the	  association	  with	  CD79α	  and	  β	  heterodimers	  as	  well	  as	  
co-­‐receptors	  such	  as	  CD19	  and	  CD2250.	  Ligation	  of	  the	  BCR	  causes	  the	  
association	  of	  protein	  tyrosine	  kinases	  such	  as	  Syk	  (spleen	  tyrosine	  kinase)	  and	  
Lyn	  (V-­‐yes-­‐1	  Yamaguchi	  sarcoma	  viral	  related	  oncogene	  homolog),	  and	  the	  
phosphorylation	  of	  ITAM	  motifs	  on	  the	  intracellular	  region	  of	  CD79a	  and	  b.	  This	  
leads	  to	  further	  activation	  of	  Syk	  and	  also	  Btk	  (Bruton’s	  tyrosine	  kinase).	  
Through	  a	  complex	  signalling	  pathway	  (reviewed	  by	  Niiro	  et	  al,	  200250)	  this	  
leads	  to	  the	  activation	  of	  NF-­‐κB	  and	  NFAT	  (nuclear	  factor	  of	  activated	  T	  cells)	  
via	  p38	  MAPK,	  ERK,	  Jnk,	  Iκκ	  and	  Akt	  (protein	  kinase	  B)	  activation50.	  
Mature,	  follicular	  B	  cells	  co-­‐express	  IgM	  and	  IgD	  on	  their	  surface50.	  While	  the	  
function	  of	  IgD	  remains	  unclear51,52,	  surface	  IgM	  on	  follicular	  B	  cells	  is	  a	  highly	  
specific	  receptor,	  allowing	  for	  the	  recognition	  of	  a	  single	  antigen50.	  To	  allow	  for	  
the	  multitude	  of	  possible	  antigens,	  each	  B	  cell	  clone	  expresses	  a	  different	  B	  cell	  
receptor,	  meaning	  that	  any	  single	  specificity	  of	  B	  cell	  is	  particularly	  rare	  before	  
antigen	  exposure.	  On	  other	  B	  cell	  subsets,	  such	  as	  B1	  cells,	  the	  BCR	  is	  limited	  to	  
specificities	  that	  recognise	  conserved	  pathogenic	  regions	  (much	  like	  PRRs),	  
such	  as	  glycolipids	  and	  lipoproteins53,54.	  While	  cross-­‐linking	  of	  the	  BCR	  on	  
Chapter	  1	  -­‐	  Introduction	  
	   10	  
immature	  B	  cells	  causes	  apoptosis55,	  mature	  	  B	  cells	  respond	  by	  differentiation	  
to	  plasma	  cells,	  the	  production	  of	  cytokines	  and	  proliferation50.	  
TLR	  signalling	  in	  B	  cells	  
B	  cells	  are	  known	  to	  express	  the	  TLRs	  1-­‐9	  in	  mice.	  Their	  expression	  at	  protein	  
level	  has	  been	  shown	  to	  vary	  between	  subsets	  of	  B	  cells31.	  Stimulation	  has	  three	  
effects,	  depending	  on	  the	  subset.	  Follicular	  B	  cells,	  when	  stimulated	  through	  
TLRs	  alone,	  produce	  cytokine;	  notably	  IL-­‐6	  and	  IL-­‐10	  when	  stimulated	  by	  LPS31.	  
Interestingly,	  when	  differing	  combinations	  of	  TLRs	  stimulate	  B	  cells	  
simultaneously,	  they	  secrete	  other	  cytokines	  (such	  as	  IFN-­‐γ when	  stimulated	  
through	  TLRs	  2,	  4	  and	  9)31.	  Secondly,	  B	  cells	  stimulated	  through	  TLRs	  
upregulate	  T	  cell	  stimulatory	  and	  co-­‐stimulatory	  molecules	  such	  as	  MHC	  II,	  
CD80	  and	  CD86.	  Combined,	  this	  allows	  B	  cells	  activated	  by	  TLRs	  to	  function	  as	  
capable	  APC	  and	  programmers	  of	  the	  CD4	  T	  cell	  response31,44,56.	  Thirdly,	  signals	  
through	  TLRs	  drive	  B	  cells	  to	  differentiate	  to	  plasma	  cells.	  In	  B1	  and	  marginal	  
zone	  B	  cells,	  TLR	  signals	  alone	  are	  sufficient	  to	  drive	  differentiation,	  at	  least	  in	  
vitro57,58.	  Follicular	  B	  cells	  require	  other	  signals	  to	  efficiently	  differentiate	  to	  
plasma	  cells,	  however	  they	  undergo	  modest	  differentiation	  to	  plasma	  cells	  when	  
stimulated	  in	  vitro59.	  TLR	  signalling,	  however,	  is	  critical	  to	  the	  generation	  of	  
successful	  germinal	  centre	  responses60,	  and	  can	  control	  antibody	  class	  
switching	  in	  activated	  B	  cells,	  as	  will	  be	  discussed	  below. 
Antigen	  presentation	  by	  B	  cells	  
Activated	  follicular	  B	  cells	  process	  and	  present	  antigen	  that	  is	  bound	  by	  their	  
surface	  BCR.	  The	  BCR,	  with	  bound	  antigen	  is	  internalised	  into	  vesicles,	  where	  
changes	  in	  pH	  mediate	  the	  release	  of	  bound	  antigen41,61.	  This	  is	  then	  broken	  
down	  into	  peptides	  by	  the	  proteases	  cathepsin	  B,	  D	  and	  L	  (which	  are	  also	  
activated	  by	  the	  acidic	  pH	  in	  the	  endosomal	  compartment)61,62.	  These	  vesicles	  
fuse	  with	  MHC	  II	  containing	  vesicles	  (called	  the	  MIIC	  compartment).	  The	  
peptides	  are	  loaded	  onto	  MHC	  II	  by	  HLA-­‐DM,	  also	  present	  in	  the	  vesicles	  (firstly,	  
the	  MHC	  II	  molecule	  has	  the	  invariant	  chain	  ‘Ii’	  and	  stabilising	  peptide	  ‘CLIP’	  
degraded	  and	  removed	  by	  cathepsin	  L	  and	  HLA-­‐DR	  respectively)9.	  Once	  this	  is	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accomplished,	  the	  MHC	  II:peptide	  complex	  is	  transported	  to	  the	  cell	  surface	  
where	  it	  is	  presented	  to	  CD4	  T	  cells.	  
TD	  activation	  of	  B	  cells	  
IgD+	  B2	  B	  cells	  found	  in	  the	  follicles	  (hereafter	  referred	  to	  as	  “follicular	  B	  cells”)	  
are	  recirculating	  cells.	  After	  around	  a	  day	  in	  any	  particular	  follicle,	  they	  migrate	  
into	  the	  blood	  stream	  towards	  other	  secondary	  lymphoid	  organs.	  Entering	  via	  
the	  high	  endothelial	  venule	  (lymph	  node)	  or	  central	  arteriole	  (spleen)	  into	  the	  
marginal	  zone,	  they	  then	  migrate	  to	  the	  T	  zone	  (fig	  1.3)63,64.	  From	  here	  they	  
migrate	  to	  the	  follicle	  where	  again	  they	  will	  rest	  for	  around	  a	  day63.	  When	  
antigen	  is	  encountered,	  this	  migration	  pattern	  changes.	  Due	  to	  the	  up-­‐regulation	  
of	  CCR7	  and	  the	  down-­‐regulation	  of	  CXCR5,	  follicular	  B	  cells	  migrate	  directly	  to	  
the	  T	  zone65.	  Antigen-­‐specific	  CD4	  T	  cells	  (that	  have	  been	  previously	  activated	  
by	  APC)	  and	  activated	  B	  cells	  presenting	  peptide	  on	  MHC	  II	  molecules	  engage	  in	  
cognate	  interactions.	  This	  involves	  the	  T	  cell	  engaging	  the	  MHC	  II:peptide	  
complex	  with	  its	  T	  cell	  receptor	  (TCR)	  and	  CD4,	  followed	  by	  the	  engagement	  of	  
accessory	  signalling	  molecules	  such	  as,	  CD40L:CD40,	  CD28:CD80/CD869,66,67.	  
Further	  downstream	  signalling	  occurs	  including	  the	  inducible	  T	  cell	  co-­‐
stimulator	  (ICOS):B7H68,69.	  These	  signals	  function	  to	  further	  activate	  the	  T	  cell	  
and	  induce	  the	  differentiation	  of	  B	  cells	  to	  either	  plasma	  cells	  or	  germinal	  centre	  
B	  cells	  (discussed	  later).	  	  
Plasma	  cell	  responses	  
Plasma	  cells	  differentiate	  from	  activated	  B	  cells.	  They	  secrete	  large	  amounts	  of	  
antibody,	  which	  is	  critical	  for	  the	  clearance	  of	  many	  pathogens	  through	  both	  
their	  ability	  to	  opsonise	  invading	  organisms	  and	  by	  mediating	  the	  activation	  of	  
innate	  cells	  and	  complement	  pathways.	  
T	  cell	  independent	  (TI)	  activation	  
B1	  cells	  
Certain	  subsets	  of	  B	  cells,	  including	  B1	  and	  marginal	  zone	  B	  cells	  do	  not	  require	  
T	  cell	  help	  to	  become	  activated	  (fig	  1.1)54,57.	  This	  however,	  often	  requires	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signals	  through	  PRRs,	  or	  certain	  types	  of	  highly	  repetitive	  antigens	  capable	  of	  
extensively	  cross-­‐linking	  the	  BCRs	  expressed	  on	  these	  more	  ‘innate’	  B	  cells.	  B1	  
cells	  are	  a	  self-­‐renewing	  population	  that	  are	  found	  in	  large	  numbers	  in	  the	  
peritoneal	  cavity,	  but	  also	  are	  seen	  in	  the	  secondary	  lymphoid	  organs.	  They	  can	  
be	  further	  subdivided	  into	  B1a	  cells	  (which	  are	  CD5+)	  and	  B1b	  cells	  (which	  are	  
CD5-­‐).	  B1	  cells	  express	  restricted	  repertoires	  of	  BCR70.	  B1a	  cells	  are	  responsible	  
for	  the	  production	  of	  ‘natural	  antibody’;	  IgM	  antibodies,	  which	  are	  often	  of	  
broad	  specificity,	  found	  in	  the	  serum	  of	  naïve	  (or	  even	  germ	  free)	  mice.	  This	  
includes	  antibodies	  that	  bind	  to	  conserved	  regions	  on	  pathogens	  with	  both	  low	  
and	  high	  affinity71,72.	  B1b	  cells	  are	  thought	  to	  rapidly	  produce	  antibodies	  of	  
broad	  specificity	  on	  stimulation	  through	  BCR	  or	  TLRs71.	  	  
Marginal	  zone	  B	  cells	  
Marginal	  zone	  B	  cells	  are	  located	  in	  a	  prime	  position	  to	  recognise	  blood-­‐borne	  
pathogens	  or	  antigen,	  and	  are	  able	  to	  sample	  the	  blood	  as	  it	  filters	  into	  the	  
spleen14,57,73.	  Marginal	  zone	  B	  cells	  rapidly	  differentiate	  to	  plasma	  cells	  
following	  encounter	  of	  TI	  antigens,	  primarily	  secreting	  low	  affinity	  IgM57.	  These	  
cell	  types	  have	  a	  lower	  threshold	  of	  activation	  than	  follicular	  B	  cells,	  due	  to	  their	  
high	  expression	  of	  complement	  receptor	  CD21,	  which	  when	  stimulated	  in	  
combination	  with	  the	  BCR	  significantly	  lowers	  the	  threshold	  of	  activation74.	  In	  
addition,	  they	  differentiate	  to	  plasma	  cells	  more	  readily	  following	  stimulation	  
with	  LPS	  in	  vitro59.	  Although	  these	  cells	  do	  not	  express	  a	  restricted	  repertoire	  
like	  B1	  cells,	  their	  repertoire	  is	  enriched	  for	  certain	  specificities	  recognising	  
conserved	  domains75.	  These	  cells	  are	  seemingly	  capable	  of	  taking	  part	  in	  (or	  at	  
least	  enhancing)	  early	  TI	  responses	  through	  their	  skewing	  towards	  ‘innate-­‐like’	  
BCR,	  their	  propensity	  to	  respond	  to	  polyclonal	  stimulation	  through	  TLRs,	  and	  
their	  ability	  to	  concentrate	  TI	  antigens.	  In	  addition,	  marginal	  zone	  B	  cells	  take	  
part	  in	  TD	  responses	  through	  the	  mechanisms	  described	  below.	  	  
The	  plasma	  cells	  generated	  during	  TI	  responses	  are	  generally	  short-­‐lived	  and	  
often	  secrete	  antibody	  that,	  while	  antigen	  specific,	  is	  of	  relatively	  low	  affinity	  
compared	  to	  antibody	  secreted	  by	  plasma	  cells	  emerging	  from	  germinal	  centres.	  
However,	  that	  they	  arise	  rapidly	  following	  infection	  or	  injection	  of	  TI	  antigen	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has	  been	  shown	  to	  be	  critical	  for	  protection	  as	  they	  slow	  the	  early	  spread	  of	  
infection71,76.	  	  
TD	  B	  cell	  activation	  
For	  follicular	  B	  cells,	  T	  cell	  help	  is	  a	  requirement	  for	  efficient	  activation	  in	  vivo	  
(fig	  1.1)59,77.	  Once	  activated,	  follicular	  B	  cells	  provide	  two	  waves	  of	  plasma	  cells.	  
An	  early	  wave	  contributes	  to	  the	  extrafollicular	  plasma	  cell	  response,	  whereas	  
the	  later	  phase	  provides	  high	  affinity	  plasma	  cells	  that	  often	  migrate	  to	  the	  bone	  
marrow78.	  	  
The	  ‘choice’	  between	  differentiation	  to	  germinal	  centre	  B	  cell	  or	  plasma	  cell	  is	  
mediated	  by	  the	  affinity	  of	  the	  responding	  B	  cell’s	  BCR	  to	  the	  antigen.	  B	  cells	  
binding	  antigen	  with	  relatively	  high	  affinity	  differentiate	  to	  plasma	  cells,	  while	  
relatively	  low	  affinity	  mediates	  the	  differentiation	  to	  germinal	  centre	  B	  cell79-­‐81.	  
It	  should	  be	  stressed	  that	  these	  cells,	  although	  of	  lower	  affinity,	  must	  still	  be	  
able	  to	  bind	  the	  antigen	  and	  generate	  a	  strong	  enough	  signal	  to	  cause	  cellular	  
activation.	  
TD	  activation	  of	  marginal	  zone	  B	  cells	  
Marginal	  zone	  B	  cells	  can	  also	  participate	  in	  TD	  responses.	  These	  cells	  express	  
both	  MHC	  II	  and	  CD1d	  (an	  invariant,	  MHC-­‐like	  molecule	  that	  binds	  lipid	  
antigens).	  Lipid	  bound	  to	  CD1d	  is	  recognised	  by	  invariant	  TCR-­‐expressing	  
natural	  killer	  T	  cells	  (iNKT).	  Interestingly,	  the	  cognate	  interactions	  between	  
iNKT	  cells	  and	  marginal	  zone	  B	  cells	  leads	  to	  the	  generation	  of	  early	  class-­‐
switched	  plasma	  cells,	  while	  IL-­‐21	  secretion	  leads	  to	  enhanced	  responses	  from	  
follicular	  B	  cells,	  as	  will	  be	  described	  later82,83.	  
Extrafollicular	  plasma	  cell	  responses	  
Early	  plasma	  cell	  responses	  are	  critical	  for	  providing	  antibody	  that	  can	  slow	  the	  
spread	  of	  invading	  pathogens.	  As	  mentioned	  above,	  B	  cell	  clones	  expressing	  
BCRs	  of	  relatively	  high	  affinity	  are	  recruited	  to	  the	  extrafollicular	  plasma	  cell	  
response.	  In	  TD	  responses,	  following	  T	  cell	  help	  at	  the	  border	  of	  the	  T	  zone,	  
activated	  follicular	  B	  cells	  initially	  migrate	  from	  the	  T	  zone	  to	  the	  follicle	  and	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divide	  for	  around	  2	  days	  (fig	  1.3)81.	  Following	  this,	  many	  B	  cells	  differentiate	  to	  
plasmablasts,	  mediating	  an	  upregulation	  of	  the	  chemokine	  receptor	  CXCR4	  and	  
down-­‐regulation	  of	  CXCR584.	  This	  causes	  a	  migration	  from	  the	  follicle	  to	  the	  red	  
pulp	  (where	  stromal	  cells	  secrete	  CXCL12)78,84,85.	  These	  plasmablasts	  are	  
capable	  of	  cellular	  division	  and	  migration,	  express	  MHC	  II	  and	  CD138	  and	  also	  
secrete	  antibody.	  Plasmablasts	  are	  capable	  of	  exponential	  growth,	  and	  the	  
number	  of	  plasma	  cells	  produced	  is	  limited	  only	  by	  the	  number	  of	  B	  cells	  
recruited	  into	  the	  response86.	  Each	  plasmablast	  undergoes	  at	  least	  5	  divisions,	  
over	  the	  course	  of	  around	  two	  days	  before	  maturation	  into	  non-­‐dividing	  plasma	  
cells	  occurs81,86.	  In	  contrast,	  immunisation	  with	  the	  TI	  type	  2	  antigen	  NP-­‐Ficoll	  
produces	  a	  continuous	  B	  cell	  and	  plasmablast	  response	  from	  B1b	  cells	  that	  
produces	  new	  NP-­‐specific	  plasma	  cells	  for	  months	  after	  immunisation87.	  The	  
explanation	  for	  the	  observed	  differences	  between	  TI	  and	  TD	  responses	  are	  
unknown.	  As	  plasma	  cells	  mature	  from	  plasmablasts,	  they	  migrate	  further	  out	  
into	  the	  red	  pulp	  where	  they	  associate	  with	  myeloid	  cells	  and	  stromal	  cells	  (fig	  
1.5)88,89.	  Most	  extrafollicular	  plasma	  cells	  are	  short-­‐lived,	  surviving	  for	  just	  a	  
few	  days78,86.	  However,	  as	  will	  be	  described	  later,	  through	  their	  association	  with	  
the	  aforementioned	  myeloid	  cells,	  their	  lifespan	  can	  be	  increased88.	  In	  addition,	  
some	  of	  these	  plasma	  cells	  can	  survive	  in	  the	  secondary	  lymphoid	  organs	  for	  
long	  periods86.	  
Transcription	  factors	  	  
Plasma	  cells	  express	  a	  phenotype	  that	  is	  indicative	  of	  their	  progression	  away	  
from	  B	  cells	  towards	  terminal	  differentiation.	  This	  includes	  the	  down-­‐regulation	  
of	  many	  B	  cell	  surface	  markers,	  such	  as	  CD19,	  B220,	  MHC	  II,	  and	  the	  BCR90.	  
These	  phenotypic	  changes	  are	  brought	  about	  by	  a	  change	  in	  gene	  expression,	  
caused	  by	  the	  upregulation	  of	  the	  master	  transcription	  factor	  ‘B	  lymphocyte	  
maturation	  protein	  1’	  (BLIMP-­‐1)91,92.	  This	  is	  suppressed	  in	  naïve	  B	  cells	  by	  ‘B	  
cell	  lymphoma	  6’	  Bcl-­‐6,	  however	  on	  differentiation	  to	  plasma	  cells	  a	  decrease	  in	  
Bcl-­‐6	  mediates	  an	  increase	  in	  BLIMP-­‐193.	  This	  is	  a	  key	  step	  in	  the	  differentiation	  
to	  plasma	  cells,	  and	  the	  resulting	  decrease	  in	  c-­‐Myc	  (V-­‐myc	  myelocytomatosis	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viral	  oncogene	  homolog)	  causes	  the	  cell	  to	  exit	  cell	  cycle	  and	  undergo	  terminal	  
differentiation94.	  Similarly,	  IRF-­‐4	  further	  suppresses	  Bcl-­‐695,96.	  
BLIMP-­‐1	  also	  suppresses	  ‘paired	  box	  protein	  5’	  (PAX-­‐5),	  a	  transcription	  factor	  
that	  is	  central	  to	  B	  cell	  development	  and	  the	  maintenance	  of	  the	  B	  cell	  
phenotype,	  as	  it	  controls	  the	  expression	  of	  many	  B	  cell-­‐related	  proteins,	  
including	  BCR	  associated	  signalling	  proteins	  such	  as	  CD19	  and	  CD8091.	  It	  is	  
therefore	  unsurprising	  that	  many	  such	  proteins	  gradually	  decline	  on	  the	  surface	  
of	  plasma	  cells.	  The	  down-­‐regulation	  of	  PAX-­‐5	  also	  leads	  to	  increased	  levels	  of	  
another	  transcription	  factor,	  ‘X-­‐box	  binding	  protein	  1’	  (XBP-­‐1)	  that	  is	  required	  
for	  commitment	  to	  the	  plasma	  cell	  lineage97.	  This	  transcription	  factor	  brings	  
about	  the	  unfolded	  protein	  response	  (UPR),	  a	  dramatic	  expansion	  of	  the	  
endoplasmic	  reticulum	  and	  golgi	  apparatus	  that	  allows	  for	  the	  production	  and	  
secretion	  of	  vast	  amounts	  of	  antibody98.	  This	  response	  (usually	  a	  response	  to	  
cellular	  stress)	  is	  brought	  about	  as	  a	  natural	  part	  of	  differentiation	  to	  plasma	  
cells99.	  	  
The	  changes	  in	  transcriptional	  profiles	  of	  B	  cells	  as	  they	  differentiate	  to	  plasma	  
cells	  mediate	  a	  shift	  from	  cells	  with	  numerous	  functions	  to	  highly	  specialised,	  
antibody	  secreting	  cells.	  
Germinal	  centre	  responses	  
Germinal	  centre	  responses	  occur	  during	  TD	  immune	  responses	  and	  are	  a	  
mechanism	  by	  which	  high	  affinity	  B	  cell	  clones	  are	  generated100.	  Following	  
engagement	  with	  activated	  CD4	  T	  cells	  in	  the	  T	  zone,	  activated	  follicular	  B	  cells	  
proliferate	  for	  1-­‐2	  days	  before	  either	  migrating	  to	  the	  red	  pulp	  and	  plasma	  cell	  
differentiation,	  or	  migrating	  back	  into	  the	  B	  cell	  follicle	  to	  establish	  a	  germinal	  
centre78.	  Those	  that	  adopt	  this	  fate	  increase	  their	  expression	  of	  CXCR5	  and	  
migrate	  to	  networks	  of	  CXCL13-­‐secreting	  FDC	  located	  in	  the	  B	  cell	  follicle101.	  
Here,	  they	  begin	  the	  processes	  of	  rapid	  division	  and	  somatic	  hypermutation	  as	  
centroblasts	  in	  the	  dark	  zones	  of	  the	  germinal	  centre102.	  Centroblasts	  increase	  
their	  expression	  of	  Bcl-­‐6,	  which	  suppresses	  the	  plasma	  cell	  phenotype,	  and	  
encourages	  rapid	  cellular	  division103,104.	  Through	  the	  Bcl-­‐6	  mediated	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suppression	  of	  p53	  and	  the	  DNA	  damage	  sensor	  ATR	  (ataxia	  telangiectasia	  and	  
RAD3	  related),	  mutations	  in	  DNA	  are	  allowed	  to	  arise	  without	  apoptosis	  
occurring103,105.	  	  
Simultaneously,	  centroblasts	  up	  regulate	  the	  enzyme	  ‘activation-­‐induced	  
cytosine	  deaminase’	  (AID)100.	  This	  mediates	  mutations	  in	  the	  variable	  region	  of	  
genes	  encoding	  the	  BCR	  (somatic	  hypermutation).	  	  
Centroblasts	  then	  migrate	  to	  the	  light	  zone	  of	  the	  germinal	  centre,	  and	  re-­‐
express	  the	  BCR,	  now	  termed	  centrocytes.	  During	  this	  time	  class-­‐switch	  
recombination	  (CSR)	  is	  initiated,	  switching	  the	  isotype	  of	  immunoglobulin	  from	  
IgM	  to	  IgG,	  IgA	  or	  IgE	  by	  moving	  the	  variable	  (VDJ)	  region	  to	  associate	  with	  a	  
different	  constant	  (CH)	  region106.	  	  In	  the	  light	  zone,	  they	  ‘test’	  their	  newly	  
mutated	  BCR	  against	  antigen	  deposits	  on	  the	  surface	  of	  FDCs100	  (antigen,	  
captured	  on	  the	  surface	  of	  these	  cells	  by	  the	  high	  expression	  of	  Fc	  receptors	  and	  
complement	  receptors,	  amalgamates	  into	  antigen	  deposits	  known	  as	  
iccosomes107).	  Centrocytes	  which	  recognise	  the	  antigen	  through	  their	  BCR	  are	  
provided	  with	  short-­‐term	  survival	  signals	  by	  FDC100,108	  (cross-­‐linking	  of	  the	  BCR	  
causes	  the	  transient	  up-­‐regulation	  of	  the	  anti-­‐apoptotic	  factor	  Bcl-­‐2109).	  It	  is	  still	  
debated	  as	  to	  whether	  iccosomes	  are	  required	  for	  this	  process;	  mice	  with	  no	  
detectable	  iccosomes	  still	  form	  germinal	  centres110,	  however,	  without	  FDCs,	  
both	  germinal	  centres	  and	  follicles	  rapidly	  dissolve101.	  Further	  rounds	  of	  
mutation	  may	  occur	  before	  centrocytes	  engage	  in	  interactions	  with	  T	  follicular	  
helper	  cells	  (Tfh).	  Tfh	  are	  a	  subset	  of	  CD4	  T	  cells	  activated	  during	  T	  cell:B	  cell	  
interactions	  that	  express	  Bcl-­‐6,	  ICOS,	  PD-­‐1	  and	  CXCR5	  	  and	  migrate	  into	  the	  
follicle	  during	  TD	  immune	  responses111.	  They	  require	  ICOS	  expression	  for	  their	  
generation	  and	  maintenance,	  and	  are	  necessary	  for	  germinal	  centre	  
reactions112,113.	  Interactions	  with	  germinal	  centre	  B	  cells,	  once	  again	  through	  
MHC	  II:peptide	  complexes	  recognised	  by	  the	  TCR,	  CD40:CD40L,	  ICOS:B7H	  and	  
further	  downstream	  interactions,	  mediate	  long	  term	  survival	  signals114	  (again	  
through	  Bcl-­‐2	  expression109).	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As	  well	  as	  mediating	  the	  survival	  of	  cells	  exiting	  the	  germinal	  centre,	  Tfh	  may	  
also	  play	  a	  role	  in	  maintaining	  germinal	  centres,	  as	  injecting	  anti-­‐CD40L	  
following	  the	  establishment	  of	  germinal	  centre	  responses	  (and	  therefore	  
blocking	  their	  interaction	  with	  B	  cells)	  causes	  their	  rapid	  abrogation115.	  	  
Two	  cell	  types	  emerge	  from	  the	  germinal	  centre:	  B	  memory	  cells	  and	  long-­‐lived	  
plasma	  cells	  (described	  in	  detail	  later)102.	  What	  causes	  the	  decision	  between	  
differentiation	  to	  B	  memory	  cell	  or	  plasma	  cell	  is	  still	  poorly	  understood.	  Phan	  
et	  al	  showed	  that	  higher	  affinity	  cells	  are	  recruited	  to	  the	  plasma	  cell	  
compartment116.	  Additionally,	  the	  decision	  may	  even	  be	  a	  stochastic	  event	  as,	  in	  
vitro,	  uniform	  populations	  of	  B	  cells	  appear	  to	  respond	  differently	  to	  the	  same	  
signals117-­‐119.	  The	  authors	  of	  these	  studies	  suggested	  that	  at	  each	  division,	  there	  
is	  a	  probability	  of	  each	  B	  cell	  differentiating	  to	  B	  memory	  cell	  or	  plasma	  cell,	  
which	  may	  or	  may	  not	  be	  influenced	  by	  extrinsic	  or	  genetic	  factors117.	  
Studies	  have	  however	  noted	  that	  early	  in	  a	  germinal	  centre	  reaction,	  most	  
exiting	  cells	  are	  B	  memory	  cells,	  whereas	  later	  on,	  more	  long-­‐lived	  plasma	  cells	  
are	  generated120,	  and	  that	  the	  memory	  cell	  compartment	  is	  far	  less	  mutated	  
than	  the	  long-­‐lived	  plasma	  cell	  compartment121.	  Whether	  the	  microenvironment	  
changes	  during	  this	  time,	  or	  it	  is	  advantageous	  to	  generate	  long-­‐lived	  plasma	  
cells	  of	  very	  high	  affinity	  (and	  memory	  cells	  of	  lower	  affinity)	  is	  unknown.	  
B	  memory	  cells	  themselves,	  following	  the	  resolution	  of	  the	  immune	  response,	  
are	  transcriptionally	  similar	  to	  naïve	  B	  cells117,122.	  On	  restimulation,	  however,	  
they	  rapidly	  produce	  both	  high-­‐affinity	  class	  switched	  plasma	  cells	  and	  germinal	  
centres.	  Memory	  B	  cells	  are	  fairly	  long-­‐lived	  and	  capable	  of	  self-­‐renewal123;	  
while	  many	  reside	  in	  the	  splenic	  marginal	  zone,	  some	  recirculate	  through	  the	  
blood	  stream124.	  Although	  phenotypically	  similar	  to	  virgin	  B	  cells,	  many	  
memory	  B	  cells	  express	  a	  class	  switched	  BCR.	  On	  re-­‐exposure	  to	  antigen	  they	  
respond	  rapidly	  by	  forming	  high-­‐affinity	  plasma	  cells	  and	  the	  initiation	  of	  
further	  germinal	  centre	  reactions125.	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Factors	  influencing	  germinal	  centre	  formation	  
In	  addition	  to	  cognate	  signals	  supplied	  by	  Tfh	  cells,	  other	  signals	  can	  influence	  
germinal	  centre	  formation	  and	  outcome.	  TLR	  stimulation	  plays	  an	  important	  
role	  in	  germinal	  centre	  formation.	  It	  has	  long	  been	  known	  that	  adjuvant	  can	  
enhance	  antigen-­‐specific	  antibody	  responses,	  and	  some	  form	  of	  ‘danger	  signal’	  
is	  required	  to	  initiate	  TD	  responses2.	  However,	  it	  was	  only	  relatively	  recent	  
work	  that	  directly	  showed	  that	  TLR	  signalling	  is	  a	  requirement	  for	  optimal	  
germinal	  centre	  formation	  and	  antigen-­‐specific	  antibody	  in	  TD	  responses39,60.	  
Follicular	  B	  cells	  stimulated	  by	  antigen	  and	  T	  cell	  help	  become	  activated,	  
however	  TLR	  stimulation	  often	  enhances	  activation,	  and	  controls	  the	  nature	  of	  
the	  response39,126.	  This	  is	  intuitive,	  as	  the	  nature	  of	  the	  immune	  response	  that	  is	  
required	  is	  indicated	  by	  the	  PAMPs	  present	  on	  a	  pathogen.	  	  
Cytokine	  environment	  too,	  plays	  a	  role	  in	  germinal	  centre	  development.	  IL-­‐21	  
and	  IL-­‐6	  are	  important	  for	  the	  generation	  of	  Tfh;	  the	  absence	  of	  IL-­‐21	  mediates	  
the	  loss	  of	  germinal	  centres	  (in	  acute	  LCMV	  infection),	  while	  the	  loss	  of	  IL-­‐6	  and	  
IL-­‐21	  mediates	  a	  large	  drop	  in	  antigen-­‐specific	  IgG127.	  The	  loss	  of	  IL-­‐6	  mediates	  
altered	  expression	  of	  co-­‐stimulatory	  molecules	  and	  reduced	  synthesis	  of	  the	  
complement	  pathway	  component	  C3d,	  both	  implicated	  in	  reduced	  IgG128.	  IL-­‐21	  
has	  also	  been	  shown	  to	  be	  effective	  at	  skewing	  the	  output	  of	  the	  germinal	  centre	  
from	  memory	  B	  cells	  to	  plasma	  cells129,	  as	  has	  IL-­‐10,	  at	  least	  in	  human	  tonsillar	  
B	  cells	  cultured	  with	  an	  FDC-­‐like	  cell	  line130.	  IL-­‐4	  has	  been	  shown	  to	  inhibit	  the	  
germinal	  centre	  response	  in	  secondary	  responses	  to	  ovalbumin	  in	  complete	  
Freund’s	  adjuvant131.	  This	  creates	  a	  complicated	  picture	  of	  germinal	  centre	  
reactions,	  which	  can	  be	  influenced	  by	  both	  TLR	  signalling,	  cytokine	  
environment	  and	  contact-­‐dependent	  signals.	  
Class-­‐switching	  is	  controlled	  by	  TLR	  signals	  and	  cytokine	  environment	  
In	  much	  the	  same	  way	  that	  dendritic	  cells	  (and	  B	  cells56)	  prime	  T	  cell	  responses	  
differentially	  depending	  on	  the	  type	  pathogen	  they	  encounter,	  B	  cell	  antibody	  
class-­‐switching	  is	  controlled	  by	  TLR	  stimulation39.	  It	  has	  been	  known	  for	  many	  
years	  that	  Th1	  responses	  generate	  IgG2	  isotypes,	  whereas	  Th2	  responses	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generate	  IgG1,	  G3	  and	  IgE	  responses132-­‐134.	  Originally,	  this	  was	  thought	  to	  be	  
entirely	  mediated	  by	  the	  hallmark	  cytokines	  of	  these	  responses	  (IFN-­‐γ	  and	  IL-­‐4	  
respectively)	  from	  activated	  CD4	  T	  cells.	  However,	  Pasare	  and	  Medzhitov	  
showed	  that	  IgG2	  switching,	  and	  to	  a	  lesser	  extent	  IgG1	  switching,	  was	  
dependent	  on	  B	  cell	  intrinsic	  TLR	  signalling	  through	  MyD88	  following	  
immunisation	  with	  OVA-­‐LPS	  in	  incomplete	  Freund’s	  adjuvant39.	  Similarly,	  data	  
from	  our	  own	  lab	  has	  shown	  that	  B	  cell	  intrinsic	  signalling	  through	  MyD88	  
mediates	  the	  switch	  to	  IgG2c	  in	  Salmonella	  infection.	  When	  chimeras	  in	  which	  B	  
cells	  failed	  to	  express	  MyD88	  were	  infected,	  switching	  to	  other	  isotypes	  
occurred	  (notably	  IgG1)56.	  So,	  while	  T	  helper	  associated	  cytokines	  can	  direct	  
and	  enhance	  class	  switching,	  TLR	  ligands	  are	  also	  powerful	  drivers	  of	  switching	  
to	  appropriate	  isotypes.	  	  
Non-­‐germinal	  centre	  class	  switching	  
Class-­‐switching	  does	  not	  only	  occur	  in	  the	  germinal	  centre,	  and	  also	  not	  only	  TD	  
responses135.	  While	  it	  is	  true	  that	  IgM	  is	  the	  main	  isotype	  of	  immunoglobulin	  
produced	  during	  TI	  responses,	  it	  is	  by	  no	  means	  the	  only	  isotype.	  IgA	  switching,	  
for	  example,	  is	  seen	  rapidly	  in	  cultures	  of	  peritoneal	  B1	  cells	  stimulated	  with	  
LPS,	  BLyS	  (B	  lymphocyte	  stimulator,	  also	  called	  ‘BAFF’)	  and	  TGF-­‐β136.	  
TI	  class	  switching	  is	  enhanced	  by	  numerous	  soluble	  factors	  (fig	  1.4).	  The	  TNF	  
family	  members	  BLyS	  and	  APRIL	  (‘A	  proliferation	  inducing	  ligand’)	  are	  two	  of	  
these137,138.	  These	  factors	  bind	  to	  receptors	  expressed	  on	  B	  cells	  such	  as	  TACI	  
(‘transmembrane	  activator	  and	  CAML-­‐interactor’),	  BCMA	  (‘B	  cell	  maturation	  
antigen’)	  and	  (for	  BLyS)	  BAFF-­‐R	  (‘B	  cell	  activating	  factor	  receptor’)139,140.	  These	  
glycoproteins	  are	  expressed	  as	  both	  transmembrane	  proteins	  on	  the	  surface	  of	  
many	  innate	  cells,	  and	  also	  in	  soluble	  form	  from	  many	  cell	  types	  including	  
monocytes,	  dendritic	  cells	  and	  activated	  B	  cells88,141-­‐143.	  They	  play	  roles	  in	  many	  
areas	  of	  B	  cell	  biology:	  BLyS	  signalling	  is	  essential	  in	  the	  later	  stages	  of	  B	  cell	  
development	  and	  survival	  of	  mature	  B	  cells144,145,	  the	  regulation	  of	  B	  cell	  
homeostasis146,	  and	  plasma	  cell	  generation	  and	  survival88,147,148.	  Signals	  through	  
TACI	  on	  activated	  B	  cells	  also	  induce	  class	  switching	  to	  IgA	  or	  IgG	  isotypes,	  by	  
recruiting	  MyD88,	  which	  activates	  NF-­‐κB	  and	  subsequently	  AID149.	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It	  is	  known	  that	  dendritic	  cells,	  following	  stimulation	  with	  IFN-­‐γ,	  CD40L	  or	  
(more	  potently)	  IFN-­‐α,	  up	  regulate	  APRIL	  and	  BLyS138.	  This	  is	  especially	  true	  of	  
plasmacytoid	  dendritic	  cells	  stimulated	  with	  IFN-­‐α150.	  This	  facilitates	  class	  
switching	  to	  IgG,	  IgA	  or	  (when	  IL-­‐4	  is	  present)	  IgE138.	  Many	  other	  cell	  types	  
present	  in	  the	  red	  pulp	  of	  the	  spleen,	  including	  monocytes,	  macrophages,	  
eosinophils,	  neutrophils	  and	  others	  produce	  these	  factors88,143,151,152.	  
Epithelial	  cells,	  too,	  have	  been	  implicated	  in	  the	  release	  of	  factors	  that	  initiate	  
class	  switch	  recombination	  following	  TLR	  ligation	  at	  mucus	  membranes	  in	  a	  
mechanism	  that	  may	  be	  distinct	  from	  those	  described	  above153.	  	  
Mechanisms	  that	  act	  on	  germinal	  centre	  B	  cells	  in	  influencing	  class	  switching	  
are	  also	  important	  in	  non-­‐germinal	  centre	  class	  switching.	  B	  cell	  intrinsic	  TLR	  
stimulation	  during	  activation	  causes	  class	  switch	  recombination	  to	  occur,	  such	  
as	  stimulation	  through	  TLR9	  leading	  to	  switching	  to	  IgG2a154-­‐156.	  In	  humans	  at	  
least,	  this	  is	  enhanced	  by	  IL-­‐10155.	  	  
T	  cell	  help,	  too,	  is	  an	  important	  factor	  for	  class	  switching	  in	  TD	  extrafollicular	  
plasma	  cell	  responses.	  Toellner	  et	  al	  and	  Marshall	  et	  al	  showed	  that	  class	  
switching	  occurs	  before	  the	  differentiation	  of	  activated	  B	  cells	  to	  plasmablasts,	  
and	  is	  likely	  induced	  during	  interactions	  of	  activated	  T	  cells	  and	  B	  cells	  in	  the	  T	  
zone157,158.	  During	  this	  phase,	  it	  is	  likely	  that	  TLR	  signals,	  cytokines	  and	  further	  
signals	  from	  BLyS	  and	  APRIL	  control	  the	  class	  of	  antibody	  that	  is	  switched	  to.	  	  
In	  addition,	  Tfh-­‐like	  cells	  in	  the	  red	  pulp	  have	  been	  shown	  to	  induce	  class	  switch	  
recombination	  through	  their	  secretion	  of	  IL-­‐21,	  and	  expression	  of	  CD40L	  in	  
autoimmune	  mice159.	  Whether	  these	  T	  cells	  are	  important,	  or	  even	  induced,	  in	  
responses	  to	  exogenous	  antigen	  is	  not	  yet	  known.	  
Help	  For	  B	  cells	  in	  plasma	  cell	  responses	  
While	  TI	  plasma	  cell	  responses	  may	  require	  only	  signals	  through	  the	  TLR	  or	  
BCR,	  and	  TD	  responses	  require	  signals	  through	  the	  BCR	  and	  T	  cell	  help,	  there	  
are	  also	  soluble	  factors	  that	  can	  enhance	  the	  differentiation	  of	  B	  cells	  to	  plasma	  
cells	  (fig	  1.4).	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It	  has	  been	  known	  for	  some	  time	  that	  the	  cytokine	  IL-­‐21,	  from	  activated	  CD4	  T	  
cells,	  can	  support	  and	  enhance	  class-­‐switched	  antibody	  responses160,161.	  IL-­‐21-­‐/-­‐	  
mice	  exhibit	  reduced	  numbers	  of	  IgG	  plasma	  cells162.	  Interestingly,	  IL-­‐21	  
signalling	  must	  be	  in	  the	  context	  of	  BCR	  signalling,	  as	  naïve	  B	  cells	  which	  
encounter	  IL-­‐21	  are	  induced	  to	  die	  by	  apoptosis161,163,164.	  Although	  IL-­‐6	  was	  
originally	  thought	  to	  induce	  a	  similar	  enhancement	  in	  plasma	  cell	  generation,	  it	  
was	  found	  to	  be	  through	  IL-­‐6-­‐mediated	  increases	  in	  IL-­‐21165,	  although	  IL-­‐6	  does	  
act	  as	  a	  survival	  factor	  for	  plasma	  cells88,166.	  In	  extrafollicular	  and	  germinal	  
centre	  responses,	  IL-­‐21	  is	  provided	  by	  Tfh-­‐like	  and	  Tfh	  cells	  respectively	  during	  
T	  cell:B	  cell	  interactions,	  which	  may	  be	  dependent	  on	  ICOS	  signalling159,164.	  	  
In	  addition,	  IL-­‐21	  plays	  an	  important	  role	  in	  germinal	  centre	  formation,	  B	  
memory	  cell	  formation	  and	  long-­‐lived	  antibody	  responses161,167-­‐170.	  In	  seeming	  
contradiction,	  it	  is	  capable	  of	  causing	  the	  expression	  of	  Bcl-­‐6	  or	  BLIMP-­‐1	  in	  
germinal	  centre	  B	  cells	  that	  would	  lead	  to	  memory	  B	  cell	  or	  plasma	  cell	  fates	  
respectively161.	  It	  is	  likely	  that	  context	  is	  of	  great	  importance	  to	  the	  outcome	  of	  
IL-­‐21	  signalling	  in	  B	  cells.	  In	  humans,	  IL-­‐21	  in	  synergy	  with	  BLyS	  causes	  the	  
differentiation	  of	  marginal	  zone	  memory	  B	  cells	  to	  plasma	  cells,	  although	  it	  is	  
unknown	  whether	  BLyS	  affects	  the	  decision	  between	  memory	  B	  cell	  or	  plasma	  
cell	  fates	  in	  the	  germinal	  centre171.	  	  
IL-­‐6,	  secreted	  by	  CD11c+	  CD8-­‐	  myeloid	  dendritic	  cells	  in	  the	  secondary	  
lymphoid	  organs	  mediate	  the	  support	  of	  plasmablast	  populations88,172.	  It	  was	  
found	  that	  when	  large	  numbers	  of	  B	  cells	  were	  recruited	  into	  antibody	  
responses,	  they	  outgrew	  the	  available	  support	  from	  dendritic	  cells,	  and	  only	  
those	  in	  tight	  association	  survived172.	  Increased	  numbers	  of	  plasma	  cell	  
associated	  dendritic	  cells	  (through	  the	  injection	  of	  anti-­‐CD40,	  which	  causes	  
their	  proliferation)	  led	  to	  the	  generation	  of	  greater	  numbers	  of	  plasma	  cells	  due	  
to	  the	  support	  of	  increased	  levels	  of	  dividing	  plasmablasts	  for	  up	  to	  2	  days172-­‐174.	  
The	  TNF-­‐α	  family	  members	  APRIL	  and	  BLyS	  are	  known	  to	  support	  the	  
differentiation	  of	  plasma	  cells,	  however	  this	  is	  context	  dependent175,176.	  Signals	  
through	  BAFF-­‐R	  in	  synergy	  with	  BCR	  and	  CD40	  signalling	  leads	  to	  increased	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antibody	  responses177.	  However,	  signalling	  through	  TACI,	  lead	  to	  repression	  of	  
BLIMP-­‐1	  and	  reduced	  antibody	  levels	  in	  TD	  responses175.	  In	  contrast,	  mice	  
deficient	  in	  TACI	  have	  hyper-­‐responsive	  B	  cells	  which	  proliferate	  and	  
differentiate	  into	  plasma	  cells,	  causing	  SLE-­‐like	  disorders	  and	  cancers146.	  The	  
precise	  roles	  of	  these	  factors	  are	  still	  debated,	  as	  in	  vitro	  data	  and	  human	  
studies	  have	  provided	  confounding	  evidence140,178.	  
IFN-­‐α	  is	  a	  cytokine	  that	  has	  been	  shown	  to	  enhance	  the	  production	  of	  plasma	  
cells179.	  Although	  whether	  this	  is	  a	  direct	  effect	  is	  unknown;	  it	  may	  be	  a	  result	  of	  
stimulation	  of	  dendritic	  cells	  and	  the	  generation	  of	  increased	  levels	  of	  other	  
cytokines	  and	  soluble	  factors,	  including	  APRIL	  and	  BLyS138,179.	  It	  is	  also	  possible	  
that	  IFN-­‐α	  acts	  directly	  on	  B	  cells	  to	  induce	  their	  differentiation	  to	  plasma	  cells.	  
This	  has	  been	  shown	  by	  human	  in	  vitro	  data	  where	  IFN-­‐α	  secreting	  
plasmacytoid	  dendritic	  cells,	  cultured	  in	  combination	  with	  B	  cells	  activated	  with	  
anti-­‐CD40	  and	  IL-­‐6	  caused	  an	  enhanced	  differentiation	  to	  plasmablasts180.	  
Mathian	  et	  al	  have	  shown	  that	  IFN-­‐α	  causes	  early	  onset	  of	  SLE	  in	  lupus-­‐prone	  
(New	  Zealand	  Black	  x	  New	  Zealand	  White)F1	  mice	  due	  to	  the	  early	  and	  
enhanced	  production	  of	  short-­‐lived	  plasma	  cells181,182.	  This	  was	  not	  sufficient	  to	  
cause	  the	  induction	  of	  plasma	  cells	  in	  non-­‐autoimmune	  mice,	  and	  may	  be	  due	  to	  
increased	  levels	  of	  BLyS	  in	  the	  context	  of	  autoimmune	  activatory	  signals181.	  
Finally,	  CD4	  T	  cells	  provide	  cognate	  signals	  to	  B	  cells,	  which	  cause	  
differentiation	  to	  plasma	  cells	  as	  previously	  described.	  In	  extrafollicular	  plasma	  
cell	  responses,	  two	  populations	  of	  cells	  have	  been	  described;	  Tfh-­‐like	  cells	  that	  
express	  Bcl-­‐6	  and	  localise	  to	  the	  T-­‐B	  border	  or	  similar	  cells	  that	  localise	  to	  the	  
red	  pulp,	  require	  ICOS	  for	  their	  generation159,183.	  Whether	  these	  are	  two	  distinct	  
populations	  or	  one	  and	  the	  same	  is	  unknown.	  However,	  they	  both	  enhance	  
extrafollicular	  plasma	  cell	  responses	  through	  the	  provision	  of	  CD40L	  and	  IL-­‐
21159,183.	  In	  the	  germinal	  centre,	  Tfh	  provide	  these	  signals.	  The	  role	  of	  ICOS	  
during	  plasma	  cell	  development	  is	  less	  well	  defined.	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Models	  of	  humoral	  memory	  and	  plasma	  cell	  lifespan	  
Antibody	  levels	  following	  vaccination	  or	  infection	  are	  maintained	  for	  many	  
years.	  There	  are	  a	  number	  of	  models	  of	  how	  this	  is	  accomplished.	  Firstly,	  
antigen	  could	  be	  retained	  in	  the	  body,	  causing	  the	  periodic	  restimulation	  of	  
memory	  B	  cells	  and	  the	  generation	  of	  new	  plasma	  cells	  capable	  of	  maintaining	  
antibody	  levels	  to	  prior	  infections	  or	  vaccinations184,185.	  This	  idea	  initially	  was	  
popular	  as	  it	  was	  thought	  that	  all	  plasma	  cells	  were	  short-­‐lived,	  and	  that	  B	  
memory	  cells	  required	  antigen	  for	  their	  maintenance184,186.	  Similarly,	  antigen	  
has	  been	  shown	  to	  be	  retained	  in	  B	  cell	  follicles	  for	  long	  periods	  after	  a	  single	  
immunisation187.	  Secondly,	  Bernasconi	  et	  al	  showed	  that	  in	  vitro	  stimulation	  of	  
human	  B	  memory	  cells	  with	  TLR	  agonists	  lead	  to	  their	  differentiation	  to	  plasma	  
cells188.	  This	  data	  implied	  that	  memory	  B	  cells	  were	  induced,	  by	  polyclonal	  
stimulation,	  to	  generate	  new	  plasma	  cells	  specific	  for	  prior	  infections	  during	  
times	  of	  inflammation,	  which	  could	  ‘top	  up’	  waning	  plasma	  cell	  populations	  and	  
maintain	  serum	  antibody	  levels.	  Finally,	  the	  discovery	  of	  long-­‐lived	  plasma	  cells,	  
and	  strong	  evidence	  that	  suggests	  no	  requirement	  for	  B	  memory	  cells	  or	  antigen	  
for	  their	  maintenance	  has	  caused	  a	  shift	  in	  opinion189,190.	  	  
Long-­‐lived	  plasma	  cells	  maintain	  serum	  antibody	  
Early	  studies	  utilising	  thymidine	  labelling	  and	  retention	  of	  that	  label	  to	  measure	  
the	  turnover	  and	  lifespan	  of	  plasma	  cells	  indicated	  that	  mature	  plasma	  cells	  
were	  non-­‐dividing,	  and	  had	  a	  short	  half-­‐life	  of	  around	  8-­‐12	  hours186.	  These	  
studies,	  however,	  measured	  the	  lifespan	  of	  plasma	  cells	  generated	  at	  early	  time	  
points	  following	  immunisation.	  When	  studies	  were	  conducted	  looking	  at	  the	  
lifespan	  of	  plasma	  cells	  later	  in	  the	  response,	  it	  was	  found	  that	  some	  plasma	  
cells	  survived	  for	  far	  longer191.	  Later,	  Ho	  et	  al	  showed	  that	  plasma	  cells	  have	  
variable	  lifespan,	  some	  short-­‐lived	  (with	  a	  projected	  lifespan	  of	  less	  than	  3	  
days)	  and	  others	  long-­‐lived	  (in	  this	  study,	  a	  lifespan	  in	  excess	  of	  3	  weeks)192.	  
This	  was	  dependent	  on	  site	  rather	  than	  antibody	  class	  (with	  the	  exception	  of	  
IgM	  plasma	  cells,	  which	  were	  all	  short-­‐lived),	  and	  plasma	  cells	  in	  the	  spleen	  and	  
lymph	  nodes	  were	  found	  to	  be	  mainly	  short-­‐lived,	  whereas	  those	  in	  the	  bone	  
marrow	  were	  found	  to	  be	  mainly	  long-­‐lived192.	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In	  the	  late	  1990s,	  Manz	  et	  al	  showed	  that	  many	  plasma	  cells	  generated	  in	  the	  
secondary	  response	  to	  ovalbumin	  migrated	  to	  the	  bone	  marrow	  and	  persisted,	  
without	  cellular	  division	  for	  90	  days189.	  Similarly,	  Slifka	  et	  al	  tracked	  the	  
survival	  of	  LCMV-­‐specific	  plasma	  cells	  and	  antibody	  levels	  in	  mice	  following	  the	  
depletion	  of	  B	  memory	  cells	  (through	  irradiation),	  and	  the	  transfer	  of	  LCMV-­‐
specific	  plasma	  cells	  to	  naïve	  hosts.	  In	  both	  models	  it	  was	  found	  that	  LCMV-­‐
specific	  plasma	  cells	  survived	  for	  long	  periods	  without	  further	  input	  from	  the	  
peripheral	  B	  cell	  pool:	  with	  a	  half-­‐life	  of	  94	  days	  in	  the	  bone	  marrow,	  and	  172	  
days	  in	  the	  spleen193.	  These	  long-­‐lived	  plasma	  cells	  were	  found	  in	  both	  the	  
spleen	  and	  bone	  marrow,	  although	  far	  more	  in	  the	  latter193.	  	  
Further	  studies	  by	  Manz	  et	  al	  suggested	  that	  antigen	  was	  not	  required	  for	  the	  
maintenance	  of	  long-­‐lived	  plasma	  cells,	  and	  that	  long-­‐lived	  plasma	  cells	  were	  
unresponsive	  to	  restimulation	  with	  antigen,	  unlike	  memory	  B	  cells,	  which	  
rapidly	  provided	  new	  antigen-­‐specific	  plasma	  cells194.	  
Bernasconi	  et	  al	  showed	  that	  human	  B	  memory	  cells	  expressed	  TLRs	  
constitutively,	  and	  could	  be	  induced	  to	  differentiate	  to	  plasma	  cells	  when	  
stimulated	  through	  these	  receptors	  in	  vitro188,195.	  This	  data	  suggested	  that,	  even	  
in	  the	  absence	  of	  antigen,	  B	  memory	  cells	  could	  periodically	  be	  stimulated	  in	  a	  
polyclonal	  manner	  and	  ‘top	  up’	  plasma	  cell	  populations	  specific	  for	  prior	  
infections	  that	  would	  otherwise	  gradually	  wane.	  
In	  agreement,	  Slifka’s	  data	  suggested	  that	  the	  periodic	  restimulation	  of	  memory	  
B	  cells	  may	  contribute	  to	  the	  maintenance	  of	  antibody	  levels,	  as	  when	  memory	  
B	  cells	  were	  depleted	  by	  irradiation,	  numbers	  of	  long-­‐lived	  plasma	  cells	  fell	  
compared	  to	  levels	  in	  control	  (non-­‐irradiated)	  mice193.These	  initial	  studies	  by	  
Slifka	  et	  al	  were	  criticised,	  as	  the	  sub-­‐lethal	  irradiation	  used	  to	  deplete	  B	  
memory	  cells	  was	  not	  B	  cell	  specific,	  and	  may	  have	  affected	  other	  populations	  in	  
the	  bone	  marrow	  which	  supported	  plasma	  cell	  survival190.	  Therefore	  Ahuja	  et	  al	  
used	  anti-­‐CD20	  to	  deplete	  B	  cells	  (but	  not	  CD20-­‐	  plasma	  cells)	  from	  mice	  that	  
had	  been	  previously	  immunised	  with	  NP-­‐CGG.	  These	  data	  showed	  that	  numbers	  
of	  NP-­‐specific	  plasma	  cells	  did	  not	  fall	  in	  the	  bone	  marrow	  16-­‐weeks	  after	  B	  cell	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depletion	  (antibody	  levels	  were	  not	  shown)190.	  Similar	  studies	  by	  DiLillo	  et	  al	  
showed	  that	  following	  B	  cell	  depletion	  with	  anti-­‐CD20,	  previously	  established	  
populations	  of	  long-­‐lived	  bone	  marrow	  plasma	  cells	  were	  not	  affected196.	  
Interestingly,	  they	  showed	  that	  when	  bone	  marrow	  plasma	  cells	  were	  depleted	  
by	  the	  blockade	  of	  the	  intergrins	  LFA-­‐1	  and	  VLA-­‐4	  (described	  below),	  they	  were	  
replenished	  if	  B	  memory	  cells	  were	  present,	  but	  not	  if	  B	  memory	  cells	  were	  
depleted	  by	  co-­‐injection	  of	  anti-­‐CD20196.	  So,	  although	  B	  memory	  cells	  are	  not	  
required	  for	  the	  maintenance	  of	  plasma	  cells	  under	  homeostatic	  conditions,	  
they	  may	  play	  a	  role	  in	  maintaining	  these	  populations	  under	  certain	  
circumstances.	  This,	  however,	  is	  unlikely	  to	  be	  mediated	  by	  polyclonal	  
restimulation	  of	  memory	  B	  cells	  through	  TLRs,	  as	  Richard	  et	  al	  demonstrated	  
that	  TLR	  ligands	  alone	  were	  not	  sufficient	  to	  induce	  B	  memory	  cells	  to	  
differentiate	  to	  plasma	  cells	  in	  vivo.	  For	  this,	  antigen	  was	  an	  absolute	  
requirement197.	  
Short-­‐lived	  and	  long-­‐lived	  plasma	  cells	  
Short-­‐lived	  plasma	  cells	  are	  produced	  in	  large	  numbers	  during	  extrafollicular	  
responses	  and	  tend	  to	  reside	  in	  the	  red	  pulp	  of	  the	  spleen,	  or	  the	  medullary	  
chords	  of	  the	  lymph	  nodes78.	  The	  majority	  of	  plasma	  cells	  that	  home	  to	  the	  bone	  
marrow	  following	  primary	  immunisation	  with	  NP-­‐KLH	  have	  undergone	  somatic	  
hypermutation	  and	  therefore	  are	  high	  affinity	  cells	  emerging	  from	  germinal	  
centres198.	  These	  cells	  are	  produced	  in	  relatively	  low	  numbers	  following	  
primary	  immunisation	  with	  protein	  antigen,	  but	  far	  greater	  numbers	  following	  
secondary	  immunisation199,200.	  
Plasma	  cell	  migration	  
What	  determines	  whether	  plasma	  cells	  migrate	  to	  the	  bone	  marrow	  or	  stay	  in	  
the	  secondary	  lymphoid	  organs	  is	  not	  fully	  understood.	  Both	  extrafollicular	  
plasma	  cells	  and	  those	  emerging	  from	  germinal	  centres	  down	  regulate	  CXCR5	  
and	  CCR7	  (expressed	  by	  follicular	  B	  cells),	  and	  up	  regulate	  CXCR4,	  mediating	  
the	  migration	  towards	  the	  chemokine	  CXCL12	  from	  stromal	  cells78,84,85,201.	  This	  
attracts	  extrafollicular	  plasma	  cells	  towards	  the	  red	  pulp	  or	  medullary	  chords	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(alternatively	  this	  may	  simply	  be	  due	  to	  randomized	  linear	  movements202),	  
whereas	  long-­‐lived	  plasma	  cells	  migrate	  to	  the	  bone	  marrow	  via	  the	  blood.	  
Interestingly,	  CXCR4-­‐/-­‐	  mice	  show	  fewer	  plasma	  cells	  in	  the	  secondary	  lymphoid	  
organs	  and	  bone	  marrow,	  but	  more	  in	  the	  blood84,85.	  Plasma	  cell	  entry	  into	  the	  
blood	  stream	  may	  be	  regulated	  by	  the	  expression	  of	  ‘sphingosine-­‐1-­‐phosphate	  
receptor	  1’	  S1P1203.	  Plasma	  cell	  migration	  towards	  CXCL12,	  and	  the	  expression	  
of	  S1P1	  was	  found	  to	  be	  controlled	  by	  XBP-­‐1,	  although	  how	  this	  mediates	  
differential	  migration	  of	  extrafollicular	  and	  long-­‐lived	  plasma	  cells	  (when	  
expressed	  in	  both)	  is	  still	  unclear99.	  
Other	  chemokines,	  too,	  may	  be	  involved	  in	  plasma	  cell	  migration;	  CXCR3	  (and	  
its	  ligands	  CXCL9,	  CXCL10	  and	  CXCL11)	  mediate	  the	  migration	  of	  plasma	  cells	  to	  
inflamed	  sites84,201.	  CCR9	  expression	  by	  IgA	  plasma	  cells	  causes	  attraction	  to	  the	  
intestine,	  where	  its	  ligand	  CCL25	  is	  expressed84,204.	  
Plasma	  cells	  also	  express	  numerous	  adhesion	  molecules,	  including	  the	  
intergrins	  very	  late	  antigen	  4	  (VLA-­‐4)	  and	  leukocyte-­‐function	  associated	  
molecule	  1	  (LFA-­‐1)	  which	  adhere	  to	  vascular	  cell	  adhesion	  molecule	  1	  (VCAM-­‐
1)	  and	  intracellular	  adhesion	  molecule	  1	  (ICAM-­‐1)	  respectively205,	  expressed	  
throughout	  the	  red	  pulp	  of	  the	  spleen206.	  These	  ligands	  are	  also	  expressed	  
constitutively	  in	  the	  bone	  marrow207,208,	  and	  blockade	  of	  these	  molecules	  has	  
been	  shown	  to	  deplete	  bone	  marrow	  plasma	  cells196.	  Fibronectin,	  another	  ligand	  
for	  VLA-­‐4	  is	  also	  expressed	  in	  the	  splenic	  red	  pulp84.	  The	  role	  of	  these	  factors	  in	  
migration	  to	  the	  bone	  marrow	  is	  still	  unclear.	  
Selectins	  may	  play	  a	  role	  in	  plasma	  cell	  homing;	  plasma	  cells	  upregulate	  P-­‐
selectin	  glycoprotein	  ligand	  1	  (PSGL1),	  which	  binds	  both	  E	  and	  P	  selectins.	  This	  
mediates	  binding	  to	  the	  endothelium	  and	  is	  expressed	  constitutively	  by	  bone	  
marrow	  endothelial	  cells209,210.	  IgG	  plasma	  cells	  undergo	  rolling	  interactions	  
when	  cultured	  with	  E	  selectin205.	  CD22,	  a	  member	  of	  the	  siglec	  family	  
(immunoglobulin-­‐like	  lectins)	  that	  binds	  sialic	  acid,	  may	  be	  important	  for	  
migration	  to	  the	  bone	  marrow.	  In	  mature	  B	  cells	  this	  functions	  as	  a	  negative	  
regulator	  of	  BCR	  signalling,	  and	  is	  essential	  for	  homing	  to	  the	  bone	  marrow.	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CD22-­‐/-­‐	  mice	  however	  also	  exhibit	  reduced	  numbers	  of	  bone	  marrow	  plasma	  
cells84,211.	  
Plasma	  cells	  lose	  the	  ability	  to	  migrate	  towards	  chemokines	  during	  
maturation201.	  This	  occurs	  once	  they	  have	  reached	  either	  the	  red	  pulp	  or	  
medullary	  chords202,	  or	  entered	  the	  bone	  marrow,	  and	  despite	  their	  continued	  
expression	  of	  CXCR4201.	  Following	  this,	  it	  has	  been	  proposed	  that	  this	  receptor	  
plays	  a	  role	  in	  plasma	  cell	  survival166.	  It	  is	  unknown	  what	  mediates	  the	  loss	  of	  
migratory	  capacity	  in	  mature	  plasma	  cells.	  
Plasma	  cell	  survival	  niches	  
Plasma	  cells	  that	  home	  to	  the	  bone	  marrow	  are	  not	  inherently	  long-­‐lived.	  They	  
must	  be	  supported	  by	  a	  constant	  supply	  of	  survival	  factors	  (fig	  1.5).	  These	  are	  
available	  constitutively	  in	  the	  bone	  marrow	  in	  limited	  quantities,	  and	  therefore	  
the	  bone	  marrow	  plasma	  cell	  pool	  is	  of	  finite	  size166.	  Similarly,	  survival	  factors	  
are	  available	  at	  low	  levels	  in	  the	  secondary	  lymphoid	  organs	  during	  homeostatic	  
conditions,	  and	  some	  of	  these	  are	  drastically	  increased	  during	  times	  of	  
inflammation78,88,137.	  This	  allows	  for	  the	  long-­‐term	  survival	  of	  small	  numbers	  of	  
plasma	  cells	  during	  homeostasis,	  and	  the	  short-­‐term	  survival	  of	  large	  numbers	  
of	  plasma	  cells	  during	  inflammatory	  conditions.	  While	  much	  work	  has	  been	  
done	  recently	  on	  determining	  the	  survival	  factors	  required	  to	  support	  plasma	  
cells,	  the	  relative	  importance	  of	  each	  factor	  in	  each	  organ	  is	  still	  largely	  
unknown.	  
Survival	  factors	  
Many	  survival	  factors	  have	  been	  previously	  mentioned,	  as	  they	  are	  also	  
involved	  in	  other	  aspects	  of	  plasma	  cell	  biology.	  	  
APRIL	  is	  a	  key	  survival	  factor	  for	  plasma	  cells	  in	  both	  the	  bone	  marrow	  and	  
inflamed	  organs.	  On	  differentiation	  to	  plasma	  cells,	  BAFF-­‐R	  is	  down	  regulated	  
and	  TACI	  expression	  remains	  similar	  to	  B	  cells.	  BCMA,	  which	  has	  high	  affinity	  
for	  APRIL140,	  is	  up	  regulated88.	  APRIL	  is	  also	  able	  to	  bind	  the	  plasma	  cell	  surface	  
marker	  CD138,	  although	  it	  is	  unknown	  what	  the	  effects	  of	  this	  are212.	  BCMA	  
enhances	  the	  survival	  of	  bone	  marrow	  plasma	  cells	  when	  cultured	  in	  vitro213.	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That	  APRIL	  is	  secreted	  by	  many	  cells	  of	  the	  innate	  immune	  system88,151,	  as	  well	  
as	  activated	  B	  cells141,	  and	  VCAM-­‐1	  expressing	  bone	  marrow	  stromal	  cells214	  
means	  that	  it	  is	  rich	  in	  both	  the	  bone	  marrow,	  and	  in	  sites	  of	  inflammation.	  
While	  BLyS	  may	  mediate	  plasma	  cell	  survival	  in	  inflamed	  sites215,	  it	  is	  not	  
thought	  to	  be	  important	  for	  survival	  of	  bone	  marrow	  plasma	  cells148.	  
IL-­‐6	  was	  first	  shown	  to	  support	  plasma	  cell	  survival	  by	  Cassese	  et	  al;	  when	  
cultured	  in	  vitro	  plasma	  cells	  survived	  around	  3	  days	  longer	  when	  IL-­‐6	  was	  
present166.	  In	  the	  bone	  marrow,	  this	  IL-­‐6	  may	  come	  from	  stromal	  cells,	  as	  when	  
plasma	  cells	  were	  cultured	  with	  bone	  marrow	  stromal	  cells,	  they	  mediated	  the	  
survival	  of	  plasma	  cells	  for	  around	  4	  weeks216.	  Moreover,	  IL-­‐6-­‐/-­‐	  stromal	  cells	  
had	  greatly	  reduced	  capacity	  to	  support	  plasma	  cell	  survival216.	  This	  also	  may	  
be	  dependent	  on	  contact-­‐based	  signals,	  as	  the	  addition	  of	  anti-­‐VLA-­‐4	  to	  cultures	  
also	  disrupted	  stromal	  cell-­‐mediated	  survival216.	  Similarly,	  data	  from	  Winter	  
and	  Chu	  showed	  that	  megakaryocytes217	  and	  eosinophils151	  are	  both	  potent	  IL-­‐6	  
producers	  in	  the	  bone	  marrow	  and	  mediate	  the	  survival	  of	  long-­‐lived	  plasma	  
cells	  (although	  both	  also	  produce	  APRIL).	  The	  role	  of	  IL-­‐6	  in	  vivo,	  however,	  has	  
come	  into	  question.	  While	  early	  studies	  showed	  that	  excess	  IL-­‐6	  led	  to	  increased	  
numbers	  of	  IgG1	  plasma	  cells	  in	  multiple	  organs218,	  Cassese	  et	  al	  showed	  that	  
immunisation	  with	  ovalbumin	  in	  IL-­‐6	  sufficient	  or	  deficient	  mice	  lead	  to	  no	  
appreciable	  difference	  in	  numbers	  of	  OVA-­‐specific	  plasma	  cells	  or	  levels	  of	  
specific	  antibody	  after	  21	  weeks166.	  More	  recently,	  data	  from	  MacLennan’s	  
group	  showed	  that	  IL-­‐6	  is	  provided	  by	  CD11c+,	  CD8-­‐	  dendritic	  cells	  in	  the	  
inflamed	  lymph	  node,	  and	  that	  plasmablasts,	  but	  not	  mature	  plasma	  cells,	  
associate	  closely	  with	  these78,88,137,172.	  While	  the	  precise	  role	  of	  IL-­‐6	  still	  remains	  
unclear,	  it	  may	  support	  plasmablast	  growth	  in	  the	  inflamed	  secondary	  lymphoid	  
organs,	  and	  also	  act	  as	  a	  survival	  factor	  for	  long-­‐lived	  plasma	  cells	  in	  the	  bone	  
marrow.	  
While	  APRIL	  and	  IL-­‐6	  are	  the	  two	  main	  survival	  factors	  that	  have	  currently	  been	  
identified,	  limited	  data	  is	  also	  available	  for	  certain	  other	  factors.	  IL-­‐5	  was	  also	  
shown	  by	  Cassese	  et	  al	  to	  support	  plasma	  cell	  survival	  in	  vitro	  for	  up	  to	  three	  
days.	  However,	  when	  supernatants	  from	  IL-­‐5-­‐/-­‐	  bone	  marrow	  cultures	  were	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used	  to	  culture	  plasma	  cells,	  they	  were	  equally	  sufficient	  at	  supporting	  plasma	  
cell	  survival	  as	  supernatants	  from	  cultures	  of	  wild	  type	  bone	  marrow166.	  
Cassese	  et	  al	  also	  examined	  TNF-­‐α	  and,	  in	  vitro,	  it	  was	  found	  to	  provide	  survival	  
signals	  to	  plasma	  cells166.	  In	  vivo	  effects	  have	  not	  yet	  been	  explored.	  Finally,	  
CXCL12	  (usually	  associated	  with	  migration	  of	  plasma	  cells)	  may	  also	  mediate	  
survival	  of	  bone	  marrow	  plasma	  cells166.	  This	  chemokine	  is	  expressed	  by	  
stromal	  cells	  in	  the	  bone	  marrow,	  and	  many	  plasma	  cells	  are	  found	  to	  closely	  
associate	  with	  these	  cells219.	  However,	  studies	  utilising	  CXCL12	  blocking	  
antibodies	  showed	  that	  plasma	  cell	  survival	  in	  in	  vitro	  cultures	  with	  bone	  
marrow	  stromal	  cells	  was	  not	  affected	  by	  the	  lack	  of	  CXCR4	  signalling220.	  
Similarly,	  plasma	  cells	  in	  mice	  with	  a	  CXCR4	  deficiency	  in	  the	  B	  cell	  
compartment	  were	  found	  to	  populate	  the	  bone	  marrow	  and	  survive	  in	  normal	  
numbers	  90	  days	  after	  secondary	  immunisation	  with	  NP-­‐KLH,	  although	  their	  
migration	  there	  was	  delayed89,221.	  This	  highlights	  the	  apparent	  redundancy	  
between	  many	  factors,	  which	  in	  vitro	  are	  all	  capable	  of	  extending	  plasma	  cell	  
survival	  but	  in	  vivo	  may	  be	  of	  limited	  importance.	  
Contact	  based	  signals	  
As	  well	  as	  soluble	  factors	  that	  enhance	  plasma	  cell	  survival,	  contact	  based	  
signals	  may	  be	  important	  (fig	  1.4	  and	  1.5).	  Firstly	  VLA-­‐4:VCAM-­‐1	  and	  LFA-­‐
1:ICAM-­‐1	  are	  important	  adhesion	  molecules	  known	  to	  mediate	  the	  retention	  of	  
long-­‐lived	  plasma	  cells	  in	  the	  bone	  marrow6,196,205,222.	  Injection	  of	  blocking	  
antibodies	  causes	  a	  dramatic	  depletion	  of	  bone	  marrow	  plasma	  cells196.	  Plasma	  
cells	  are	  known	  to	  associate	  closely	  with	  VCAM-­‐1	  expressing	  stromal	  cells	  in	  the	  
bone	  marrow	  and	  areas	  rich	  in	  ICAM-­‐1	  and	  VCAM-­‐1	  in	  the	  spleen	  and	  lymph	  
node84.	  Blocking	  antibodies	  to	  VLA-­‐4	  caused	  the	  inhibition	  of	  antibody	  from	  
plasma	  cells	  cultured	  with	  bone	  marrow	  stromal	  cells216.	  However,	  the	  plasma	  
cell	  intrinsic	  signalling	  pathways	  and	  anti-­‐apoptotic	  factors	  that	  may	  be	  
generated	  by	  these	  interactions	  are	  not	  known.	  Indeed,	  these	  close	  associations	  
may	  be	  required	  simply	  to	  provide	  a	  constant	  supply	  of	  other	  survival	  factors.	  
CD44,	  another	  adhesion	  glycoprotein,	  is	  expressed	  on	  the	  surface	  of	  plasma	  
cells205.	  Its	  major	  ligand	  in	  vivo	  is	  hyaluronic	  acid	  (a	  component	  of	  the	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extracellular	  matrix	  produced	  by	  stromal	  cells)	  and	  it	  is	  associated	  with	  
trafficking	  cells	  to	  the	  bone	  marrow223.	  In	  vitro	  cultures	  of	  plasma	  cells	  with	  
antibody	  capable	  of	  cross-­‐linking	  CD44,	  or	  with	  hyaluronic	  acid,	  showed	  
significant	  enhancement	  in	  plasma	  cell	  survival	  over	  5	  days,	  which	  was	  further	  
enhanced	  by	  the	  addition	  of	  IL-­‐6166.	  Interestingly,	  interactions	  between	  CD44	  
expressing	  myeloma	  cells	  and	  the	  extracellular	  matrix	  causes	  the	  secretion	  of	  
IL-­‐6	  from	  stromal	  cells	  in	  the	  bone	  marrow224.	  So,	  plasma	  cells	  may	  induce	  the	  
secretion	  of	  survival	  factors	  from	  bone	  marrow	  stromal	  cells.	  
Finally,	  CD28,	  a	  co-­‐receptor	  associated	  with	  TCR	  signalling	  is	  expressed	  on	  all	  
plasma	  cells225.	  This	  molecule,	  however,	  is	  only	  functional	  in	  long-­‐lived	  plasma	  
cells,	  and	  ligation	  of	  CD28	  by	  CD80	  or	  CD86	  on	  bone	  marrow	  dendritic	  cells	  was	  
found	  to	  be	  important	  for	  maintaining	  plasma	  cell	  populations	  in	  the	  bone	  
marrow226.	  Interestingly,	  ligation	  of	  CD80/86	  by	  CD28	  has	  also	  been	  shown	  to	  
mediate	  the	  secretion	  of	  IL-­‐6	  by	  dendritic	  cells227,	  and	  indeed,	  Rozanski	  et	  al	  
showed	  that	  in	  vitro,	  plasma	  cells	  were	  able	  to	  cause	  the	  secretion	  of	  IL-­‐6	  by	  
these	  cells226.	  In	  addition,	  the	  culture	  of	  plasma	  cells	  with	  wild	  type	  or	  IL-­‐6-­‐/-­‐	  
bone	  marrow	  dendritic	  cells	  showed	  that,	  while	  dendritic	  cells	  were	  sufficient	  to	  
mediate	  survival	  of	  plasma	  cells	  for	  up	  to	  30	  days,	  IL-­‐6	  was	  required	  to	  mediate	  
the	  secretion	  of	  IgG.	  	  
Survival	  niches	  in	  the	  bone	  marrow	  
Many	  of	  the	  cell	  types	  associated	  with	  plasma	  cell	  survival	  have	  been	  previously	  
mentioned,	  however,	  they	  will	  be	  summarised	  here.	  It	  should	  be	  stressed	  that	  
their	  characterisation	  is	  incomplete;	  many	  cell	  types	  have	  been	  indicated	  to	  be	  
essential	  for	  the	  maintenance	  of	  plasma	  cell	  populations,	  but	  it	  is	  still	  not	  
entirely	  clear	  whether	  soluble	  factors	  (from	  any	  cellular	  source)	  or	  specific	  
contact-­‐dependent	  signals	  are	  required	  for	  survival,	  and	  whether	  the	  signals	  
described	  above	  act	  cumulatively	  or	  redundantly	  (fig	  1.4	  and	  1.5).	  
Eosinophils	  were	  identified	  by	  Chu	  et	  al	  as	  necessary	  for	  the	  maintenance	  of	  
bone	  marrow	  plasma	  cell	  populations151.	  These	  Gr1int	  F4/80hi	  CD11bint	  cells	  
expressed	  both	  APRIL	  and	  IL-­‐6	  and	  were	  capable	  of	  supporting	  plasma	  cells	  in	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vitro151.	  Similarly,	  bone	  marrow	  plasma	  cells	  in	  vivo	  were	  closely	  associated	  
with	  eosinophils	  and	  the	  depletion	  of	  these	  cells	  caused	  the	  apoptosis	  of	  bone	  
marrow	  plasma	  cells151.	  
In	  a	  similar	  set	  of	  experiments,	  Winter	  et	  al	  showed	  that	  platelet	  forming,	  
CD41+	  megakaryocytes	  also	  secreted	  both	  APRIL	  and	  IL-­‐6	  and	  associated	  
closely	  with	  OVA-­‐specific	  plasma	  cells	  in	  the	  bone	  marrow	  following	  
immunisation217.	  Mice	  deficient	  in	  megakaryocytes	  (thrombopoietin	  receptor	  
knockouts)	  had	  reduced	  numbers	  of	  antigen-­‐specific	  bone	  marrow	  plasma	  cells	  
following	  OVA	  immunisation,	  whereas	  the	  injection	  of	  thrombopoietin	  
(inducing	  increased	  numbers	  of	  megakaryocytes)	  caused	  the	  accumulation	  of	  
greater	  numbers.	  
Stromal	  cells,	  as	  mentioned	  above,	  have	  been	  shown	  to	  support	  plasma	  cell	  
survival	  in	  vitro.	  Again,	  a	  high	  percentage	  (around	  90%)	  of	  bone	  marrow	  plasma	  
cells	  form	  tight	  associations	  with	  CXCL12-­‐secreting	  bone	  marrow	  stromal	  
cells219	  and	  express	  VCAM-­‐1214.	  These	  cells	  however,	  express	  only	  low	  amounts	  
of	  APRIL148.	  It	  may	  be	  that	  plasma	  cells	  require	  a	  complex	  niche,	  made	  up	  of	  
stromal	  cells	  with	  which	  they	  are	  able	  to	  form	  tight	  associations	  through	  VLA-­‐
4:VCAM-­‐1,	  and	  the	  expression	  of	  CXCL12.	  Other	  cells	  such	  as	  megakaryocytes,	  
eosinophils	  and	  others	  may	  then	  provide	  other	  necessary	  survival	  factors	  such	  
as	  APRIL	  and	  IL-­‐6.	  
Survival	  niches	  in	  inflamed	  organs	  
It	  is	  thought	  that	  short-­‐lived	  and	  long-­‐lived	  plasma	  cells	  are	  distinct	  
populations.	  This	  may	  be	  true,	  however	  recent	  work	  has	  shown	  that	  many	  
plasma	  cells	  can	  exhibit	  enhanced	  survival	  in	  vivo	  when	  the	  supply	  of	  survival	  
factors	  is	  great	  enough,	  as	  seen	  under	  inflammatory	  conditions	  in	  secondary	  
lymphoid	  organs	  and	  non-­‐immune	  organs78,88,228,229.	  The	  survival	  factors	  
required	  in	  peripheral	  organs	  are	  much	  the	  same	  as	  those	  in	  the	  bone	  marrow,	  
although	  so	  far	  only	  the	  effects	  of	  APRIL	  and	  IL-­‐6	  have	  been	  characterised88.	  	  
In	  the	  inflamed	  lymph	  node	  and	  spleen,	  the	  majority	  of	  IL-­‐6	  is	  provided	  by	  
dendritic	  cells,	  which	  localise	  to	  and	  proliferate	  in	  the	  medullary	  chords	  and	  red	  
Chapter	  1	  -­‐	  Introduction	  
	   32	  
pulp,	  in	  close	  proximity	  to	  the	  bridging	  channels	  and	  perivascular	  areas	  (where	  
plasmablasts	  emerge	  from	  the	  follicle)78,81,88,172.	  As	  described	  previously,	  IL-­‐6	  at	  
this	  site	  supports	  the	  continued	  expansion	  of	  dividing	  plasmablasts.	  	  
CD11bhi,	  F4/80hi,	  Gr1hi	  monocytes	  and	  macrophages	  rapidly	  influx	  into	  the	  
secondary	  lymphoid	  organs	  under	  inflammatory	  conditions,	  colonising	  the	  
medullary	  chords	  of	  the	  lymph	  node	  and	  red	  pulp	  of	  the	  spleen78,88.	  These	  cells	  
produce	  high	  amounts	  of	  APRIL	  and	  are	  closely	  associated	  with	  mature	  plasma	  
cells88.	  Macrophages	  are	  present	  in	  the	  red	  pulp	  in	  lower	  numbers	  during	  
homeostatic	  conditions230,231,	  explaining	  the	  survival	  of	  low	  numbers	  of	  plasma	  
cells	  for	  long	  periods	  in	  the	  secondary	  lymphoid	  organs193.	  
Similarly,	  neutrophils88,143	  and	  basophils232	  have	  been	  identified	  as	  cells	  capable	  
of	  supporting	  the	  survival	  of	  plasma	  cells	  in	  mice	  and	  humans,	  through	  their	  
secretion	  of	  APRIL	  and	  IL-­‐6	  respectively143,232.	  
All	  of	  these	  cellular	  populations	  are	  also	  present	  in	  the	  bone	  marrow,	  and	  their	  
roles	  in	  that	  organ	  are	  yet	  to	  be	  determined.	  That	  innate	  cells	  produce	  many	  of	  
the	  survival	  factors	  required	  for	  plasma	  cell	  survival	  is	  intriguing;	  their	  influx	  to	  
secondary	  lymphoid	  organs	  (and	  non-­‐immune	  sites)	  during	  inflammatory	  
conditions	  allows	  for	  the	  temporary	  support	  of	  large	  numbers	  of	  plasma	  cells.	  
These	  cells	  provide	  large	  amounts	  of	  antibody	  until	  the	  inflammation	  is	  
resolved,	  at	  which	  point	  survival	  factors	  return	  to	  low	  levels,	  allowing	  for	  the	  
survival	  of	  only	  very	  few	  plasma	  cells	  at	  these	  sites.	  By	  this	  stage,	  however,	  
germinal	  centre	  formation	  has	  occurred	  in	  TD	  responses	  and	  high	  affinity	  
plasma	  cells	  that	  migrate	  to	  the	  bone	  marrow	  have	  been	  produced.	  In	  this	  
organ,	  levels	  of	  survival	  factors	  remain	  at	  a	  constant	  level,	  allowing	  for	  the	  long-­‐
term	  survival	  of	  any	  plasma	  cells	  that	  are	  able	  to	  enter	  a	  survival	  niche	  there.	  
These	  plasma	  cells	  are	  then	  able	  to	  maintain	  serum	  antibody	  levels	  for	  months	  
to	  years.	  
Effects	  of	  survival	  factors	  
While	  many	  of	  the	  survival	  factors	  required	  for	  the	  support	  of	  plasma	  cells	  have	  
been	  determined,	  less	  is	  known	  about	  their	  downstream	  actions.	  While	  in	  B	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cells,	  Bcl-­‐2	  (‘B	  cell	  lymphoma	  2’)	  and	  Bcl-­‐xL	  (‘B	  cell	  lymphoma	  extra	  large’)	  are	  
common	  anti-­‐apoptotic	  factors233	  induced	  by	  survival	  signals	  such	  as	  
CD40:CD40L	  and	  IL-­‐10	  during	  germinal	  centre	  reactions109,234,235,	  and	  by	  BLyS	  
signalling236-­‐240.	  Relatively	  little	  work	  has	  been	  done	  on	  the	  anti-­‐apoptotic	  
factors	  induced	  in	  plasma	  cells	  by	  survival	  factors.	  However	  data	  from	  multiple	  
myeloma	  patients	  and	  cell	  lines	  (a	  human	  condition	  where	  malignant	  plasma	  
cells	  accumulate	  to	  high	  numbers	  in	  the	  bone	  marrow)	  has	  shown	  that	  another	  
anti-­‐apoptotic	  factor,	  MCL-­‐1	  (‘Myeloid	  leukaemia	  cell	  differentiation	  protein	  1’),	  
and	  Bcl-­‐xL	  are	  both	  important	  to	  the	  survival	  of	  neoplastic	  plasma	  cells241,242.	  
Interestingly,	  onset	  of	  multiple	  myeloma	  is	  associated	  with	  increased	  levels	  of	  
IL-­‐6243,244,	  and	  the	  increased	  levels	  of	  MCL-­‐1	  and	  BC-­‐xL	  seen	  in	  bone	  marrow	  
plasma	  cells	  are	  IL-­‐6	  dependent241.	  In	  mice,	  O’Connor	  et	  al	  showed	  that	  
signalling	  through	  BCMA	  on	  bone	  marrow	  plasma	  cells	  induced	  MCL-­‐1	  
expression213.	  In	  addition,	  IL-­‐6	  may	  have	  additional	  survival	  effects	  on	  myeloma	  
cells	  that	  is	  independent	  of	  MCL-­‐1	  or	  Bc-­‐xL,	  including	  the	  STAT-­‐3	  dependent	  
activation	  of	  the	  micro-­‐RNA	  miR-­‐21244.	  The	  effects	  of	  IL-­‐6	  on	  normal	  human	  or	  
mouse	  bone	  marrow	  plasma	  cells’	  expression	  of	  MCL-­‐1	  and	  Bc-­‐xL	  remains	  to	  be	  
seen.	  
Limited	  survival	  niches	  lead	  to	  competition	  
The	  bone	  marrow	  plasma	  cell	  compartment,	  like	  other	  memory	  pools,	  is	  of	  
limited	  size.	  A	  finite	  amount	  of	  survival	  factors	  means	  that	  only	  a	  limited	  
number	  of	  plasma	  cells	  can	  be	  maintained	  in	  the	  bone	  marrow	  
compartment89,166,185,245,246.	  Although	  levels	  of	  these	  factors	  increase	  during	  
inflammatory	  episodes	  in	  other	  organs,	  once	  inflammation	  is	  resolved,	  these	  
levels	  once	  again	  decline88.	  This	  mediates	  competition	  between	  previously	  
established	  plasma	  cells,	  and	  newly	  generated	  plasma	  cells.	  In	  the	  human	  bone	  
marrow,	  this	  is	  thought	  to	  be	  around	  0.1-­‐1	  percent	  of	  total	  cells247.	  Estimates	  
from	  Radbruch	  et	  al	  are	  that	  the	  human	  bone	  marrow	  is	  capable	  of	  supporting	  
around	  1000	  specificities	  of	  plasma	  cells	  in	  substantial	  enough	  numbers	  to	  
provide	  effective	  serum	  antibody	  levels248.	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It	  has	  been	  observed	  in	  human	  patients	  vaccinated	  with	  tetanus	  toxoid	  that	  
mature	  plasma	  cells	  which	  are	  not	  specific	  for	  the	  immunising	  antigen	  can	  be	  
detected	  entering	  the	  blood	  stream	  at	  the	  same	  time	  as	  the	  newly	  generated	  
tetanus	  toxoid-­‐specific	  plasmablasts	  enter	  the	  bone	  marrow	  compartment249.	  It	  
is	  speculated	  that	  these	  are	  pre-­‐existing	  plasma	  cells	  (established	  in	  previous	  
immune	  responses)	  that	  have	  been	  displaced	  from	  their	  bone	  marrow	  survival	  
niches248,249.	  However,	  further	  estimations	  from	  Radbruch	  et	  al	  state	  that	  after	  
almost	  700	  subsequent	  immune	  responses,	  serum	  antibody	  levels	  to	  a	  
particular	  immunisation	  would	  only	  have	  declined	  to	  around	  50	  percent	  of	  its	  
original	  levels248.This	  is	  supported	  by	  data	  from	  Amanna	  et	  al,	  who	  show	  that	  
anti-­‐viral	  antibody	  responses	  in	  humans	  had	  half-­‐lives	  ranging	  from	  50	  to	  200	  
years,	  whereas	  those	  to	  tetanus	  and	  diphtheria	  were	  of	  11	  and	  19	  years	  
respectively250.	  	  
The	  precise	  mechanism	  mediating	  competition	  between	  plasma	  cells	  is	  
unknown,	  however	  it	  is	  thought	  that	  the	  ability	  of	  newly	  generated	  
plasmablasts	  to	  migrate	  towards	  plasma	  cell	  niches	  may	  confer	  an	  advantage	  
over	  previously	  established,	  non-­‐migratory	  plasma	  cells249.	  There	  may	  be	  
additional	  mechanisms;	  plasma	  cells	  express	  the	  death	  receptor	  FcγRIIb	  which,	  
when	  cross-­‐linked	  by	  IgG	  immune	  complexes,	  causes	  their	  apoptosis38.	  It	  could	  
be	  that	  increased	  levels	  of	  immune	  complexes	  during	  immune	  responses	  causes	  
the	  death	  of	  certain	  bone	  marrow	  plasma	  cells,	  creating	  space	  for	  the	  entry	  of	  
new	  plasma	  cells,	  although	  this	  is	  yet	  to	  be	  shown.	  	  
Plasma	  cells	  in	  autoimmunity	  
There	  is	  evidence	  that	  not	  all	  plasma	  cells	  are	  equally	  sufficient	  at	  obtaining	  
access	  to	  survival	  factors	  or	  plasma	  cell	  niches.	  Rituximab	  is	  an	  anti-­‐human	  
CD20	  antibody	  used	  to	  deplete	  B	  cells	  in	  patients	  suffering	  from	  certain	  
autoimmune	  diseases.	  This	  treatment,	  originally	  designed	  to	  treat	  B	  cell	  
lymphomas,	  is	  now	  often	  used	  to	  reduce	  levels	  of	  circulating	  autoantibodies	  by	  
the	  depletion	  of	  CD20+	  peripheral	  B	  cells.	  CD20-­‐	  short-­‐lived	  autoantibody-­‐
secreting	  plasma	  cells	  that	  are	  generated	  continuously	  by	  B	  cells	  activated	  by	  an	  
unlimited	  supply	  of	  self-­‐antigen	  would	  no	  longer	  be	  generated	  in	  the	  absence	  of	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a	  B	  cell	  compartment251-­‐258.	  It	  was	  found	  that	  in	  rheumatoid	  arthritis	  patients,	  
autoantibody	  levels	  fell	  while	  antibodies	  to	  prior	  vaccinations	  and	  infections	  
were	  maintained	  by	  long-­‐lived	  plasma	  cells253.	  	  
For	  other	  autoimmune	  conditions,	  too,	  this	  was	  the	  case,	  as	  documented	  by	  
Ferraro	  et	  al	  who	  showed	  a	  dramatic	  drop	  in	  the	  levels	  of	  autoantibodies	  
specific	  for	  protinase-­‐3	  in	  patients	  with	  active	  vasculitis	  that	  received	  rituximab	  
therapy259.	  Conversely,	  little	  decline	  was	  found	  in	  levels	  of	  antibodies	  specific	  
for	  external	  antigens	  (either	  TD	  or	  TI).	  The	  decline	  in	  autoantibody,	  however,	  
occurred	  over	  a	  5-­‐month	  period.	  This	  suggests	  that	  while	  autoantibody-­‐
secreting	  cells	  are	  able	  to	  persist	  in	  inflamed	  organs,	  they	  do	  not	  enter	  the	  bone	  
marrow	  compartment,	  and	  die	  as	  inflammation	  is	  resolved259.	  	  
In	  agreement	  with	  this	  data,	  studies	  by	  Huang	  et	  al	  showed	  that,	  in	  K/BxN	  mice	  
(a	  murine	  model	  of	  rheumatoid	  arthritis,	  described	  below),	  which	  generate	  
significant	  splenic	  populations	  of	  plasma	  cells	  secreting	  antibody	  specific	  for	  the	  
ubiquitously	  expressed	  enzyme	  glucose-­‐6-­‐phosphate-­‐isomerase	  (G6PI)260,	  the	  
vast	  majority	  of	  G6PI-­‐specific	  plasma	  cells	  were	  short-­‐lived	  and	  resided	  in	  the	  
spleen	  and	  lymph	  nodes261.	  When	  these	  mice	  co-­‐expressed	  mouse	  and	  human	  
CD20,	  and	  were	  treated	  with	  rituximab,	  B	  cells	  were	  rapidly	  depleted	  and	  G6PI-­‐
specific	  plasma	  cells	  and	  antibody	  levels	  fell	  over	  the	  course	  of	  120	  days261.	  
While	  effective	  in	  certain	  autoimmune	  diseases,	  sufferers	  of	  SLE	  did	  not	  
comprehensively	  exhibit	  reduced	  autoantibody	  titres251-­‐253.	  SLE	  patients	  exhibit	  
plasma	  cells	  secreting	  autoantibodies	  specific	  for	  self-­‐DNA	  and	  self-­‐RNA262.	  
While	  self-­‐DNA	  specific	  antibody	  levels	  fall	  following	  treatment	  with	  rituximab	  
(and	  therefore	  DNA-­‐specific	  plasma	  cells	  are	  likely	  to	  be	  short-­‐lived),	  anti-­‐RNA	  
antibodies	  do	  not	  fall,	  meaning	  that	  self-­‐RNA	  specific	  plasma	  cells	  are	  likely	  to	  
be	  long-­‐lived262.	  The	  TLR	  ligands	  involved	  in	  the	  initiation	  of	  these	  autoimmune	  
conditions	  are,	  as	  described	  previously,	  recognised	  by	  TLR7	  (RNA)	  and	  TLR9	  
(double	  stranded	  DNA).	  TLR7,	  when	  used	  as	  an	  adjuvant,	  has	  been	  shown	  to	  be	  
a	  potent	  inducer	  of	  persistent	  antibody	  responses263.	  Additionally,	  treatment	  of	  
SLE	  patients	  with	  belimumab,	  which	  blocks	  the	  binding	  of	  BLyS	  to	  BAFF-­‐R	  and	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TACI	  has	  shown	  more	  efficient	  reductions	  in	  anti-­‐RNA	  antibodies264.	  Trials	  with	  
atacicept,	  an	  APRIL-­‐blocking	  antibody,	  are	  ongoing265.	  
Studies	  in	  mice	  have	  shown	  similar,	  although	  not	  identical,	  results.	  Studies	  from	  
Rudolf	  Manz’s	  lab	  using	  the	  (NZBxNZW)F1	  model	  of	  SLE	  showed	  that	  plasma	  
cells	  were	  greatly	  expanded	  in	  the	  spleens	  and	  kidneys	  of	  these	  mice.	  Around	  40	  
percent	  of	  these	  were	  non-­‐dividing	  and	  resistant	  to	  treatment	  with	  
cyclophosphamide228,229,266.	  Of	  the	  anti-­‐DNA	  component	  of	  the	  plasma	  cell	  
response,	  only	  around	  20	  percent	  were	  in	  the	  long-­‐lived,	  non-­‐dividing	  
compartment,	  as	  determined	  by	  BrdU	  labelling228.	  	  
These	  results	  paint	  a	  complex	  picture	  of	  the	  ability	  of	  certain	  plasma	  cells,	  
especially	  those	  generated	  during	  autoimmune	  disease,	  to	  become	  long-­‐lived.	  
The	  reasons	  for	  this	  will	  require	  further	  experimentation.	  	  	  
Plasma	  cells	  as	  APC	  
Despite	  their	  down-­‐regulation	  of	  antigen	  presenting	  molecules	  such	  as	  MHC	  II,	  
CD80	  and	  CD86,	  Pelletier	  et	  al	  recently	  showed	  that	  plasma	  cells,	  were	  capable	  
of	  presenting	  antigen	  to,	  and	  activating,	  CD4	  T	  cells	  in	  vivo267.	  However,	  CD4	  T	  
cells	  activated	  by	  plasma	  cells	  did	  not	  express	  Bcl-­‐6	  or	  differentiate	  to	  Tfh	  cells,	  
likely	  due	  to	  a	  lack	  of	  IL-­‐21	  production	  by	  plasma	  cells267.	  Mice	  lacking	  plasma	  
cells	  also	  had	  increased	  numbers	  of	  Tfh267.	  This	  may	  provide	  a	  negative	  
feedback	  loop	  that	  limits	  humoral	  immunity.	  Whether	  plasma	  cells	  play	  a	  role	  in	  
recall	  responses	  or	  not	  is	  unknown.	  
Models	  used	  throughout	  this	  thesis	  
Salmonella	  
In	  this	  project	  we	  have	  used	  infection	  with	  the	  aro-­‐A-­‐	  attenuated	  strain	  of	  
Salmonella	  enterica	  serovar	  Typhimurium	  (also	  called	  SL3261).	  This	  strain	  is	  
commonly	  used	  as	  a	  live-­‐attenuated	  vaccine	  strain,	  and	  confers	  protection	  to	  
future	  infections	  with	  virulent	  strains268.	  Salmonella	  is	  a	  Gram-­‐negative	  
intracellular	  bacterium	  that	  infects	  humans	  orally.	  From	  here	  they	  enter	  the	  
Peyer’s	  patches	  via	  the	  type	  III	  secretion	  system,	  and	  through	  the	  mesenteric	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lymph	  nodes	  to	  the	  blood	  stream,	  after	  which	  they	  rapidly	  become	  
systemic269,270.	  The	  bacteria	  reside	  and	  multiply	  mainly	  in	  macrophage	  
populations.	  
Here,	  mice	  have	  been	  infected	  with	  Salmonella	  intravenously.	  While	  this	  is	  not	  
the	  route	  of	  infection	  seen	  in	  natural	  infections,	  there	  are	  a	  number	  of	  
justifications	  for	  using	  this	  method.	  Firstly,	  here	  we	  have	  simply	  used	  
Salmonella	  as	  a	  model	  of	  bacterial	  infection,	  and	  would	  hope	  that	  any	  
observations	  seen	  here	  may	  apply	  to	  infection	  with	  other	  similar	  bacteria.	  
Secondly,	  as	  the	  bacteria	  rapidly	  become	  systemic,	  infecting	  intravenously	  
should	  not	  provide	  wildly	  differing	  results	  to	  oral	  infection.	  Thirdly,	  our	  own	  
experiments	  have	  shown	  that	  oral	  infection	  provides	  a	  more	  variable	  dose	  that	  
can	  be	  controlled	  more	  tightly	  by	  intravenous	  injection	  (D.	  Gray	  unpublished	  
observations).	  	  
Infection	  with	  live	  Salmonella	  is	  initially	  controlled	  by	  macrophage	  
populations271.	  However,	  systemic	  infection	  generates	  a	  potent	  Th1	  response	  
and	  the	  cytokines	  produced	  (IFN-­‐γ,	  TNF-­‐α	  and	  IL-­‐12)	  are	  all	  crucial	  to	  
controlling	  infection272-­‐274.	  Similarly,	  TLR4	  signalling	  is	  key	  in	  controlling	  
bacterial	  loads,	  as	  C3HeJ	  mice	  (which	  cannot	  respond	  to	  LPS)	  are	  susceptible	  to	  
infection275;	  this	  is	  thought	  to	  be	  due	  to	  a	  lack	  of	  TLR4-­‐dependent	  cytokine	  
production276.	  TLR2	  is	  also	  is	  important	  later	  in	  the	  infection277.	  Similarly,	  
MyD88-­‐/-­‐	  mice	  exhibit	  significantly	  higher	  bacterial	  loads	  due	  to	  reduced	  IL-­‐12	  
and	  Th1	  cytokines44,278,279. 
B	  cells	  are	  not	  necessary	  for	  the	  primary	  responses	  to	  Salmonella	  but	  are	  
required	  for	  protection	  in	  secondary	  infections44,280.	  This	  is	  surprising,	  as	  the	  
plasma	  cell	  response	  in	  the	  spleens	  of	  infected	  mice	  is	  considerable.	  TI	  B1b	  cells	  
contribute	  to	  the	  early	  plasma	  cells	  response	  and	  secrete	  antibody	  specific	  for	  
outer	  membrane	  protein	  porins	  (OMP)	  C,	  D	  and	  F,	  which	  is	  capable	  of	  impairing	  
infection76.	  A	  TD	  plasma	  cell	  response	  also	  occurs	  in	  the	  spleen,	  which	  is	  mainly	  
class-­‐switched	  to	  IgG2c,	  but	  does	  not	  arise	  from	  germinal	  centres281.	  B	  cell	  
intrinsic	  signals	  through	  MyD88	  are	  required	  for	  the	  switch	  to	  IgG2c,	  and	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without	  these	  switching	  to	  IgG1	  occurs56.	  This	  response	  persists	  for	  around	  5-­‐
weeks	  without	  germinal	  centres,	  of	  which	  formation	  is	  considerably	  delayed	  in	  
Salmonella	  infected	  mice.	  This	  delay	  in	  germinal	  centres	  would	  appear	  to	  
correlate	  to	  bacterial	  load:	  when	  bacterial	  loads	  were	  decreased	  prematurely	  by	  
treating	  with	  antibiotic,	  germinal	  centres	  were	  found	  to	  arise	  earlier281.	  
Although	  not	  necessary	  for	  protection,	  antibody	  from	  these	  plasma	  cells	  does	  
impede	  the	  invasion	  of	  macrophages	  by	  Salmonella	  bacteria,	  and	  reduces	  
bacterial	  loads	  in	  the	  blood281.	  Interestingly,	  Salmonella-­‐specific	  antibody	  levels	  
remains	  low	  in	  infected	  mice	  until	  around	  4-­‐5	  weeks	  after	  infection,	  as	  plasma	  
cell	  numbers	  decline	  and	  germinal	  centres	  appear56,	  and	  high	  affinity	  
Salmonella-­‐specific	  antibody	  remains	  almost	  undetectable	  until	  this	  point281.	  
Further	  experiments	  are	  required	  to	  clarify	  the	  specificity	  of	  the	  large	  numbers	  
of	  plasma	  cells	  produced	  during	  the	  extrafollicular	  plasma	  cell	  response	  to	  
Salmonella.	  
K/BxN	  mice	  
K/BxN	  mice	  are	  a	  cross	  between	  KRN-­‐C57Bl/6	  mice	  (which	  express	  a	  TCR	  
transgenic	  for	  a	  bovine	  ribonuclease	  (RNase	  42-­‐56)	  presented	  by	  the	  I-­‐Ak	  MHC	  
II	  molecule,	  and	  the	  autoimmune-­‐prone	  non-­‐obese	  diabetic	  (NOD)	  mice.	  This	  
led	  to	  the	  unexpected	  finding	  that	  the	  KRN	  TCR	  recognised	  the	  ubiquitously	  
expressed	  enzyme	  glucose-­‐6-­‐phosphate	  isomerase	  (G6PI)	  on	  the	  NOD-­‐derived	  
Ag7	  MHC	  II	  molecule282.	  A	  proportion	  of	  T	  cells	  expressing	  the	  KRN	  TCR	  escape	  
tolerance-­‐induced	  death	  and	  go	  on	  to	  mediate	  severe	  chronic	  arthritic	  
symptoms	  by	  around	  3	  weeks	  of	  age,	  characterised	  by	  swollen	  joints	  and	  high	  
levels	  of	  anti-­‐G6PI	  in	  the	  serum260,282.	  While	  initiation	  of	  disease	  was	  found	  to	  be	  
dependent	  on	  the	  KRN	  TCR,	  autoantibodies	  were	  found	  to	  mediate	  disease	  
thereafter,	  and	  transfer	  to	  wild	  type,	  B	  cell	  deficient,	  or	  lymphocyte	  deficient	  
mice	  caused	  the	  onset	  of	  acute	  arthritis	  within	  24	  hours,	  lasting	  15-­‐30	  days283.	  
This	  was	  found	  to	  be	  dependent	  on	  immune	  complex-­‐dependent	  pathways,	  such	  
as	  the	  activation	  of	  the	  alternative	  complement	  pathway284,285.	  This	  mouse	  
strain	  has	  commonly	  been	  used	  as	  a	  model	  of	  rheumatoid	  arthritis,	  and	  to	  
clarify	  the	  mechanisms	  behind	  autoantibody-­‐induced	  arthritis282.	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Recently,	  as	  described	  earlier,	  Huang	  et	  al	  used	  K/BxN	  mice	  co-­‐expressing	  
human	  and	  mouse	  CD20	  to	  show	  that	  in	  this	  model	  of	  autoantibody-­‐induced	  
arthritis,	  autoantibody	  is	  secreted	  by	  short-­‐lived	  plasma	  cells,	  which	  can	  be	  
depleted	  using	  rituximab	  treatment,	  mediating	  a	  decline	  in	  anti-­‐G6PI	  antibody	  
levels261.	  
5-­‐bromo-­‐2-­‐deoxyuridine	  	  
5-­‐bromo-­‐2-­‐deoxyuridine	  (BrdU)	  is	  a	  synthetic	  thymidine	  analogue	  that	  can	  be	  
used	  to	  label	  dividing	  cells	  either	  in	  vitro	  or	  in	  vivo.	  Dividing	  cells	  incorporate	  
BrdU	  into	  their	  DNA	  as	  it	  is	  synthesised,	  in	  place	  of	  thymidine286.	  In	  these	  
experiments,	  BrdU	  has	  been	  used	  in	  vivo.	  Here	  it	  can	  be	  injected	  into	  the	  
peritoneal	  cavity,	  or	  added	  to	  the	  drinking	  water.	  Importantly,	  once	  BrdU	  is	  
removed	  from	  the	  water	  (or	  injections	  stop),	  it	  is	  rapidly	  removed	  from	  the	  
body	  (presumably	  as	  it	  is	  rapidly	  used	  by	  dividing	  cells),	  but	  once	  incorporated	  
into	  the	  DNA,	  BrdU	  remains	  stable	  for	  long	  periods287.	  However,	  if	  further	  
cellular	  division	  occurs	  once	  BrdU	  provision	  has	  been	  stopped,	  detectable	  levels	  
of	  BrdU	  are	  rapidly	  lost	  in	  just	  2-­‐3	  divisions86,288.	  
BrdU	  has	  been	  used	  for	  many	  years	  to	  detect	  the	  lifespan	  and	  turnover	  of	  
plasma	  cells287.	  This	  can	  be	  done	  in	  two	  ways:	  firstly	  a	  sustained	  period	  of	  BrdU	  
injection	  or	  feeding	  (here	  termed	  a	  BrdU	  ‘pulse’)	  before	  the	  mouse	  is	  culled	  (for	  
example,	  for	  10	  days)	  allows	  the	  differentiation	  between	  non-­‐dividing,	  long-­‐
lived	  plasma	  cells	  (which	  do	  not	  incorporate	  the	  label)	  and	  dividing	  
plasmablasts	  or	  short-­‐lived	  plasma	  cells,	  which	  have	  both	  turned	  over	  during	  
the	  pulse228,229.	  A	  second	  technique	  involves	  giving	  the	  label	  for	  a	  defined	  pulse	  
to	  label	  plasma	  cells	  generated	  during	  this	  time	  (for	  example,	  following	  
immunisation),	  followed	  by	  a	  ‘chase’	  period	  where	  BrdU	  is	  not	  provided189,287.	  
When	  mice	  are	  culled,	  cells	  that	  contain	  the	  label	  must	  have	  been	  generated	  
during	  the	  defined	  pulse,	  as	  those	  that	  were	  generated	  before	  or	  after	  will	  be	  
BrdU-­‐.	  The	  fact	  that	  mature	  plasma	  cells	  do	  not	  divide	  means	  that	  in	  this	  way	  
their	  lifespan	  can	  be	  tracked	  over	  long	  periods189.	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Hapten-­‐carrier	  proteins	  
Haptens	  are	  chemically	  defined	  molecules	  that	  are	  capable	  of	  binding	  to	  certain	  
antibodies,	  but	  by	  themselves	  cannot	  illicit	  an	  immune	  response.	  For	  this	  reason	  
they	  are	  conjugated	  to	  ‘carrier’	  proteins	  that	  can	  initiate	  either	  TD	  (e.g.	  keyhole	  
limpet	  hemocyanin	  (KLH),	  ovalbumin	  (OVA),	  hen	  egg	  lysosyme	  (HEL))	  or	  TI-­‐2	  
(e.g.	  ficoll)	  responses289,290.	  The	  advantage	  to	  hapten-­‐carrier	  immunisations	  is	  
that	  hapten-­‐specific	  antibody	  responses	  can	  be	  easily	  measured,	  as	  the	  hapten	  
provides	  a	  defined	  epitope,	  unlike	  the	  carrier	  protein,	  which	  is	  broken	  down	  to	  
form	  many	  epitopes291.	  Similarly,	  high	  frequencies	  of	  hapten-­‐specific	  plasma	  
cells	  are	  induced	  following	  immunisation.	  In	  this	  study,	  we	  have	  used	  three	  
hapten-­‐carrier	  proteins:	  4-­‐hydroxy-­‐3-­‐nitrophenyl	  conjugated	  to	  KLH	  (NP-­‐KLH),	  
2,4-­‐dinitrophenyl	  conjugated	  to	  OVA	  (DNP-­‐OVA)	  and	  fluorescein	  conjugated	  to	  
OVA	  (FITC-­‐OVA).	  
Sheep	  red	  blood	  cell	  immunisation	  
The	  response	  to	  sheep	  red	  blood	  cells	  in	  mice	  is	  entirely	  TD	  and	  generates	  large	  
populations	  of	  extrafollicular	  plasma	  cells	  by	  day	  581,292,293.	  At	  the	  same	  time,	  
germinal	  centres	  are	  apparent81,294.	  The	  rapid	  TD	  response	  seen	  is	  equivalent	  to	  
that	  in	  mice	  with	  increased	  availability	  of	  T	  cell	  help	  (generated	  by	  priming	  with	  
a	  carrier	  protein,	  followed	  by	  boosting	  with	  a	  hapten	  conjugated	  to	  the	  same	  
carrier)86.	  The	  response	  is	  associated	  with	  large	  numbers	  of	  extrafollicular	  
plasma	  cells	  that	  persist	  for	  just	  2-­‐3	  days81,	  however	  the	  germinal	  centre	  
response	  has	  been	  reported	  to	  persist	  for	  up	  to	  240	  days294.	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  Aims	  of	  this	  PhD	  
	  The	  aims	  of	  this	  PhD	  were	  to:	  
1. Develop	  models	  to	  identify	  and	  measure	  the	  turnover	  and	  lifespan	  of	  
plasma	  cells	  
	  
2. Determine	  the	  requirements	  for	  the	  generation	  of	  extrafollicular	  plasma	  
cells	  in	  Salmonella	  infection	  compared	  to	  the	  TD	  response	  to	  SRBC	  
	  
3. Determine	  whether	  the	  lifespan	  of	  plasma	  cells	  is	  affected	  by	  the	  
chronicity	  of	  antigen	  delivery	  
	  
4. Determine	  the	  effects	  of	  infection	  and	  inflammation	  on	  previously	  
established	  bone	  marrow	  plasma	  cell	  populations	  and	  circulating	  
antibody
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Chapter	  2	  -­	  Materials	  and	  Methods	  
Mice	  and	  license	  
C57Bl/6,	  MyD88-­‐/-­‐295,	  TRIF-­‐/-­‐296,	  MyD88/TRIF-­‐/-­‐,	  TLR	  4-­‐/-­‐297,	  ICOS-­‐/-­‐298,	  	  Aβ-­‐/-­‐299,	  
MD4300	  CD1d-­‐/-­‐301,	  CD40-­‐/-­‐66(a	  kind	  gift	  from	  Andrew	  MacDonald,	  University	  of	  
Edinburgh),	  IFNα/βR-­‐/-­‐302	  (a	  kind	  gift	  from	  Caetano	  Reis	  e	  Sousa,	  London	  
Research	  Institute)	  mice	  (all	  on	  C57Bl/6	  backgrounds)	  were	  bred	  and	  
maintained	  in	  specific	  pathogen	  free	  conditions	  at	  the	  School	  of	  Biological	  
Sciences	  Animal	  Facility	  at	  the	  University	  of	  Edinburgh.	  Mice	  were	  aged	  6-­‐10	  
weeks	  at	  the	  start	  of	  experiments,	  unless	  otherwise	  stated.	  
K/BxN260	  mice	  were	  a	  kind	  gift	  from	  Mohini	  Gray	  at	  the	  University	  of	  Edinburgh	  
Queen’s	  Medical	  Research	  Unit.	  These	  mice	  are	  the	  F1	  progeny	  of	  NOD	  and	  KRN	  
mice	  and	  were	  aged	  30	  days	  before	  use.	  	  Arthritis	  development	  was	  determined	  
by	  scoring	  joint	  swelling.	  	  
Experiments	  were	  covered	  by	  a	  Project	  License	  granted	  by	  the	  Home	  Office	  
under	  the	  Animal	  (Scientific	  Procedures)	  Act	  1986.	  This	  license	  was	  approved	  
locally	  by	  the	  University	  of	  Edinburgh	  Ethical	  Review	  Committee.	  
Protein	  conjugations	  
Proteins	  used	  are	  detailed	  in	  each	  experiment.	  For	  most	  immunisation	  
experiments,	  hapten-­‐carrier	  conjugates	  are	  used	  (DNP-­‐OVA,	  NP-­‐KLH	  or	  FITC-­‐
OVA)	  
2,4-­‐Dinitrophenyl	  (DNP)	  was	  coupled	  to	  ovalbumin	  from	  chicken	  egg	  white	  
(OVA)	  (Sigma)	  by	  reacting	  32µl	  dinitroflurobenzene	  (DNFB)	  (Sigma,	  D1529-­‐
10ML)	  per	  mg	  OVA	  (Sigma,	  A5503)	  in	  an	  equal	  volume	  of	  0.1M	  borate	  buffer	  
(pH	  8.4)	  for	  30	  minutes	  at	  37°C	  with	  regular	  mixing.	  To	  remove	  free	  hapten	  
molecules,	  the	  resulting	  solution	  was	  transferred	  to	  10,000MW	  cut	  off	  dialysis	  
tubing	  and	  dialysed	  against	  5	  changes	  of	  PBS	  (3	  litres	  per	  change)	  with	  constant	  
stirring.	  For	  the	  first	  3	  changes	  of	  PBS,	  dialysis	  was	  at	  room	  temperature	  for	  2	  
hours.	  For	  the	  final	  2	  changes	  of	  PBS,	  dialysis	  was	  at	  4°C	  overnight.	  The	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conjugate	  was	  then	  concentrated	  to	  5mg/ml	  (assuming	  no	  loss	  of	  protein)	  using	  
vivaspin-­‐6	  centrifugal	  ultrafiltration	  tubes	  (Sartorius-­‐Stedim	  Biotech)	  following	  
manufacturer’s	  instructions.	  	  
For	  NP-­‐KLH	  conjugation,	  4-­‐hydroxy-­‐3-­‐nitrophenylacetic	  acid	  active	  ester	  (NP-­‐
OSu)	  (Biosearch	  technologies,	  N-­‐1010-­‐100)	  was	  dissolved	  in	  dimethyl	  
sulphoxide	  (DMSO)	  (Sigma,	  472301)	  at	  100mg/ml.	  100µl	  of	  this	  was	  added	  to	  
25mg	  keyhole	  limpet	  hemocyanin	  (KLH)	  (Calbiochem,	  374811)	  in	  an	  equal	  
volume	  of	  0.1M	  borate	  buffer	  (pH	  8.4)	  for	  30	  minutes	  at	  37°C	  before	  dialysis	  
and	  concentration	  adjustment	  as	  above.	  	  
FITC-­‐OVA	  was	  bought	  from	  Biosearch	  Technologies	  (F-­‐1511-­‐10)	  and	  suspended	  
in	  sterile	  PBS	  at	  1mg/ml.	  
To	  detect	  hapten-­‐specific	  antibody,	  enzyme-­‐linked	  immunosorbent	  assay	  
(ELISA)	  plates	  were	  coated	  with	  the	  relevant	  hapten,	  conjugated	  to	  bovine	  
serum	  albumin	  (BSA).	  Conjugation	  was	  performed	  as	  follows:	  
NP-­‐OSu	  (Biosearch	  technologies)	  was	  conjugated	  to	  BSA	  (Sigma,	  A7906)	  by	  
reacting	  100µl	  of	  NP-­‐OSu	  (dissolved	  in	  DMSO	  at	  100mg/ml)	  to	  50mg	  BSA	  
(dissolved	  in	  0.1M	  borate	  buffer,	  pH	  8.4)	  for	  30	  minutes	  at	  37°C	  before	  dialysis	  
and	  concentration	  adjustment	  as	  above.	  
For	  detection	  of	  Hen	  Egg	  Lysosyme	  (HEL)-­‐specific	  plasma	  cells	  (and	  B	  cells)	  by	  
FACS,	  HEL	  (Sigma,	  L6876)	  was	  biotinylated	  using	  the	  Pierce	  ‘EZ-­‐Link	  Sulfo-­‐NHS-­‐
LC-­‐Biotin’	  kit	  (21435).	  HEL	  at	  1mg/ml	  was	  reacted	  with	  75µl	  of	  10mM	  Sulpho-­‐
NHS-­‐LC-­‐Biotin	  (2.2mg	  in	  400µl	  of	  ultrapure	  water)	  per	  mg	  of	  HEL.	  This	  was	  left	  
on	  ice	  for	  2	  hours	  with	  regular	  mixing	  before	  dialysis	  as	  before.	  The	  conjugate	  
was	  used	  from	  a	  stock	  solution	  (stored	  at	  -­‐80°C)	  at	  3.5mg/ml	  as	  determined	  by	  
BCA	  protein	  assay	  (Pierce,	  23225).	  
Primary	  immunisations	  
Sub-­‐Cutaneous	  immunisations	  were	  administered	  to	  the	  hind	  flanks	  (100µl	  to	  
each).	  100µg	  protein	  and	  10µg	  LPS	  (Invivogen,	  LPS-­‐SM)	  were	  suspended	  in	  an	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emulsion	  of	  incomplete	  Freund’s	  adjuvant	  (IFA)	  (Sigma,	  F5506)	  and	  PBS	  (1:1).	  
This	  was	  sonicated	  on	  ice,	  until	  a	  thick	  solution	  was	  obtained.	  
For	  intraperitoneal	  immunisations,	  proteins	  were	  alum-­‐precipitated	  (briefly;	  
protein	  at	  5mg/ml	  was	  mixed	  1:1	  with	  9%	  aluminium	  potassium	  sulphate	  in	  
PBS.	  Solutions	  were	  neutralised	  by	  the	  addition	  of	  sterile	  sodium	  hydroxide.	  
After	  1	  hour	  at	  room	  temperature,	  solutions	  were	  washed	  three	  times	  in	  PBS	  
and	  resuspended	  at	  5mg/ml).	  100µg	  alum-­‐precipitated	  protein	  was	  injected	  
with	  2.5x108	  killed	  Bordetella	  pertussis	  (BD,	  225851)	  in	  200µl	  PBS.	  
Secondary	  immunisations	  were	  performed	  5	  weeks	  after	  primary.	  Unless	  
otherwise	  stated,	  100µg	  soluble	  protein	  (in	  200µl	  PBS)	  was	  injected	  
intravenously	  (I.V.)	  into	  lateral	  tail	  veins.	  For	  ‘chronically	  stimulated’	  mice,	  
20x5µg	  doses	  every	  3	  days	  over	  a	  60-­‐day	  period	  (also	  I.V.	  in	  PBS).	  In	  some	  
experiments,	  secondary	  immunisations	  were	  given	  I.P.	  (either	  with	  soluble	  
protein	  or	  alum-­‐precipitated	  with	  B.	  pertussis	  as	  described	  above).	  
Sheep	  red	  blood	  cell	  immunisations	  
Heparinised	  blood	  from	  sheep	  housed	  indoors	  was	  purchased	  from	  the	  
Moredun	  Research	  Institute	  (University	  of	  Edinburgh).	  The	  blood	  cells	  were	  
washed	  three	  times	  in	  PBS	  and	  used	  within	  8	  weeks.	  Mice	  received	  5x108	  SRBC	  
(diluted	  in	  PBS	  for	  a	  total	  volume	  of	  200µl)	  I.V.	  
Salmonella	  enterica	  serovar	  Typhimurium	  infection	  
Salmonella	  vaccine	  strain	  SL3261	  was	  grown	  in	  Luria-­‐Bertani	  (LB)	  broth	  (Difco	  
labs)	  at	  37°C	  for	  16	  hours.	  Cultures	  were	  diluted	  in	  sterile	  PBS	  so	  as	  to	  give	  
approximately	  1x10^6	  colony	  forming	  units	  (CFU)	  per	  200µl.	  This	  was	  injected	  
I.V.	  into	  tail	  veins.	  Doses	  were	  plated	  out	  onto	  LB	  agar	  plates	  in	  serial	  dilution	  to	  
determine	  infectious	  dose	  for	  each	  experiment.	  To	  determine	  the	  bacterial	  load	  
per	  organ	  in	  infected	  animals,	  organs	  were	  removed	  and	  total	  organ	  weight	  was	  
determined.	  A	  section	  of	  organ	  was	  removed	  and	  weighed,	  before	  mashing	  
between	  sterile	  gauze	  into	  a	  known	  volume	  of	  PBS.	  This	  was	  diluted	  and	  plated	  
into	  5ml	  of	  molten	  LB	  agar	  at	  a	  range	  of	  concentrations	  in	  duplicate.	  LB	  agar	  
was	  allowed	  to	  set,	  and	  cultures	  were	  incubated	  at	  37°C for	  24	  hours	  and	  CFU	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were	  counted.	  From	  this,	  total	  CFU	  per	  organ	  (or	  per	  gram	  of	  organ)	  was	  
calculated. 
Schistosoma	  mansoni	  infections	  
Biomphalaria	  glabrata	  snails	  infected	  with	  S.	  mansoni	  were	  obtained	  from	  F.	  
Lewis	  (Biomedical	  Research	  Insti-­‐	  tute,	  Rockville,	  MD).	  Mice	  were	  infected	  
percutaneously	  with	  20,	  40,	  80	  or	  120	  cercariae.	  
BrdU	  labelling	  
	  5-­‐Bromo-­‐2’-­‐deoxyuridine	  (BrdU)	  (Sigma,	  B5002)	  was	  either	  injected	  I.P.	  daily	  
(2mg	  per	  mouse	  per	  day)	  in	  200µl	  PBS,	  or	  (for	  pulses	  over	  3	  days)	  given	  in	  the	  
drinking	  water	  at	  0.8mg/ml	  (protected	  from	  light	  and	  changed	  every	  3	  days).	  
BrdU	  incorporation	  from	  the	  two	  methods	  was	  tested	  and	  found	  to	  be	  
comparable.	  	  
Histology	  
Spleens	  were	  removed	  and	  cut	  into	  pieces.	  A	  central	  piece	  was	  suspended	  in	  
embedding	  medium	  and	  rapidly	  frozen	  by	  placing	  on	  dry	  ice,	  followed	  by	  
storage	  at	  -­‐70°C.	  Tissue	  sections	  were	  cut	  at	  5-­‐6µm	  thicknesses	  and	  mounted	  
onto	  slides.	  These	  were	  dried	  for	  1	  hour	  at	  room	  temperature	  and	  fixed	  in	  
acetone	  for	  10	  minutes	  before	  storage	  at	  -­‐20°C.	  Sections	  were	  thawed,	  washed	  
in	  PBS	  for	  5	  minutes	  and	  blocked	  with	  PBS+0.5%	  BSA	  (Sigma)	  for	  a	  further	  20	  
minutes.	  Subsequently,	  sections	  were	  stained	  with	  a	  combination	  of	  antibodies	  
listed	  in	  table	  2.2	  for	  2	  hours	  before	  washing	  in	  PBS	  three	  times	  (for	  20	  minutes	  
per	  wash).	  For	  biotinylated	  antibodies,	  a	  second	  staining	  step	  with	  streptavidin-­‐
conjugated	  Alexa	  Fluor	  350	  (Invitrogen)	  for	  1	  hour	  before	  washing	  in	  PBS	  as	  
before.	  Cover	  slips	  were	  mounted	  using	  the	  mounting	  agent	  Mowiol	  (Clariant,	  
Frankfurt,	  Germany)	  with	  the	  anti-­‐fading	  agent	  1,4-­‐Diazabicyclooctane	  
(DABCO)	  (Sigma,	  D27802)	  (at	  25mg/ml).	  Slides	  were	  viewed	  on	  a	  fluorescent	  
microscope	  (Olympus	  BX50)	  and	  images	  captured	  using	  Openlab	  software	  
(Improvision,	  MA,	  USA).	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Medium	  
Medium	  used	  throughout	  was	  Iscove’s	  Modified	  Dolbecco’s	  Medium	  (IMDM)	  
supplemented	  with	  5%	  FCS,	  1%	  penicillin-­‐streptomycin	  (Gibco,	  UK),	  0.1%	  2-­‐
mercaptoethanol	  (BDH	  laboratory	  supplies,	  Poole,	  UK).	  Hereafter,	  this	  shall	  be	  
referred	  to	  simply	  as	  medium.	  
Tissue	  preparation	  
	  Spleens	  were	  removed	  and	  single	  cell	  suspensions	  produced	  by	  mashing	  
between	  gauze	  squares	  into	  medium.	  Femurs	  were	  removed	  and	  flushed	  with	  
3ml	  medium	  (3ml	  per	  femur).	  Erythrocytes	  were	  lysed	  by	  suspension	  in	  red	  
blood	  lysis	  buffer	  (Sigma)	  for	  3	  minutes.	  Cells	  were	  washed	  and	  re-­‐suspended	  in	  
medium,	  and	  counted	  by	  dilution	  in	  0.1%	  trypan	  blue	  solution	  (Sigma).	  	  
FACS	  staining	  
2-­‐5x106	  cells,	  prepared	  as	  described	  above,	  were	  transferred	  to	  FACS	  tubes	  and	  
washed	  three	  times	  by	  centrifugation,	  aspiration	  of	  supernatants,	  and	  re-­‐
suspension	  in	  FACS	  buffer	  (PBS	  supplemented	  with	  4%	  FCS	  and	  0.05%	  sodium	  
azide).	  For	  experiments	  using	  the	  ‘Aqua	  Live/Dead	  kit’	  (Invitrogen),	  cells	  were	  
first	  washed	  in	  PBS	  and	  stained	  with	  20µl	  of	  the	  kit	  (diluted	  in	  PBS)	  for	  15	  
minutes	  at	  4°C,	  followed	  by	  washing	  in	  FACS	  buffer.	  Cells	  were	  routinely	  
blocked	  with	  50µl	  of	  1%	  FcR	  block	  (2.4G2	  supernatant,	  produced	  in	  house),	  2%	  
mouse	  serum	  (Calbiochem,	  NS03L)	  and	  2%	  rat	  serum	  (Invitrogen,	  01-­‐9601)	  for	  
20	  minutes.	  Cells	  were	  washed	  and	  stained	  with	  50µl	  of	  antibodies	  against	  
surface	  markers,	  diluted	  in	  FACS	  buffer,	  for	  30	  minutes	  at	  4°C	  before	  washing	  3	  
times	  in	  FACS	  buffer	  (see	  table	  2.1	  for	  a	  complete	  list	  of	  antibodies	  used,	  and	  
their	  respective	  dilutions	  etc).	  If	  biotinylated	  antibodies	  were	  used,	  a	  second	  
staining	  step	  was	  performed	  where	  streptavidin-­‐conjugated	  fluorochrome	  of	  
the	  required	  colour	  was	  added,	  diluted	  in	  FACS	  buffer,	  for	  30	  minutes	  at	  4°C,	  
followed	  by	  a	  further	  3	  washes.	  
Intracellular	  staining	  
Where	  intracellular	  markers	  were	  of	  interest,	  cells	  were	  suspended	  overnight	  in	  
the	  eBioscience	  FoxP3	  fixation/permeabilisation	  kit	  (00-­‐5521-­‐00)	  at	  4°C,	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followed	  by	  washing	  3	  times	  with	  permeabilisation	  buffer	  (eBioscience,	  00-­‐
8333-­‐00)	  (hereafter	  referred	  to	  as	  ‘PB’).	  Cells	  were	  then	  suspended	  in	  50µl	  of	  
antibodies	  against	  intracellular	  markers,	  diluted	  in	  PB,	  for	  30	  minutes	  at	  4°C,	  
followed	  by	  washing	  3	  times	  in	  PB	  and	  suspension	  in	  FACS	  buffer	  (see	  table	  2.1	  
for	  a	  complete	  list	  of	  antibodies	  used).	  
BrdU	  staining	  
For	  BrdU	  staining,	  cells	  were	  blocked,	  surface	  stained,	  and	  fixed/permeabalised	  
as	  described	  above	  before	  treatment	  with	  1mg	  of	  DNase	  I	  (Sigma,	  DN25),	  
dissolved	  in	  PB,	  for	  1	  hour	  at	  37°C.	  Cells	  were	  washed	  in	  PB	  and	  incubated	  with	  
50µl	  of	  a	  1:20	  dilution	  of	  anti-­‐BrdU-­‐FITC	  (BD)	  for	  30	  minutes	  at	  room	  
temperature.	  Finally,	  cells	  were	  washed	  in	  PB	  and	  resuspended	  in	  FACS	  buffer.	  	  
FACS	  samples	  were	  acquired	  on	  a	  FACS	  Canto	  or	  LSRII	  (BD)	  and	  analysed	  using	  
FlowJo	  (Treestar,	  USA).	  
Antibody	  ELISA	  
To	  measure	  anti-­‐NP	  antibodies,	  anti-­‐FITC-­‐OVA	  antibodies,	  anti-­‐Salmonella	  
antibodies	  and	  anti-­‐SRBC	  antibodies,	  96-­‐well	  Nunc-­‐maxisorp	  plates	  (Fischer	  
Scientific)	  were	  coated	  in	  NP-­‐BSA,	  FITC-­‐OVA,	  or	  a	  crude	  sonicate	  of	  Salmonella	  
or	  SRBC	  respectively	  (all	  at	  10µg/ml,	  diluted	  in	  PBS)	  and	  incubated	  overnight	  at	  
4°C.	  Serum	  was	  separated	  from	  whole	  blood	  by	  centrifugation	  for	  10	  minutes	  at	  
13,000g	  in	  a	  micro-­‐centrifuge	  (this	  was	  stored	  at	  -­‐20°C	  until	  required).	  Plates	  
were	  washed	  twice	  in	  PBS+0.1%	  tween,	  and	  blocked	  for	  2	  hours	  at	  room	  
temperature	  with	  100µl	  PBS+1%	  BSA	  per	  well.	  Plates	  were	  again	  washed	  twice	  
with	  PBS+0.1%	  tween	  before	  serum	  was	  added,	  in	  duplicate,	  at	  a	  pre-­‐
determined	  top	  dilution,	  and	  2-­‐fold	  dilutions	  made	  down	  the	  plate	  (in	  
PBS+1%BSA).	  A	  positive	  control	  (‘standard’)	  was	  also	  added	  to	  each	  plate.	  After	  
a	  2-­‐hour	  incubation,	  plates	  were	  washed	  three	  times	  in	  PBS+0.1%	  tween	  and	  
alkaline	  phosphotase-­‐labelled	  detection	  antibodies	  (specific	  for	  IgM	  (1020-­‐04),	  
IgG1	  (1070-­‐04),	  IgG2b	  (1090-­‐04),	  IgG2c	  (1079-­‐04)	  or	  IgG3	  (1100-­‐04)	  –	  all	  from	  
Southern	  Biotech)	  were	  added	  for	  1	  hour,	  diluted	  in	  PBS	  (at	  1:2000,	  1:2000,	  
1:2500,	  1:1000	  and	  1:1000	  respectively).	  Plates	  were	  again	  washed	  3	  times	  in	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PBS+0.1%	  tween	  and	  50µl	  of	  P-­‐Nitrophenyl	  phosphate	  (Sigma,	  N1891)	  
dissolved	  in	  Diethanolamide	  buffer	  at	  1mg/ml.	  Plates	  were	  read	  at	  405nm	  using	  
Labsystems	  Multiskan	  plus	  and	  analysed	  using	  Graphpad	  Prism.	  Titres	  are	  the	  
dilution	  at	  which	  samples	  reached	  half	  of	  the	  maximal	  optical	  density	  (OD)	  of	  
the	  standard	  for	  each	  plate.	  Limits	  of	  detection	  are	  the	  top	  dilution	  for	  each	  
sample.	  
Statistics	  
Throughout	  the	  study,	  students’	  t-­‐test,	  one-­‐way	  or	  two-­‐way	  ANOVA	  were	  used	  
to	  determine	  statistical	  significance	  Where	  required,	  for	  one-­‐way	  ANOVA,	  the	  
Dunnet	  post-­‐test	  or	  Bonferroni	  post-­‐test	  were	  used.	  For	  two-­‐way	  ANOVA	  the	  
Bonferroni	  post-­‐test	  was	  used.	  Tests	  were	  performed	  on	  Graphpad	  Prism	  
software	  (Graphpad	  Software	  Inc.,	  San	  Diego,	  CA).	  P	  values	  are	  represented	  as	  
asterisks	  (where	  ‘*’	  represents	  p=0.01	  to	  p=0.05,	  ‘**’	  represents	  p=0.001	  to	  
p=0.01,	  ‘***’	  represents	  p<0.001	  and	  ‘NS’	  represents	  not	  significant	  (p>0.05)).	  
Contributions	  by	  others	  
Schistosoma	  mansoni	  infections	  and	  BrdU	  labelling	  of	  mice	  presented	  in	  figure	  
6.2	  were	  performed	  by	  Alex	  Phythian-­‐Adams	  and	  Stefano	  Casserta.	  Dissection	  of	  
animals	  and	  tissue	  preparation	  was	  a	  combined	  effort.	  
Salmonella	  infections	  and	  dissection	  of	  mice	  shown	  in	  figure	  4.3a	  and	  4.4a	  were	  
performed	  by	  Sheila	  Brown.	  Histology	  shown	  in	  figure	  4.4a	  was	  also	  performed	  
by	  Sheila	  Brown.	  
Data	  shown	  in	  figure	  4.11	  was	  in	  collaboration	  with	  Marta	  Trueb.	  
DNP-­‐OVA	  used	  in	  this	  project	  was	  conjugated	  by	  Sheila	  Brown.	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  2.2.	  Antibodies	  used	  for	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Chapter	  3	  –	  Plasma	  cell	  identification,	  measurement	  of	  lifespan	  and	  
long-­‐lived	  plasma	  cell	  accumulation	  in	  the	  bone	  marrow	  of	  naïve	  mice	  
Introduction	  
Plasma	  cells	  are	  focused	  on	  synthesising	  and	  secreting	  antibody,	  and	  although	  
originating	  from	  B	  cells,	  lose	  many	  of	  the	  functions	  associated	  with	  their	  
precursors.	  This	  results	  from	  reduced	  expression	  of	  many	  receptors	  and	  
signalling	  molecules	  expressed	  on	  the	  cell	  surface	  of	  B	  cells.	  A	  secondary	  effect	  
of	  this	  is	  that	  there	  are	  fewer	  markers	  with	  which	  to	  identify	  the	  cells	  using	  flow	  
cytometry.	  CD138	  is	  one	  marker	  that	  is	  up	  regulated	  on	  the	  surface	  of	  plasma	  
cells	  and	  is	  frequently	  used	  for	  their	  identification.	  
Here	  we	  observe	  that	  CD138	  is	  not	  expressed	  on	  all	  plasma	  cells;	  during	  
Salmonella	  infection	  we	  show	  that	  many	  antibody-­‐secreting	  cells	  express	  only	  
low	  levels	  of	  CD138,	  comparable	  to	  that	  of	  B	  cells.	  We	  demonstrate	  that	  
labelling	  with	  intracellular	  Ig	  is	  a	  more	  accurate	  method	  of	  identifying	  antibody-­‐
secreting	  plasma	  cells.	  	  
The	  lifespan	  of	  plasma	  cells	  is	  key	  to	  long-­‐lasting	  humoral	  immunity303.	  The	  
constant	  production	  of	  antibody	  undoubtedly	  puts	  plasma	  cells	  under	  high	  
levels	  of	  stress,	  resulting	  in	  the	  rapid	  death	  of	  many	  such	  cells304.	  However,	  
some	  plasma	  cells	  are	  able	  to	  persist	  for	  months	  or	  even	  years	  without	  cellular	  
division189.	  Although	  it	  is	  unknown	  why	  some	  plasma	  cells	  are	  able	  to	  survive	  
while	  others	  are	  not,	  it	  is	  clear	  that	  the	  provision	  of	  certain	  survival	  factors,	  such	  
as	  APRIL	  and	  IL-­‐6,	  is	  vital88,89,142,147,148,166.	  The	  bone	  marrow	  is	  known	  to	  be	  a	  
major	  site	  where	  these	  factors	  are	  enriched	  under	  homeostatic	  
conditions151,166,217.	  	  
Plasma	  cell	  responses	  occur	  in	  two	  phases	  following	  infection	  or	  immunisation.	  
In	  the	  first	  few	  days,	  extrafollicular	  plasma	  cells	  arise;	  these	  plasma	  cells	  secrete	  
antibody	  of	  low	  affinity	  and	  are	  thought	  to	  survive	  for	  only	  a	  few	  days.	  Secondly,	  
in	  TD	  responses,	  plasma	  cells	  are	  generated	  during	  the	  germinal	  centre	  
reaction.	  These	  plasma	  cells	  arise	  from	  B	  cell	  clones	  that	  have	  undergone	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affinity	  maturation	  through	  hypermutation	  and	  selection,	  and	  they	  secrete	  
antibody	  of	  high	  affinity90,245,305.	  These	  plasma	  cells	  migrate	  to	  the	  bone	  
marrow,	  where	  they	  survive	  for	  long	  periods	  without	  division	  or	  re-­‐
stimulation189,194.	  
We	  document	  the	  accumulation	  of	  a	  population	  of	  long-­‐lived	  plasma	  cells	  in	  the	  
bone	  marrow	  of	  naïve	  mice	  over	  time.	  This	  population	  was	  found	  to	  contribute	  
to	  serum	  antibody	  levels,	  and	  required	  T	  cell	  help,	  as	  well	  as	  both	  BCR	  and	  TLR	  
signals	  for	  its	  generation.	  	  
Results	  
Identification	  of	  plasma	  cells	  through	  intracellular	  immunoglobulin	  
CD138	  is	  the	  prototypical	  plasma	  cell	  marker.	  We	  immunised	  C57Bl/6	  mice	  
with	  alum	  precipitated	  NP-­‐KLH	  with	  killed	  Bordetella	  pertussis	  I.P.	  and	  looked	  at	  
the	  peak	  of	  the	  plasma	  cell	  response	  in	  the	  spleen	  (at	  day	  8).	  Some	  mice	  were	  
boosted	  4-­‐weeks	  after	  the	  primary	  response	  with	  soluble	  NP-­‐KLH	  I.V.	  By	  day	  8	  
following	  primary	  immunisation,	  a	  substantial	  population	  of	  CD19int,	  CD138hi	  
cells	  were	  induced	  in	  the	  spleen	  (2.25%	  (±0.34)	  of	  total	  cells)	  (fig	  3.1a).	  
However,	  this	  was	  far	  smaller	  than	  the	  response	  seen	  at	  day	  5	  following	  
secondary	  immunisation,	  where	  CD138hi	  cells	  accounted	  for	  12.51%	  (±1.16)	  of	  
total	  spleen	  cells	  (fig	  3.1a).	  Mice	  primed	  at	  the	  same	  time	  as	  boosted	  mice,	  but	  
not	  receiving	  secondary	  immunisation	  contained	  low	  frequencies	  of	  plasma	  
cells	  in	  the	  spleen	  (0.60%	  (±0.11)	  of	  total	  spleen	  cells,	  data	  not	  shown).	  Due	  to	  
greater	  populations,	  we	  chose	  to	  characterise	  splenic	  plasma	  cell	  responses	  
following	  secondary	  immunisation	  with	  NP-­‐KLH.	  Co-­‐staining	  for	  both	  surface	  
and	  intracellular	  immunoglobulin	  showed	  that	  CD138hi	  cells	  express	  low	  levels	  
of	  surface	  immunoglobulin	  (BCR)	  and	  high	  levels	  of	  cytoplasmic	  
immunoglobulin	  (secreted	  antibody)	  when	  compared	  to	  CD138lo,	  CD19hi	  B	  cells;	  
thus	  confirming	  their	  identity	  as	  antibody-­‐secreting	  plasma	  cells	  (fig	  3.1b).	  Low	  
staining	  of	  CD19hi	  B	  cells	  when	  stained	  for	  intracellular	  Igκ	  likely	  represents	  Igκ	  
on	  the	  surface	  of	  B	  cells	  (i.e.	  the	  BCR).	  A	  population	  of	  BCRlo	  CD19hi	  cells	  could	  
also	  be	  seen	  (fig	  3.1b);	  this	  is	  likely	  to	  represent	  lambda	  light	  chain	  expressing	  B	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cells	  (around	  10	  percent	  of	  murine	  B	  cells),	  as	  anti-­‐kappa	  light	  chain	  (Igκ)	  was	  
used	  for	  detection.	  
Plasma	  cells	  were	  also	  identified	  in	  the	  bone	  marrow,	  however,	  populations	  
were	  not	  found	  to	  expand	  dramatically	  at	  day	  5	  following	  secondary	  
immunisation	  with	  NP-­‐KLH	  (fig	  3.1c).	  This	  will	  be	  looked	  at	  in	  more	  detail	  in	  
chapter	  5.	  	  	  
Interestingly,	  in	  certain	  situations,	  such	  as	  infection	  with	  Salmonella,	  not	  all	  
intracellular	  Ig-­‐containing	  cells	  were	  found	  to	  express	  high	  levels	  of	  CD138.	  
Figure	  3.1d	  shows	  that	  in	  a	  time	  course	  of	  infection,	  a	  population	  of	  CD138hi,	  
CD19int	  cells	  was	  generated	  at	  day	  8	  (fig	  3.1d	  top	  row).	  However,	  intracellular	  Ig	  
staining	  revealed	  a	  far	  larger	  population	  (fig	  3.1d	  middle	  row).	  Further	  disparity	  
between	  the	  populations	  was	  revealed	  by	  the	  two	  stains	  at	  later	  time	  points,	  
when	  over	  50	  percent	  of	  plasma	  cells	  did	  not	  express	  high	  levels	  of	  CD138.	  A	  
comparison	  of	  the	  two	  stains	  shows	  that	  CD138	  staining	  does	  not	  reveal	  all	  
antibody	  secreting	  cells	  (fig	  3.1d	  bottom	  row),	  and	  in	  fact,	  many	  of	  the	  cells	  
revealed	  by	  CD138	  staining	  in	  naïve	  mice,	  and	  at	  later	  points	  in	  the	  time	  course,	  
did	  not	  express	  high	  levels	  of	  intracellular	  Ig.	  	  
To	  ensure	  that	  we	  analysed	  total	  plasma	  cell	  populations	  in	  all	  experiments,	  
intracellular	  Ig,	  in	  conjunction	  with	  CD138,	  was	  subsequently	  used	  to	  identify	  
plasma	  cells.	  
Kinetics	  of	  plasma	  cell	  maturation	  in	  the	  secondary	  response	  to	  NP-­‐KLH	  
In	  figure	  3.1,	  we	  developed	  a	  more	  sensitive	  technique	  for	  identifying	  plasma	  
cells.	  In	  order	  to	  further	  our	  understanding	  of	  phenotypic	  changes	  to	  plasma	  cell	  
populations	  as	  they	  matured,	  we	  examined	  the	  phenotype	  of	  plasma	  cells	  
through	  a	  time	  course	  following	  secondary	  NP-­‐KLH	  immunisation.	  	  
Plasma	  cells	  in	  the	  spleens	  of	  naïve	  mice	  were	  found	  to	  express	  high	  levels	  of	  
intracellular	  Ig	  and	  CD138.	  They	  retained	  high	  levels	  of	  MHC	  II,	  but	  expressed	  
only	  intermediate	  levels	  of	  CD19.	  Interestingly,	  their	  forward	  and	  side	  scatter	  
was	  relatively	  low,	  suggesting	  an	  immature	  state.	  This	  was	  similar	  in	  the	  bone	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marrow,	  as	  was	  their	  expression	  of	  CD19	  and	  intracellular	  Ig.	  However,	  bone	  
marrow	  plasma	  cells	  expressed	  higher	  CD138	  and	  lower	  MHC	  II	  and	  had	  higher	  
forward	  and	  side	  scatter	  than	  their	  splenic	  counterparts	  (fig	  3.2).	  
Plasma	  cells	  arising	  in	  the	  spleen	  at	  day	  5	  of	  the	  secondary	  response	  to	  NP-­‐KLH	  
retained	  many	  of	  the	  surface	  proteins	  expressed	  on	  B	  cells	  (fig	  3.2).	  CD19	  and	  
MHC	  II	  expression	  were	  found	  to	  be	  similar	  to	  those	  of	  splenic	  B	  cells	  (with	  
CD19	  being	  higher	  than	  plasma	  cells	  found	  in	  the	  naïve	  spleen),	  however	  CD138	  
was	  up	  regulated,	  as	  was	  intracellular	  Ig.	  No	  increase	  in	  forward	  or	  side	  scatter	  
was	  observed.	  
At	  day	  9,	  splenic	  plasma	  cells	  had	  adopted	  a	  more	  mature	  phenotype,	  with	  low	  
CD19	  and	  MHC	  II	  expression	  and	  high	  forward	  and	  side	  scatter.	  Intracellular	  Ig	  
was	  further	  increased	  while	  CD138	  expression	  was	  decreased.	  At	  day	  45,	  MHC	  II	  
and	  CD19	  were	  further	  decreased,	  while	  intracellular	  Ig,	  forward	  and	  side	  
scatter	  were	  maintained.	  Interestingly,	  CD138	  levels	  had	  recovered	  to	  levels	  
seen	  at	  day	  4	  and	  in	  naïve	  mice.	  
Plasma	  cells	  in	  the	  bone	  marrow	  did	  not	  change	  as	  rapidly	  as	  those	  in	  the	  
spleen.	  This	  is	  in	  agreement	  with	  data	  from	  figure	  3.1,	  which	  shows	  that	  
frequencies	  of	  plasma	  cells	  here	  were	  not	  overtly	  affected	  at	  day	  4	  of	  secondary	  
immunisation.	  However,	  it	  can	  be	  seen	  that	  MHC	  II	  expression	  and	  CD19	  were	  
rapidly	  and	  progressively	  down	  regulated	  throughout	  the	  time	  course.	  
Intracellular	  Ig	  production	  was	  similar	  to	  that	  of	  splenic	  plasma	  cells,	  but	  
peaked	  at	  higher	  levels	  at	  days	  9	  and	  45.	  
Measurement	  of	  plasma	  cell	  turnover	  using	  BrdU	  labelling	  
In	  figure	  3.2,	  we	  saw	  that	  plasma	  cells	  down	  regulate	  MHC	  II	  as	  they	  mature.	  
Plasma	  cells	  are	  known	  to	  be	  short	  or	  long-­‐lived,	  but	  few	  phenotypic	  differences	  
have	  been	  reported	  which	  can	  be	  used	  to	  distinguish	  between	  these	  two	  plasma	  
cell	  populations193,303.	  We	  next	  looked	  at	  whether	  mature	  plasma	  cells	  are	  long-­‐
lived	  cells	  with	  slow	  turnover,	  or	  short-­‐lived	  with	  rapid	  turnover.	  We	  assessed	  
the	  turnover	  of	  plasma	  cells	  through	  BrdU	  labelling.	  Mice	  were	  continuously	  fed	  
BrdU	  in	  their	  drinking	  water	  for	  10-­‐day	  periods.	  Cells	  that	  divided	  in	  this	  period	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would	  incorporate	  BrdU	  into	  their	  DNA,	  and	  this	  was	  detected	  through	  staining	  
with	  anti-­‐BrdU	  antibodies.	  Dividing	  plasma	  cells	  were	  termed	  ‘short-­‐lived’	  
plasma	  cells;	  those	  that	  did	  not	  divide	  in	  a	  10-­‐day	  period	  were	  termed	  ‘long-­‐
lived’	  plasma	  cells.	  Following	  BrdU	  labelling	  of	  naïve	  6-­‐week	  old	  C57Bl/6	  mice,	  
turnover	  of	  total	  (intracellular	  Igκ+)	  plasma	  cell	  populations	  was	  assessed	  
under	  homeostatic	  conditions.	  It	  was	  found	  that	  42.24%	  (±2.57)	  of	  plasma	  cells	  
in	  the	  spleen	  had	  divided	  in	  this	  time,	  and	  slightly	  higher	  percentages	  (53.86%	  
(±2.00))	  in	  the	  bone	  marrow	  (fig	  3.3a).	  	  
We	  next	  examined	  whether	  mature,	  MHC	  IIlo	  plasma	  cells	  were	  dividing	  at	  a	  
different	  rate	  to	  immature,	  MHC	  IIhi	  plasma	  cells.	  It	  was	  found	  that	  the	  spleen	  
contained	  a	  larger	  fraction	  of	  MHC	  IIlo	  plasma	  cells	  than	  the	  bone	  marrow	  
(47.06%	  (±4.07)	  and	  41.54%	  (±2.73)	  respectively)	  (fig	  3.3b).	  In	  both	  spleen	  and	  
bone	  marrow,	  we	  observed	  a	  statistically	  significant	  difference	  in	  turnover	  of	  
MHC	  IIhi	  and	  MHC	  IIlo	  plasma	  cells,	  with	  28.40%	  (±3.69)	  and	  38.64%	  (±2.60)	  of	  
mature	  MHC	  IIlo	  plasma	  cells	  turning	  over	  in	  the	  spleen	  and	  bone	  marrow	  
respectively.	  In	  contrast	  to	  this,	  54.12%	  (±3.47)	  and	  65.82%	  (±1.71)	  of	  
immature,	  MHC	  IIhi	  plasma	  cells	  turned	  over	  during	  a	  10-­‐day	  period	  in	  the	  
spleen	  and	  bone	  marrow	  respectively	  (fig	  3.3b	  and	  c).	  
Plasma	  cells	  accumulate	  in	  the	  bone	  marrow	  over	  time	  and	  contribute	  to	  serum	  
antibody	  levels	  
Although	  we	  had	  developed	  a	  model	  to	  distinguish	  short	  and	  long-­‐lived	  plasma	  
cells,	  our	  data	  was	  not	  complimentary	  to	  that	  published	  in	  the	  literature.	  The	  
frequency	  of	  bone	  marrow	  plasma	  cells	  that	  we	  had	  observed	  in	  6-­‐week	  old	  
C57Bl/6	  mice	  was	  0.081%	  (±0.013)	  (fig	  3.1c).	  This	  was	  towards	  the	  lower	  end	  
of	  those	  published	  in	  the	  literature38,247.	  Likewise,	  we	  had	  observed	  that	  the	  
turnover	  of	  plasma	  cells	  was	  more	  rapid	  in	  the	  bone	  marrow	  than	  the	  spleen	  
(fig	  3.3a),	  contradictory	  to	  reports	  suggesting	  that	  long-­‐lived	  plasma	  cells	  
primarily	  reside	  in	  the	  bone	  marrow193.	  We	  therefore	  hypothesised	  that	  long-­‐
lived	  plasma	  cells	  may	  take	  time	  to	  accumulate	  in	  the	  bone	  marrow	  and	  
therefore	  were	  not	  present	  in	  high	  numbers	  in	  6-­‐week	  old	  mice.	  This	  could	  be	  
due	  to	  increased	  support	  for	  long-­‐lived	  plasma	  cells	  in	  the	  bone	  marrow	  of	  older	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mice	  (through	  increased	  availability	  of	  survival	  factors),	  or	  the	  fact	  that	  only	  
certain	  plasma	  cells	  (generated	  during	  germinal	  centre	  reactions)	  are	  able	  to	  
become	  long-­‐lived	  and	  therefore	  are	  not	  present	  in	  high	  numbers	  in	  young	  mice	  
that	  have	  undergone	  few	  such	  responses.	  	  
We	  first	  tested	  whether	  plasma	  cells	  increased	  over	  time	  in	  the	  spleen	  and	  bone	  
marrow.	  C57Bl/6	  mice	  from	  age-­‐matched	  litters	  were	  aged	  to	  5,	  15	  and	  30-­‐
weeks	  after	  birth	  before	  examination	  of	  the	  spleen	  and	  bone	  marrow	  for	  plasma	  
cell	  frequency	  and	  number.	  As	  shown	  in	  figure	  3.4a,	  frequencies	  of	  total	  (Igκ),	  
IgM	  and	  IgG	  plasma	  cells	  increased	  in	  mice	  as	  they	  aged.	  In	  the	  spleen,	  
frequencies	  of	  both	  total	  and	  IgG	  plasma	  cells	  increased	  significantly	  between	  
the	  age	  of	  5	  and	  30-­‐weeks.	  In	  the	  bone	  marrow	  the	  increase	  was	  greater,	  with	  
total,	  IgM	  and	  IgG	  plasma	  cells	  increasing	  significantly	  by	  30-­‐weeks	  of	  age.	  Igκ	  
plasma	  cells	  in	  these	  mice	  reached	  frequencies	  0.76%	  (±0.08)	  of	  total	  bone	  
marrow	  cells.	  
When	  absolute	  numbers	  of	  plasma	  cells	  were	  calculated,	  30	  week	  old	  mice	  had	  
not	  accumulated	  significantly	  higher	  numbers	  of	  plasma	  cells	  in	  the	  spleen	  over	  
this	  period.	  However,	  in	  the	  bone	  marrow	  numbers	  of	  total,	  IgM	  and	  IgG	  plasma	  
cells	  had	  increased	  significantly	  compared	  to	  5	  week	  old	  mice	  (fig	  3.4b).	  This	  
10-­‐fold	  increase	  occurred	  predominantly	  between	  the	  15	  and	  30-­‐week	  time	  
points.	  
To	  determine	  whether	  the	  accumulation	  of	  bone	  marrow	  plasma	  cells	  
significantly	  affected	  serum	  antibody	  levels,	  the	  serum	  of	  5,	  15	  and	  30	  week	  old	  
naïve	  C57Bl/6	  mice	  (from	  figure	  3.4)	  was	  evaluated	  for	  total	  IgM,	  IgA,	  IgG1,	  
IgG2b,	  IgG2c	  and	  IgG3.	  Many	  of	  the	  antibody	  classes	  increased	  significantly	  over	  
time.	  IgM	  increased	  by	  week	  30	  and	  IgA	  by	  week	  15.	  IgG2b,	  IgG2c	  and	  IgG3	  had	  
significantly	  increased	  by	  week	  15	  and	  continued	  to	  increase	  until	  week	  30.	  
Interestingly	  IgG1	  did	  not	  appear	  to	  increase	  throughout	  the	  time	  course	  (fig	  
3.5).	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Most	  plasma	  cells	  accumulating	  in	  the	  bone	  marrow	  of	  naïve	  C57Bl/6	  mice	  are	  
long-­‐lived	  
As	  stated	  above,	  we	  had	  observed	  that	  the	  turnover	  of	  plasma	  cells	  in	  the	  bone	  
marrow	  of	  young	  mice	  was	  surprisingly	  high	  (fig	  3.3),	  as	  this	  is	  cited	  as	  the	  
major	  organ	  in	  which	  long-­‐lived	  plasma	  cells	  reside189,193,306.	  To	  determine	  
whether	  the	  accumulation	  of	  plasma	  cells	  seen	  in	  the	  bone	  marrow	  (fig	  3.4)	  was	  
due	  to	  an	  increase	  in	  short	  or	  long-­‐lived	  plasma	  cells,	  5	  or	  30-­‐week	  old	  C57Bl/6	  
mice	  were	  given	  BrdU	  in	  the	  drinking	  water	  for	  a	  10-­‐day	  period,	  and	  plasma	  cell	  
populations	  in	  the	  spleen	  and	  bone	  marrow	  were	  assessed	  for	  BrdU	  
incorporation.	  Figure	  3.6a	  shows	  example	  plasma	  cell	  gating	  and	  representative	  
FACS	  plots	  of	  BrdU	  incorporation	  and	  MHC	  II	  expression	  on	  total	  plasma	  cells	  in	  
the	  spleen	  and	  bone	  marrow	  of	  5	  and	  30-­‐week	  old	  mice.	  From	  these	  plots,	  it	  is	  
clear	  that	  frequencies	  of	  plasma	  cells	  increased	  both	  in	  the	  spleen	  and	  bone	  
marrow	  between	  the	  two	  time	  points	  (fig	  3.6a	  top	  row).	  In	  fact,	  splenic	  plasma	  
cells	  increased	  2.4	  fold,	  whereas	  bone	  marrow	  plasma	  cells	  increased	  8-­‐fold.	  10-­‐
day	  BrdU	  pulses	  given	  to	  5	  or	  30-­‐week	  old	  mice	  revealed	  that	  in	  both	  the	  spleen	  
and	  bone	  marrow,	  the	  proportion	  of	  plasma	  cells	  dividing	  during	  this	  time	  was	  
lower	  in	  30-­‐week	  old	  mice.	  Turnover	  was	  higher	  in	  the	  bone	  marrow	  than	  the	  
spleen	  in	  5-­‐week	  old	  mice,	  but	  this	  was	  reversed	  in	  30-­‐week	  old	  mice	  (fig	  3.6a	  
middle	  row).	  While	  the	  proportion	  of	  plasma	  cells	  expressing	  MHC	  II	  in	  the	  
spleen	  did	  not	  change	  between	  the	  two	  time	  points,	  a	  higher	  proportion	  of	  
plasma	  cells	  were	  MHC	  IIlo	  in	  the	  bone	  marrow	  of	  30-­‐week	  old	  mice	  compared	  
to	  5-­‐week	  old	  mice	  (fig	  3.6a	  bottom	  row).	  	  
In	  this	  experiment,	  splenic	  Igκ	  and	  IgG	  plasma	  cells	  had	  significantly	  increased	  
in	  terms	  of	  frequency	  and	  number	  between	  the	  two	  time	  points	  (although	  IgM	  
plasma	  cell	  numbers	  were	  not	  significantly	  different,	  the	  trend	  was	  also	  towards	  
an	  increase)	  (fig	  3.6b	  and	  c).	  Bone	  marrow	  plasma	  cells	  had	  increased	  as	  seen	  in	  
earlier	  experiments,	  and	  both	  frequencies	  and	  numbers	  of	  Igκ,	  IgM	  and	  IgG	  
plasma	  cells	  were	  significantly	  increased	  in	  30-­‐week	  old	  mice	  compared	  to	  5-­‐
week-­‐old	  mice	  (fig	  3.6b	  and	  c).	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The	  BrdU	  incorporation	  of	  these	  plasma	  cells	  was	  assessed.	  In	  the	  spleen,	  the	  
turnover	  of	  Igκ	  plasma	  cells	  in	  30-­‐week	  old	  mice	  was	  lower	  than	  that	  of	  5-­‐week	  
old	  mice	  (42.24%	  (±2.57)	  in	  5-­‐week	  old	  mice,	  29.86%	  (±3.71)	  in	  30-­‐week	  old	  
mice).	  Little	  difference	  in	  the	  turnover	  of	  IgM	  or	  IgG	  plasma	  cells	  was	  observed	  
between	  the	  two	  groups	  (fig	  3.6d).	  	  
In	  the	  bone	  marrow,	  the	  turnover	  of	  total,	  IgM	  and	  IgG	  plasma	  cells	  was	  
significantly	  lower	  in	  30-­‐week	  old	  mice	  compared	  to	  5-­‐week	  old	  mice	  (for	  total:	  
53.86%	  (±2.00)	  in	  5-­‐week	  old	  mice,	  10.71%	  (±1.11)	  in	  30-­‐week	  old	  mice)	  (fig	  
3.6d).	  
When	  numbers	  of	  either	  BrdU+	  or	  BrdU-­‐	  plasma	  cells	  were	  calculated,	  there	  
was	  no	  significant	  increase	  in	  total,	  IgM	  or	  IgG	  plasma	  cells	  in	  the	  spleen	  for	  
either	  dividing	  or	  non-­‐dividing	  plasma	  cells.	  In	  the	  bone	  marrow,	  no	  significant	  
increase	  in	  dividing	  plasma	  cells	  was	  seen,	  but	  there	  was	  a	  significant	  increase	  
in	  non-­‐dividing	  plasma	  cells	  (especially	  total	  and	  IgG)	  (fig	  3.6e).	  
Similarly,	  when	  plasma	  cells	  were	  examined	  for	  MHC	  II	  expression,	  there	  was	  
no	  significant	  difference	  in	  the	  proportion	  of	  MHC	  IIlo	  plasma	  cells	  in	  the	  spleens	  
of	  5	  or	  30-­‐week	  old	  mice.	  In	  the	  bone	  marrow	  however,	  there	  was	  a	  significant	  
increase	  in	  the	  proportion	  of	  mature	  MHC	  IIlo	  plasma	  cells	  (fig	  3.6f).	  Figure	  3.6g	  
shows	  that	  there	  was	  a	  small	  but	  statistically	  significant	  increase	  in	  MHC	  IIhi	  
plasma	  cells	  in	  both	  organs	  (with	  the	  exception	  of	  IgM	  plasma	  cells,	  which	  did	  
not	  increase	  significantly).	  While	  this	  was	  similar	  for	  MHC	  IIlo	  plasma	  cells	  in	  the	  
spleen,	  the	  bone	  marrow	  compartment	  showed	  a	  large	  and	  highly	  significant	  
increase	  in	  total	  and	  IgG	  MHC	  IIlo	  plasma	  cells	  (and	  a	  smaller	  increase	  in	  IgM	  
plasma	  cells).	  
Niche	  providing	  cells	  in	  young	  and	  aged	  mice	  
It	  has	  so	  far	  been	  shown	  that	  mature,	  long-­‐lived	  plasma	  cells	  accumulate	  in	  the	  
bone	  marrow	  of	  mice	  over	  time.	  We	  now	  investigated	  whether	  cells	  known	  to	  
support	  plasma	  cell	  survival	  also	  increased	  in	  the	  bone	  marrow	  of	  mice	  aged.	  
Frequencies	  of	  total	  APRIL-­‐producing	  cells	  in	  either	  the	  spleen	  or	  bone	  marrow	  
of	  5	  and	  30-­‐week	  old	  mice	  did	  not	  differ	  significantly	  (data	  not	  shown).	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However,	  a	  population	  of	  cells	  which	  produced	  10-­‐fold	  higher	  levels	  of	  APRIL	  
than	  other	  cell	  types	  (including	  the	  various	  ‘niche-­‐providing	  cells’	  cited	  in	  the	  
literature)	  were	  identified	  and	  are	  hereafter	  referred	  to	  as	  APRILhi	  cells.	  These	  
cells,	  along	  with	  CD11c+	  dendritic	  cells;	  CD41+	  megakaryocytes;	  CD11b+	  Gr1int	  
F4/80+	  monocytes	  and	  macrophages;	  CD11bint	  Gr1int	  F4/80+	  eosinophils	  were	  
quantified.	  
In	  the	  spleen,	  only	  monocytes/macrophages	  increased	  significantly	  in	  terms	  of	  
numbers	  (and	  not	  frequency).	  In	  the	  bone	  marrow,	  it	  was	  found	  that	  APRILhi	  
cells	  and	  dendritic	  cells	  increased	  significantly	  in	  terms	  of	  both	  frequency	  and	  
number	  (fig	  3.7).	  	  
Long-­‐lived	  plasma	  cell	  accumulation	  in	  the	  bone	  marrow	  of	  naïve	  mice	  requires	  
signals	  through	  the	  BCR	  and	  T	  cell	  interactions	  through	  MHC	  II	  and	  CD40	  
To	  determine	  whether	  TLR	  signalling,	  T	  cell-­‐B	  cell	  interactions	  or	  antigen	  
recognition	  through	  the	  BCR	  were	  important	  for	  the	  accumulation	  of	  long-­‐lived	  
bone	  marrow	  plasma	  cells,	  we	  aged	  naïve	  wild	  type,	  MyD88/TRIF-­‐/-­‐,	  Aβ-­‐/-­‐,	  	  
CD40-­‐/-­‐	  and	  MD4	  mice,	  in	  which	  all	  B	  cells	  express	  a	  BCR	  that	  recognises	  HEL.	  
Firstly,	  we	  assessed	  splenic	  and	  bone	  marrow	  plasma	  cells	  in	  wild	  type	  and	  
knockout	  mice	  aged	  5-­‐7	  weeks.	  It	  was	  found	  that	  at	  this	  age,	  most	  strains	  had	  
approximately	  comparable	  numbers	  of	  plasma	  cells	  in	  both	  organs,	  although	  
MD4	  mice	  had	  fewer	  plasma	  cells	  in	  the	  spleen	  (fig	  3.8a).	  The	  frequency	  of	  
plasma	  cells	  was	  higher	  in	  Aβ-­‐/-­‐	  spleens	  due	  to	  a	  reduction	  in	  certain	  other	  cell	  
types;	  absolute	  numbers	  of	  plasma	  cells	  in	  the	  spleens	  of	  these	  mice	  were	  
comparable	  to	  those	  of	  wild	  type	  mice.	  
Next,	  wild	  type	  and	  genetically	  modified	  mice	  were	  aged	  to	  30	  weeks,	  before	  
assessment	  of	  spleen	  and	  bone	  marrow	  for	  accumulation	  of	  long-­‐lived	  plasma	  
cells.	  All	  strains	  of	  mice	  had	  similar	  frequencies	  and	  numbers	  of	  plasma	  cells	  in	  
the	  spleen.	  Wild	  type	  mice	  had	  accumulated	  plasma	  cells	  in	  the	  bone	  marrow,	  
while	  Aβ	  -­‐/-­‐,	  CD40-­‐/-­‐	  and	  MD4	  mice	  had	  not.	  MyD88/TRIF-­‐/-­‐	  mice	  had	  
significantly	  greater	  variance	  than	  wild	  type	  mice	  (p=0.0016)	  and	  therefore	  any	  
difference	  was	  not	  significant.	  Aβ	  -­‐/-­‐,	  CD40-­‐/-­‐	  and	  MD4	  mice	  all	  had	  significantly	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lower	  frequencies	  and	  numbers	  of	  bone	  marrow	  plasma	  cells	  compared	  to	  wild	  
type	  mice.	  
To	  determine	  if	  reduced	  numbers	  of	  plasma	  cells	  in	  the	  bone	  marrow	  of	  these	  
mice	  was	  due	  to	  a	  lack	  of	  accumulation	  of	  long-­‐lived	  plasma	  cells,	  we	  next	  gave	  
aged	  genetically	  modified	  mice	  10-­‐day	  BrdU	  pulses	  and	  assessed	  turnover	  of	  
splenic	  and	  bone	  marrow	  plasma	  cells.	  Figure	  3.9a	  shows	  that	  in	  the	  spleen,	  
only	  CD40-­‐/-­‐	  mice	  had	  lower	  turnover	  than	  wild	  type	  mice,	  and	  differences	  were	  
small.	  In	  the	  bone	  marrow	  however,	  wild	  type	  mice	  showed	  significantly	  lower	  
turnover	  than	  the	  genetically	  modified	  strains	  (except	  for	  MD4	  mice)	  suggesting	  
that	  they	  have	  more	  long-­‐lived	  plasma	  cells.	  	  
When	  numbers	  of	  BrdU+,	  short-­‐lived	  plasma	  cells	  were	  calculated,	  there	  was	  
little	  difference	  between	  any	  of	  the	  strains	  in	  either	  spleen	  or	  bone	  marrow	  
(only	  Aβ-­‐/-­‐	  had	  significantly	  fewer	  short-­‐lived	  plasma	  cells	  in	  the	  bone	  marrow)	  
(fig	  3.9b).	  Interestingly	  in	  the	  spleen,	  MyD88/TRIF-­‐/-­‐	  mice	  had	  significantly	  
fewer	  long-­‐lived	  plasma	  cells	  than	  wild	  type	  mice,	  whereas	  in	  the	  bone	  marrow	  
they	  were	  the	  only	  group	  to	  have	  no	  significant	  difference	  in	  long-­‐lived	  plasma	  
cells.	  All	  other	  strains	  had	  significantly	  fewer	  long-­‐lived	  plasma	  cells	  than	  wild	  
type	  mice.	  Taken	  together,	  these	  data	  show	  that	  many	  of	  these	  strains	  fail	  to	  
accumulate	  long-­‐lived	  plasma	  cells	  in	  the	  bone	  marrow	  over	  time.	  	  
To	  investigate	  whether	  knockout	  mice	  do	  not	  accumulate	  bone	  marrow	  plasma	  
cells	  due	  to	  reduced	  ‘niche-­‐providing-­‐cells’,	  we	  stained	  for	  markers	  revealing	  a	  
number	  of	  cell	  populations	  known	  to	  support	  plasma	  cell	  survival.	  APRILhi	  cells	  
were	  significantly	  decreased	  in	  the	  spleens	  of	  Aβ-­‐/-­‐,	  and	  also	  in	  the	  bone	  marrow	  
of	  both	  Aβ-­‐/-­‐	  and	  MyD88/TRIF-­‐/-­‐	  mice	  (fig	  3.10).	  Only	  MyD88/TRIF-­‐/-­‐	  had	  fewer	  
dendritic	  cells	  in	  the	  bone	  marrow	  compartment.	  There	  were	  no	  significant	  
differences	  in	  numbers	  of	  eosinophils	  or	  megakaryocytes	  in	  the	  spleen	  or	  bone	  
marrow	  of	  any	  of	  the	  strains	  used.	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Discussion	  
Plasma	  cells	  are	  end	  stage	  B	  cells	  that	  secrete	  large	  amounts	  of	  antibody	  and	  do	  
not	  divide.	  Their	  lifespan	  can	  be	  short,	  around	  3	  days,	  or	  long,	  a	  half-­‐life	  of	  
months	  to	  years193.	  Long-­‐lived	  plasma	  cells	  are	  a	  key	  part	  of	  humoral	  immunity	  
and	  are	  the	  mechanism	  by	  which	  circulating	  antibody	  is	  maintained	  without	  
antigen	  re-­‐exposure	  or	  retention	  189,307.	  	  
Here	  we	  have	  developed	  methods	  for	  identifying	  plasma	  cells,	  and	  the	  
differentiation	  of	  short-­‐lived	  and	  long-­‐lived	  plasma	  cells	  using	  BrdU	  labelling.	  
We	  document	  the	  accumulation	  of	  long-­‐lived	  plasma	  cells	  in	  the	  bone	  marrow	  
over	  time	  in	  naïve	  mice	  and	  determine	  the	  likely	  requirements	  for	  this	  to	  occur.	  
Identifying	  plasma	  cells	  using	  intracellular	  antibody	  
We	  detected	  large	  populations	  of	  CD138hi	  cells	  in	  the	  spleen	  5	  days	  after	  
secondary	  immunisation	  with	  NP-­‐KLH	  (fig	  3.1a).	  These	  cells	  had	  high	  levels	  of	  
intracellular	  Ig	  (fig	  3.1b).	  However,	  by	  day	  10,	  CD138	  was	  expressed	  only	  at	  low	  
levels	  on	  intracellular	  Ighi	  cells	  (fig	  3.2).	  Similarly,	  at	  early	  time	  points	  during	  
Salmonella	  infection	  CD138hi	  cells	  could	  be	  detected,	  many	  of	  which	  were	  
intracellular	  Ighi	  (fig	  3.1d).	  This	  was	  not	  the	  case	  at	  later	  time	  points,	  where	  
intracellular	  Ighi	  cells	  did	  not	  express	  high	  levels	  of	  CD138.	  This	  is	  a	  reported	  
phenomenon	  in	  other	  infection	  models	  such	  as	  Trypanosoma	  cruzi,	  where	  
CD138lo	  plasma	  cells	  are	  reported	  in	  both	  the	  peritoneum	  and	  spleen	  following	  
infection308,309.	  Many	  plasma	  cells	  in	  humans	  do	  not	  express	  CD138,	  however	  in	  
contrast	  to	  the	  data	  shown	  here	  (where	  early	  plasma	  cells	  express	  the	  marker,	  
while	  more	  mature	  plasma	  cells	  do	  not),	  CD138hi	  plasma	  cells	  in	  humans	  
express	  a	  more	  mature	  phenotype	  than	  CD138lo	  plasma	  cells310.	  Intriguingly,	  
plasma	  cells	  seen	  45	  days	  after	  secondary	  immunisation	  with	  NP-­‐KLH	  once	  
again	  expressed	  high	  levels	  of	  CD138,	  suggesting	  that	  both	  early	  plasmablasts	  
and	  highly	  mature	  plasma	  cells	  express	  the	  marker,	  but	  an	  intermediate	  stage	  of	  
low	  CD138	  expression	  occurs	  on	  plasma	  cells	  in	  mice.	  	  
Plasma	  cells	  are	  known	  to	  downregulate	  many	  other	  surface	  markers	  as	  they	  
mature	  (such	  as	  MHC	  II,	  B220,	  CD19	  and	  the	  BCR245),	  and	  this	  was	  observed	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here.	  These	  markers,	  in	  contrast	  to	  CD138,	  remained	  low	  at	  day	  45	  after	  
secondary	  NP-­‐KLH	  immunisation.	  CD138	  is	  predominantly	  used	  as	  a	  phenotypic	  
marker	  for	  plasma	  cells,	  and	  its	  function	  is	  not	  clear,	  although	  it	  may	  play	  a	  role	  
in	  cellular	  adhesion	  and	  trafficking	  to	  the	  bone	  marrow212.	  Further	  experiments	  
would	  be	  required	  to	  determine	  why	  some	  plasma	  cells	  do	  not	  express	  high	  
levels	  of	  CD138,	  and	  whether	  this	  affects	  their	  entry	  to	  the	  bone	  marrow	  
compartment.	  
Based	  on	  the	  markers	  analysed	  in	  this	  experiment,	  we	  could	  not	  detect	  any	  
phenotypic	  difference	  between	  splenic	  and	  bone	  marrow	  plasma	  cells	  in	  6-­‐week	  
old	  naïve	  mice	  (fig	  3.2).	  However,	  immunisation	  appeared	  to	  affect	  these	  
populations	  in	  different	  ways.	  The	  rapid	  generation	  of	  splenic	  plasmablasts	  
expressing	  high	  levels	  of	  CD19,	  MHC	  II	  and	  CD138	  has	  been	  previously	  
reported87.	  These	  cells	  subsequently	  matured,	  expressing	  lower	  amounts	  of	  
MHC	  II	  and	  CD19	  while	  increasing	  the	  amount	  of	  antibody	  they	  produced	  by	  day	  
9.	  It	  is	  likely	  that	  these	  cells	  no	  longer	  divide,	  characteristic	  of	  mature	  plasma	  
cells78,87.	  
In	  the	  bone	  marrow	  changes	  were	  not	  so	  rapid;	  reflecting	  the	  fact	  that	  plasma	  
cells	  are	  produced	  in	  secondary	  lymphoid	  organs	  and	  must	  migrate	  there311.	  
There	  was	  only	  a	  modest	  increase	  in	  plasma	  cell	  frequency	  in	  the	  bone	  marrow	  
after	  secondary	  immunisation	  with	  NP-­‐KLH	  (fig	  3.1c)	  despite	  the	  dramatic	  
increases	  seen	  in	  the	  spleen.	  This	  supports	  the	  idea	  that	  the	  bone	  marrow	  
plasma	  cell	  pool	  is	  of	  limited	  size	  and,	  like	  many	  memory	  pools,	  the	  influx	  of	  
new	  cells	  comes	  at	  the	  expense	  of	  older,	  pre-­‐established	  cells185,249.	  Plasma	  cells	  
entering	  the	  bone	  marrow	  at	  day	  5	  expressed	  intermediate	  levels	  of	  MHC	  II,	  
CD19	  and	  relatively	  low	  levels	  of	  intracellular	  Ig	  (fig	  3.2),	  but	  continued	  to	  
mature	  thereafter.	  In	  fact,	  bone	  marrow	  plasma	  cells	  were	  found	  to	  produce	  
more	  antibody	  than	  their	  splenic	  counterparts.	  This	  is	  likely	  due	  to	  the	  
increased	  expansion	  of	  intracellular	  machinery	  for	  producing	  and	  secreting	  
antibody	  such	  as	  the	  endoplasmic	  reticulum	  and	  Golgi	  apparatus.	  The	  expansion	  
of	  these	  are	  controlled	  by	  the	  transcription	  factor	  XBP-­‐1,	  downstream	  of	  the	  
master	  transcription	  factor	  for	  plasma	  cells,	  BLIMP-­‐198.	  Why	  bone	  marrow	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plasma	  cells	  have	  an	  enhanced	  ability	  to	  secrete	  antibody	  is	  unknown,	  but	  may	  
be	  mediated	  by	  signals	  enriched	  in	  the	  bone	  marrow166.	  
Turnover	  of	  plasma	  cells	  using	  BrdU	  labelling	  
It	  was	  surprising	  that	  all	  bone	  marrow	  plasma	  cells	  had	  an	  altered	  phenotype	  
10	  days	  after	  secondary	  immunisation	  with	  NP-­‐KLH	  (fig	  3.2).	  This	  population	  is	  
reported	  to	  be	  a	  pool	  of	  long-­‐lived,	  non-­‐dividing	  ‘memory’	  plasma	  cells,	  
maintaining	  serum	  antibody	  levels	  to	  a	  range	  of	  different	  specificities	  (i.e.	  from	  
previous	  immune	  responses)	  78,193,194,307.	  It	  would	  be	  expected	  that	  only	  newly	  
generated	  plasma	  cells	  coming	  into	  the	  bone	  marrow	  would	  express	  immature	  
phenotypes,	  whereas	  pre-­‐established	  plasma	  cells,	  generated	  in	  prior	  immune	  
responses,	  would	  maintain	  mature	  phenotypes.	  BrdU	  labelling	  experiments	  
showed	  that	  bone	  marrow	  plasma	  cells	  turned	  over	  at	  a	  similar	  rate	  to	  those	  in	  
the	  spleen	  (tending	  towards	  higher	  turnover	  in	  the	  bone	  marrow)	  (fig	  3.3a).	  
Similarly,	  the	  fact	  that	  the	  bone	  marrow	  also	  contained	  a	  higher	  proportion	  of	  
MHC	  IIhi	  plasma	  cells	  than	  the	  spleen	  suggested	  that	  the	  bone	  marrow	  of	  these	  6	  
to	  8-­‐week	  old	  naïve	  mice	  did	  not	  contain	  high	  numbers	  of	  long-­‐lived	  plasma	  
cells.	  
This	  data	  confirmed	  that	  MHC	  IIhi	  plasma	  cells	  were	  mainly	  immature,	  dividing	  
plasmablasts,	  while	  MHC	  IIlo	  plasma	  cells	  were	  mainly	  non-­‐dividing	  plasma	  cells	  
(fig	  3.3b	  and	  c),	  however	  some	  MHC	  IIlo	  plasma	  cells	  were	  seen	  to	  divide	  in	  both	  
spleen	  and	  bone	  marrow.	  Pelletier	  et	  al	  have	  shown	  that	  plasma	  cells	  are	  
capable	  antigen	  presenting	  cells267.	  It	  is	  possible	  that	  MHC	  II	  is	  actively	  
maintained	  on	  the	  surface	  of	  some	  long-­‐lived,	  non-­‐dividing	  plasma	  cells,	  or	  can	  
be	  up	  regulated	  through	  unknown	  signals.	  CD4	  memory	  T	  cells	  also	  reside	  in	  the	  
bone	  marrow,	  where	  (similar	  to	  long-­‐lived	  plasma	  cells)	  they	  occupy	  survival	  
niches,	  and	  slow	  their	  rate	  of	  division	  and	  gene	  expression,	  allowing	  for	  long-­‐
term	  survival312,313.	  It	  is	  an	  attractive	  proposition	  that	  bone	  marrow	  plasma	  
cells	  play	  a	  role	  in	  the	  activation	  of	  resting	  CD4	  memory	  T	  cells,	  mediated	  by	  
periodic	  increases	  in	  (or	  maintenance	  of)	  MHC	  II.	  These	  ideas	  will	  be	  explored	  
further	  in	  Chapter	  6.	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Plasma	  cells	  accumulate	  in	  the	  bone	  marrow	  over	  time	  
Through	  the	  course	  of	  our	  experiments	  we	  observed	  that	  young	  naïve	  (5-­‐8	  
week	  old)	  mice	  had	  fewer	  plasma	  cells	  in	  the	  bone	  marrow	  than	  older	  (15-­‐30	  
week	  old)	  naïve	  mice.	  To	  quantify	  this,	  we	  performed	  experiments	  looking	  at	  
frequencies	  and	  numbers	  of	  plasma	  cells	  through	  a	  30-­‐week	  time	  course	  (fig	  
3.4a	  and	  b).	  Indeed,	  mice	  were	  found	  to	  accumulate	  significantly	  higher	  
frequencies	  and	  numbers	  of	  plasma	  cells	  in	  the	  bone	  marrow	  over	  time.	  These	  
plasma	  cells	  were	  of	  a	  mature,	  MHC	  IIlo	  phenotype	  and	  turned	  over	  slowly	  (fig	  
3.6d).	  This	  was	  not	  an	  inherent	  change	  in	  the	  lifespan	  of	  plasma	  cells	  generated	  
in	  these	  mice	  as	  turnover	  of	  splenic	  plasma	  cells	  was	  not	  significantly	  altered	  
(fig	  3.6d).	  
We	  found	  that	  both	  IgM	  and	  IgG	  plasma	  cells	  accumulated	  in	  the	  bone	  marrow,	  
with	  IgM	  plasma	  cells,	  surprisingly,	  increasing	  to	  higher	  frequencies	  and	  
numbers	  than	  IgG	  plasma	  cells	  (fig	  3.4a	  and	  b).	  IgM	  plasma	  cells	  turned	  over	  at	  a	  
similar	  rate	  to	  IgG	  plasma	  cells	  (fig	  3.6d),	  contrary	  to	  the	  idea	  that	  only	  class-­‐
switched	  plasma	  cells	  can	  become	  long-­‐lived89.	  In	  fact,	  long-­‐lived	  IgM	  plasma	  
cells	  were	  found	  in	  greater	  numbers	  than	  IgG	  plasma	  cells	  in	  both	  the	  bone	  
marrow	  and	  spleens	  of	  these	  mice.	  This	  does	  not	  necessarily	  contradict	  reports	  
claiming	  that	  the	  majority	  of	  long-­‐lived	  plasma	  cells	  are	  class	  switched	  following	  
a	  TD	  immune	  response248.	  IgG	  plasma	  cells	  are	  somewhat	  under-­‐represented	  in	  
the	  naïve	  mouse’s	  repertoire;	  the	  majority	  of	  plasma	  cells	  generated	  in	  the	  
spleen	  are	  IgM	  (fig	  3.4b	  and	  3.6c).	  This	  may	  mean	  that,	  while	  class	  switched	  
plasma	  cells	  are	  more	  proficient	  at	  accessing	  survival	  niches,	  by	  simple	  ‘weight	  
of	  numbers’	  IgM	  plasma	  cells	  come	  to	  occupy	  the	  majority	  of	  niches	  in	  naïve	  
mice.	  It	  is	  certainly	  true	  that	  IgM	  plasma	  cells	  are	  not	  impaired	  in	  their	  ability	  to	  
migrate	  to	  the	  bone	  marrow	  compartment,	  as	  they	  outnumber	  class	  switched	  
plasma	  cells	  here	  as	  well	  (fig	  3.4b	  and	  3.6c).	  It	  is	  known	  that	  long-­‐lived	  IgM	  
plasma	  cells	  are	  generated	  to	  bacterial	  infection	  with	  Ehrlichia	  muris314,	  
parasitic	  infection	  with	  Plasmodium	  chabaudi	  chabaudi315	  and	  a	  polysaccharide	  
antigen	  from	  Streptococcus	  pneumoniae316.	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Despite	  accumulation	  of	  long-­‐lived	  IgM	  plasma	  cells	  in	  the	  bone	  marrow,	  many	  
of	  these	  were	  MHC	  IIhi.	  This	  is	  similar	  to	  data	  from	  figure	  3.3,	  where	  many	  non-­‐
dividing	  plasma	  cells	  in	  the	  spleen	  (and	  to	  a	  lesser	  extent	  the	  bone	  marrow)	  of	  6	  
to	  8-­‐week	  old	  naïve	  mice	  expressed	  MHC	  II.	  Likewise,	  Racine	  et	  al	  showed	  that	  
many	  IgM	  plasma	  cells	  accumulating	  in	  the	  bone	  marrow	  following	  infection	  
with	  E.	  muris	  continued	  to	  express	  B	  cell	  markers314.	  In	  that	  paper	  this	  was	  
interpreted	  as	  an	  accumulation	  of	  short-­‐lived	  plasmablasts,	  however	  our	  data	  
suggests	  that	  these	  MHC	  IIhi	  IgM	  secreting	  cells	  are	  predominantly	  long-­‐lived.	  
This	  would	  make	  sense,	  as	  their	  data	  show	  that	  IgM	  cells	  persisted	  for	  long	  
periods	  after	  E.	  muris	  was	  cleared	  by	  antibiotic	  treatment;	  it	  would	  therefore	  be	  
surprising	  if	  short-­‐lived	  plasmablasts	  continued	  to	  be	  generated.	  
That	  total	  antibody	  in	  the	  serum	  of	  the	  mice	  we	  analysed	  increased	  with	  age	  
supports	  the	  idea	  that	  long-­‐lived	  bone	  marrow	  plasma	  cells	  are	  responsible	  for	  
maintaining	  serum	  levels	  to	  previously	  encountered	  antigens	  (fig	  3.5)189,193,317.	  
Why	  different	  antibody	  classes	  increased	  with	  different	  kinetics	  is	  unknown.	  
The	  plasma	  cells	  producing	  this	  antibody	  are	  likely	  generated	  in	  response	  to	  
environmental	  antigens	  and	  gut	  microflora.	  The	  elevated	  levels	  of	  some	  classes	  
rather	  than	  others	  may	  simply	  reflect	  the	  type	  of	  immune	  response	  generated	  to	  
encountered	  antigens.	  It	  would	  be	  interesting	  to	  test	  whether	  antibody	  levels,	  
and	  bone	  marrow	  plasma	  cell	  numbers	  increased	  in	  germ-­‐free	  mice,	  which	  
would	  encounter	  few	  antigens.	  It	  is	  known	  that	  these	  mice	  have	  reduced	  
circulating	  IgG,	  but	  similar	  levels	  of	  IgM72,318.	  
Aged	  mice	  have	  increased	  levels	  of	  plasma	  cell	  survival	  factors	  in	  the	  bone	  
marrow	  
It	  is	  thought	  that	  mainly	  post-­‐germinal	  centre,	  class-­‐switched	  plasma	  cells	  
migrate	  to	  the	  bone	  marrow	  where	  they	  persist	  for	  long	  periods,	  as	  mice	  
deficient	  in	  germinal	  centres	  generate	  reduced	  numbers	  of	  long-­‐lived	  bone	  
marrow	  plasma	  cells	  following	  immunisation319.	  Also,	  plasma	  cells	  that	  persist	  
for	  long	  periods	  require	  the	  support	  of	  survival	  factors	  such	  as	  APRIL,	  IL-­‐6,	  IL-­‐5	  
and	  others	  that	  are	  secreted	  from	  a	  number	  of	  sources.	  Chu	  et	  al	  observed	  that	  
in	  mice	  with	  a	  reduced	  number	  of	  eosinophils,	  bone	  marrow	  plasma	  cells	  were	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reduced151,	  while	  Winter	  et	  al	  used	  mice	  with	  an	  absence	  of	  megakaryocyte	  
populations	  and	  saw	  a	  similar	  reduction	  in	  bone	  marrow	  plasma	  cells217.	  It	  has	  
been	  shown	  by	  Mohr	  et	  al	  (and	  confirmed	  by	  our	  own	  data	  in	  chapter	  4)	  that	  
monocyte	  and	  macrophage	  populations	  produce	  APRIL	  and	  support	  plasma	  cell	  
survival	  in	  the	  spleen,	  although	  this	  has	  not	  been	  shown	  to	  be	  important	  in	  the	  
bone	  marrow88.	  Similarly,	  dendritic	  cells	  are	  known	  to	  produce	  both	  APRIL	  and	  
IL-­‐6,	  and	  are	  thought	  to	  be	  important	  in	  supporting	  the	  early	  stages	  of	  plasma	  
cell	  responses,	  although	  their	  role	  in	  the	  bone	  marrow	  (if	  any)	  is	  still	  
unclear88,137.	  
We	  therefore	  looked	  at	  frequencies	  and	  numbers	  of	  relevant	  cell	  types	  (all	  
which	  stained	  positive	  for	  intracellular	  APRIL,	  see	  figure	  4.10	  for	  a	  detailed	  
analysis	  of	  APRIL	  secreting	  cells),	  as	  well	  as	  a	  population	  of	  cells	  that	  secreted	  
very	  high	  amounts	  of	  APRIL	  (‘APRILhi	  cells’),	  but	  were	  not	  labelled	  with	  any	  
antibodies	  against	  common	  leukocyte	  surface	  markers	  (CD11b,	  Gr1,	  F4/80,	  
B220,	  CD19,	  CD4,	  CD3,	  CD8,	  CD11c,	  NK1.1,	  IgM,	  IgG,	  CD138	  and	  the	  endothelial	  
marker	  VCAM-­‐1	  were	  all	  tested,	  data	  not	  shown).	  	  
We	  saw	  little	  statistically	  significant	  accumulation	  of	  niche-­‐providing	  cells	  in	  the	  
spleen	  or	  bone	  marrow	  in	  terms	  of	  frequency	  or	  number	  between	  5	  and	  30-­‐
week-­‐old	  naïve	  mice	  (fig	  3.7).	  In	  the	  bone	  marrow,	  ‘APRILhi	  cells’	  significantly	  
increased,	  as	  did	  dendritic	  cells,	  but	  this	  was	  only	  around	  a	  2-­‐fold	  increase.	  As	  
plasma	  cells	  increased	  around	  10-­‐fold	  over	  the	  same	  time	  period,	  it	  is	  unlikely	  
that	  this	  is	  the	  sole	  reason	  for	  the	  accumulation	  of	  plasma	  cells.	  Although	  we	  
have	  not	  evaluated	  certain	  other	  plasma	  cell	  survival	  factors	  (such	  as	  IL-­‐6),	  the	  
cell	  types	  analysed	  in	  this	  experiment	  cover	  the	  majority	  of	  those	  thought	  to	  
contribute	  to	  plasma	  cell	  survival,	  and	  the	  lack	  of	  a	  substantial	  increase	  in	  their	  
numbers	  indicates	  that	  an	  increase	  in	  survival	  factors	  is	  not	  the	  primary	  reason	  
for	  plasma	  cell	  accumulation	  in	  naïve	  mice.	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Accumulation	  of	  long-­‐lived	  plasma	  cells	  in	  the	  bone	  marrow	  of	  strains	  of	  knockout	  
mice	  with	  defects	  in	  germinal	  centre	  responses	  
Long-­‐lived	  bone	  marrow	  plasma	  cells	  have	  been	  shown	  to	  arise	  mainly	  from	  the	  
germinal	  centre	  response87.	  To	  determine	  the	  factors	  required	  for	  the	  
accumulation	  of	  bone	  marrow	  plasma	  cells	  over	  time,	  we	  utilised	  a	  number	  of	  
strains	  of	  knockout	  mice	  deficient	  in	  either	  TLR	  signalling	  (MyD88/TRIF-­‐/-­‐),	  T	  
cell	  activation	  and	  therefore	  T	  cell	  help	  for	  B	  cells	  (Aβ	  -­‐/-­‐	  and	  CD40-­‐/-­‐),	  and	  BCR	  
signalling	  (MD4	  mice	  in	  which	  all	  B	  cells	  express	  a	  BCR	  specific	  for	  hen	  egg	  
lysosyme).	  All	  of	  these	  mice	  are	  impaired	  in	  germinal	  centre	  formation,	  as	  T	  cell	  
help	  and	  BCR	  signalling	  are	  required,	  and	  TLR	  signalling	  has	  been	  shown	  to	  
enhance	  germinal	  centre	  formation39,67,80,115,299.	  
There	  were	  few	  differences	  in	  numbers	  of	  plasma	  cells	  in	  the	  spleen	  or	  bone	  
marrow	  of	  wild	  type	  and	  knock	  out	  mice	  at	  5	  weeks	  of	  age	  (fig	  3.8a).	  In	  fact,	  only	  
MD4	  mice	  had	  lower	  numbers	  than	  wild	  type	  mice	  in	  the	  spleen,	  likely	  relating	  
to	  this	  strain’s	  deficiency	  in	  B1	  cells300.	  Aβ-­‐/-­‐	  mice	  had	  higher	  frequencies	  of	  
splenic	  plasma	  cells,	  but	  similar	  numbers	  to	  wild	  type	  mice.	  This	  is	  due	  to	  the	  
smaller	  spleen	  size	  of	  this	  strain	  (data	  not	  shown).	  There	  was	  no	  deficiency	  in	  
bone	  marrow	  plasma	  cells	  at	  this	  stage	  (fig	  3.8a).	  This	  is	  likely	  due	  to	  the	  fact	  
that	  even	  wild	  type	  mice	  have	  few	  long-­‐lived	  plasma	  cells	  in	  the	  bone	  marrow	  
by	  5-­‐weeks	  of	  age.	  	  
Despite	  generating	  similar	  numbers	  of	  plasma	  cells	  in	  the	  spleen,	  30-­‐week-­‐old	  
Aβ-­‐/-­‐,	  CD40-­‐/-­‐	  and	  MD4	  mice	  did	  not	  accumulate	  long-­‐lived	  plasma	  cells	  in	  the	  
bone	  marrow	  (fig	  3.8b).	  This	  implies	  that	  there	  is	  a	  requirement	  for	  T	  cell	  help,	  
and	  BCR	  signalling	  for	  the	  accumulation	  of	  long-­‐lived	  bone	  marrow	  plasma	  cells.	  
This	  is	  in	  agreement	  with	  data	  suggesting	  that	  most	  long-­‐lived	  plasma	  cells	  arise	  
from	  germinal	  centre	  responses86,	  which	  require	  both	  T	  cell	  help	  and	  
recognition	  of	  antigen	  through	  the	  BCR.	  
It	  is	  perhaps	  surprising	  that	  all	  mouse	  strains	  contained	  similar	  numbers	  of	  
splenic	  plasma	  cells	  at	  both	  time	  points.	  Many	  of	  these	  likely	  arise	  from	  B1	  cell	  
populations,	  which	  secrete	  ‘natural’	  antibody	  in	  response	  to	  either	  BCR	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stimulation	  through	  weak	  recognition	  of	  self-­‐antigen	  (B1a	  cells),	  or	  TLR	  
stimulation	  and	  conserved	  pathogenic	  antigens	  recognised	  by	  a	  limited	  BCR	  
repertoire	  (both	  B1a	  and	  B1b	  cells)53,54,320.	  MD4	  mice	  have	  been	  shown	  to	  be	  
deficient	  in	  B1	  cell	  populations	  and	  this	  may	  explain	  their	  reduced	  (although	  
not	  absent)	  splenic	  plasma	  cell	  numbers	  at	  5-­‐7	  weeks	  of	  age300.	  However,	  they	  
were	  not	  significantly	  lower	  at	  the	  30-­‐week	  time	  point,	  suggesting	  that	  plasma	  
cells	  present	  under	  homeostatic	  conditions	  (i.e.	  plasma	  cells	  found	  in	  the	  
spleens	  of	  unimmunised	  mice)	  in	  the	  spleen	  do	  not	  all	  arise	  from	  B1	  cells.	  
MyD88/TRIF	  signalling	  is	  not	  essential	  for	  the	  generation	  of	  natural	  antibody	  
from	  B1a	  cells	  (although	  is	  critical	  for	  that	  of	  B1b	  cells	  and	  does	  stimulate	  
plasma	  cell	  differentiation	  from	  B1a	  cells)321.	  This	  may	  explain	  why	  
MyD88/TRIF-­‐/-­‐	  mice	  have	  similar	  numbers	  of	  splenic	  plasma	  cells	  to	  wild	  type	  
mice.	  B1a	  cells	  may	  differentiate	  readily	  to	  plasma	  cells	  in	  the	  naïve	  state,	  but	  
these	  plasma	  cells	  are	  exclusively	  short-­‐lived;	  in	  fact	  B1	  cells	  do	  not	  enter	  
germinal	  centre	  reactions87.	  Therefore	  it	  is	  likely	  that	  plasma	  cell	  accumulation	  
in	  wild	  type	  mice	  arises	  from	  the	  B2	  compartment,	  responding	  to	  
environmental	  antigens	  and	  gut	  microflora.	  	  
Few	  significant	  differences	  were	  seen	  in	  niche-­‐providing	  cell	  populations	  in	  the	  
spleens	  of	  30-­‐week	  old	  wild	  type	  or	  knockout	  mice,	  reflecting	  similar	  numbers	  
and	  turnover	  of	  plasma	  cell	  populations	  at	  this	  site.	  In	  the	  bone	  marrow,	  lower	  
proportions	  of	  APRILhi	  cells	  and	  dendritic	  cells	  were	  seen	  in	  MyD88/TRIF-­‐/-­‐	  
mice,	  and	  similarly	  lower	  proportions	  of	  APRILhi	  cells	  were	  seen	  in	  Aβ	  -­‐/-­‐	  mice	  
(fig	  3.10).	  Without	  further	  characterisation	  of	  APRILhi	  cells,	  it	  remains	  unclear	  
why	  their	  frequencies	  were	  lower	  in	  these	  strains.	  It	  is	  not	  surprising	  that	  fewer	  
dendritic	  cells	  were	  seen	  in	  MyD88/TRIF-­‐/-­‐	  mice	  as	  TLR	  signalling	  is	  essential	  
for	  dendritic	  cell	  function	  and	  controls	  their	  differentiation	  from	  progenitor	  
populations322.	  These	  results	  seemed	  to	  have	  little	  bearing	  on	  plasma	  cell	  
number	  and	  turnover	  in	  the	  bone	  marrow;	  Aβ	  -­‐/-­‐	  mice	  had	  similar	  number	  and	  
turnover	  of	  plasma	  cells	  to	  CD40-­‐/-­‐	  and	  MD4	  mice	  despite	  having	  lower	  
frequencies	  of	  APRILhi	  cells,	  while	  MyD88/TRIF-­‐/-­‐	  had	  higher	  numbers	  of	  long-­‐
lived	  plasma	  cells	  in	  the	  bone	  marrow,	  despite	  lower	  frequencies	  of	  both	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APRILhi	  cells	  and	  dendritic	  cells.	  It	  is	  therefore	  likely	  that	  the	  deficiency	  in	  the	  
accumulation	  of	  long-­‐lived	  bone	  marrow	  plasma	  cells	  in	  these	  strains	  of	  mice	  is	  
one	  of	  generation,	  and	  not	  provision	  of	  survival	  factors	  and	  niches.	  
Conclusion	  
In	  this	  chapter	  we	  have	  described	  methods	  for	  identifying	  plasma	  cells	  by	  
staining	  for	  intracellular	  Ig,	  and	  shown	  that	  (at	  least	  in	  certain	  immune	  
responses)	  this	  is	  a	  more	  appropriate	  marker,	  as	  not	  all	  antibody	  secreting	  cells	  
express	  high	  levels	  of	  the	  conventional	  plasma	  cell	  marker	  CD138.	  Following	  
this,	  we	  identified	  plasma	  cells	  in	  the	  bone	  marrow	  of	  6	  to	  8-­‐week	  old	  naïve	  
mice,	  which	  appeared	  phenotypically	  similar	  to	  plasma	  cells	  found	  in	  the	  spleen.	  
In	  contradiction	  to	  the	  literature,	  these	  plasma	  cells	  had	  a	  relatively	  rapid	  rate	  
of	  turnover,	  as	  measured	  by	  BrdU	  incorporation.	  It	  was	  found	  that	  naïve	  mice	  
accumulated	  long-­‐lived	  plasma	  cells	  in	  the	  bone	  marrow	  over	  time,	  and	  this	  
correlated	  with	  an	  increase	  in	  serum	  antibody	  levels.	  These	  plasma	  cells	  
required	  signals	  through	  the	  BCR,	  and	  T	  cell	  help	  for	  their	  generation.	  
Availability	  of	  plasma	  cell	  survival	  factors	  in	  the	  bone	  marrow	  did	  not	  
substantially	  increase	  over	  time,	  and	  therefore	  was	  unlikely	  to	  play	  a	  major	  role	  
in	  the	  accumulation	  of	  long-­‐lived	  plasma	  cells.	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Chapter	  4	  –	  Factors	  required	  for	  extrafollicular	  plasma	  cell	  responses	  
to	  SRBC	  immunisation	  and	  Salmonella	  infection	  
Introduction	  
Plasma	  cell	  responses	  in	  the	  spleen	  can	  arise	  as	  part	  of	  either	  the	  early	  
extrafollicular	  response	  or	  the	  later	  germinal	  centre	  response78.	  Plasma	  cells	  
derived	  from	  germinal	  centres	  are	  relatively	  well	  defined;	  they	  secrete	  high	  
affinity	  antibody,	  are	  generally	  class-­‐switched	  and	  have	  the	  capacity	  to	  travel	  to	  
the	  bone	  marrow	  where	  they	  persist	  for	  long	  periods6,306,323.	  Germinal	  centre	  
responses	  take	  time	  however,	  first	  antigen-­‐specific	  CD4	  T	  cells	  must	  be	  primed	  
by	  activated	  APC,	  followed	  by	  their	  encounter	  with	  activated	  antigen-­‐specific	  B	  
cells.	  This	  is	  followed	  by	  a	  period	  of	  proliferation	  by	  B	  cells	  before	  germinal	  
centres	  are	  initiated	  at	  the	  centre	  of	  B	  cell	  follicles81.	  FDCs	  are	  an	  important	  
component	  of	  the	  germinal	  centre;	  they	  express	  many	  Fc	  and	  complement	  
receptors	  on	  their	  surface	  and	  bind	  large	  amounts	  of	  antigen	  in	  the	  form	  of	  
immune	  complexes	  and	  complement	  components	  bound	  to	  antigen324,325.	  
During	  the	  germinal	  centre	  reaction,	  B	  cells	  that	  have	  undergone	  somatic	  
hypermutation	  ‘test’	  their	  B	  cell	  receptors	  against	  antigen	  bound	  to	  the	  surface	  
of	  FDCs.	  If	  their	  receptors	  recognise	  the	  antigen,	  they	  are	  provided	  with	  short-­‐
term	  survival	  signals	  and	  either	  undergo	  further	  rounds	  of	  mutation,	  or	  exit	  the	  
germinal	  centre	  and	  differentiate	  to	  B	  memory	  cells	  or	  long-­‐lived	  plasma	  
cells101,102,326,327.	  This	  process	  takes	  a	  number	  of	  days,	  during	  which	  time	  
mechanisms	  exist	  to	  provide	  antibody	  which	  is	  of	  low-­‐affinity,	  but	  crucial	  to	  
limiting	  the	  spread	  of	  infections	  during	  the	  early	  stages	  through	  opsonisation	  of	  
bacteria,	  and	  activating	  innate	  cells	  through	  Fc	  receptor	  cross-­‐linking	  and	  
complement	  activation.	  This	  antibody	  is	  provided	  by	  plasma	  cells	  generated	  in	  
extrafollicular	  sites78.	  
It	  is	  known	  that	  extrafollicular	  plasma	  cell	  responses	  to	  TI	  antigen	  are	  
generated	  through	  mechanisms	  such	  as	  TLR	  stimulation,	  and	  often	  arise	  from	  
the	  B1	  and	  marginal	  zone	  B	  cell	  compartments57.	  Extrafollicular	  responses	  to	  
TD	  antigens	  require	  T	  cell	  help,	  arise	  from	  follicular	  B	  cells,	  and	  are	  generally	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slower	  to	  appear78,81.	  However,	  no	  definitive	  study	  exists	  comparing	  the	  factors	  
required	  for	  extrafollicular	  plasma	  cell	  responses	  in	  a	  purely	  T-­‐dependent	  
response	  (SRBC)	  with	  both	  the	  early	  and	  late	  stages	  of	  the	  extrafollicular	  
responses	  to	  a	  complex	  bacterial	  infection	  with	  both	  TI	  and	  TD	  components	  
(Salmonella	  infection).	  Here,	  we	  utilise	  strains	  of	  mice	  with	  deficiencies	  in	  parts	  
of	  the	  pathway	  vital	  for	  T	  cell-­‐B	  cell	  interactions	  (Aβ-­‐/-­‐,	  CD40-­‐/-­‐	  and	  ICOS-­‐/-­‐	  mice),	  
B	  cell	  receptor	  signalling	  (MD4	  mice)	  or	  TLR	  signalling	  (MyD88/TRIF-­‐/-­‐	  mice)	  to	  
determine	  the	  relative	  contributions	  of	  these	  pathways	  to	  extrafollicular	  plasma	  
cell	  responses.	  
Results	  
Requirements	  for	  extrafollicular	  plasma	  cell	  and	  germinal	  centre	  responses	  to	  TD	  
antigen	  
Mice	  were	  immunised	  with	  either	  SRBC	  or	  alum-­‐precipitated	  NP-­‐KLH	  with	  
killed	  Bordetella	  pertussis.	  At	  day	  0	  (pre-­‐immunisation),	  5,	  8	  and	  14	  spleens	  
were	  harvested	  and	  histology	  sections	  prepared	  and	  stained	  with	  anti-­‐IgM,	  IgG	  
and	  PNA.	  At	  D0	  plasma	  cells	  were	  seen	  at	  only	  low	  frequencies	  in	  the	  spleen,	  
however,	  5	  days	  after	  immunisation	  with	  SRBC	  substantial	  plasma	  cell	  
responses	  were	  observed.	  Plasma	  cells	  appeared	  grouped	  into	  large	  clusters	  in	  
the	  red	  pulp	  and	  were	  often	  in	  close	  proximity	  to	  the	  bridging	  channels,	  which	  
cut	  across	  the	  marginal	  zone	  and	  allow	  entry	  to	  the	  red	  pulp	  (fig	  4.1a).	  These	  
plasma	  cells	  were	  a	  mix	  of	  IgM	  and	  IgG,	  indicating	  that	  class	  switching	  had	  
already	  occurred	  in	  these	  mice.	  Large	  germinal	  centres	  had	  already	  formed	  in	  
the	  follicles,	  although	  at	  this	  stage	  there	  were	  few	  obvious	  light	  and	  dark	  zones	  
(indicating	  that	  germinal	  centres	  were	  recently	  formed).	  By	  day	  8	  of	  this	  
response,	  germinal	  centres	  had	  matured	  considerably	  and	  now	  had	  obvious	  
light	  (patches	  of	  bright	  IgM	  and	  IgG	  staining	  where	  immune	  complexes	  are	  
bound	  to	  Fc	  receptors	  on	  networks	  of	  FDCs)	  and	  dark	  zones.	  By	  this	  point	  in	  the	  
response	  the	  frequency	  of	  plasma	  cells	  was	  considerably	  reduced,	  with	  
remaining	  plasma	  cells	  either	  found	  at	  the	  bridging	  channels,	  or	  further	  out	  in	  
the	  red	  pulp,	  often	  not	  in	  close	  proximity	  to	  the	  follicles.	  These	  plasma	  cells	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were	  still	  arranged	  in	  clusters,	  but	  each	  cluster	  was	  far	  smaller	  than	  those	  seen	  
at	  day	  5.	  By	  day	  14,	  the	  germinal	  centre	  response	  persisted,	  but	  the	  frequency	  of	  
plasma	  cells	  had	  returned	  to	  levels	  seen	  in	  naïve	  mice.	  
NP-­‐KLH	  immunised	  mice	  responded	  with	  different	  kinetics.	  At	  day	  5	  only	  small	  
clusters	  of	  plasma	  cells	  were	  observed,	  located	  almost	  exclusively	  at	  the	  
bridging	  channels	  between	  follicles.	  Many	  plasma	  cells	  were	  class	  switched	  at	  
this	  time	  point.	  Germinal	  centres	  were	  not	  yet	  apparent,	  however,	  small	  patches	  
of	  bright	  IgM	  and	  IgG	  staining	  could	  be	  seen	  at	  the	  centre	  of	  some	  follicles,	  
indicating	  that	  FDC	  networks	  had	  accumulated	  immune	  complexes	  on	  their	  
surfaces.	  By	  day	  8,	  small	  germinal	  centres	  were	  seen	  in	  a	  minority	  of	  follicles.	  
Clusters	  of	  extrafollicular	  plasma	  cells	  had	  formed;	  these	  were	  mainly	  located	  in	  
close	  proximity	  to	  follicles	  and	  again	  were	  fairly	  evenly	  split	  between	  IgM	  and	  
IgG	  plasma	  cells.	  By	  day	  14,	  large	  germinal	  centres	  (often	  occupying	  much	  of	  the	  
follicle)	  could	  be	  seen	  with	  well-­‐developed	  dark	  and	  light	  zones.	  Large	  numbers	  
of	  class	  switched	  plasma	  cells	  were	  now	  evident	  throughout	  the	  red	  pulp	  
(although	  these	  were	  more	  concentrated	  nearer	  the	  follicles).	  
We	  were	  interested	  in	  dissecting	  the	  relative	  roles	  of	  T	  cell	  help,	  B	  cell	  receptor	  
signalling	  and	  TLR	  signalling	  in	  the	  extrafollicular	  plasma	  cell	  response	  to	  SRBC.	  	  
We	  immunised	  a	  number	  of	  strains	  of	  mice	  with	  deficiencies	  in	  TLR	  signalling	  
(MyD88/TRIF-­‐/-­‐	  mice),	  T	  cell-­‐B	  cell	  interactions	  and	  CD4	  T	  cell	  activation	  (Aβ-­‐/-­‐,	  
CD40-­‐/-­‐	  and	  ICOS-­‐/-­‐	  mice),	  and	  B	  cell	  receptor	  signalling	  (MD4	  mice)	  with	  SRBC.	  
At	  day	  5	  mice	  were	  culled	  and	  examined	  for	  plasma	  cells	  and	  germinal	  centre	  
formation	  by	  FACS	  and	  histology.	  
As	  seen	  in	  figure	  4.1,	  4.2a	  and	  4.2c,	  wild	  type	  mice	  responded	  at	  day	  5	  with	  
simultaneous	  class	  switched	  extrafollicular	  plasma	  cell	  and	  germinal	  centre	  
responses.	  Aβ-­‐/-­‐	  mice	  (and	  MD4	  mice,	  which	  cannot	  class	  switch)	  exhibited	  a	  
severe	  impairment	  in	  the	  IgG	  response;	  CD40-­‐/-­‐	  and	  ICOS-­‐/-­‐	  mice	  were	  also	  
impaired	  in	  the	  class-­‐switched	  plasma	  cell	  response,	  although	  less	  so	  than	  Aβ-­‐/-­‐	  
mice.	  Interestingly,	  MyD88/TRIF-­‐/-­‐	  mice	  were	  also	  significantly	  impaired	  in	  
their	  ability	  to	  mount	  a	  class-­‐switched	  plasma	  cell	  and	  germinal	  centre	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response,	  despite	  there	  being	  no	  obvious	  PAMP	  component	  to	  the	  immunisation	  
(fig	  4.2a,	  b	  and	  c).	  Aβ-­‐/-­‐,	  CD40-­‐/-­‐	  and	  ICOS-­‐/-­‐	  mice	  and	  MD4	  mice	  also	  failed	  to	  
mount	  germinal	  centre	  responses	  (fig	  4.2b).	  Although	  IgM	  plasma	  cells	  are	  not	  a	  
major	  component	  of	  the	  response	  to	  SRBC,	  they	  were	  not	  significantly	  impaired	  
in	  any	  of	  the	  knockout	  strains	  (fig	  4.2c).	  
Delay	  of	  germinal	  centre	  formation	  and	  enduring	  extrafollicular	  plasma	  cell	  
response	  following	  Salmonella	  infection	  
Mice	  receiving	  1x106	  CFU	  of	  Salmonella	  undergo	  a	  long-­‐term	  infection,	  taking	  
60-­‐70	  days	  to	  clear.	  During	  this	  time,	  mice	  exhibit	  significant	  splenomegaly,	  
with	  spleens	  expanding	  up	  to	  ten	  times	  their	  size	  in	  naïve	  mice.	  Previous	  
experiments	  by	  Cunningham	  et	  al281,	  and	  our	  own	  lab	  (unpublished)	  had	  shown	  
that	  during	  the	  first	  25	  days	  of	  infection	  (when	  germinal	  centres	  usually	  peak	  in	  
standard	  hapten-­‐carrier	  immunisation	  protocols),	  there	  was	  no	  formation	  of	  
germinal	  centres.	  We	  therefore	  extended	  this	  time	  course	  to	  look	  for	  germinal	  
centres	  throughout	  the	  duration	  of	  infection.	  Germinal	  centres	  are	  best	  
visualised	  through	  microscopy	  and	  therefore	  this	  technique	  was	  utilised.	  As	  
shown	  in	  figure	  4.3a,	  infected	  mice	  displayed	  considerable	  disruption	  of	  splenic	  
architecture.	  By	  day	  25,	  follicles	  were	  reduced	  in	  size	  and	  often	  T	  cell	  zones	  and	  
follicles	  were	  often	  intermixed.	  This	  continued	  until	  day	  43	  of	  infection	  when	  
normal	  splenic	  architecture	  began	  to	  return.	  Not	  until	  day	  53	  were	  germinal	  
centres	  apparent,	  and	  B	  cell	  follicles	  and	  T	  cell	  zones	  returned	  to	  their	  normal	  
sizes	  and	  appeared	  more	  distinct.	  By	  day	  77,	  spleens	  had	  regained	  normal	  
architecture.	  	  
Plasma	  cell	  frequencies	  were	  examined	  over	  a	  65-­‐day	  time	  course	  of	  infection.	  
By	  day	  8,	  frequencies	  of	  both	  IgM	  and	  IgG	  plasma	  cells	  had	  increased	  
substantially	  compared	  to	  naïve	  mice	  (fig	  4.3b).	  IgG	  plasma	  cells	  had	  increased	  
to	  3.59%	  (±0.68)	  of	  the	  spleen,	  and	  this	  corresponded	  to	  1.31x107	  cells	  
(±4.22x106);	  this	  represents	  a	  163-­‐fold	  increase	  over	  naïve	  mice.	  Similarly,	  IgM	  
plasma	  cells	  peaked	  at	  5.81x106	  cells	  (±5.84x105),	  representing	  around	  a	  16-­‐
fold	  increase	  over	  naïve	  mice.	  Plasma	  cell	  numbers	  then	  gradually	  declined	  until	  
day	  65,	  when	  frequencies	  and	  numbers	  were	  equivalent	  to	  those	  in	  naïve	  mice.	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These	  kinetics	  were	  comparable	  to	  bacterial	  loads	  in	  the	  spleen,	  although	  these	  
peaked	  slightly	  later,	  at	  day	  18	  (fig	  4.3b).	  
We	  stained	  for	  FDC	  networks	  using	  anti-­‐CD35	  (complement	  receptor	  1),	  which	  
is	  expressed	  on	  the	  surface	  of	  these	  cells.	  Figure	  4.4	  shows	  that	  in	  the	  naïve	  
spleen,	  FDC	  networks	  can	  be	  seen	  in	  the	  centre	  of	  B	  cell	  follicles.	  Following	  
infection,	  these	  rapidly	  disappeared,	  only	  to	  re-­‐establish	  later,	  by	  day	  53	  of	  
infection.	  This	  coincides	  with	  the	  emergence	  of	  germinal	  centres,	  as	  shown	  in	  
figure	  4.3.	  	  
We	  tested	  whether	  the	  delayed	  appearance	  of	  germinal	  centres	  was	  an	  inherent	  
property	  of	  the	  Salmonella	  bacterium,	  or	  whether	  it	  required	  live	  bacterial	  
infection.	  Mice	  were	  immunised	  with	  1x108	  heat	  killed	  Salmonella	  (SL3261)	  or	  
1x108	  heat	  killed	  B.	  pertussis.	  We	  chose	  this	  control	  as	  prior	  experiments	  had	  
shown	  that,	  when	  immunised	  with	  B.	  pertussis,	  mice	  developed	  germinal	  
centres	  with	  typical	  timing	  (i.e.	  appearing	  early	  in	  the	  second	  week	  (around	  day	  
7),	  and	  persisting	  for	  around	  2-­‐weeks	  (to	  day	  21)	  before	  gradually	  dissipating	  
(see	  fig	  4.1)).	  We	  saw	  that,	  12-­‐days	  following	  immunisation	  with	  heat	  killed	  
Salmonella	  and	  B.	  pertussis,	  mice	  generated	  germinal	  centre	  responses,	  although	  
B.	  pertussis	  induced	  a	  substantially	  greater	  response	  (7.74%	  (±0.77)	  of	  B	  cells	  
following	  B.	  pertussis	  and	  2.65%	  (±0.52)	  of	  B	  cells	  following	  Salmonella)(fig	  4.4b	  
and	  c).	  At	  day	  55	  following	  immunisation	  with	  either	  species	  of	  heat	  killed	  
bacteria	  (i.e.	  when	  germinal	  centres	  were	  seen	  to	  form	  following	  infection	  with	  
live	  Salmonella)	  germinal	  centres	  had	  declined	  to	  background	  levels.	  	  	  
Requirements	  for	  early	  (day	  4)	  extrafollicular	  plasma	  cell	  responses	  to	  Salmonella	  
infection	  
We	  determined	  the	  factors	  required	  for	  the	  early	  (day	  4)	  plasma	  cell	  response	  
to	  Salmonella	  by	  infection	  of	  various	  knockout	  strains	  of	  mice	  with	  deficiencies	  
in	  TLR	  signalling	  (MyD88/TRIF-­‐/-­‐	  mice),	  T	  cell-­‐B	  cell	  interactions/CD4	  T	  cell	  
activation	  (Aβ-­‐/-­‐,	  CD40-­‐/-­‐	  and	  ICOS-­‐/-­‐	  mice)	  and	  B	  cell	  receptor	  signalling	  (MD4	  
mice).	  At	  day	  4,	  spleens	  were	  taken	  and	  analysed	  by	  histology	  and	  FACS	  for	  
plasma	  cell	  induction.	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We	  found	  that	  the	  response	  at	  this	  early	  time	  point	  was	  dominated	  by	  non-­‐
class-­‐switched	  IgM	  plasma	  cells	  (fig	  4.5a	  and	  b).	  	  In	  wild	  type	  mice,	  0.332%	  
(±0.048)	  of	  the	  spleen	  had	  differentiated	  to	  IgM	  plasma	  cells	  (1.13x106	  
(±1.67x105)	  cells).	  This	  was	  unaffected	  in	  Aβ-­‐/-­‐,	  CD40-­‐/-­‐	  and	  ICOS-­‐/-­‐	  mice,	  
however	  MyD88/TRIF-­‐/-­‐	  and	  MD4	  mice	  were	  severely	  impaired	  with	  
significantly	  lower	  frequencies	  and	  numbers.	  IgG	  plasma	  cells	  do	  not	  play	  a	  
major	  role	  at	  this	  stage	  of	  the	  response,	  but	  wild	  type	  mice	  had	  5.12x104	  
(±7.35x103)	  class	  switched	  plasma	  cells.	  Frequencies	  of	  IgG	  plasma	  cells	  in	  all	  
genetically	  modified	  strains	  were	  significantly	  affected,	  although	  differences	  in	  
numbers	  did	  not	  reach	  statistical	  significance	  apart	  from	  in	  MD4	  mice.	  Bacterial	  
loads	  were	  also	  significantly	  higher	  in	  MyD88/TRIF-­‐/-­‐	  mice,	  but	  not	  in	  other	  
strains	  of	  mice	  (fig	  4.5c).	  	  	  	  
We	  had	  shown	  in	  figure	  4.5	  that	  early	  extrafollicular	  responses	  to	  Salmonella	  
consisted	  largely	  of	  IgM	  plasma	  cells.	  These	  did	  not	  require	  T	  cell	  help,	  but	  TLR	  
signalling	  was	  essential	  for	  their	  formation.	  To	  further	  characterise	  where	  these	  
TI	  plasma	  cells	  arose	  from,	  we	  used	  mice	  deficient	  in	  either	  MyD88	  (and	  
therefore	  impaired	  in	  TLR	  signalling),	  or	  CD1d	  (these	  mice	  lack	  the	  marginal	  
zone	  B	  cell	  compartment).	  We	  compared	  IgM	  plasma	  cell	  formation	  in	  these	  
mice	  at	  day	  1,	  4	  and	  8	  of	  Salmonella	  infection.	  As	  can	  be	  seen	  in	  figure	  4.6a,	  thick	  
marginal	  zones	  could	  be	  seen	  in	  naive	  wild	  type	  mice,	  surrounding	  the	  white	  
pulp.	  These	  cells	  were	  identified	  through	  their	  expression	  of	  high	  levels	  of	  IgM,	  
and	  lack	  of	  expression	  of	  IgD.	  Similarly,	  MyD88-­‐/-­‐	  mice	  had	  marginal	  zones,	  but	  
these	  were	  absent	  in	  CD1d-­‐/-­‐	  mice.	  As	  early	  as	  day	  1	  after	  infection	  with	  
Salmonella,	  marginal	  zones	  rapidly	  disappeared	  from	  the	  spleens	  of	  wild	  type	  
mice.	  This	  was	  not	  the	  case	  in	  MyD88-­‐/-­‐	  mice,	  which	  maintained	  marginal	  zones	  
at	  day	  1,	  and	  even	  at	  day	  4	  (albeit	  by	  this	  stage,	  marginal	  zones	  had	  thinned	  
considerably).	  	  
Wild	  type	  mice	  mounted	  a	  TI	  IgM	  plasma	  cell	  response	  at	  day	  4,	  but	  this	  was	  
absent	  in	  both	  MyD88-­‐/-­‐	  and	  CD1d-­‐/-­‐	  mice	  (fig	  4.6a	  and	  b).	  Wild	  type	  mice	  also	  
mounted	  class	  switched	  IgG	  plasma	  cell	  responses	  at	  day	  8	  of	  infection,	  which	  
will	  be	  examined	  further	  in	  the	  subsequent	  figure	  (fig	  4.8).	  While	  spleens	  of	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MyD88-­‐/-­‐	  mice	  contained	  significantly	  fewer	  class	  switched	  plasma	  cells,	  
differences	  were	  relatively	  small	  compared	  to	  wild	  type	  mice.	  CD1d-­‐/-­‐	  mice	  
exhibited	  a	  far	  greater	  impairment	  (fig	  4.6b).	  	  
Requirements	  for	  late	  (day	  8)	  extrafollicular	  plasma	  cell	  responses	  to	  Salmonella	  
infection	  
To	  examine	  the	  factors	  required	  for	  the	  class	  switched	  plasma	  cell	  response	  
seen	  in	  figure	  4.7,	  wild	  type	  or	  knockout	  mice	  (MyD88/TRIF-­‐/-­‐,	  Aβ-­‐/-­‐,	  CD40-­‐/-­‐,	  
ICOS-­‐/-­‐	  and	  MD4)	  were	  infected	  with	  Salmonella,	  and	  spleens	  harvested	  at	  day	  8.	  
These	  were	  analysed	  for	  plasma	  cell	  formation	  by	  FACS	  analysis	  and	  histology.	  
By	  day	  8	  of	  infection,	  wild	  type	  mice	  made	  a	  substantial	  class-­‐switched	  IgG	  
plasma	  cell	  response	  (fig	  4.7a	  and	  c).	  Interestingly,	  at	  this	  stage	  MyD88/TRIF-­‐/-­‐	  
mice	  made	  an	  equivalent	  response,	  in	  contrast	  to	  day	  4.	  Aβ-­‐/-­‐,	  CD40-­‐/-­‐	  and	  ICOS-­‐/-­‐	  
mice	  were	  all	  significantly	  impaired,	  although	  Aβ-­‐/-­‐	  mice	  exhibited	  the	  greatest	  
deficiency.	  	  
At	  this	  stage	  of	  the	  response,	  although	  IgG	  plasma	  cells	  dominate	  in	  wild	  type	  
mice,	  IgM	  plasma	  cells	  are	  present	  at	  similar	  frequencies	  to	  those	  seen	  at	  day	  4	  
(fig	  4.5c	  and	  4.7c).	  Due	  to	  continued	  expansion	  of	  the	  spleen,	  total	  numbers	  of	  
IgM	  plasma	  cells	  are	  higher	  than	  those	  seen	  at	  day	  4.	  Interestingly	  however,	  by	  
day	  8	  none	  of	  the	  knockout	  strains	  (including	  MD4	  mice)	  were	  significantly	  
impaired	  in	  terms	  of	  numbers	  of	  IgM	  plasma	  cells.	  MD4	  mice,	  which	  only	  
recognise	  Hen	  Egg	  Lysosyme	  (HEL)	  through	  the	  BCR,	  produced	  equivalent	  
numbers	  of	  IgM	  plasma	  cells	  to	  wild	  type	  mice.	  The	  specificity	  of	  these	  plasma	  
cells	  was	  tested	  via	  intracellular	  staining	  with	  fluorescently	  labelled	  HEL	  (fig	  
4.7b).	  While	  few	  IgM	  plasma	  cells	  in	  wild	  type	  mice	  bound	  HEL	  (1.73%	  (±0.33),	  
the	  majority	  of	  IgM	  plasma	  cells	  in	  MD4	  mice	  bound	  the	  protein	  (91.8%	  (±1.02).	  
We	  presume	  these	  plasma	  cells	  in	  MD4	  mice	  have	  been	  generated	  in	  a	  BCR-­‐
independent,	  TLR-­‐dependent	  manner.	  
At	  day	  8,	  as	  at	  day	  4,	  MyD88/TRIF-­‐/-­‐	  mice	  were	  the	  only	  strain	  of	  mice	  to	  have	  
significantly	  higher	  bacterial	  loads	  than	  wild	  type	  mice	  (fig	  4.6d).	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Salmonella-­‐specific	  antibody	  levels	  remain	  low	  throughout	  the	  first	  8	  days	  of	  the	  
response,	  and	  do	  not	  correlate	  to	  bacterial	  load	  
Salmonella	  specific	  serum	  antibody	  titres	  of	  the	  mice	  in	  figure	  4.7	  were	  
quantified	  by	  ELISA	  (fig	  4.8a).	  While	  all	  mouse	  strains	  had	  produced	  equivalent	  
numbers	  of	  IgM	  plasma	  cells	  at	  day	  8	  of	  the	  response	  (fig	  4.7c),	  interestingly	  Aβ-­‐
/-­‐	  mice	  failed	  to	  accumulate	  Salmonella	  specific	  IgM	  in	  the	  serum.	  MD4	  mice	  also	  
did	  not	  produce	  Salmonella-­‐specific	  antibody,	  confirming	  that	  the	  plasma	  cells	  
seen	  in	  figure	  4.7c	  were	  not	  Salmonella	  specific.	  While	  CD40-­‐/-­‐,	  ICOS-­‐/-­‐	  and	  
MyD88/TRIF-­‐/-­‐	  mice	  made	  IgM	  responses,	  these	  were	  still	  significantly	  lower	  
than	  those	  seen	  in	  wild	  type	  mice	  (table	  4.1).	  Interestingly,	  MyD88/TRIF-­‐/-­‐	  mice	  
made	  significantly	  higher	  IgG1	  responses	  than	  all	  other	  mouse	  strains	  (fig	  4.8a	  
and	  table	  4.1).	  No	  strains	  made	  any	  detectable	  IgG2b	  at	  this	  time	  point,	  and	  only	  
wild	  type	  mice	  were	  able	  to	  produce	  IgG2c.	  There	  was	  little	  detectable	  IgG3	  in	  
any	  mouse	  strain,	  and	  no	  significant	  differences	  between	  strains	  were	  seen.	  
It	  can	  be	  seen	  in	  figure	  4.8b	  that	  class-­‐switched	  Salmonella-­‐specific	  antibody	  
responses	  do	  not	  peak	  until	  late	  in	  the	  response,	  while	  Salmonella-­‐specific	  IgM	  
levels	  peak	  by	  day	  8,	  but	  remain	  low	  throughout	  the	  course	  of	  infection.	  	  
At	  day	  4	  of	  infection	  MyD88/TRIF-­‐/-­‐	  mice	  exhibited	  lower	  numbers	  of	  plasma	  
cells	  and	  higher	  bacterial	  loads	  than	  wild	  type	  mice	  (fig	  4.5b	  and	  c).	  By	  day	  8,	  
their	  bacterial	  loads	  remained	  high	  despite	  plasma	  cell	  numbers	  being	  
equivalent	  to	  wild	  type	  mice.	  Their	  Salmonella-­‐specific	  IgM	  antibody	  levels,	  
while	  reduced	  compared	  to	  wild	  type	  mice,	  were	  equivalent	  to	  CD40-­‐/-­‐	  and	  	  
ICOS-­‐/-­‐	  mice,	  which	  had	  normal	  bacterial	  loads	  (fig	  4.7c	  and	  d	  and	  fig	  4.8a).	  	  
Innate	  cells	  are	  known	  to	  be	  of	  importance	  in	  the	  response	  to	  Salmonella	  
infection,	  as	  the	  bacteria	  invade	  macrophage	  populations	  that	  must	  be	  activated	  
to	  mediate	  clearance.	  Therefore	  we	  looked	  at	  CD11b+	  cells	  in	  wild	  type	  and	  
knockout	  mice	  at	  day	  8	  of	  infection	  to	  determine	  whether	  there	  was	  a	  deficiency	  
of	  innate	  cell	  infiltration	  into	  the	  spleen	  in	  MyD88/TRIF-­‐/-­‐	  mice.	  Indeed,	  
MyD88/TRIF-­‐/-­‐	  mice	  had	  significantly	  fewer	  CD11b+	  cells	  in	  the	  spleen.	  While	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Aβ-­‐/-­‐	  mice	  also	  had	  a	  significant	  reduction	  in	  numbers,	  this	  was	  not	  as	  great	  as	  
the	  decrease	  seen	  in	  MyD88/TRIF-­‐/-­‐	  mice	  (fig	  4.8c).	  
Extended	  survival	  of	  extrafollicular	  plasma	  cell	  populations	  in	  the	  response	  to	  
Salmonella	  infection	  likely	  reflects	  an	  increase	  in	  the	  survival	  factor	  APRIL	  from	  
multiple	  sources	  
Extrafollicular	  plasma	  cell	  responses	  persist	  for	  long	  periods	  in	  Salmonella	  
infection,	  maintaining	  high	  numbers	  until	  around	  day	  35	  (fig	  4.3b).	  We	  tested	  
whether	  these	  plasma	  cells	  were	  rapidly	  dividing	  short-­‐lived	  plasma	  cells,	  or	  
whether	  a	  single	  cohort	  of	  plasma	  cells,	  produced	  early	  in	  the	  response,	  
persisted	  for	  the	  duration	  of	  the	  response.	  Salmonella	  infected	  mice	  were	  given	  
4-­‐day	  BrdU	  pulses	  at	  various	  time	  points,	  and	  the	  percentage	  and	  numbers	  of	  
plasma	  cells	  incorporating	  BrdU	  was	  determined.	  In	  naïve	  mice,	  32.70%	  (±5.16)	  
of	  splenic	  plasma	  cells	  incorporated	  BrdU	  during	  a	  4-­‐day	  pulse	  (fig	  4.9a).	  During	  
days	  1-­‐4	  of	  infection,	  this	  rapidly	  increased	  to	  66.75%	  (±4.04)	  and	  further	  
increased	  to	  81.58%	  (±2.37)	  during	  days	  5-­‐8	  (fig	  4.9a	  and	  b).	  When	  mice	  were	  
pulsed	  at	  days	  14-­‐17,	  turnover	  had	  slowed	  considerably;	  23.10%	  (±3.92)	  of	  
plasma	  cells	  incorporated	  BrdU.	  Mice	  were	  also	  pulsed	  later	  in	  infection,	  at	  days	  
51-­‐54,	  when	  13.34%	  (±4.33)	  of	  plasma	  cells	  divided.	  Interestingly,	  the	  turnover	  
of	  IgM	  plasma	  cells	  at	  this	  time	  point	  was	  even	  lower,	  with	  3.19%	  (±0.69)	  
dividing.	  
Although	  turnover	  of	  plasma	  cells	  slowed	  throughout	  the	  time	  course,	  
considerable	  numbers	  of	  plasma	  cells	  were	  found	  to	  be	  still	  dividing	  at	  days	  14-­‐
17,	  as	  total	  plasma	  cell	  numbers	  are	  very	  high	  at	  this	  time	  point	  (fig	  4.9b).	  
To	  conclusively	  show	  that	  plasma	  cells	  were	  not	  all	  generated	  at	  early	  time	  
points	  following	  infection,	  and	  were	  able	  to	  persist	  until	  the	  resolution	  of	  
infection,	  we	  gave	  mice	  BrdU	  for	  4-­‐day	  pulses	  at	  days	  1-­‐4	  or	  5-­‐8	  of	  infection.	  
The	  survival	  of	  IgM	  and	  IgG	  plasma	  cells	  incorporating	  BrdU	  during	  these	  times	  
was	  tracked	  out	  for	  16	  days	  (fig	  4.9c).	  Despite	  66.75%	  (±4.04)	  of	  IgG	  plasma	  
cells	  incorporating	  BrdU	  during	  days	  1-­‐4	  and	  81.58%	  (±2.37)	  at	  days	  5-­‐8,	  only	  
12.66%	  (±2.13)	  and	  16.93%	  (±4.86)	  contained	  the	  label	  16	  days	  later.	  Similarly,	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68.30%	  (±4.27)	  and	  70.95%	  (±8.25)	  of	  IgM	  plasma	  cells	  incorporated	  BrdU	  at	  
days	  1-­‐4	  and	  5-­‐9	  respectively,	  however	  only	  8.48%	  (±1.10)	  and	  14.33%	  (±1.09)	  
contained	  the	  label	  16-­‐days	  later.	  This	  data	  implies	  a	  slow	  but	  continuous	  
turnover	  of	  splenic	  plasma	  cells	  during	  Salmonella	  infection,	  with	  a	  half-­‐life	  of	  
4.0	  days	  for	  IgM	  plasma	  cells	  generated	  at	  day	  1-­‐4	  of	  infection	  and	  6.4	  days	  for	  
IgM	  plasma	  cells	  generated	  at	  day	  5-­‐8.	  IgG	  plasma	  cells	  generated	  at	  days	  1-­‐4	  
had	  a	  half-­‐life	  of	  6.1	  days,	  while	  those	  generated	  at	  days	  5-­‐8	  had	  a	  half-­‐life	  of	  6.6	  
days.	  
In	  figure	  4.9,	  we	  showed	  that	  extrafollicular	  plasma	  cell	  responses	  in	  Salmonella	  
infection	  persist,	  but	  that	  plasma	  cells	  are	  not	  continuously	  produced	  at	  the	  
very	  high	  rate	  seen	  in	  the	  first	  8	  days	  of	  infection.	  We	  investigated	  whether	  the	  
plasma	  cell	  survival	  factor	  APRIL,	  or	  certain	  ‘niche-­‐providing	  cells’	  were	  
induced	  in	  the	  infected	  spleen.	  
Firstly,	  we	  looked	  at	  APRIL	  induction	  in	  the	  spleen	  of	  infected	  mice.	  It	  can	  be	  
seen	  in	  figure	  4.10a	  that	  a	  population	  of	  intracellular	  APRILhi	  cells	  were	  induced	  
on	  infection.	  This	  population	  increased	  from	  less	  than	  0.24%	  (±0.05)	  of	  the	  
spleen	  in	  naïve	  mice	  to	  over	  12.06%	  (±1.63)	  of	  the	  spleen	  in	  infected	  mice	  
(figure	  4.10a	  and	  c).	  Previous	  reports	  identified	  a	  number	  of	  cells	  that	  produce	  
high	  amounts	  of	  APRIL.	  These	  included	  monocytes	  and	  macrophages,	  which	  
express	  intermediate	  amounts	  of	  the	  granulocyte	  marker	  Gr1.	  However,	  Gr1int	  
cells	  produced	  only	  intermediate	  amounts	  of	  APRIL.	  By	  gating	  on	  Gr1int	  cells	  
(figure	  4.10b-­‐top	  row)	  and	  examining	  for	  F4/80	  and	  CD11b	  expression	  (further	  
markers	  of	  monocyte/macrophage	  populations),	  it	  was	  shown	  that	  Gr1int	  cells	  
are	  a	  heterogeneous	  population.	  In	  naïve	  mice,	  few	  of	  these	  cells	  express	  CD11b	  
or	  F4/80,	  however	  this	  increases	  as	  infection	  progresses.	  Despite	  the	  induction	  
of	  monocyte/macrophage	  populations	  in	  the	  spleen,	  these	  cells	  did	  not	  produce	  
high	  amounts	  of	  APRIL,	  as	  APRILhi	  cells	  at	  no	  point	  expressed	  CD11b,	  F4/80,	  or	  
Gr1	  (fig	  4.10a	  and	  b-­‐bottom	  row).	  	  
We	  further	  examined	  a	  number	  of	  ‘niche-­‐providing	  cells’	  for	  their	  expression	  of	  
APRIL	  in	  either	  naïve	  or	  day-­‐16	  infected	  mice	  (fig	  4.10d,	  e	  and	  f).	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Megakaryocytes	  (CD41+)	  were	  induced	  to	  produce	  relatively	  high	  amounts	  of	  
APRIL	  in	  infection	  (MFI	  2.94x103	  ±1.81x102),	  albeit	  lower	  than	  ‘APRILhi	  cells’	  
(3.18x104	  ±4.45x102).	  Their	  frequency	  also	  remained	  low	  in	  the	  infected	  spleen	  
(0.255%	  ±0.06).	  	  
CD11c+,	  CD11blo	  dendritic	  cells	  expanded	  moderately	  (from	  0.224%	  (±0.015)	  to	  
0.354%	  (±0.024))	  but	  their	  production	  of	  APRIL	  significantly	  decreased	  
following	  infection	  (3.68x103	  ±6.15x101	  in	  naïve	  mice	  to	  2.93x103	  ±1.14x102	  in	  
infected	  mice)	  (fig	  4.10f).	  CD11c+,	  CD11bhi	  dendritic	  cells	  expanded	  to	  a	  far	  
greater	  extent	  on	  infection	  (from	  0.607%	  (±0.015)	  to	  2.56%	  (±0.037))	  and	  also	  
significantly	  increased	  their	  APRIL	  production	  (from	  2.35x103	  (±5.43x101)	  to	  
3.79x103	  (±8.1x101)).	  	  
Eosinophils	  (CD11bint,	  F4/80hi,	  Gr1int)	  and	  monocyte/macrophage	  (CD11bhi,	  
F4/80int,	  Gr1int)	  populations	  expanded	  greatly	  on	  infection,	  as	  did	  neutrophils	  
(CD11bhi,	  F4/80lo,	  Gr1hi)	  (Eosinophils;	  0.02%	  ±0.00,	  to	  1.16%	  ±0.11,	  
Monocytes/macrophages;	  1.31%	  ±0.08	  to	  10.51%	  ±0.80,	  Neutrophils;	  4.40%	  
±0.74	  to	  7.58%	  ±1.45)	  While	  monocytes/macrophages	  and	  eosinophils	  also	  
increased	  their	  APRIL	  production	  on	  infection,	  neutrophils	  did	  not	  (Eosinophils;	  
4.59x103	  ±1.50x102,	  Monocytes/macrophages;	  2.61x103	  ±6.98x101,	  
Neutrophils;	  1.76x103	  ±3.24x101	  to	  1.87x103	  ±4.41x101)	  (fig	  4.10d	  and	  f).	  	  
APRILhi	  cells	  increased	  greatly	  in	  terms	  of	  both	  number	  and	  frequency	  
(6.84x104	  ±5.08x103	  to	  4.22x107	  ±2.64x106;	  and	  0.15%	  ±0.04	  to	  7.27%	  ±0.32),	  
but	  did	  not	  further	  up	  regulate	  APRIL	  production	  on	  infection	  (fig	  4.10e	  and	  f).	  
These	  results	  imply	  that	  the	  infected	  spleen	  is	  rich	  in	  APRIL,	  as	  many	  APRIL	  
secreting	  cells	  expand	  and	  up	  regulate	  its	  production	  on	  infection.	  	  
In	  figure	  4.1,	  we	  had	  shown	  that	  extrafollicular	  plasma	  cell	  responses	  generated	  
following	  SRBC	  immunisation	  were	  short	  lived,	  surviving	  just	  2-­‐3	  days.	  
Therefore	  we	  next	  looked	  at	  whether	  APRIL	  producing	  cell	  populations	  were	  
induced	  following	  SRBC	  immunisation.	  At	  day	  3,	  7	  and	  14	  following	  SRBC	  
immunisation	  (or	  Salmonella	  infection)	  we	  looked	  at	  the	  frequencies	  of	  APRILhi	  
cells,	  monocytes	  and	  macrophages	  and	  dendritic	  cells	  in	  the	  spleen	  (fig	  4.11a).	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We	  saw	  little	  change	  in	  the	  frequency	  of	  any	  of	  these	  three	  populations	  in	  the	  
spleens	  of	  SRBC	  immunised	  mice,	  while	  Salmonella	  infected	  mice	  generated	  far	  
greater	  populations	  of	  all	  three.	  
To	  further	  show	  that	  APRIL	  induction	  can	  enhance	  the	  lifespan	  of	  splenic	  
plasma	  cell	  responses,	  NP-­‐KLH	  primed	  mice	  were	  boosted	  with	  either	  soluble	  
NP-­‐KLH	  or	  alum-­‐precipitated	  NP-­‐KLH	  with	  killed	  B.	  pertussis	  (referred	  to	  as	  
alum-­‐NP-­‐KLH).	  While	  soluble	  NP-­‐KLH	  induced	  a	  transient	  increase	  in	  the	  
frequencies	  of	  APRIL	  producing	  cells,	  this	  rapidly	  returned	  to	  naïve	  levels	  (fig	  
4.11b).	  The	  decline	  of	  APRIL	  producing	  cells	  in	  alum-­‐NP-­‐KLH	  boosted	  mice	  was	  
slower,	  with	  significantly	  higher	  frequencies	  at	  day	  4,	  day	  8	  and	  day	  20	  
(although	  by	  this	  point	  frequencies	  were	  low	  in	  both	  immunisation	  protocols).	  
NP-­‐specific	  plasma	  cells	  were	  detected	  through	  intracellular	  staining	  with	  
fluorescently	  labelled	  NP.	  Although	  there	  was	  no	  difference	  in	  the	  frequency	  of	  
splenic	  NP-­‐specific	  IgG	  plasma	  cells	  induced	  by	  either	  immunisation	  at	  day	  4,	  
those	  mice	  boosted	  with	  alum-­‐NP-­‐KLH	  maintained	  high	  frequencies	  of	  NP-­‐
specific	  plasma	  cells	  at	  day	  8,	  unlike	  soluble	  NP-­‐KLH	  boosted	  mice.	  At	  day	  20,	  
alum-­‐NP-­‐KLH	  boosted	  mice	  maintained	  higher	  frequencies	  of	  splenic	  NP-­‐
specific	  plasma	  cells,	  although	  differences	  were	  not	  statistically	  significant.	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Discussion	  
Extrafollicular	  plasma	  cell	  responses	  arise	  in	  the	  first	  few	  days	  following	  
immunisation	  or	  infection,	  and	  provide	  early	  antibodies	  that	  can	  opsonise	  
infecting	  organisms,	  activate	  complement	  pathways	  and	  activate	  innate	  cells	  
through	  cross-­‐linking	  of	  Fc	  receptors78.	  This	  allows	  time	  for	  plasma	  cells	  that	  
secrete	  high	  affinity	  antibody	  to	  be	  generated	  in	  germinal	  centre	  reactions.	  
Extrafollicular	  plasma	  cells	  are	  short-­‐lived	  cells,	  and	  do	  not	  migrate	  to	  the	  bone	  
marrow86,199.	  However,	  it	  has	  been	  shown	  that	  during	  inflammatory	  episodes,	  
survival	  factors	  such	  as	  APRIL	  and	  IL-­‐6	  are	  induced	  and	  support	  the	  survival	  of	  
these	  cells	  for	  extended	  periods88.	  	  	  
The	  data	  presented	  here	  examine	  the	  requirements	  for	  extrafollicular	  plasma	  
cell	  responses	  in	  complex	  bacterial	  infection	  and	  in	  the	  response	  to	  SRBC.	  In	  
addition,	  we	  examine	  how	  the	  lifespan	  of	  extrafollicular	  plasma	  cells	  can	  be	  
extended	  by	  the	  provision	  of	  survival	  factors.	  
Rapid	  extrafollicular	  plasma	  cell	  responses	  and	  germinal	  centre	  responses	  
following	  SRBC	  immunisation	  
We	  observed	  striking	  differences	  between	  the	  timing	  of	  extrafollicular	  plasma	  
cell	  responses	  and	  germinal	  centre	  responses	  following	  primary	  immunisation	  
with	  alum-­‐precipitated	  NP-­‐KLH	  with	  killed	  B.	  pertussis	  or	  SRBC.	  	  
Splenic	  plasma	  cells	  (both	  IgG	  and	  IgM)	  peaked	  5-­‐days	  after	  immunisation	  with	  
SRBC,	  whereas	  this	  peak	  was	  not	  until	  day	  8	  in	  NP-­‐KLH	  immunised	  mice.	  
Similarly,	  germinal	  centres	  formed	  at	  least	  3	  days	  earlier	  in	  SRBC	  immunised	  
mice.	  We	  hypothesised	  that	  this	  accelerated	  response	  is	  likely	  to	  be	  the	  result	  of	  
rapid	  T	  cell	  priming,	  although	  it	  is	  unclear	  why	  this	  is	  the	  case.	  The	  kinetics	  
were	  similar	  to	  those	  seen	  in	  mice	  with	  availability	  of	  increased	  levels	  of	  T	  cell	  
help,	  as	  observed	  by	  Sze	  et	  al	  who	  saw	  more	  rapid	  production	  of	  NP-­‐specific	  
plasma	  cells	  in	  NP-­‐CGG	  (NP-­‐Chicken	  gamma	  globulin	  (CGG))	  immunised	  mice	  
when	  they	  were	  first	  primed	  mice	  with	  the	  carrier	  protein	  (CGG),	  to	  increase	  the	  
frequency	  of	  antigen-­‐specific	  CD4	  T	  cells86.	  The	  kinetics	  are	  also	  similar	  to	  those	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seen	  during	  secondary	  responses	  to	  hapten-­‐carrier	  protein	  antigens	  such	  as	  NP-­‐
KLH	  (see	  fig	  3.1),	  although	  in	  this	  situation	  memory	  cells	  abound.	  
Mice	  deficient	  in	  the	  expression	  of	  genes	  relating	  to	  T	  cell	  activation	  and	  T	  cell-­‐B	  
cell	  interactions	  (Aβ-­‐/-­‐,	  CD40-­‐/-­‐	  and	  ICOS-­‐/-­‐)	  were	  deficient	  in	  germinal	  centre	  
and	  class-­‐switched	  extrafollicular	  plasma	  cell	  formation	  following	  SRBC	  
immunisation.	  T	  cell	  help	  is	  an	  absolute	  requirement	  for	  germinal	  centres,	  and	  
MHC	  II	  and	  CD40	  are	  crucial	  for	  their	  interactions	  with	  B	  cells299,328.	  
Interestingly,	  ICOS	  was	  found	  to	  be	  of	  absolute	  importance	  to	  germinal	  centre	  
formation,	  whereas	  Dong	  et	  al	  had	  previously	  reported	  that	  ICOS-­‐/-­‐	  mice	  
immunised	  with	  SRBC	  exhibit	  germinal	  centres	  of	  reduced	  size	  in	  primary	  
immunisation,	  and	  complete	  absence	  in	  secondary	  responses68.	  This	  may	  relate	  
to	  differences	  in	  dose	  (which	  is	  unspecified	  in	  this	  article).	  
Aβ-­‐/-­‐	  mice	  were	  completely	  impaired	  in	  making	  class	  switched	  plasma	  cell	  
responses,	  demonstrating	  the	  complete	  requirement	  for	  T	  cell	  help	  for	  this	  
process	  in	  SRBC	  immunised	  mice.	  It	  is	  likely	  that	  the	  impairment	  seen	  here	  is	  
due	  to	  a	  failure	  of	  T	  cell	  priming.	  CD40-­‐/-­‐	  mice	  and	  ICOS-­‐/-­‐	  mice	  were	  
progressively	  less	  impaired;	  while	  MHC	  II	  was	  crucial	  for	  class	  switching,	  the	  co-­‐
stimulatory	  stages	  of	  T	  cell	  interactions	  were	  less	  important.	  Interestingly,	  ICOS-­‐
/-­‐	  mice	  had	  slightly	  enhanced	  IgM	  plasma	  cell	  responses.	  This	  may	  be	  due	  to	  
commitment	  to	  a	  plasma	  cell	  fate,	  but	  failure	  to	  class	  switch.	  It	  is	  known	  that	  
ICOS	  is	  required	  for	  the	  generation	  of	  a	  population	  of	  CD4	  T	  cells	  that	  help	  class	  
switching	  in	  extrafollicular	  sites	  through	  IL-­‐21	  production	  in	  a	  mouse	  model	  of	  
lupus,	  however	  the	  impairment	  of	  T	  cell	  activation	  is	  not	  absolute	  in	  ICOS-­‐/-­‐	  
mice159.	  It	  is	  not	  known	  whether	  these	  cells	  play	  a	  role	  in	  extrafollicular	  
responses	  to	  exogenous	  antigens.	  
MyD88/TRIF-­‐/-­‐	  mice	  were	  entirely	  deficient	  in	  germinal	  centre	  production	  (fig	  
4.2a	  and	  b).	  Although	  it	  is	  widely	  accepted	  that	  B	  cell	  signaling	  through	  TLRs	  
enhances	  germinal	  centre	  formation	  and	  antibody	  responses39,	  this	  result	  is	  
surprising	  as	  SRBCs	  contain	  no	  obvious	  PAMP.	  MyD88	  is	  also	  required	  for	  
signaling	  through	  the	  IL-­‐1	  receptor,	  and	  this	  can	  enhance	  TD	  antibody	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responses	  and	  germinal	  centre	  formation	  by	  up-­‐regulating	  CD40	  and	  OX40	  on	  
CD4	  T	  cells295,329.	  Similarly,	  Meyer-­‐Bahlburg	  et	  al	  have	  shown	  that	  B	  cell-­‐
intrinsic	  MyD88	  signaling	  is	  of	  particular	  importance	  to	  germinal	  centre	  B	  cells,	  
which	  express	  more	  of	  this	  key	  adaptor	  molecule60.	  That	  MyD88/TRIF-­‐/-­‐	  mice	  
were	  impaired	  in	  making	  class-­‐switched	  plasma	  cell	  responses	  was	  again	  
surprising.	  This	  may	  be	  due	  to	  the	  observed	  deficiency	  in	  germinal	  centre	  
formation,	  and	  therefore	  reduced	  numbers	  of	  class-­‐switched	  plasma	  cells.	  
Similarly,	  defects	  in	  TI	  methods	  of	  class	  switching	  may	  account	  for	  this	  deficit,	  
such	  as	  reduced	  APRIL	  or	  BLyS	  from	  dendritic	  cells	  (and	  other	  sources),	  which	  
are	  able	  to	  induce	  class	  switching	  through	  binding	  to	  TACI	  and	  BCMA	  on	  
activated	  B	  cells138.	  In	  addition,	  signalling	  through	  TACI	  has	  been	  shown	  to	  
require	  MyD88149.	  Further	  experiments,	  such	  as	  the	  immunisation	  of	  chimeras	  
in	  which	  B	  cells	  alone	  were	  deficient	  in	  MyD88,	  could	  help	  to	  determine	  
whether	  these	  mice	  failed	  to	  generate	  class-­‐switched	  plasma	  cells	  due	  to	  an	  
intrinsic	  defect	  in	  B	  cell	  stimulation	  or	  due	  to	  reduced	  factors	  produced	  by	  other	  
cells,	  requiring	  MyD88	  signaling.	  
HEL-­‐specific	  B	  cells	  in	  MD4	  mice	  did	  not	  respond	  in	  terms	  of	  germinal	  centre	  
formation	  or	  extrafollicular	  plasma	  cell	  formation.	  Antigen	  recognition	  through	  
the	  BCR	  is	  required	  for	  entry	  into	  germinal	  centres330.	  These	  mice	  are	  incapable	  
of	  class	  switching,	  and	  therefore	  could	  not	  produce	  IgG	  plasma	  cell	  responses.	  
Germinal	  centre	  formation	  is	  delayed	  in	  Salmonella	  infected	  mice	  
Following	  infection	  with	  Salmonella,	  we	  observed	  striking	  disruption	  of	  splenic	  
architecture	  (fig	  4.3a).	  B	  cell	  follicles	  were	  reduced	  in	  size	  and	  spatially	  distinct,	  
separated	  by	  expanded	  red	  pulp.	  This	  may	  explain	  the	  delay	  in	  germinal	  centre	  
formation	  following	  infection,	  as	  splenic	  architecture	  is	  important	  for	  the	  
efficient	  meeting	  of	  rare,	  activated	  antigen-­‐specific	  B	  and	  CD4	  T	  cell	  clones115.	  
Similarly,	  we	  observed	  a	  depletion	  of	  FDC	  networks	  from	  B	  cell	  follicles	  (fig	  
4.4a),	  which	  are	  crucial	  to	  the	  establishment	  of	  successful	  germinal	  centre	  
responses326,331.	  Indeed,	  the	  disruption	  of	  B	  cell	  follicles	  and	  depletion	  of	  FDC	  
networks	  may	  be	  linked,	  as	  Wang	  et	  al	  recently	  showed	  that	  FDCs	  maintain	  B	  
cell	  follicular	  structure101.	  Germinal	  centres	  formed	  at	  day	  53,	  when	  splenic	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architecture	  and	  FDC	  networks	  were	  comparable	  to	  naïve	  spleens	  (fig	  4.3a	  and	  
4.4a).	  This	  also	  corresponded	  to	  low	  bacterial	  loads	  (fig	  4.3c).	  Data	  from	  
Cunningham	  et	  al	  suggests	  that	  high	  and	  persistent	  bacterial	  loads	  in	  the	  spleen	  
impeded	  germinal	  centre	  formation	  during	  Salmonella	  infection,	  as	  when	  
infected	  mice	  were	  treated	  with	  antibiotic	  (to	  reduce	  bacterial	  loads),	  germinal	  
centres	  formed	  sooner.	  Our	  own	  data	  support	  this,	  as	  immunisation	  with	  killed	  
Salmonella	  bacteria	  (which	  are	  likely	  to	  be	  rapidly	  cleared)	  generates	  germinal	  
centres	  by	  day	  12,	  and	  not	  at	  day	  55	  (fig	  4.4b).	  
Factors	  required	  for	  the	  extrafollicular	  plasma	  cell	  response	  to	  Salmonella	  
Despite	  delayed	  germinal	  centre	  formation,	  plasma	  cell	  responses	  in	  the	  spleens	  
of	  infected	  mice	  were	  maintained	  for	  the	  duration	  of	  infection	  (fig	  4.3b).	  
Infection	  of	  wild	  type	  mice	  revealed	  a	  biphasic	  plasma	  cell	  response.	  At	  day	  4,	  
plasma	  cells	  were	  mainly	  IgM	  (fig	  4.5a	  and	  b),	  whereas	  by	  day	  8	  plasma	  cells	  
were	  mainly	  IgG	  (fig	  4.7a	  and	  c).	  	  
Numbers	  of	  IgM	  plasma	  cells	  at	  day	  4	  were	  not	  significantly	  affected	  in	  mouse	  
strains	  where	  CD4	  T	  cell	  activation,	  and	  interactions	  with	  B	  cells,	  are	  impaired	  
(Aβ-­‐/-­‐,	  CD40-­‐/-­‐	  and	  ICOS-­‐/-­‐	  mice).	  Similarly,	  MyD88/TRIF-­‐/-­‐	  mice	  were	  
significantly	  impaired	  in	  making	  IgM	  plasma	  cell	  responses	  at	  day	  4.	  This	  is	  
strong	  evidence	  that	  IgM	  plasma	  cells	  seen	  at	  this	  time	  point	  are	  TI,	  requiring	  
TLR	  signalling	  for	  their	  generation.	  TLR	  signalling	  alone,	  however,	  was	  
seemingly	  not	  sufficient	  to	  generate	  early	  IgM	  plasma	  cells	  as	  MD4	  mice	  failed	  
to	  respond,	  indicating	  a	  role	  for	  B	  cell	  receptor	  signalling.	  	  
Surprisingly,	  MD4	  mice	  responded	  at	  day	  8	  by	  the	  generation	  of	  IgM	  plasma	  
cells	  in	  equivalent	  numbers	  to	  wild	  type	  mice	  (fig	  4.7a	  and	  c).	  These	  plasma	  
cells	  were	  specific	  for	  HEL	  (fig	  4.7b).	  This	  implies	  that	  BCR	  signalling	  (and	  
antigen	  specificity)	  is	  irrelevant	  for	  the	  generation	  of	  IgM	  plasma	  cells	  at	  day	  8.	  
That	  MyD88/TRIF-­‐/-­‐	  mice	  also	  were	  not	  deficient	  in	  IgM	  plasma	  cells	  by	  day	  8	  
leads	  to	  a	  number	  of	  possible	  explanations	  of	  how	  these	  plasma	  cells	  arise.	  
Firstly,	  B	  cells	  at	  day	  4	  may	  require	  signals	  through	  both	  TLR	  and	  BCR	  for	  
efficient	  differentiation	  to	  IgM	  plasma	  cells.	  If	  antigen	  cannot	  be	  recognised	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through	  the	  B	  cell	  receptor,	  their	  differentiation	  may	  be	  delayed.	  Factors,	  such	  
as	  BLyS,	  IL-­‐6	  (via	  IL-­‐21)	  and	  IFN-­‐α	  have	  all	  been	  shown	  to	  enhance	  
differentiation	  of	  B	  cells	  to	  plasma	  cells165,175,176,181	  and	  are	  likely	  to	  be	  present	  
at	  high	  levels	  in	  the	  inflamed	  spleen.	  It	  is	  possible	  that	  these	  signals	  alone,	  or	  
combined	  with	  TLR	  signalling	  are	  sufficient	  to	  induce	  the	  differentiation	  of	  B	  
cells	  to	  plasma	  cells	  in	  a	  polyclonal	  manner.	  Secondly,	  MD4	  mice	  are	  deficient	  in	  
B1	  cell	  populations300.	  As	  these	  are	  known	  to	  be	  important	  in	  the	  first	  few	  days	  
of	  infection76,	  this	  may	  explain	  the	  lack	  of	  IgM	  plasma	  cells	  seen	  at	  day	  4	  in	  these	  
mice.	  Thirdly,	  many	  PRRs	  other	  than	  TLRs	  exist	  that	  do	  not	  signal	  through	  
MyD88	  or	  TRIF	  (such	  as	  NOD	  receptors).	  Signalling	  through	  these	  receptors	  
may	  lead	  to	  the	  differentiation	  of	  B	  cells	  to	  plasma	  cells	  by	  day	  8	  of	  infection.	  
This	  leads	  to	  the	  probability	  that,	  in	  other	  mouse	  strains	  too,	  IgM	  plasma	  cells	  
seen	  at	  day	  4	  or	  day	  8	  may	  not	  be	  Salmonella-­‐specific.	  Indeed,	  antigen-­‐specific	  
IgM	  antibody	  levels	  were	  reduced	  in	  Aβ-­‐/-­‐	  and	  MD4	  mice,	  but	  not	  MyD88/TRIF-­‐/-­‐	  
mice.	  Despite	  the	  fact	  that	  MHC	  II	  was	  not	  required	  to	  generate	  the	  large	  
number	  of	  IgM	  plasma	  cells	  seen	  in	  the	  first	  8	  days	  of	  infection,	  it	  is	  required	  for	  
the	  generation	  of	  Salmonella-­‐specific	  IgM.	  This	  implies	  a	  role	  for	  T	  cells	  in	  the	  
generation	  of	  Salmonella-­‐specific	  IgM.	  
The	  observation	  that	  MyD88/TRIF-­‐/-­‐	  mice	  retained	  marginal	  zone	  B	  cells	  at	  day	  
4	  of	  infection,	  and	  that	  MyD88-­‐/-­‐	  mice	  had	  similar	  deficiencies	  in	  day	  4	  IgM	  
plasma	  cell	  responses	  as	  CD1d-­‐/-­‐	  mice	  (which	  lack	  marginal	  zone	  B	  cells)	  may	  
indicate	  that	  many	  IgM	  plasma	  cells	  seen	  at	  this	  time	  point	  arise	  from	  marginal	  
zone	  B	  cells	  stimulated	  through	  TLRs.	  It	  is	  thought	  that	  marginal	  zone	  B	  cells	  are	  
early	  responders;	  they	  rapidly	  differentiate	  into	  plasma	  cells,	  requiring	  TLR	  and	  
BCR	  signals	  following	  injection	  NP-­‐Ficoll57.	  However,	  Gil	  Cruz	  et	  al	  have	  shown	  
that	  B1b	  cells	  also	  provide	  early	  IgM	  plasma	  cells	  in	  Salmonella	  infection	  (and	  
Salmonella-­‐specific	  antibody)76.	  Chimeras	  in	  which	  B	  cell	  deficient	  μMT	  mice	  are	  
reconstituted	  with	  a	  mix	  of	  CD1d-­‐/-­‐	  and	  DS-­‐RED	  bone	  marrow	  would	  create	  
mice	  in	  which	  marginal	  zone	  B	  cells	  expressed	  the	  DS-­‐RED	  protein	  (DS-­‐RED	  
mice	  express	  the	  red	  fluorescent	  protein	  variant	  ‘DS-­‐RED’	  under	  the	  control	  of	  
the	  chicken	  beta	  actin	  promoter	  coupled	  with	  the	  cytomegalovirus	  immediate	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early	  enhancer,	  producing	  ubiquitous	  expression	  of	  DS-­‐RED	  in	  all	  tissues).	  If	  
early	  IgM	  plasma	  cells	  arise	  from	  the	  marginal	  zone	  compartment	  following	  
Salmonella	  infection,	  they	  would	  express	  the	  DS-­‐RED	  protein,	  while	  most	  
follicular	  B	  cells	  would	  not.	  This	  system	  could	  be	  used	  to	  more	  definitively	  
identify	  the	  source	  of	  these	  plasma	  cells.	  	  
IgG	  plasma	  cells,	  arising	  at	  day	  8,	  required	  MHC	  II	  signalling,	  as	  Aβ-­‐/-­‐	  mice	  were	  
entirely	  impaired	  in	  their	  generation.	  CD40-­‐/-­‐	  and	  ICOS-­‐/-­‐	  mice	  were	  also	  
impaired	  in	  the	  generation	  of	  class	  switched	  plasma	  cells,	  although	  the	  
deficiency	  was	  far	  smaller	  than	  in	  Aβ-­‐/-­‐	  mice	  (fig	  4.5b	  and	  4.7c).	  Indeed,	  ICOS-­‐/-­‐	  
mice	  generated	  100-­‐fold	  greater	  numbers.	  This	  shows	  an	  absolute	  requirement	  
for	  MHC	  II	  signalling	  in	  the	  generation	  of	  class	  switched	  plasma	  cells	  in	  
Salmonella	  infection,	  but	  not	  co-­‐stimulatory	  signals.	  Class	  switching	  of	  B	  cells	  is	  
not	  necessarily	  mediated	  through	  interactions	  with	  CD4	  T	  cells.	  Litinskiy	  
showed	  that	  APRIL	  or	  BLyS,	  in	  combination	  with	  IL-­‐10	  or	  TGF-­‐β	  induces	  
switching	  to	  IgG	  and	  IgA138.	  In	  addition,	  direct	  signalling	  through	  TLRs	  
expressed	  on	  B	  cells	  can	  initiate	  class-­‐switching155.	  These	  mechanisms	  can	  
bypass	  the	  requirement	  for	  CD40	  signalling	  for	  class	  switching149.	  In	  Salmonella	  
infection,	  however,	  MHC	  II	  signalling	  appears	  to	  be	  required.	  Whether	  this	  is	  B	  
cell	  intrinsic	  MHC	  II,	  or	  that	  on	  other	  cell	  populations	  is	  unknown.	  
It	  is	  likely	  that	  IgG	  plasma	  cells	  are	  mainly	  antigen-­‐specific,	  as	  MHC	  II	  (and	  
therefore	  the	  activation	  of	  antigen-­‐specific	  CD4	  T	  cells)	  was	  required	  for	  their	  
generation.	  In	  agreement	  with	  this,	  only	  wild	  type	  and	  MyD88/TRIF-­‐/-­‐	  mice	  
were	  able	  to	  generate	  Salmonella-­‐specific	  antibody	  by	  day	  8	  (albeit	  
MyD88/TRIF-­‐/-­‐	  mice	  switching	  to	  the	  Th2-­‐associated	  isotype	  IgG1).	  However,	  
the	  slow	  accumulation	  of	  Salmonella-­‐specific	  IgG	  in	  the	  serum	  of	  wild	  type	  mice	  
(first	  appearing	  at	  day	  20	  and	  not	  peaking	  until	  day	  65),	  despite	  large	  numbers	  
of	  IgG	  plasma	  cells	  in	  the	  spleen	  from	  day	  8,	  does	  not	  support	  this	  idea	  (fig	  4.7	  
and	  8b).	  This	  could	  be	  tested	  by	  the	  infection	  of	  SW-­‐HEL	  mice,	  which	  contain	  a	  
high	  proportion	  of	  HEL-­‐specific	  B	  cells	  and,	  unlike	  MD4	  B	  cells,	  are	  able	  to	  class	  
switch.	  If	  many	  HEL-­‐specific	  IgG	  plasma	  cells	  were	  seen	  at	  day	  8,	  it	  would	  be	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strong	  evidence	  that	  even	  many	  IgG	  plasma	  cells	  are	  not	  antigen-­‐specific	  during	  
the	  early	  stages	  of	  Salmonella	  infection.	  	  
Finally,	  CD1d-­‐/-­‐	  mice	  failed	  to	  respond	  efficiently	  at	  day	  8.	  This	  may	  imply	  that	  
either	  all	  plasma	  cells	  seen	  in	  the	  first	  8	  days	  of	  Salmonella	  infection	  arise	  from	  
the	  marginal	  zone	  B	  cell	  compartment,	  or	  that	  a	  deficiency	  in	  NK	  T	  cells	  (seen	  in	  
this	  strain	  of	  mice301)	  impairs	  plasma	  cell	  formation	  and	  class-­‐switching.	  The	  
contribution	  of	  these	  cells	  may	  be	  of	  great	  importance,	  as	  they	  recognise	  lipid	  
antigens	  presented	  on	  CD1d,	  and	  have	  been	  shown	  to	  directly	  activate	  CD1d-­‐
expressing	  marginal	  zone	  B	  cells	  through	  cognate	  interactions82,	  and	  to	  enhance	  
activation	  of	  other	  (CD1d-­‐)	  B	  cell	  subsets	  through	  the	  secretion	  of	  IL-­‐2183.	  The	  
contribution	  of	  marginal	  zone	  and	  follicular	  B	  cells,	  and	  the	  importance	  of	  NK	  T	  
cells	  for	  their	  differentiation	  to	  plasma	  cells	  could	  be	  further	  dissected	  by	  the	  
transfer	  of	  sorted	  follicular	  or	  marginal	  zone	  B	  cells,	  with	  or	  without	  NK	  T	  cells	  
to	  RAG-­‐/-­‐	  (T	  and	  B	  cell	  deficient)	  hosts,	  followed	  by	  infection	  with	  Salmonella.	  If	  
B	  cell	  subsets	  were	  taken	  from	  different	  strains,	  such	  as	  wild	  type,	  MD4	  and	  
MyD88/TRIF-­‐/-­‐	  mice,	  this	  would	  allow	  for	  a	  greater	  understanding	  of	  the	  
requirements	  for	  plasma	  cell	  generation	  in	  Salmonella	  infection.	  
Extrafollicular	  plasma	  cells	  are	  generated	  throughout	  Salmonella	  infection	  and	  are	  
supported	  by	  survival	  factors	  
Many	  plasma	  cells	  were	  generated	  during	  the	  first	  8-­‐days	  of	  Salmonella	  
infection	  (fig	  4.5	  and	  4.7),	  and	  high	  numbers	  of	  plasma	  cells	  could	  be	  detected	  in	  
the	  spleen	  throughout	  the	  course	  of	  infection,	  declining	  gradually	  over	  time	  (fig	  
4.3b).	  Using	  BrdU-­‐pulses	  we	  determined	  that	  plasma	  cells	  generated	  in	  the	  first	  
8	  days	  were	  not	  maintained	  throughout	  infection,	  and	  in	  fact	  they	  turned	  over	  
gradually.	  That	  turnover	  was	  high	  during	  the	  first	  8	  days	  is	  unsurprising;	  the	  
number	  of	  plasma	  cells	  in	  the	  spleen	  rose	  dramatically	  during	  this	  time,	  and	  
therefore	  BrdU	  incorporation	  was	  high	  (fig	  4.9a	  and	  b).	  Following	  the	  
generation	  of	  these	  cells,	  turnover	  dropped	  dramatically.	  This,	  however,	  did	  not	  
reflect	  long-­‐term	  survival	  of	  these	  plasma	  cells	  as	  only	  few	  survived	  for	  more	  
than	  16	  days	  (fig	  4.9c).	  Instead,	  we	  observed	  a	  continuous	  (but	  not	  rapid)	  
turnover	  of	  plasma	  cells	  with	  a	  half-­‐life	  of	  around	  6-­‐days.	  This	  is	  in	  stark	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contrast	  to	  the	  lifespan	  of	  plasma	  cells	  generated	  following	  SRBC	  immunisation,	  
which	  peaked	  at	  day	  5,	  but	  had	  mostly	  died	  by	  day	  8	  (fig	  4.1).	  
As	  shown	  by	  Mohr	  et	  al,	  populations	  of	  plasma	  cells	  in	  the	  lymph	  nodes	  can	  be	  
supported	  by	  APRIL	  from	  numerous	  sources	  following	  immunisation	  with	  
alum-­‐precipitated	  NP-­‐OVA88.	  APRIL	  in	  the	  lymph	  node	  comes	  predominantly	  
from	  CD11bhi,	  GR1int,	  F4/80hi	  monocytes	  and	  macrophages.	  In	  the	  spleens	  of	  
Salmonella	  infected	  mice,	  we	  found	  numerous	  APRIL	  producing	  populations,	  of	  
which	  monocytes	  and	  macrophages	  were	  just	  one.	  Gr1int	  cells	  were	  
heterogeneous,	  but	  uniformly	  expressed	  intermediate	  amounts	  of	  APRIL.	  
APRILhi	  cells	  (as	  described	  in	  chapter	  3)	  were	  dramatically	  expanded	  in	  the	  
infected	  spleen	  and	  likely	  provided	  much	  of	  the	  APRIL	  found	  in	  the	  organ.	  Here	  
we	  have	  not	  quantified	  APRIL,	  nor	  have	  we	  quantified	  the	  proximity	  of	  the	  many	  
APRIL	  producing	  cell	  populations	  to	  plasma	  cells.	  However,	  it	  is	  clear	  from	  
figures	  4.10a,	  d	  and	  e	  that	  the	  inflamed	  spleen	  is	  rich	  in	  APRIL	  and	  that	  many	  
cell	  types	  that	  are	  known	  to	  support	  plasma	  cell	  survival	  expand	  considerably.	  	  
That	  SRBC	  immunised	  mice	  did	  not	  increase	  in	  APRILhi	  cells,	  
monocytes/macrophages	  or	  dendritic	  cells	  (fig	  4.11a)	  likely	  means	  that	  the	  
spleens	  in	  these	  mice	  are	  not	  rich	  in	  APRIL.	  This	  may	  explain	  why	  plasma	  cells	  
generated	  during	  this	  immunisation	  survive	  for	  just	  2-­‐3	  days.	  Similarly,	  
secondary	  immunisation	  with	  NP-­‐KLH	  and	  adjuvant	  allowed	  NP-­‐specific	  IgG	  
plasma	  cells	  to	  persist	  for	  greater	  periods	  through	  the	  generation	  of	  APRILhi	  
cells	  (fig	  4.11b).	  	  
APRIL	  is	  likely	  not	  the	  only	  plasma	  cell	  survival	  factor	  in	  the	  inflamed	  spleen,	  
and	  here	  we	  have	  not	  looked	  at	  the	  generation	  of	  other	  survival	  factors	  such	  as	  
IL-­‐6,	  TNF-­‐α,	  IL-­‐5	  and	  CXCL12,	  which	  are	  thought	  to	  be	  of	  importance	  in	  the	  bone	  
marrow78,88,166.	  The	  role	  of	  many	  of	  these	  cytokines	  in	  the	  spleen	  is	  unknown,	  
although	  IL-­‐6	  is	  known	  to	  support	  plasmablast	  survival88.	  Similarly,	  the	  
proximity	  of	  plasma	  cells	  to	  APRIL-­‐producing	  cells	  (which	  could	  be	  evaluated	  by	  
histology)	  could	  be	  important	  in	  determining	  which	  cell	  types	  are	  critical	  to	  the	  
survival	  of	  plasma	  cells.	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While	  this	  data	  is	  correlative,	  together	  with	  previously	  published	  reports	  on	  the	  
importance	  of	  APRIL	  in	  maintaining	  splenic	  plasma	  cell	  responses,	  we	  conclude	  
that	  APRIL	  from	  numerous	  sources	  contributes	  to	  the	  maintenance	  of	  splenic	  
plasma	  cell	  responses.	  These	  populations	  are	  induced	  in	  inflammatory	  
conditions,	  although	  the	  precise	  signals	  required	  are	  as	  yet	  unknown.	  
The	  advantages	  to	  supporting	  plasma	  cells	  during	  inflammation	  are	  unknown,	  
but	  it	  seems	  likely	  that	  the	  continuous	  generation	  of	  extrafollicular	  plasma	  cells	  
that	  survive	  for	  just	  2-­‐3	  days	  would	  require	  a	  high	  level	  of	  resources.	  To	  extend	  
the	  lifespan	  of	  these	  cells	  through	  the	  provision	  of	  survival	  factors	  may	  relieve	  
some	  of	  the	  burden	  of	  maintaining	  high	  antibody	  levels	  before	  the	  generation	  of	  
high	  affinity	  long-­‐lived	  plasma	  cells	  that	  travel	  to	  the	  bone	  marrow.	  	  
Conclusion	  
These	  data	  show	  that,	  following	  SRBC	  immunisation,	  short-­‐lived	  extrafollicular	  
responses	  are	  induced.	  This	  response	  is	  TD,	  requiring	  MHC	  II,	  CD40,	  ICOS	  and	  
BCR	  signalling.	  Following	  infection	  with	  Salmonella,	  mice	  generate	  an	  early	  IgM	  
response	  that	  is	  TI,	  requires	  TLR	  signalling	  and	  may	  arise	  (at	  least	  in	  part)	  from	  
the	  marginal	  zone	  B	  cell	  compartment.	  By	  day	  8,	  mice	  generate	  a	  class	  switched	  
response,	  which	  requires	  MHC	  II	  signalling	  but	  is	  less	  impaired	  in	  CD40	  or	  ICOS	  
deficient	  mice.	  Antigen-­‐specific	  antibody	  responses	  are	  entirely	  MHC	  II	  
dependent	  in	  this	  infection,	  and	  the	  possibility	  exists	  that	  many	  of	  the	  early	  
plasma	  cells	  seen	  in	  Salmonella	  infection	  are	  induced	  non-­‐specifically,	  as	  MD4	  
mice	  make	  a	  significant	  plasma	  cell	  response	  by	  day	  8.	  Turnover	  of	  
extrafollicular	  plasma	  cells	  in	  Salmonella	  infected	  spleens	  is	  relatively	  slow,	  
with	  a	  half-­‐life	  of	  around	  6-­‐days,	  unlike	  those	  that	  arise	  during	  SRBC	  
immunisation	  which	  die	  within	  2-­‐3	  days.	  This	  is	  likely	  due	  to	  the	  dramatic	  
increase	  in	  availability	  of	  survival	  factors	  in	  the	  infected	  spleen.	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Chapter	  5	  –	  Chronic	  antigen	  supply	  impairs	  the	  establishment	  of	  long-­‐
lived	  bone	  marrow	  plasma	  cell	  populations	  
Introduction	  
Certain	  plasma	  cells,	  especially	  those	  arising	  from	  germinal	  centres	  during	  TD	  
immune	  responses,	  travel	  to	  the	  bone	  marrow,	  where	  they	  are	  supported	  by	  
survival	  factors	  and	  persist	  for	  long	  periods	  of	  time147,148,151,166,189.	  Unlike	  the	  
extrafollicular	  plasma	  cells	  discussed	  in	  chapter	  4	  (which	  could	  be	  supported	  
for	  a	  few	  days),	  these	  plasma	  cells	  can	  survive	  for	  months	  or	  even	  
years88,189,193,194.	  This	  is	  likely	  a	  result	  of	  the	  constant	  availability	  of	  survival	  
factors	  such	  as	  APRIL	  and	  IL-­‐6	  in	  the	  bone	  marrow	  under	  homeostatic	  
conditions,	  but	  may	  also	  result	  from	  inherent	  differences	  between	  ‘short’	  and	  
‘long’	  lived	  plasma	  cells192.	  Similarly,	  the	  factors	  that	  control	  a	  plasma	  cell’s	  
migration	  from	  its	  site	  of	  generation	  to	  the	  bone	  marrow	  is	  also	  poorly	  
understood;	  CXCL12	  and	  it’s	  receptor	  CXCR4	  are	  thought	  to	  play	  a	  role166,	  but	  
this	  chemokine	  also	  controls	  plasma	  cell	  migration	  from	  the	  follicle	  to	  the	  red	  
pulp	  of	  the	  spleen78.	  Further	  (as	  yet	  unknown)	  levels	  of	  control	  likely	  exist.	  
Long-­‐lived	  plasma	  cells	  are	  generated	  in	  large	  numbers	  following	  secondary	  
immunisation	  with	  TD	  antigens249.	  They	  are	  also	  generated	  from	  the	  second	  
week	  onwards	  during	  primary	  responses	  to	  such	  antigens,	  although	  in	  lower	  
numbers.	  These	  plasma	  cells	  have	  been	  shown	  to	  persist	  for	  long	  periods	  
without	  the	  need	  for	  further	  input	  from	  activated	  B	  cells	  or	  antigenic	  
stimulation194,196.	  Experiments	  utilising	  irradiation	  (which	  depletes	  B	  cells,	  but	  
not	  long-­‐lived	  plasma	  cells)	  showed	  that	  bone	  marrow	  plasma	  cells	  generated	  
by	  prior	  immunisation	  persist	  for	  long	  periods	  even	  when	  peripheral	  B	  cells	  are	  
entirely	  depleted,	  and	  corresponding	  antibody	  levels	  are	  hardly	  affected193.	  
These	  results	  were	  confirmed	  by	  efficient	  B	  cell	  specific	  depletion	  using	  anti-­‐
CD20196.	  As	  discussed	  earlier,	  long-­‐lived	  plasma	  cells	  do	  not	  require	  cellular	  
division,	  which	  likely	  accounts	  for	  their	  ability	  to	  persist	  despite	  B	  cell	  
depletion189.	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Interestingly,	  however,	  the	  persistence	  of	  pre-­‐existing	  antibody	  levels	  following	  
B	  cell	  depletion	  does	  not	  always	  occur.	  It	  was	  found	  that	  antibody	  levels	  to	  
autoimmune	  conditions	  such	  as	  rheumatoid	  arthritis	  and	  (in	  some	  cases	  at	  
least)	  SLE,	  characterised	  by	  high	  levels	  of	  circulating	  anti-­‐self	  antibodies,	  fell	  
following	  injection	  of	  anti-­‐CD20253,256,259.	  These	  diseases	  are	  the	  result	  of	  TD	  
anti-­‐self	  responses,	  which	  lead	  to	  the	  spontaneous	  generation	  of	  germinal	  
centres	  and	  anti-­‐self	  plasma	  cells	  (and	  antibody).	  This	  led	  to	  the	  use	  of	  human	  
anti-­‐CD20	  (rituximab)	  as	  a	  treatment	  for	  such	  diseases,	  which	  has	  proved	  
effective	  especially	  in	  rheumatoid	  arthritis.	  	  
The	  implication	  of	  these	  data	  is	  that	  antibody	  produced	  during	  certain	  
autoimmune	  disease	  is	  generated	  exclusively	  by	  short-­‐lived	  plasma	  cells.	  That	  
short-­‐lived	  plasma	  cells	  are	  major	  contributors	  is	  not	  entirely	  surprising;	  the	  
unlimited	  availability	  of	  auto-­‐antigen	  in	  these	  diseases	  would	  lead	  to	  a	  constant	  
generation	  of	  new	  plasma	  cells	  from	  activated	  B	  cells,	  not	  all	  of	  which	  could	  
survive	  in	  the	  bone	  marrow.	  However,	  there	  appears	  to	  be	  no	  phenotypic	  
reason	  why	  some	  of	  these	  plasma	  cells	  could	  not	  access	  bone	  marrow	  survival	  
‘niches’	  and	  survive	  for	  long	  periods,	  even	  following	  B	  cell	  depletion.	  
As	  there	  is	  no	  known	  phenotypic	  difference	  between	  plasma	  cells	  generated	  
during	  autoimmune	  disease	  and	  infectious	  disease	  (or	  immunisation	  with	  
exogenous	  antigen),	  we	  hypothesised	  chronic	  immune	  responses	  (whether	  
against	  self	  or	  exogenous	  antigen)	  exclusively	  generate	  short-­‐lived	  plasma	  cells,	  
whereas	  acute	  immune	  responses	  generate	  both	  short	  and	  long-­‐lived	  plasma	  
cells.	  	  
In	  the	  present	  chapter,	  this	  hypothesis	  has	  been	  tested	  by	  measuring	  the	  
turnover	  and	  lifespan	  of	  plasma	  cells	  generated	  during	  the	  immune	  response	  to	  
a	  number	  of	  acute	  and	  chronic	  inflammatory	  conditions	  (protein	  antigen,	  
autoimmunity	  and	  bacterial	  infection).	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Results	  
Lifespan	  of	  plasma	  cells	  following	  primary	  and	  secondary	  immunisation	  with	  the	  
TD	  protein	  antigen	  DNP-­‐OVA	  
We	  sought	  to	  develop	  a	  system	  whereby	  the	  lifespan	  of	  plasma	  cells	  generated	  
during	  a	  defined	  time	  (i.e.	  following	  immunisation)	  could	  be	  tracked.	  To	  
accomplish	  this,	  we	  took	  advantage	  of	  the	  fact	  that	  antibody	  secreting	  cells	  
divide	  rapidly	  during	  their	  formation	  (as	  plasmablasts),	  but	  stop	  division	  upon	  
maturation	  into	  plasma	  cells.	  By	  providing	  a	  sustained	  ‘pulse’	  of	  BrdU,	  all	  
plasmablasts	  generated	  during	  that	  pulse	  are	  labelled.	  Those	  that	  mature	  to	  
non-­‐dividing	  plasma	  cells	  during	  this	  time	  retain	  BrdU	  in	  their	  DNA	  until	  cell	  
death	  occurs.	  BrdU	  is	  rapidly	  lost	  from	  cells	  that	  continue	  to	  divide	  after	  the	  
‘pulse’	  has	  ended.	  Therefore,	  long-­‐lived	  plasma	  cells	  generated	  during	  a	  BrdU	  
pulse	  can	  be	  detected,	  as	  they	  will	  maintain	  BrdU	  for	  long	  periods	  after	  the	  
pulse	  has	  finished.	  
Figure	  5.1a	  shows	  a	  schematic	  of	  the	  experimental	  design.	  Mice	  were	  
immunised	  sub-­‐cutaneously	  with	  DNP-­‐OVA	  (suspended	  in	  incomplete	  Freund’s	  
adjuvant	  with	  10ug	  LPS)	  at	  day	  1.	  Either	  ‘early’	  (days	  4-­‐6)	  or	  ‘late’	  (days	  12-­‐14)	  
following	  immunisation,	  mice	  were	  injected	  with	  2mg	  BrdU	  into	  the	  
intraperitoneal	  cavity	  at	  24	  hour	  intervals;	  labelling	  plasma	  cells	  generated	  
during	  the	  extrafollicular	  and	  germinal	  centre	  phases	  respectively.	  A	  control	  
group	  received	  a	  3-­‐day	  BrdU	  pulse,	  but	  was	  not	  immunised.	  Finally,	  a	  forth	  
group	  was	  boosted	  intravenously	  with	  100ug	  soluble	  DNP-­‐OVA	  (at	  day	  35	  after	  
primary	  immunisations).	  This	  was	  followed	  with	  a	  3-­‐day	  BrdU	  pulse	  at	  days	  38-­‐
40.	  Mice	  were	  then	  culled	  at	  7	  and	  22	  days	  following	  BrdU.	  
Figure	  5.1b	  shows	  representative	  FACS	  plots	  (summarised	  in	  fig	  5.1d)	  of	  BrdU	  
retention	  by	  splenic	  plasma	  cells	  either	  7	  days	  (middle	  row)	  or	  22	  days	  (bottom	  
row)	  after	  BrdU	  pulses	  in	  the	  various	  groups	  (for	  plasma	  cell	  gating,	  see	  top	  
row).	  In	  all	  immunised	  groups	  just	  6.93%	  (±1.21),	  7.34%	  (±0.47)	  and	  7.81%	  
(±0.77)	  of	  splenic	  plasma	  cells	  in	  early,	  late	  or	  boosted	  mice	  respectively	  
retained	  BrdU	  7-­‐days	  after	  pulsing.	  After	  22	  days,	  1.52%	  (±0.12),	  1.93%	  (±0.59)	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and	  3.01%	  (±1.08)	  of	  splenic	  plasma	  cells	  retained	  BrdU.	  There	  was	  no	  
significant	  difference	  between	  any	  of	  the	  immunised	  groups.	  Naïve	  mice	  had	  a	  
lower	  proportion	  of	  labelled	  splenic	  plasma	  cells	  at	  both	  7	  after	  pulsing	  (3.07%	  
±0.59),	  with	  only	  very	  low	  proportions	  of	  labelled	  plasma	  cells	  surviving	  to	  22	  
days	  after	  pulsing	  (0.025%	  ±0.015).	  
11.14%	  (±1.59)	  of	  bone	  marrow	  plasma	  cells	  in	  primed	  mice	  pulsed	  ‘late’	  (day	  
12-­‐14)	  retained	  BrdU	  7	  days	  after	  pulsing,	  however	  few	  of	  these	  (1.66%	  ±0.19)	  
survived	  for	  22	  days	  (fig	  5.1c	  and	  5.1d,	  left).	  This	  was	  similar	  for	  primed	  mice	  
pulsed	  ‘early’	  (days	  4-­‐6)	  and	  naïve	  mice,	  which	  generated	  few	  plasma	  cells	  that	  
survived	  for	  22	  days	  after	  pulsing	  (6.94%	  ±0.44	  to	  0.71	  ±0.04).	  Boosted	  mice	  
however,	  generated	  detectable	  populations	  of	  plasma	  cells	  that	  retained	  their	  
BrdU	  label.	  This	  population	  did	  not	  decline	  between	  days	  7	  and	  22	  following	  
BrdU	  and	  therefore	  is,	  by	  definition,	  long-­‐lived	  (4.43%	  ±0.61	  to	  4.25%	  ±0.89).	  
Generation	  of	  stable,	  antigen-­‐specific	  populations	  of	  bone	  marrow	  plasma	  cells	  
following	  secondary	  immunisation	  with	  the	  TD	  protein	  antigen	  NP-­‐KLH	  
The	  data	  shown	  in	  figure	  5.1	  confirmed	  the	  data	  of	  others;	  following	  secondary	  
immunisation,	  populations	  of	  long-­‐lived	  plasma	  cells	  could	  be	  detected	  in	  the	  
bone	  marrow.	  We	  sought	  to	  enhance	  this	  system,	  with	  the	  aim	  of	  detecting	  the	  
lifespan	  of	  antigen-­‐specific	  plasma	  cells	  following	  immunisation.	  We	  therefore	  
modified	  our	  protocol,	  and	  instead	  used	  the	  TD	  protein	  antigen	  NP-­‐KLH,	  as	  it	  is	  
possible	  to	  detect	  NP-­‐specific	  plasma	  cells	  on	  a	  flow	  cytometer	  by	  intracellular	  
staining	  with	  fluorescently	  labelled	  NP	  (we	  had	  little	  success	  in	  using	  labelled	  
DNP	  to	  detect	  DNP-­‐specific	  plasma	  cells).	  Similarly,	  we	  found	  that	  larger	  splenic	  
plasma	  cell	  responses	  were	  obtained	  through	  primary	  immunisation	  with	  alum-­‐
precipitated	  NP-­‐KLH	  with	  killed	  Bordetella	  pertussis	  via	  intraperitoneal	  
injection.	  
Initially,	  we	  examined	  the	  kinetics	  of	  NP-­‐specific	  plasma	  cell	  generation	  
following	  primary	  and	  secondary	  immunisation	  with	  NP-­‐KLH.	  Figure	  5.2a	  
shows	  representative	  FACS	  plots	  from	  spleen	  and	  bone	  marrow	  of	  naïve	  mice	  
(left)	  and	  NP-­‐KLH	  primed	  mice	  at	  day	  5,	  9	  and	  45,	  gated	  on	  IgG	  plasma	  cells.	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Despite	  substantial	  splenic	  plasma	  cell	  generation	  (see	  fig	  3.1a)	  in	  primed	  mice,	  
only	  low	  proportions	  of	  these	  bound	  intracellular	  NP	  (fig	  5.2a	  and	  c).	  Similarly,	  
in	  the	  bone	  marrow,	  few	  NP-­‐specific	  plasma	  cells	  were	  seen.	  45	  days	  following	  
immunisation,	  around	  3.57%	  (±0.31)	  splenic	  and	  6.17%	  (±0.52)	  bone	  marrow	  
plasma	  cells	  were	  NP-­‐specific.	  	  
In	  contrast	  to	  this,	  following	  secondary	  immunisation,	  a	  rapid	  generation	  of	  NP-­‐
specific	  plasma	  cells	  could	  be	  seen	  in	  the	  spleen	  by	  day	  5	  (fig	  5.2b	  and	  c).	  
Initially,	  these	  were	  immature,	  MHC	  IIhi	  plasma	  cells	  but	  rapidly	  matured	  into	  
MHC	  IIlo	  plasma	  cells	  by	  day	  9.	  NP-­‐specific	  plasma	  cells	  appeared	  in	  the	  bone	  
marrow	  rapidly	  and	  came	  to	  dominate	  the	  bone	  marrow	  plasma	  cell	  
compartment	  just	  9	  days	  following	  secondary	  immunisation	  (41.10%	  ±7.97).	  
Plasma	  cells	  generated	  during	  the	  secondary	  immune	  response	  to	  NP-­‐KLH	  
continued	  to	  dominate	  the	  bone	  marrow	  plasma	  cell	  compartment	  to	  day	  45,	  
and	  numbers	  were	  also	  maintained	  (figures	  5.2b,	  c	  and	  d).	  In	  the	  spleen,	  
numbers	  of	  NP-­‐specific	  plasma	  cells	  declined	  rapidly	  between	  day	  9	  and	  25	  
(4.87x106	  ±1.53x106	  to	  1.87x105	  ±7.92x104;	  fig	  5.2d)	  and	  continued	  to	  decline	  
at	  a	  slower	  rate	  until	  day	  45	  (1.09x105	  ±2.99x104).	  This	  represented	  a	  decline	  in	  
the	  total	  plasma	  cell	  population,	  as	  proportionally	  NP-­‐specific	  plasma	  cells	  
continued	  to	  dominate	  the	  splenic	  plasma	  cell	  pool.	  
NP-­‐specific	  antibody	  levels	  (IgM	  and	  the	  IgG	  isotypes)	  were	  measured	  
throughout	  the	  time	  course	  of	  primary	  and	  secondary	  immunisations	  (fig	  5.2e).	  
As	  would	  be	  expected,	  NP-­‐specific	  IgM	  was	  rapidly	  generated	  following	  primary	  
immunisation	  (levels	  rose	  by	  day	  5,	  but	  continued	  to	  climb	  until	  day	  25),	  
whereas	  NP-­‐specific	  IgG	  was	  not	  generated	  until	  day	  9.	  This	  too	  peaked	  at	  day	  
25	  and	  was	  maintained	  until	  the	  end	  of	  the	  study	  (day	  45).	  Kinetics	  were	  similar	  
for	  all	  IgG	  isotypes.	  By	  day	  9	  following	  secondary	  immunisation,	  antibody	  levels	  
rose	  to	  around	  a	  log	  fold	  higher	  than	  at	  the	  peak	  of	  the	  primary	  response.	  This	  
was	  accompanied	  by	  a	  slow	  decline	  throughout	  the	  remainder	  of	  the	  time	  
course,	  with	  levels	  remaining	  higher	  than	  mice	  only	  receiving	  primary	  
immunisation.	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NP-­‐specific	  plasma	  cells	  in	  the	  spleen	  and	  bone	  marrow	  of	  mice	  25	  days	  after	  
secondary	  immunisation	  with	  NP-­‐KLH	  are	  non-­‐dividing,	  long-­‐lived	  plasma	  cells	  
To	  confirm	  that	  the	  NP-­‐specific	  plasma	  cells	  seen	  in	  the	  bone	  marrow	  of	  NP-­‐KLH	  
boosted	  mice	  were	  long-­‐lived,	  NP-­‐KLH	  boosted	  mice	  were	  provided	  with	  BrdU	  
for	  a	  10-­‐day	  period	  (at	  days	  16-­‐25	  after	  boost).	  Long-­‐lived	  plasma	  cells	  (which	  
survive	  for	  long	  periods	  without	  division)	  would	  not	  incorporate	  BrdU,	  whereas	  
short-­‐lived	  plasma	  cells	  (which	  require	  constant	  replenishment	  from	  the	  
activated	  B	  cell	  pool	  every	  few	  days,	  involving	  cellular	  division)	  would	  
incorporate	  BrdU.	  Figure	  5.3a	  shows	  representative	  FACS	  plots	  gated	  on	  IgG	  
plasma	  cells	  from	  boosted	  mice	  or	  primed	  controls	  (which	  were	  primed	  at	  the	  
same	  time	  as	  boosted	  mice,	  but	  received	  no	  secondary	  immunisation)	  showing	  
BrdU	  incorporation	  of	  NP-­‐specific	  or	  non-­‐NP-­‐specific	  plasma	  cells	  in	  the	  spleen	  
and	  bone	  marrow.	  NP-­‐specific	  plasma	  cells,	  at	  this	  stage	  following	  secondary	  
immunisation,	  had	  only	  a	  very	  low	  turnover.	  It	  can	  be	  seen	  in	  figure	  5.3b	  that	  
NP-­‐specific	  plasma	  cells	  in	  both	  spleen	  and	  bone	  marrow	  were	  primarily	  long-­‐
lived,	  with	  just	  6.26%	  (±2.40)	  and	  7.01%	  (±2.54)	  incorporating	  BrdU	  in	  the	  
spleen	  and	  bone	  marrow	  respectively	  in	  a	  10-­‐day	  pulse.	  	  
Long-­‐lived	  bone	  marrow	  plasma	  cell	  generation	  is	  impaired	  in	  mice	  receiving	  a	  
continuous	  ‘chronic’	  supply	  of	  NP-­‐KLH	  compared	  to	  those	  receiving	  a	  single	  
‘acute’	  dose	  
The	  above	  figures	  confirmed	  that	  an	  acute	  secondary	  immunisation	  with	  NP-­‐
KLH	  generated	  long-­‐lived	  bone	  marrow	  plasma	  cells.	  We	  next	  sought	  to	  directly	  
compare	  the	  generation	  of	  long-­‐lived	  plasma	  cells	  when	  antigen	  was	  delivered	  
in	  a	  single	  acute	  dose,	  or	  a	  continuous	  supply	  over	  a	  long	  period.	  We	  chose	  to	  
use	  a	  secondary	  immunisation	  system,	  as	  the	  above	  figures	  show	  it	  produces	  a	  
higher	  proportion	  of	  antigen-­‐specific	  bone	  marrow	  plasma	  cells;	  as	  these	  cells	  
are	  relatively	  rare,	  this	  was	  an	  important	  consideration	  to	  produce	  more	  
reliable	  data.	  
A	  schematic	  of	  the	  experiment	  is	  shown	  in	  figure	  5.4a.	  Briefly,	  mice	  were	  
primed	  with	  alum-­‐precipitated	  NP-­‐KLH	  and	  B.	  pertussis	  and	  rested	  for	  5	  weeks.	  
The	  first	  group	  of	  mice	  received	  no	  secondary	  immunisation	  (primed	  controls),	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a	  second	  group	  of	  mice	  received	  a	  single	  dose	  of	  100ug	  soluble	  NP-­‐KLH	  
intravenously	  (acute	  group),	  while	  a	  third	  group	  received	  20	  doses	  of	  5ug	  
soluble	  NP-­‐KLH	  (for	  a	  total	  of	  100ug)	  intravenously	  at	  3-­‐day	  intervals	  over	  a	  60-­‐
day	  period	  (chronic	  group).	  At	  three	  time	  points,	  separate	  groups	  of	  mice	  were	  
given	  a	  10-­‐day	  pulse	  of	  BrdU	  and	  culled	  immediately	  afterwards.	  This	  allowed	  
us	  to	  assess	  the	  number	  of	  NP-­‐specific	  plasma	  cells	  in	  the	  spleen	  and	  bone	  
marrow,	  and	  whether	  NP-­‐specific	  plasma	  cells	  were	  short	  or	  long-­‐lived.	  BrdU	  
was	  given	  at	  day	  1-­‐10	  (day	  1	  was	  the	  day	  when	  the	  acute	  group	  received	  their	  
secondary	  immunisation,	  and	  when	  the	  chronic	  group’s	  series	  of	  immunisations	  
began),	  day	  51-­‐60	  (day	  60	  was	  when	  the	  chronic	  group’s	  series	  of	  
immunisations	  ended)	  and	  day	  111-­‐120.	  
It	  can	  be	  seen	  in	  figure	  5.4b	  that	  at	  day	  10,	  the	  acute	  group	  had	  high	  numbers	  of	  
NP-­‐specific	  plasma	  cells	  and,	  as	  in	  figure	  5.3,	  had	  established	  substantial	  
populations	  of	  NP-­‐specific	  plasma	  cells	  in	  the	  bone	  marrow.	  Figure	  5.4c	  shows	  
that	  the	  majority	  (70.85%	  ±6.31)	  of	  NP-­‐specific	  plasma	  cells	  in	  the	  spleen	  of	  
acutely	  immunised	  group	  had	  incorporated	  BrdU	  in	  the	  first	  10-­‐days	  following	  
immunisation.	  Similarly	  in	  the	  bone	  marrow	  56.98%	  (±4.79)	  of	  NP-­‐specific	  
plasma	  cells	  had	  incorporated	  BrdU.	  Numbers	  of	  NP-­‐specific	  plasma	  cells	  in	  the	  
spleen	  had	  declined	  dramatically	  by	  day	  60	  and,	  although	  turnover	  had	  
decreased	  from	  the	  day	  10	  time	  point	  (to	  39.45%	  ±2.76).	  The	  dramatic	  drop	  in	  
dividing	  NP-­‐specific	  plasma	  cells	  can	  be	  seen	  in	  figure	  5.4d.	  These	  trends	  were	  
continued	  out	  to	  day	  120,	  although	  by	  this	  time	  point	  turnover	  of	  NP-­‐specific	  
plasma	  cells	  in	  the	  spleen	  had	  decreased	  further	  to	  20.17%	  (±3.90).	  In	  the	  bone	  
marrow	  at	  day	  60,	  NP-­‐specific	  plasma	  cells	  had	  declined	  only	  very	  slightly,	  
populations	  remained	  stable	  until	  the	  end	  of	  the	  experiment.	  Turnover	  of	  NP-­‐
specific	  plasma	  cells	  in	  the	  bone	  marrow	  was	  also	  low,	  21.08%	  (±2.47)	  at	  day	  
60,	  and	  5.91%	  (±1.03)	  by	  day	  120.	  These	  data,	  in	  agreement	  with	  that	  from	  
earlier	  figures,	  suggests	  that	  acute	  secondary	  immunisation	  with	  NP-­‐KLH	  
generates	  long-­‐lived	  bone	  marrow	  plasma	  cell	  populations.	  
The	  chronic	  group	  had	  generated	  significantly	  fewer	  NP-­‐specific	  splenic	  plasma	  
cells	  by	  day	  10	  compared	  to	  mice	  in	  the	  acute	  group	  (fig	  5.4b).	  This	  was	  not	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surprising,	  as	  they	  had	  received	  only	  a	  sixth	  of	  their	  complete	  dose	  at	  this	  point	  
of	  the	  experiment.	  Similarly,	  they	  had	  significantly	  fewer	  NP-­‐specific	  plasma	  
cells	  in	  the	  bone	  marrow.	  Turnover	  of	  NP-­‐specific	  plasma	  cells	  was	  high	  in	  
spleen	  and	  bone	  marrow	  (71.52%	  (±2.74)	  and	  45.63%	  (±3.85)	  respectively).	  At	  
day	  60,	  when	  chronically	  stimulated	  mice	  had	  received	  the	  full	  dose	  of	  NP-­‐KLH,	  
the	  number	  of	  splenic	  plasma	  cells	  remained	  similar	  to	  that	  seen	  at	  day	  10,	  as	  
would	  be	  expected.	  In	  fact,	  figure	  5.4c	  and	  d	  show	  that	  a	  similar	  proportion	  and	  
number	  of	  NP-­‐specific	  plasma	  cells	  incorporated	  BrdU	  when	  pulsed	  at	  days	  1-­‐
10	  or	  days	  50-­‐60,	  showing	  that	  NP-­‐specific	  plasma	  cells	  were	  continuously	  
generated	  throughout	  the	  60-­‐day	  period	  of	  immunisations.	  Remarkably,	  despite	  
this	  fact,	  populations	  of	  NP-­‐specific	  plasma	  cells	  in	  the	  bone	  marrow	  had	  not	  
increased	  since	  day	  10.	  BrdU	  incorporation	  of	  NP-­‐specific	  plasma	  cells	  in	  the	  
bone	  marrow	  fell	  considerably	  by	  day	  60	  (22.13%	  ±2.19)	  and	  was	  comparable	  
to	  turnover	  of	  NP-­‐specific	  plasma	  cells	  in	  the	  bone	  marrow	  of	  acutely	  
immunised	  mice.	  Figure	  5.4d	  confirms	  that	  only	  very	  few	  ‘new’	  NP-­‐specific	  
plasma	  cells	  were	  generated	  during	  days	  51-­‐60.	  As	  immunisations	  in	  these	  mice	  
had	  now	  stopped,	  we	  looked	  at	  day	  120	  to	  see	  if	  the	  NP-­‐specific	  plasma	  cells	  
that	  were	  seen	  in	  chronically	  stimulated	  mice	  would	  persist	  without	  further	  
antigenic	  stimulation.	  Indeed,	  numbers	  at	  day	  120	  were	  similar	  to	  those	  at	  
earlier	  time	  points,	  while	  the	  percentage	  of	  these	  plasma	  cells	  incorporating	  
BrdU	  had	  dropped	  to	  7.12%	  (±1.30).	  Figure	  5.4d	  shows	  that	  very	  few	  new	  NP-­‐
specific	  plasma	  cells	  were	  generated	  in	  the	  spleen	  or	  bone	  marrow	  of	  these	  mice	  
between	  days	  111-­‐120.	  
These	  data	  indicate	  that,	  despite	  continuous	  generation	  of	  new	  splenic	  plasma	  
cells	  in	  chronically	  stimulated	  mice,	  few	  bone	  marrow	  plasma	  cells	  were	  formed	  
compared	  to	  acutely	  stimulated	  mice.	  The	  NP-­‐specific	  plasma	  cells	  that	  were	  
formed	  appeared	  to	  be	  generated	  primarily	  in	  the	  first	  10-­‐days	  of	  the	  response,	  
and	  were	  able	  to	  persist	  after	  NP-­‐KLH	  immunisations	  had	  ceased.	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NP-­‐specific	  antibody	  levels	  following	  acute	  or	  chronic	  secondary	  immunisation	  
with	  NP-­‐KLH	  
To	  evaluate	  whether	  chronic	  provision	  of	  NP-­‐KLH	  leads	  to	  reduced	  NP-­‐specific	  
antibody	  levels,	  or	  antibody	  levels	  that	  fall	  once	  antigen	  provision	  has	  stopped,	  
we	  assessed	  the	  serum	  of	  the	  mice	  described	  above	  for	  NP-­‐specific	  antibody	  (fig	  
5.5).	  Acutely	  immunised	  mice	  generated	  antibody	  similarly	  to	  mice	  evaluated	  
previously.	  NP-­‐specific	  IgM	  and	  IgG	  (of	  all	  isotypes)	  levels	  peaked	  at	  day	  10	  
following	  secondary	  immunisation	  and	  gradually	  declined	  thereafter.	  Generally	  
this	  was	  a	  fairly	  linear	  decline	  to	  day	  120,	  when	  the	  experiment	  finished.	  During	  
that	  period,	  levels	  fell	  by	  around	  10-­‐fold.	  This	  was	  similar	  to	  the	  decline	  seen	  in	  
primed	  controls,	  in	  which	  levels	  fell	  at	  a	  similar	  rate	  (albeit	  starting	  from	  
around	  a	  log-­‐fold	  lower).	  
Chronically	  stimulated	  mice	  received	  antigen	  for	  the	  first	  60-­‐days	  of	  the	  study,	  
and	  therefore	  it	  was	  not	  surprising	  that	  levels	  of	  most	  of	  the	  classes	  assessed	  
here	  remained	  constant	  during	  that	  period	  (although	  levels	  to	  IgG2b	  and	  IgG3	  
fell	  during	  this	  period).	  Following	  this,	  when	  antigen	  was	  no	  longer	  provided	  to	  
these	  mice,	  levels	  uniformly	  fell.	  In	  many	  cases	  (IgM,	  IgG1	  and	  IgG2b)	  levels	  fell	  
slightly	  faster	  than	  those	  of	  the	  acute	  group.	  However,	  IgG2b	  fell	  slower,	  while	  
IgG3	  fell	  at	  approximately	  the	  same	  rate	  in	  the	  two	  groups.	  Only	  for	  IgM	  and	  
IgG1	  were	  the	  differences	  between	  the	  acute	  and	  chronic	  groups	  significantly	  
different	  by	  day	  120.	  
Autoimmune	  K/BxN	  mice	  continuously	  generate	  large	  splenic	  plasma	  cell	  
populations,	  but	  few	  long-­‐lived	  bone	  marrow	  plasma	  cells	  	  
The	  data	  above	  suggest	  that	  while	  acute	  immunisation	  generates	  both	  short	  and	  
long-­‐lived	  plasma	  cells,	  chronic	  antigenic	  stimulation	  with	  NP-­‐KLH	  generates	  
mainly	  short-­‐lived	  splenic	  plasma	  cells	  and	  few	  long-­‐lived	  bone	  marrow	  plasma	  
cells.	  As	  this	  very	  property	  is	  utilised	  to	  treat	  autoimmune	  patients	  via	  depletion	  
of	  B	  cells,	  we	  were	  interested	  in	  testing	  the	  principle	  in	  autoimmune	  mice.	  
K/BxN	  mice	  are	  the	  F1	  progeny	  of	  NOD	  mice	  and	  TCR	  transgenic	  KRN	  mice.	  By	  
chance	  T	  cells	  in	  these	  mice	  recognise	  the	  ubiquitous	  glycolytic	  enzyme	  glucose-­‐
6-­‐phosphate	  isomerase	  (G6PI)	  in	  the	  context	  of	  the	  I-­‐Ag7	  MHC	  II	  molecule	  (the	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only	  MHC	  II	  molecule	  expressed	  by	  NOD	  mice).	  These	  mice	  go	  on	  to	  
spontaneously	  develop	  a	  TD,	  antibody	  mediated	  autoimmune	  disease	  
characterised	  by	  swollen	  joints,	  germinal	  centres,	  splenic	  plasma	  cells	  and	  high	  
levels	  of	  anti-­‐G6PI.	  This	  has	  made	  these	  mice	  a	  commonly	  used	  model	  of	  
rheumatoid	  arthritis;	  a	  disease	  where	  the	  use	  of	  rituximab	  to	  deplete	  B	  cells	  
(and	  thereby	  reduce	  levels	  of	  auto-­‐antibody	  secreted	  by	  short-­‐lived	  plasma	  
cells)	  is	  a	  widespread	  one.	  At	  our	  facility,	  these	  mice	  are	  bred	  as	  heterozygotes,	  
which	  generates	  50%	  of	  mice	  that	  develop	  arthritis	  and	  50%	  that	  do	  not.	  
We	  first	  compared	  the	  spleens	  of	  non-­‐arthritic	  and	  arthritic	  K/BxN	  mice	  
(hereafter	  referred	  to	  as	  non-­‐arthritic	  and	  arthritic	  mice)	  for	  plasma	  cell	  
generation.	  Figure	  5.6a	  (top	  row)	  shows	  that	  arthritic	  mice	  had	  considerably	  
larger	  splenic	  plasma	  cell	  populations	  compared	  to	  non-­‐arthritic	  controls	  
(0.41%	  (±0.02)	  in	  arthritic	  mice,	  0.11%	  (±0.02)	  in	  non-­‐arthritic).	  Figure	  5.6b	  
confirms	  that	  arthritic	  mice	  had	  significantly	  higher	  numbers	  of	  plasma	  cells	  per	  
spleen	  compared	  to	  non-­‐arthritic	  control	  mice	  (1.93x106	  (±1.90x105)	  in	  
arthritic	  mice	  and	  1.13x105	  (±1.07x104)	  in	  non-­‐arthritic).	  By	  pulsing	  mice	  with	  
BrdU	  for	  3-­‐days,	  it	  was	  revealed	  that	  plasma	  cells	  in	  the	  spleens	  of	  arthritic	  mice	  
turned	  over	  slightly	  faster	  than	  those	  in	  control	  mice	  (40.79%	  (±3.06)	  in	  
arthritic	  mice,	  28.69%	  (±1.74)	  in	  non-­‐arthritic	  mice).	  We	  next	  performed	  a	  
BrdU	  pulse-­‐chase	  experiment,	  where	  age	  matched	  arthritic	  and	  non-­‐arthritic	  
mice	  were	  given	  a	  3-­‐day	  BrdU	  pulse	  following	  the	  onset	  of	  disease	  (at	  days	  21-­‐
24	  after	  birth).	  Immediately	  after	  BrdU	  pulsing	  (day	  1),	  some	  mice	  were	  culled	  
and	  analysed	  for	  BrdU	  labelled	  plasma	  cells.	  Following	  this,	  a	  ‘chase’	  period	  
ensued,	  whereby	  mice	  were	  culled	  and	  analysed	  for	  surviving	  BrdU	  labelled	  
plasma	  cells	  at	  day	  8,	  18	  and	  28	  after	  BrdU	  pulsing.	  Plasma	  cells	  retaining	  the	  
label	  are	  long-­‐lived	  by	  definition.	  
Immediately	  after	  BrdU	  pulsing,	  arthritic	  mice	  contained	  a	  higher	  proportion	  of	  
labelled	  plasma	  cells	  than	  non-­‐arthritic	  control	  mice,	  and	  this	  corresponded	  to	  
5-­‐fold	  higher	  numbers	  (fig	  5.6d	  and	  e,	  left	  graphs).	  Conversely,	  non-­‐arthritic	  
mice	  had	  higher	  proportions	  of	  labelled	  plasma	  cells	  in	  the	  bone	  marrow,	  
corresponding	  to	  significantly	  higher	  numbers	  (fig	  5.6d	  and	  e,	  right).	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Interestingly,	  just	  8	  days	  after	  pulsing,	  labelled	  plasma	  cells	  had	  entirely	  
decayed	  in	  both	  groups.	  This	  suggests	  that,	  although	  arthritic	  mice	  generate	  
significantly	  higher	  numbers	  of	  splenic	  plasma	  cells	  in	  a	  3-­‐day	  period,	  very	  few	  
of	  these	  travel	  to	  the	  bone	  marrow	  (as	  fewer	  BrdU	  labelled	  plasma	  cells	  were	  
seen	  in	  the	  bone	  marrow	  of	  arthritic	  mice	  than	  control	  mice).	  Similarly,	  
although	  28.06%	  (±3.69)	  of	  bone	  marrow	  plasma	  cells	  were	  labelled	  in	  arthritic	  
mice,	  few	  of	  these	  plasma	  cells	  survived	  for	  more	  than	  a	  few	  days	  (1.13%	  
(±0.39)	  7-­‐days	  after	  BrdU	  pulsing,	  and	  0.47%	  (±0.08)	  21-­‐days	  after	  BrdU);	  and	  
no	  more	  than	  survived	  in	  non-­‐arthritic	  control	  mice.	  This	  is	  strongly	  indicative	  
that	  arthritic	  K/BxN	  mice	  do	  not	  generate	  long-­‐lived	  plasma	  cells.	  
Few	  long-­‐lived	  bone	  marrow	  plasma	  cells	  are	  generated	  during	  the	  peak	  of	  
Salmonella	  infection	  
In	  the	  previous	  data,	  we	  observed	  that	  chronic	  antigen	  supply	  leads	  to	  
decreased	  long-­‐lived	  bone	  marrow	  plasma	  cell	  formation.	  This	  has	  been	  shown	  
using	  a	  protein	  immunisation	  system,	  and	  in	  an	  autoimmune	  setting.	  We	  next	  
infected	  mice	  with	  Salmonella.	  This	  model	  has	  been	  described	  elsewhere	  (see	  
chapter	  4),	  but	  briefly	  is	  a	  long-­‐term	  bacterial	  infection,	  taking	  around	  65	  days	  
to	  clear.	  During	  this	  time,	  large	  numbers	  of	  splenic	  plasma	  cells	  are	  produced.	  
We	  now	  used	  a	  similar	  BrdU	  pulse-­‐chase	  system	  to	  determine	  whether	  any	  of	  
these	  plasma	  cells	  were	  travelling	  to	  the	  bone	  marrow	  and	  surviving	  for	  long	  
periods	  of	  time.	  
Firstly,	  we	  infected	  mice	  with	  Salmonella	  and	  examined	  the	  spleen	  and	  bone	  
marrow	  for	  plasma	  cells	  over	  a	  time	  course	  of	  65	  days.	  Plasma	  cells	  in	  the	  
spleen	  peaked	  at	  day	  8	  and	  declined	  gradually	  thereafter	  until	  the	  resolution	  of	  
infection	  at	  day	  65.	  Interestingly,	  as	  plasma	  cell	  generation	  peaked	  in	  the	  spleen,	  
there	  was	  a	  significant	  decrease	  in	  plasma	  cells	  in	  the	  bone	  marrow	  (fig	  5.7a).	  
Bone	  marrow	  plasma	  cells	  gradually	  recovered	  by	  day	  65.	  
Secondly,	  we	  infected	  mice	  and	  gave	  4-­‐day	  BrdU	  pulses	  at	  various	  times	  
following	  infection.	  Mice	  were	  culled	  immediately	  after	  BrdU	  and	  the	  
proportion	  and	  number	  of	  BrdU	  labelled	  plasma	  cells	  in	  the	  spleen	  and	  bone	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marrow	  was	  calculated.	  Figure	  5.7b	  shows	  that,	  early	  following	  infection,	  
turnover	  of	  plasma	  cells	  in	  both	  the	  spleen	  and	  bone	  marrow	  is	  high	  (66.75%	  
(±4.04)	  and	  81.58%	  (±2.37)	  in	  the	  spleen	  during	  days	  1-­‐4	  and	  5-­‐8,	  and	  40.93%	  
(±1.39)	  and	  51.75%	  (±4.75)	  in	  the	  bone	  marrow	  during	  days	  1-­‐4	  and	  5-­‐8	  
respectively).	  The	  number	  of	  plasma	  cells	  produced	  in	  the	  spleen	  maps	  closely	  
to	  the	  bacterial	  loads	  of	  the	  organ	  (fig	  5.7c).	  There	  was,	  however,	  a	  sharp	  
decline	  in	  new	  plasma	  cell	  entry	  to	  the	  bone	  marrow	  after	  day	  8,	  which	  
persisted	  until	  bacteria	  loads	  were	  extremely	  low	  at	  day	  55	  (fig	  5.7b	  and	  c).	  
These	  data	  imply	  that	  early	  following	  infection,	  even	  when	  antigen	  is	  in	  constant	  
supply,	  some	  plasma	  cells	  enter	  the	  bone	  marrow.	  Following	  this,	  few	  plasma	  
cells	  enter	  the	  bone	  marrow	  until	  bacterial	  loads	  fall.	  
Finally,	  we	  performed	  a	  BrdU	  pulse-­‐chase	  experiment,	  whereby	  mice	  were	  
infected	  with	  Salmonella	  and	  given	  3-­‐day	  BrdU	  pulses	  at	  either	  days	  5-­‐8	  (early)	  
or	  days	  25-­‐28	  (late).	  Mice	  were	  culled	  7	  or	  28	  days	  after	  BrdU	  pulses	  and	  spleen	  
and	  bone	  marrow	  examined	  for	  BrdU	  labelled	  plasma	  cells.	  Mice	  pulsed	  early	  or	  
late	  following	  infection	  rapidly	  lost	  BrdU	  labelled	  plasma	  cells	  in	  both	  the	  spleen	  
and	  bone	  marrow	  (fig	  5.7d).	  In	  the	  early	  group,	  just	  3.07%	  (±0.59)	  of	  splenic	  
plasma	  cells	  retained	  the	  BrdU	  label	  7	  days	  after	  pulsing	  and	  no	  plasma	  cells	  
retained	  the	  label	  28	  days	  after	  pulsing	  (0.00%	  ±0.00).	  Similarly,	  in	  the	  bone	  
marrow,	  only	  2.48%	  (±0.54)	  and	  0.52%	  (±0.32)	  retained	  the	  label	  at	  8	  and	  28	  
days	  after	  pulsing	  respectively.	  Results	  were	  similar	  for	  mice	  pulsed	  later,	  with	  
few	  plasma	  cells	  surviving	  in	  the	  spleen.	  However	  28	  days	  after	  labelling,	  1.57%	  
(±0.22)	  of	  bone	  marrow	  plasma	  cells	  retained	  BrdU	  in	  this	  group.	  These	  data	  
indicate	  that,	  despite	  plasma	  cell	  entry	  into	  the	  bone	  marrow	  early	  on	  following	  
infection,	  these	  plasma	  cells	  are	  relatively	  short-­‐lived.	  Although	  fewer	  plasma	  
cells	  enter	  the	  bone	  marrow	  at	  later	  time	  points,	  these	  cells	  do	  have	  an	  
increased	  capacity	  to	  become	  long-­‐lived.	  It	  could	  be	  speculated	  that	  plasma	  cells	  
labelled	  around	  day	  55	  (when	  antigenic	  loads	  are	  relatively	  low)	  may	  persist	  for	  
longer	  periods.	  
Figure	  5.7e	  shows	  that,	  despite	  failure	  of	  plasma	  cells	  in	  infected	  mice	  to	  enter	  
the	  bone	  marrow,	  they	  express	  similar	  levels	  of	  CXCR4	  to	  plasma	  cells	  from	  the	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spleens	  of	  mice	  5	  days	  after	  boosting	  with	  NP-­‐KLH	  (MFI=	  1.46x103	  ±6.05x101	  in	  
NP-­‐boosted	  mice,	  1.64x103	  ±7.02x101	  at	  day	  20	  of	  infection).	  Interestingly,	  bone	  
marrow	  plasma	  cells	  from	  infected	  mice	  express	  significantly	  higher	  levels	  of	  
CXCR4	  (MFI=	  1.38x103	  ±4.51x101	  in	  NP-­‐boosted	  mice,	  1.73x103	  ±4.57x101	  at	  
day	  20	  of	  infection).	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Discussion	  
In	  this	  chapter	  we	  show	  that	  during	  chronic	  inflammatory	  conditions,	  few	  long-­‐
lived	  bone	  marrow	  plasma	  cells	  are	  formed.	  We	  use	  protein	  immunisation,	  and	  
models	  of	  autoimmune	  conditions	  and	  long-­‐term	  bacterial	  infection	  to	  confirm	  
these	  findings.	  
Acute	  secondary	  immunisation	  with	  protein	  antigen	  generates	  detectable	  long-­‐
lived	  plasma	  cells	  
It	  is	  well	  established	  in	  the	  literature	  that	  long-­‐lived	  bone	  marrow	  plasma	  cells	  
are	  formed	  following	  immunisation	  with	  protein	  antigen193,303.	  Additionally,	  it	  is	  
known	  that	  greater	  numbers	  of	  these	  plasma	  cells	  are	  generated	  by	  secondary	  
immunisation189.	  However,	  as	  discussed	  previously,	  there	  are	  no	  known	  
phenotypic	  markers	  by	  which	  to	  distinguish	  long-­‐lived	  plasma	  cells.	  We	  
therefore	  developed	  a	  model	  by	  which	  we	  could	  track	  the	  lifespan	  of	  plasma	  
cells	  generated	  during	  a	  defined	  period.	  A	  sustained	  pulse	  of	  BrdU	  given	  to	  mice	  
following	  immunisation,	  labels	  any	  dividing	  plasmablasts.	  As	  these	  mature	  into	  
non-­‐dividing	  plasma	  cells,	  they	  retain	  BrdU	  for	  an	  indefinite	  period.	  Therefore	  
survival	  of	  plasma	  cells	  generated	  during	  the	  BrdU	  pulse	  can	  be	  evaluated	  at	  
later	  time	  points	  by	  their	  retention	  of	  the	  label.	  
We	  tested	  this	  method	  using	  mice	  that	  were	  primed	  or	  boosted	  with	  DNP-­‐OVA.	  
Mice	  given	  BrdU	  at	  days	  4-­‐6	  following	  primary	  immunisation	  maintained	  few	  
plasma	  cells	  in	  the	  spleen	  or	  bone	  marrow	  (fig	  5.1b	  and	  c),	  likely	  due	  to	  the	  fact	  
that	  mainly	  extrafollicular	  plasma	  cells	  are	  formed	  during	  this	  time,	  and	  these	  
are	  not	  thought	  to	  become	  long-­‐lived199.	  That	  few	  surviving	  plasma	  cells	  were	  
seen	  from	  day	  12-­‐14	  (during	  the	  germinal	  centre	  phase)	  of	  primary	  
immunisation	  likely	  reflects	  data	  from	  other	  groups	  which	  states	  that	  far	  more	  
long-­‐lived	  plasma	  cells	  are	  formed	  after	  secondary	  immunisation189,193,194.	  
Indeed,	  we	  could	  identify	  detectable	  surviving	  plasma	  cells	  in	  the	  bone	  marrow,	  
but	  not	  the	  spleen,	  of	  boosted	  mice,	  in	  agreement	  with	  data	  that	  suggests	  that	  
the	  bone	  marrow	  is	  the	  major	  site	  of	  long-­‐lived	  plasma	  cell	  retention193,194,317.	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Our	  own	  data	  confirmed	  that,	  when	  using	  a	  system	  allowing	  for	  the	  detection	  of	  
antigen-­‐specific	  (NP-­‐specific)	  plasma	  cells,	  primary	  immunisation	  generates	  
only	  relatively	  few	  NP-­‐specific	  plasma	  cells	  in	  comparison	  to	  secondary	  
immunisation	  (fig	  5.2b	  and	  c).	  Additionally,	  far	  fewer	  of	  these	  travelled	  to	  the	  
bone	  marrow.	  Following	  secondary	  immunisation,	  conversely,	  almost	  half	  of	  all	  
bone	  marrow	  plasma	  cells	  were	  NP-­‐specific,	  and	  these	  persisted	  in	  the	  bone	  
marrow	  throughout	  the	  course	  of	  the	  experiment.	  These	  likely	  provided	  much	  
of	  the	  NP-­‐specific	  serum	  antibody,	  which	  exhibited	  only	  a	  very	  slow	  decline	  (fig	  
5.2e)	  (unlike	  NP-­‐specific	  plasma	  cells	  in	  the	  spleen,	  which	  declined	  more	  rapidly	  
(fig	  5.2d)).	  
It	  can	  be	  seen	  in	  figure	  5.3	  that	  by	  day	  15	  following	  secondary	  immunisation	  
NP-­‐specific	  plasma	  cells	  in	  the	  spleen	  and	  bone	  marrow	  are	  long-­‐lived,	  non-­‐
dividing	  cells.	  However,	  there	  is	  an	  important	  distinction	  between	  these.	  While	  
the	  spleen	  is	  able	  to	  support	  non-­‐dividing	  plasma	  cells	  during	  periods	  of	  
inflammation,	  when	  survival	  factors	  are	  readily	  available	  in	  the	  organ	  (see	  
chapter	  4),	  these	  survival	  factors	  decline	  as	  inflammation	  resolves,	  and	  this	  
causes	  a	  gradual	  decline	  in	  the	  number	  of	  non-­‐dividing	  plasma	  cells	  which	  the	  
spleen	  can	  support	  (fig	  5.2d)88.	  The	  bone	  marrow,	  however,	  provides	  a	  constant	  
level	  of	  plasma	  cell	  survival	  factors,	  even	  after	  inflammation	  has	  resolved,	  and	  
therefore	  is	  able	  to	  support	  the	  survival	  of	  plasma	  cells	  for	  truly	  long	  
periods151,189,217.	  Therefore,	  for	  generating	  long	  term,	  high	  levels	  of	  antibody,	  
entry	  into	  the	  bone	  marrow	  is	  critical.	  
Chronic	  secondary	  immunisation	  with	  NP-­‐KLH	  generates	  few	  bone	  marrow	  
plasma	  cells	  
By	  providing	  NP-­‐KLH	  in	  a	  chronic	  fashion,	  we	  saw	  that	  NP-­‐specific	  plasma	  cells	  
were	  produced	  continuously	  in	  the	  spleen	  throughout	  the	  60-­‐day	  period	  of	  
antigen	  administration	  (fig	  5.4c	  and	  d,	  left).	  Despite	  this	  fact,	  few	  NP-­‐specific	  
plasma	  cells	  entered	  the	  bone	  marrow	  (fig	  5.4b,	  right).	  It	  is	  likely	  that	  the	  vast	  
majority	  of	  NP-­‐specific	  plasma	  cells	  that	  were	  able	  to	  enter	  the	  bone	  marrow	  
did	  so	  in	  the	  first	  10	  days	  of	  antigen	  administration,	  as	  it	  can	  be	  seen	  that	  few	  
newly	  generated	  (BrdU	  labelled)	  NP-­‐specific	  plasma	  cells	  were	  present	  in	  the	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bone	  marrow	  during	  the	  final	  10	  days	  of	  antigen	  administration	  (fig	  5.4d,	  right).	  
In	  fact,	  the	  BrdU	  incorporation	  of	  NP-­‐specific	  plasma	  cells	  was	  not	  different	  to	  
that	  seen	  in	  the	  acutely	  immunised	  group	  (fig	  5.4c,	  left).	  
Why	  this	  may	  be	  is	  unknown,	  however	  it	  would	  seem	  reasonable	  that	  
mechanisms	  exist	  to	  stop	  the	  bone	  marrow	  plasma	  cell	  compartment	  from	  
becoming	  overrun	  by	  plasma	  cells	  of	  a	  single	  specificity.	  This	  compartment	  is	  of	  
limited	  size,	  and	  does	  not	  expand	  greatly	  following	  immunisation	  (fig	  3.1c).	  In	  
much	  the	  same	  way	  as	  other	  ‘memory’	  pools	  are	  regulated,	  newly	  generated	  
cells	  enter	  the	  pool	  and	  compete	  with	  older	  cells	  (generated	  during	  previous	  
immune	  responses)	  for	  a	  limited	  supply	  of	  survival	  factors.	  Therefore,	  if	  a	  
constant	  stream	  of	  long-­‐lived	  plasma	  cells	  of	  a	  single	  specificity	  were	  produced	  
(during	  chronic	  immune	  responses),	  they	  would	  eventually	  come	  to	  dominate	  
the	  pool,	  and	  antibody	  levels	  to	  prior	  infections	  would	  fall.	  Our	  data	  suggests	  
that	  there	  is	  a	  finite	  window	  during	  which	  long-­‐lived	  plasma	  cells	  are	  able	  to	  
enter	  the	  bone	  marrow	  during	  chronic	  inflammation	  (i.e.	  the	  first	  10	  days	  
during	  secondary	  responses),	  and	  once	  past,	  despite	  the	  continued	  generation	  
of	  plasma	  cells,	  they	  do	  not	  migrate	  to	  the	  bone	  marrow.	  
In	  this	  experiment,	  we	  saw	  that	  NP-­‐specific	  antibody	  levels	  were	  maintained	  in	  
both	  the	  acute	  and	  chronic	  group,	  even	  following	  the	  termination	  of	  
administration	  of	  antigen	  (fig	  5.5).	  Antibody	  levels	  declined	  in	  both	  groups	  at	  
similar	  rates,	  although	  were	  significantly	  lower	  in	  the	  chronic	  group.	  This	  likely	  
reflects	  the	  generation	  of	  fewer	  NP-­‐specific	  bone	  marrow	  plasma	  cells	  in	  the	  
chronic	  group.	  However,	  the	  plasma	  cells	  that	  did	  enter	  the	  bone	  marrow	  
appear	  to	  be	  as	  proficient	  as	  those	  generated	  by	  acute	  immunisation	  at	  
surviving	  and	  secreting	  antibody.	  This	  is	  in	  contrast	  to	  reports	  from	  human	  and	  
mouse	  studies	  of	  chronic	  autoimmune	  disease	  treated	  with	  rituximab	  or	  anti-­‐
mouse	  CD20	  respectively,	  where	  autoantibody	  levels	  were	  reported	  to	  drop	  far	  
more	  rapidly	  than	  anti-­‐vaccine	  antibodies196,253,259,261,332.	  This	  would	  suggest	  a	  
more	  complete	  failure	  of	  plasma	  cells	  to	  enter	  the	  bone	  marrow	  compartment.	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Autoimmune	  K/BxN	  mice	  generate	  few	  long-­‐lived	  bone	  marrow	  plasma	  cells	  
Autoimmune	  K/BxN	  mice	  generated	  large	  numbers	  of	  splenic	  plasma	  cells	  
during	  a	  3-­‐day	  BrdU	  pulse	  (fig	  5.6a).	  Turnover	  was	  significantly	  higher	  than	  that	  
seen	  in	  non-­‐arthritic	  control	  mice	  (fig	  5.6c),	  but	  was	  not	  rapid	  (40.79%	  (±3.06)	  
in	  arthritic	  mice,	  28.69%	  (±1.74)	  in	  non-­‐arthritic	  mice).	  This	  was	  similar	  to	  data	  
from	  Salmonella	  infected	  mice,	  where	  populations	  of	  plasma	  cells	  in	  the	  spleen	  
turned	  over	  with	  a	  half-­‐life	  of	  over	  6	  days	  (fig	  4.9).	  In	  agreement	  with	  our	  data,	  
Huang	  et	  al	  showed	  a	  similar	  turnover	  of	  plasma	  cells	  in	  the	  spleen261.	  This	  
moderate	  turnover	  likely	  results	  from	  an	  increased	  availability	  of	  plasma	  cell	  
survival	  factors	  present	  in	  the	  inflamed	  spleen	  of	  these	  mice.	  Indeed,	  plasma	  
cells	  generated	  during	  chronic	  autoimmune	  conditions	  have	  no	  impairment	  in	  
their	  ability	  to	  persist	  in	  inflamed	  organs	  provided	  there	  are	  sufficient	  survival	  
factors;	  Hoyer	  et	  al	  used	  NZB/W	  mice	  (a	  model	  of	  SLE)	  to	  show	  that	  plasma	  
cells	  in	  the	  inflamed	  spleen	  and	  kidney	  were	  not	  rapidly	  dividing,	  and	  could	  
survive	  for	  significant	  periods	  without	  division228.	  Similarly,	  Ferraro	  et	  al	  
hypothesised	  that	  the	  relatively	  slow	  decline	  of	  autoantibody	  levels	  following	  
depletion	  of	  B	  cells	  is	  due	  to	  the	  persistence	  of	  plasma	  cells	  in	  survival	  niches	  in	  
inflamed	  organs,	  which	  gradually	  diminish259.	  
Despite	  this,	  arthritic	  mice	  generated	  large	  numbers	  of	  plasma	  cells	  during	  a	  3-­‐
day	  period	  (fig	  5.6d,	  left),	  far	  larger	  than	  the	  numbers	  generated	  in	  non-­‐arthritic	  
control	  mice.	  This	  indicates	  that,	  while	  some	  plasma	  cells	  may	  be	  able	  to	  persist	  
for	  relatively	  long	  periods	  in	  inflamed	  organs,	  constant	  availability	  of	  antigen	  in	  
chronic	  conditions	  still	  drives	  the	  continuous	  generation	  of	  new	  plasma	  cells.	  In	  
agreement	  with	  data	  from	  mice	  chronically	  stimulated	  with	  NP-­‐KLH,	  plasma	  
cells	  generated	  in	  the	  spleen	  of	  arthritic	  mice	  did	  not	  travel	  to	  the	  bone	  marrow	  
or	  survive	  for	  long	  periods.	  In	  fact,	  fewer	  labelled	  plasma	  cells	  were	  seen	  in	  the	  
bone	  marrow	  of	  arthritic	  mice	  than	  non-­‐arthritic	  controls,	  and	  only	  background	  
numbers	  of	  labelled	  plasma	  cells	  survived	  for	  7-­‐days	  or	  more	  (fig	  5.6d,	  right).	  
Data	  from	  Huang	  et	  al,	  showing	  that	  treating	  K/BxN	  mice	  co-­‐expressing	  mouse	  
and	  human	  CD20	  with	  rituximab	  depleted	  G6PI-­‐specific	  plasma	  cells	  in	  the	  
spleen	  and	  lymph	  nodes,	  and	  caused	  a	  decline	  of	  anti-­‐G6PI	  antibody	  levels261.	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Our	  data	  compliments	  theirs,	  by	  showing	  that	  plasma	  cells	  produced	  in	  the	  
spleen	  of	  arthritic	  mice	  fail	  to	  accumulate	  in	  the	  bone	  marrow,	  and	  this	  is	  likely	  
the	  reason	  why	  treatment	  with	  anti-­‐CD20	  antibodies	  is	  effective	  for	  
autoimmune	  conditions,	  but	  does	  not	  diminish	  antibody	  levels	  to	  prior	  
vaccination	  (or	  infection).	  
Salmonella	  infection	  generates	  early	  plasma	  cells	  that	  travel	  to	  the	  bone	  marrow	  
but	  do	  not	  survive	  
Salmonella	  is	  a	  long	  term	  infection,	  during	  which	  bacterial	  loads	  peak	  in	  the	  first	  
10	  days	  followed	  by	  a	  gradual	  decline,	  taking	  around	  65-­‐70	  days	  to	  clear.	  We	  
saw	  a	  depletion	  of	  bone	  marrow	  plasma	  cells	  in	  the	  first	  20	  days,	  followed	  by	  a	  
gradual	  recovery	  (fig	  5.7a).	  Despite	  a	  decrease	  in	  numbers	  of	  bone	  marrow	  
plasma	  cells	  during	  this	  time,	  newly	  generated	  plasma	  cells	  did	  enter	  the	  bone	  
marrow	  in	  the	  first	  10-­‐days	  of	  infection	  (as	  determined	  by	  BrdU	  labelling,	  fig	  
5.7b,	  right).	  Indeed,	  this	  may	  itself	  mediate	  the	  observed	  loss	  of	  bone	  marrow	  
plasma	  cells,	  as	  plasma	  cells	  generated	  at	  days	  7-­‐10	  of	  infection	  likely	  displace	  
pre-­‐established	  long-­‐lived	  plasma	  cells,	  but	  do	  not	  survive	  for	  more	  than	  a	  few	  
days	  (fig	  5.7d,	  right).	  	  
When	  BrdU-­‐pulsed	  at	  days	  15-­‐18,	  few	  new	  plasma	  cells	  entered	  the	  bone	  
marrow	  of	  infected	  mice	  (fig	  5.7b,	  right).	  This	  is	  similar	  to	  data	  from	  chronic	  NP-­‐
KLH	  immunisations,	  where	  plasma	  cells	  entered	  the	  bone	  marrow	  in	  the	  first	  
10-­‐days	  of	  antigen	  administration,	  but	  not	  after.	  In	  that	  experiment,	  NP-­‐specific	  
plasma	  cells	  survived	  for	  long	  periods;	  this	  likely	  reflects	  the	  fact	  that	  these	  
were	  generated	  as	  part	  of	  a	  secondary	  response,	  which	  rapidly	  generates	  long-­‐
lived	  plasma	  cells,	  whereas	  those	  generated	  during	  the	  first	  week	  of	  Salmonella	  
infection	  are	  extrafollicular	  plasma	  cells,	  which	  do	  not	  become	  long-­‐lived.	  The	  
very	  fact	  that	  they	  enter	  the	  bone	  marrow	  is	  surprising,	  and	  the	  reason	  for	  their	  
entry	  is	  unknown.	  
Plasma	  cells	  generated	  during	  days	  28-­‐31	  (i.e.	  the	  chronic	  phase	  of	  Salmonella	  
infection)	  did	  not	  survive	  in	  the	  bone	  marrow	  for	  long	  periods	  (fig	  5.7d,	  right).	  
However,	  data	  from	  this	  model	  is	  confounded	  by	  the	  fact	  that	  germinal	  centres	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do	  not	  form	  in	  Salmonella	  infection	  until	  day	  50-­‐55	  (fig	  4.3a),	  so	  these	  plasma	  
cells	  are	  still	  extrafollicular.	  It	  would	  therefore	  be	  interesting	  to	  see	  if	  plasma	  
cells	  generated	  around	  the	  time	  of	  germinal	  centre	  formation	  do	  migrate	  to	  the	  
bone	  marrow	  and	  become	  long-­‐lived.	  Our	  data	  indicates	  that	  a	  second	  ‘wave’	  of	  
plasma	  cells	  is	  generated	  and	  enters	  the	  bone	  marrow	  at	  days	  51-­‐55	  (fig	  5.7b,	  
right),	  although	  whether	  these	  survive	  for	  long	  periods	  would	  require	  further	  
experimentation.	  
Despite	  the	  failure	  of	  plasma	  cells	  from	  day	  20	  of	  infected	  mice	  to	  enter	  the	  
bone	  marrow,	  they	  expressed	  similar	  levels	  of	  CXCR4	  to	  plasma	  cells	  generated	  
at	  day	  5	  following	  secondary	  NP-­‐KLH	  immunisation	  (fig	  5.7f).	  This	  chemokine	  
receptor	  is	  thought	  to	  mediate	  migration	  to	  the	  bone	  marrow	  in	  response	  to	  
CXCL12	  from	  bone	  marrow	  stromal	  cells166.	  Similar	  expression	  of	  the	  
chemokine	  receptor	  does	  not	  necessarily	  mean	  similar	  responsiveness	  to	  
CXCL12,	  as	  K/BxN	  mice	  that	  lacked	  T	  regulatory	  cells	  generated	  plasma	  cells	  
that	  failed	  to	  migrate	  in	  response	  to	  CXCL12,	  despite	  similar	  expression	  of	  
CXCR4333.	  Additionally,	  following	  establishment	  of	  plasma	  cells	  in	  the	  bone	  
marrow,	  plasma	  cells	  lose	  the	  ability	  to	  migrate	  towards	  the	  chemokine,	  but	  
maintain	  expression	  of	  CXCR4;	  it	  is	  thought	  to	  be	  required	  for	  their	  survival	  and	  
may	  also	  provide	  signals	  which	  mediate	  plasma	  cell	  survival	  in	  the	  bone	  
marrow166.	  Intriguingly,	  it	  is	  known	  that	  CXCL12	  from	  bone	  marrow	  stromal	  
cells	  is	  reduced	  during	  inflammation	  (mediated	  by	  increased	  TNF-­‐α	  and	  IL-­‐
1β)334.	  It	  is	  therefore	  likely	  that	  continued	  high	  levels	  of	  these	  cytokines	  during	  
chronic	  inflammation	  lead	  to	  a	  decrease	  in	  CXCL12	  from	  bone	  marrow	  cells,	  and	  
this	  may	  mediate	  a	  reduction	  in	  migration	  of	  plasma	  cells	  from	  secondary	  
lymphoid	  organs	  to	  the	  bone	  marrow,	  or	  their	  survival	  once	  established	  there.	  
Conclusion	  
Our	  data	  strongly	  indicates	  that,	  while	  acute	  immunisation	  with	  protein	  antigen	  
(especially	  secondary	  immunisation)	  generates	  plasma	  cells	  that	  travel	  to	  the	  
bone	  marrow	  where	  they	  persist	  without	  division	  for	  long	  periods.	  Chronic	  
immunisation,	  autoimmunity,	  and	  the	  ‘chronic-­‐phase’	  of	  long-­‐term	  bacterial	  
infection	  fail	  to	  generate	  plasma	  cells	  that	  become	  established	  in	  the	  bone	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marrow.	  Therefore,	  once	  inflammation	  is	  resolved,	  only	  low	  antibody	  levels	  are	  
maintained.	  Plasma	  cells	  appear	  to	  enter	  the	  bone	  marrow	  during	  a	  defined	  
window	  early	  following	  secondary	  immunisation.	  This	  may	  be	  a	  control	  
mechanism,	  to	  stop	  plasma	  cells	  of	  a	  single	  specificity	  overrunning	  the	  bone	  
marrow	  plasma	  cell	  pool.	  	  
Interestingly,	  there	  is	  no	  difference	  in	  the	  ability	  of	  plasma	  cells	  to	  receive	  
survival	  signals,	  as	  plasma	  cells	  may	  survive	  in	  the	  spleen	  (or	  other	  inflamed	  
organs)	  during	  times	  of	  inflammation.	  It	  is	  therefore	  likely	  that	  migration	  of	  
plasma	  cells	  is	  altered	  by	  responsiveness	  of	  plasma	  cells	  to	  CXCL12,	  or	  a	  lack	  of	  
CXCL12	  secretion	  from	  bone	  marrow	  cells.	  This	  could	  be	  tested	  using	  a	  
migration	  assay	  of	  plasma	  cells	  from	  the	  spleens	  of	  mice	  undergoing	  long-­‐term	  
inflammation,	  compared	  to	  those	  arising	  following	  acute	  secondary	  
immunisation	  with	  NP-­‐KLH.	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Chapter	  6	  –	  Bone	  marrow	  plasma	  cells	  are	  depleted	  during	  infection	  
mediating	  establishment	  of	  new	  bone	  marrow	  plasma	  cells	  
Introduction	  
Bone	  marrow	  plasma	  cells	  maintain	  serum	  antibody	  levels	  to	  prior	  infections	  
for	  long	  periods	  without	  the	  need	  for	  division,	  replenishment	  from	  the	  
peripheral	  B	  cell	  pool	  or	  division.	  They	  are	  supported	  by	  survival	  factors	  
secreted	  by	  cells	  that	  provide	  a	  survival	  niche.	  These	  niches	  are	  limited	  in	  
number;	  only	  a	  finite	  number	  of	  bone	  marrow	  plasma	  cells	  can	  be	  maintained.	  
Therefore,	  newly	  generated	  bone	  marrow	  plasma	  cells	  must	  compete	  with	  pre-­‐
established	  ones	  for	  access	  to	  these	  niches.	  In	  this	  chapter	  we	  look	  at	  a	  possible	  
mechanism	  of	  competition,	  by	  which	  plasma	  cells	  are	  depleted	  from	  the	  bone	  
marrow	  during	  bacterial	  and	  helminth	  infection,	  as	  well	  as	  the	  intriguing	  finding	  
that	  established	  bone	  marrow	  plasma	  cells	  increase	  their	  expression	  of	  MHC	  II	  
during	  infection.	  
Results	  
Bone	  marrow	  plasma	  cells	  are	  depleted	  during	  Salmonella	  infection	  
Figure	  6.1a	  (top	  row)	  and	  6.1b	  shows	  that	  during	  the	  course	  of	  Salmonella	  
infection,	  large	  numbers	  of	  plasma	  cells	  were	  produced	  in	  the	  spleen,	  peaking	  at	  
day	  8	  (1.52x107	  ±2.07x106).	  However,	  the	  bone	  marrow	  plasma	  cell	  
compartment	  was	  significantly	  reduced	  in	  terms	  of	  frequency	  (naïve,	  0.173%	  
±0.006;	  day	  16,	  0.032%	  ±0.005)	  and	  number	  per	  femur	  (44.25x104	  ±5.19x103	  in	  
naïve	  mice;	  4.03x103	  ±1.01x103	  at	  day	  16	  of	  infection)	  (fig	  6.1a	  bottom	  row	  and	  
6.1b	  left).	  B	  cells,	  too,	  were	  significantly	  depleted	  from	  the	  bone	  marrow,	  
reduced	  from	  5.35x106	  (±6.89x105)	  per	  femur	  of	  naïve	  mice	  to	  3.66x105	  
(±4.13x104)	  at	  day	  16	  (fig	  6.1c).	  Figure	  6.1e	  shows	  that	  two	  populations	  of	  B	  
cells	  exist	  in	  the	  spleen,	  with	  differential	  expression	  of	  surface	  antibody	  (i.e.	  the	  
BCR).	  Those	  expressing	  little	  BCR	  (bottom	  gate)	  were	  also	  found	  to	  express	  
higher	  levels	  of	  CD138	  (fig	  6.1f,	  left)	  and	  thus	  likely	  to	  be	  pre	  B	  cells	  and	  
immature	  B	  cells,	  whereas	  those	  expressing	  high	  levels	  of	  BCR	  expressed	  low	  
Chapter	  6	  –	  Effects	  of	  inflammation	  on	  bone	  marrow	  plasma	  cells	  
	   166	  
levels	  of	  CD138	  and	  were	  likely	  to	  be	  mature	  B	  cells.	  Although	  both	  populations	  
were	  depleted	  from	  the	  bone	  marrow,	  pre	  and	  immature	  B	  cells	  were	  almost	  
entirely	  absent	  from	  the	  infected	  organ	  (12.28	  ±0.82	  in	  naïve	  mice	  to	  0.14	  ±0.02	  
at	  day	  16	  of	  infection;	  an	  87.7-­‐fold	  decrease),	  whereas	  mature	  B	  cells	  were	  
reduced	  5.7-­‐fold	  (10.64%	  ±0.68	  in	  naïve	  mice	  to	  1.87%	  ±0.22	  at	  day	  16	  of	  
infection)	  (fig	  6.1e	  and	  data	  not	  shown).	  
Although	  a	  statistically	  significant	  reduction	  in	  the	  frequency	  of	  B	  cells	  also	  
occurred	  in	  the	  spleen,	  absolute	  numbers	  in	  the	  organ	  remained	  constant	  
throughout	  infection	  (fig	  6.1c),	  reflecting	  the	  large	  changes	  in	  cellularity	  and	  
influx	  of	  other	  cell	  populations	  to	  the	  inflamed	  spleen.	  	  
Cells	  expressing	  CD11b	  increased	  dramatically	  from	  14.57%	  (±0.959)	  in	  the	  
spleen	  of	  naïve	  mice,	  to	  39.10%	  (±1.99)	  at	  day	  16	  of	  infection	  (fig	  6.1d,	  left).	  
Similarly,	  an	  increase	  in	  frequency	  was	  seen	  in	  the	  bone	  marrow,	  where	  
CD11bhi	  cells	  came	  to	  dominate	  the	  organ	  during	  infection	  (increasing	  from	  
57.69%	  (±1.34)	  in	  the	  bone	  marrow	  of	  naïve	  mice	  to	  82.24%	  (±0.53)	  at	  day	  16	  
of	  infection)	  (fig	  6.1d,	  right).	  
Long-­‐lived	  bone	  marrow	  plasma	  cells	  are	  depleted	  during	  chronic	  infection	  with	  
Schistosoma	  mansoni	  
To	  test	  whether	  other	  types	  of	  infection	  also	  depleted	  bone	  marrow	  plasma	  
cells,	  we	  implanted	  mice	  with	  various	  doses	  of	  Schistosoma	  mansoni	  cercariae.	  
8-­‐weeks	  post	  implantation,	  mice	  were	  culled	  and	  spleen	  and	  bone	  marrow	  
examined	  for	  plasma	  cells.	  Similar	  to	  infection	  with	  Salmonella,	  Schistosoma	  
mansoni	  infection	  generated	  significant	  populations	  of	  plasma	  cells	  in	  the	  spleen	  
(fig	  6.2a,	  left),	  while	  reducing	  the	  proportion	  and	  number	  of	  plasma	  cells	  found	  
in	  the	  bone	  marrow	  in	  a	  dose	  dependent	  fashion	  (fig	  6.2a,	  right).	  Plasma	  cells	  
were	  reduced	  from	  0.284%	  (±0.045)	  in	  the	  bone	  marrow	  of	  naïve	  mice,	  to	  
0.083%	  (±0.013)	  in	  the	  bone	  marrow	  of	  mice	  receiving	  160	  cercariae.	  This	  
equated	  to	  6.3x104	  (±5.7x103)	  per	  femur	  of	  naïve	  mice,	  and	  2.4x104	  (±5.4x103)	  
per	  femur	  of	  mice	  receiving	  160	  cercariae,	  on	  average	  a	  2.6-­‐fold	  reduction.	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To	  determine	  whether	  this	  was	  a	  reduction	  of	  short-­‐	  or	  long-­‐lived	  plasma	  cells	  
in	  the	  bone	  marrow,	  mice	  were	  given	  an	  8-­‐day	  BrdU	  pulse	  from	  days	  49-­‐56	  of	  
infection	  and	  culled	  immediately	  afterward.	  It	  was	  found	  that,	  while	  there	  was	  
little	  difference	  in	  the	  number	  of	  short-­‐lived	  (BrdU+)	  plasma	  cells	  in	  the	  bone	  
marrow	  (fig	  6.2b,	  left),	  the	  number	  of	  long-­‐lived	  plasma	  cells	  was	  significantly	  
reduced	  in	  the	  groups	  receiving	  higher	  numbers	  of	  cercariae	  (fig	  6.2,	  right).	  	  
Eosinophils	  are	  depleted	  from	  the	  bone	  marrow	  during	  Salmonella	  infection	  
As	  similar	  results	  were	  seen	  for	  infection	  with	  both	  Salmonella	  and	  Schistosoma	  
mansoni,	  we	  now	  focussed	  our	  experiments	  on	  the	  Salmonella	  model.	  We	  
hypothesised	  that	  the	  depletion	  of	  bone	  marrow	  plasma	  cells	  seen	  during	  
infection	  may	  be	  due	  to	  the	  egress	  of	  certain	  cell	  types	  from	  the	  bone	  marrow	  
that	  are	  known	  to	  support	  plasma	  cell	  survival.	  Figure	  6.3a	  shows	  the	  frequency	  
of	  eosinophils	  (blue	  gate),	  Gr1int	  cells	  (red	  gate)	  and	  Gr1hi	  cells	  (green	  gate)	  in	  
the	  bone	  marrow	  of	  naïve	  or	  day	  16	  infected	  mice,	  and	  their	  relative	  expression	  
of	  APRIL	  (fig	  6.3b).	  It	  can	  be	  seen	  that	  eosinophils	  are	  depleted	  during	  infection	  
(from	  3.94%	  ±0.22	  in	  the	  bone	  marrow	  of	  naïve	  mice	  to	  0.89%	  ±0.16	  at	  day	  16	  
of	  infection)	  (fig	  6.3a	  and	  c).	  These	  cells,	  although	  producing	  relatively	  low	  
amounts	  of	  APRIL	  (fig	  6.3b),	  have	  been	  shown	  to	  be	  vital	  to	  the	  support	  of	  bone	  
marrow	  plasma	  cell	  populations151.	  Other	  cell	  types	  that	  have	  been	  shown	  to	  
support	  plasma	  cell	  survival,	  or	  produce	  plasma	  cell	  survival	  factors	  by	  our	  own	  
data	  and	  that	  of	  others,	  such	  as	  dendritic	  cells88,	  Gr1hi	  cells	  (monocytes	  and	  
macrophages)88	  and	  Gr1int	  cells	  (a	  major	  source	  of	  APRIL	  in	  the	  inflamed	  spleen,	  
see	  fig	  4.10a)	  are	  not	  depleted,	  and	  significantly	  increase	  during	  infection	  (fig	  
6.3c).	  APRILhi	  cells	  were	  not	  found	  to	  significantly	  change	  in	  frequency	  during	  
infection,	  whereas	  megakaryocytes217	  were	  slightly	  reduced	  (fig	  6.3c).	  These	  
data	  show	  that,	  while	  eosinophils	  were	  significantly	  reduced,	  other	  cell	  
populations	  that	  produce	  plasma	  cell	  survival	  factors	  are	  increased	  or	  
unaffected	  by	  infection.	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Mice	  deficient	  in	  signalling	  components	  of	  the	  TLR	  pathway	  are	  not	  resistant	  to	  
depletion	  of	  bone	  marrow	  plasma	  cells	  
We	  hypothesised	  that	  TLR	  signalling	  may	  mediate	  the	  depletion	  of	  plasma	  cells	  
from	  the	  bone	  marrow,	  either	  through	  direct	  signals	  or	  indirectly,	  through	  the	  
release	  of	  inflammatory	  cytokines	  from	  various	  cell	  populations	  that	  may	  cause	  
bone	  marrow	  plasma	  cells	  to	  leave	  the	  bone	  marrow	  or	  die.	  However,	  on	  
infection,	  MyD88-­‐/-­‐,	  TRIF-­‐/-­‐	  and	  TLR4-­‐/-­‐	  mice	  showed	  a	  similar	  phenotype	  to	  wild	  
type	  mice.	  Figure	  6.4a	  shows	  that	  wild	  type	  and	  knockout	  mouse	  strains	  
exhibited	  similar	  splenomegaly	  and	  a	  similar	  (or	  more	  severe)	  drop	  in	  
cellularity	  in	  the	  bone	  marrow.	  All	  three	  strains	  of	  knockout	  mice	  showed	  
significantly	  elevated	  bacterial	  loads	  compared	  to	  wild	  type	  mice	  in	  both	  the	  
spleen	  and	  bone	  marrow	  (fig	  6.4b).	  However,	  higher	  numbers	  of	  bacteria	  did	  
not	  correspond	  to	  elevated	  numbers	  of	  plasma	  cells	  in	  the	  spleen.	  In	  fact,	  while	  
TRIF-­‐/-­‐	  and	  TLR4-­‐/-­‐	  mice	  had	  similar	  numbers	  of	  plasma	  cells	  in	  the	  spleen	  to	  
wild	  type	  mice	  at	  day	  16	  of	  infection,	  MyD88-­‐/-­‐	  mice	  had	  significantly	  fewer	  
(wild	  type	  1.86x107	  ±7.43x106;	  MyD88-­‐/-­‐	  6.16x106	  ±1.02x106)(fig	  6.4c).	  	  
The	  knockout	  mouse	  strains	  used	  here	  experienced	  a	  greater	  fold-­‐reduction	  of	  
bone	  marrow	  plasma	  cells	  when	  comparing	  naïve	  and	  infected	  mice	  (fig	  6.4e),	  
and	  this	  may	  result	  from	  the	  elevated	  bacterial	  loads	  seen	  in	  the	  organ	  (per	  
femur:	  wild	  type	  8.75x103	  ±1.03x103;	  Myd88-­‐/-­‐	  5.80x104	  ±2.96x103;	  TRIF-­‐/-­‐	  
3.88x104	  ±1.97x103;	  TLR4-­‐/-­‐	  4.00x104	  ±7.67x103)	  (fig	  6.4b).	  Only	  MyD88-­‐/-­‐	  mice	  
contained	  significantly	  fewer	  bone	  marrow	  plasma	  cells	  at	  day	  16	  of	  infection	  
compared	  to	  wild	  type	  mice	  (wild	  type	  4.58x104	  ±1.13x104;	  MyD88-­‐/-­‐	  6.92x103	  
±1.01x103),	  although	  whether	  this	  was	  due	  to	  having	  fewer	  plasma	  cells	  in	  the	  
bone	  marrow	  in	  the	  naïve	  state,	  or	  due	  to	  increased	  bacterial	  loads	  in	  the	  bone	  
marrow	  during	  infection	  is	  unclear.	  
Pre-­‐established	  NP-­‐specific	  bone	  marrow	  plasma	  cells	  are	  depleted	  by	  Salmonella	  
infection	  
As	  bone	  marrow	  plasma	  cells	  maintain	  serum	  antibody	  levels	  to	  prior	  
infections,	  immunisations	  or	  vaccinations,	  the	  depletion	  of	  these	  cells	  could	  lead	  
to	  reduced	  circulating	  antibody	  and	  protection.	  To	  test	  this	  theory,	  we	  primed	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and	  boosted	  mice	  with	  NP-­‐KLH	  to	  establish	  long-­‐lived	  NP-­‐specific	  plasma	  cells	  
in	  the	  bone	  marrow.	  5-­‐weeks	  after	  boosting,	  mice	  were	  infected	  with	  
Salmonella,	  and	  the	  effect	  on	  NP-­‐specific	  plasma	  cells	  was	  observed	  at	  day	  16	  of	  
the	  infection.	  	  
As	  before,	  we	  observed	  a	  striking	  drop	  in	  cellularity	  in	  the	  bone	  marrow	  of	  
infected	  mice	  (4.57x107	  ±1.69x106	  per	  100mg	  femur	  of	  non-­‐infected	  mice	  to	  
2.77x107	  ±1.56x106	  per	  100mg	  femur	  of	  infected	  mice)	  (fig	  6.5a).	  Interestingly,	  
despite	  a	  significant	  decrease	  in	  the	  frequency	  of	  total	  IgG	  plasma	  cells	  in	  the	  
bone	  marrow	  of	  mice	  infected	  with	  Salmonella	  only,	  mice	  that	  were	  immunised	  
with	  NP-­‐KLH	  and	  then	  infected	  (‘NP+Salmonella’)	  did	  not	  exhibit	  a	  significant	  
decrease	  in	  bone	  marrow	  plasma	  cells	  (fig	  6.5b,	  left).	  However,	  the	  frequency	  of	  
NP-­‐specific	  IgG	  plasma	  cells	  was	  significantly	  decreased	  in	  infected	  versus	  non-­‐
infected	  mice	  (fig	  6.5b,	  right).	  	  
In	  terms	  of	  numbers	  (factoring	  in	  the	  drop	  in	  cellularity)	  total	  IgG	  plasma	  cells	  
per	  100mg	  femur	  decreased	  by	  2.2-­‐fold	  from	  2.14x104	  (±2.27x103)	  to	  9.70x103	  
(±1.06x103)	  in	  infected	  mice.	  Mice	  that	  were	  not	  immunised	  with	  NP,	  but	  were	  
infected	  were	  further	  depleted	  to	  5.45x103	  (±2.20x103),	  a	  3.9-­‐fold	  decrease	  (fig	  
6.5c,	  left).	  
NP-­‐specific	  plasma	  cells	  also	  decreased	  2.2-­‐fold	  from	  4.48x103	  (±5.9x102)	  in	  
non-­‐infected	  mice	  to	  2.02x103	  (±1.10x102)	  in	  infected	  mice	  (fig	  6.5d).	  As	  both	  
the	  decrease	  in	  total	  and	  NP-­‐specific	  IgG	  plasma	  cells	  was	  2.2-­‐fold,	  it	  was	  
unsurprising	  that	  the	  proportion	  of	  IgG	  plasma	  cells	  in	  the	  bone	  marrow	  that	  
was	  NP-­‐specific	  remained	  the	  same	  in	  both	  non-­‐infected	  and	  infected	  mice	  (fig	  
2.5c,	  right).	  	  
Interestingly,	  we	  observed	  that	  remaining	  NP-­‐specific	  plasma	  cells	  in	  the	  bone	  
marrow	  of	  infected	  mice	  had	  high	  expression	  of	  MHC	  II,	  with	  just	  26.2%	  (±4.44)	  
being	  MHC	  IIhi	  in	  non-­‐infected	  mice,	  and	  67.2%	  (±6.74)	  being	  MHC	  IIhi	  in	  
infected	  mice	  (fig	  6.5e).	  As	  there	  was	  no	  statistical	  difference	  between	  the	  
number	  of	  MHC	  IIhi	  plasma	  cells	  (fig	  6.5f,	  left),	  it	  is	  likely	  that	  MHC	  IIlo	  plasma	  
cells	  are	  depleted	  during	  infection.	  It	  is	  also	  possible	  that	  all	  MHC	  IIlo	  plasma	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cells	  are	  induced	  to	  upregulate	  MHC	  II	  on	  their	  surface.	  This	  will	  be	  explored	  in	  
later	  figures.	  In	  the	  spleen,	  we	  saw	  a	  dramatic	  increase	  in	  the	  number	  of	  NP-­‐
specific	  plasma	  cells	  in	  infected	  mice	  (3.79x104	  ±	  9.73x103	  in	  non-­‐infected	  mice	  
and	  3.94x105	  ±9.25x104	  in	  infected	  mice)	  (fig	  6.5g).	  Again,	  these	  were	  
predominantly	  MHC	  IIhi	  in	  phenotype.	  
NP-­‐specific	  plasma	  cells	  in	  Salmonella	  infected	  mice	  are	  not	  dividing,	  and	  do	  not	  
increase	  their	  expression	  of	  T	  cell	  co-­‐stimulatory	  molecules	  
As	  we	  observed	  an	  increased	  number	  of	  MHC	  IIhi	  NP-­‐specific	  plasma	  cells	  in	  the	  
spleen	  of	  infected	  mice,	  and	  an	  increase	  in	  proportion	  of	  NP-­‐specific	  plasma	  
cells	  that	  were	  MHC	  IIhi	  in	  the	  bone	  marrow,	  we	  determined	  whether	  these	  
plasma	  cells	  were	  newly	  generated,	  dividing	  plasma	  cells,	  or	  were	  long-­‐lived	  
plasma	  cells	  that	  were	  induced	  to	  express	  high	  levels	  of	  MHC	  II.	  Similar	  to	  the	  
previous	  experiment,	  we	  primed	  and	  boosted	  mice	  with	  NP-­‐KLH,	  and	  5-­‐weeks	  
later	  infected	  half	  with	  Salmonella.	  At	  days	  6-­‐8	  and	  14-­‐16,	  groups	  of	  mice	  were	  
given	  48-­‐hour	  BrdU	  pulses,	  and	  the	  proportion	  of	  NP-­‐specific	  plasma	  cells	  
incorporating	  BrdU	  was	  determined.	  As	  can	  be	  seen	  in	  figure	  6.6a,	  there	  was	  no	  
significant	  difference	  between	  the	  turnover	  of	  NP-­‐specific	  plasma	  cells	  in	  the	  
spleen	  and	  bone	  marrow	  of	  non-­‐infected	  or	  infected	  mice.	  
As	  many	  NP-­‐specific	  plasma	  cells	  expressed	  high	  levels	  of	  MHC	  II	  during	  
infection,	  we	  hypothesised	  that	  they	  may	  also	  express	  high	  levels	  of	  T	  cell	  co-­‐
stimulatory	  molecules	  CD80,	  CD86	  and	  CD40.	  Plasma	  cells	  in	  the	  spleens	  of	  
infected	  mice	  at	  day	  16	  increased	  in	  CD80	  and	  MHC	  II	  expression,	  similar	  to	  the	  
increase	  seen	  in	  B	  cell	  populations,	  but	  they	  did	  not	  increase	  in	  CD86	  expression	  
(fig	  6.6b).	  Bone	  marrow	  plasma	  cells,	  however,	  increased	  only	  in	  MHC	  II	  
expression	  (fig	  6.6b	  and	  c).	  Despite	  the	  fact	  these	  plasma	  cells	  appeared	  to	  
adopt	  a	  more	  immature	  phenotype	  through	  the	  upregulation	  of	  MHC	  II,	  they	  
expressed	  significantly	  reduced	  levels	  of	  B220,	  a	  phenotype	  usually	  associated	  
with	  mature	  plasma	  cells	  (fig	  6.6c).	  
We	  next	  determined	  the	  mechanism	  by	  which	  MHC	  II	  was	  up	  regulated	  on	  bone	  
marrow	  plasma	  cells.	  We	  infected	  wild	  type,	  MyD88-­‐/-­‐,	  TRIF-­‐/-­‐,	  TLR4-­‐/-­‐	  mice	  and	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looked	  at	  the	  expression	  of	  MHC	  II	  on	  bone	  marrow	  plasma	  cells.	  While	  TRIF-­‐/-­‐	  
and	  TLR4-­‐/-­‐	  mice	  both	  showed	  significantly	  elevated	  levels	  of	  MHC	  II	  on	  bone	  
marrow	  plasma	  cells	  following	  infection,	  those	  in	  MyD88-­‐/-­‐	  mice	  did	  not	  (fig	  
6.6d).	  In	  fact,	  MHC	  II	  on	  bone	  marrow	  plasma	  cells	  of	  infected	  MyD88-­‐/-­‐	  mice	  
was	  significantly	  lower	  than	  that	  of	  plasma	  cells	  from	  infected	  wild	  type	  mice.	  	  
Following	  depletion,	  NP-­‐specific	  plasma	  cells	  do	  not	  recover	  as	  infection	  resolves	  
To	  see	  whether	  NP-­‐specific	  plasma	  cells	  recovered	  as	  Salmonella	  infection	  
resolved,	  we	  performed	  a	  time	  course	  experiment	  whereby	  mice	  primed	  and	  
boosted	  with	  NP-­‐KLH	  were	  infected	  with	  Salmonella	  and	  mice	  culled	  16,	  45	  and	  
75	  days	  later.	  During	  this	  time,	  the	  Salmonella	  bacteria	  were	  cleared	  by	  mice,	  as	  
determined	  by	  splenic	  bacterial	  loads	  (fig	  6.7a).	  As	  bacterial	  loads	  decreased	  
over	  time,	  so	  did	  splenic	  plasma	  cell	  numbers	  (fig	  6.7b,	  left).	  By	  day	  45	  of	  
infection	  (when	  bacterial	  loads	  were	  low),	  total	  bone	  marrow	  plasma	  cells	  had	  
recovered	  to	  numbers	  seen	  in	  non-­‐infected	  controls;	  this	  was	  maintained	  at	  day	  
75,	  although	  no	  further	  increase	  was	  seen	  (fig	  6.7b,	  right).	  The	  proportion	  of	  
plasma	  cells	  in	  the	  spleen	  that	  were	  NP-­‐specific	  was	  far	  lower	  in	  infected	  mice,	  
due	  to	  the	  fact	  that	  large	  numbers	  of	  plasma	  cells	  of	  other	  specificities	  were	  
generated	  during	  Salmonella	  infection	  (fig	  6.7c,	  left).	  This	  however,	  still	  
corresponded	  to	  an	  increase	  in	  NP-­‐specific	  plasma	  cells	  in	  the	  spleen	  at	  day	  16	  
of	  infection	  (from	  3.79x104	  ±9.73x103	  in	  non-­‐infected	  mice	  to	  3.94x105	  
±9.25x104),	  although	  these	  numbers	  were	  not	  maintained	  (fig	  6.7d,	  left).	  In	  fact,	  
infected	  mice	  contained	  fewer	  NP-­‐specific	  plasma	  cells	  in	  the	  spleen	  at	  day	  75	  
than	  non-­‐infected	  mice	  (1.59x103	  ±2.76x102	  in	  infected	  mice	  compared	  to	  
1.93x104	  ±8.31x103	  in	  non-­‐infected	  mice).	  As	  plasma	  cell	  numbers	  in	  the	  bone	  
marrow	  recovered,	  the	  proportion	  that	  were	  NP-­‐specific	  fell,	  indicating	  that	  
new	  plasma	  cells	  entering	  the	  bone	  marrow	  were	  not	  NP-­‐specific	  (and	  were	  
likely	  specific	  for	  Salmonella	  antigens).	  Numbers	  of	  NP-­‐specific	  plasma	  cells	  
remained	  significantly	  lower	  in	  the	  bone	  marrow	  of	  infected	  mice	  following	  the	  
clearance	  of	  Salmonella	  infection	  (2.94x103	  ±9.85x102	  in	  infected	  mice	  
compared	  to	  9.48x103	  ±2.22x102	  in	  non-­‐infected	  mice)	  (fig	  6.7d,	  left).	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The	  elevated	  levels	  of	  MHC	  II	  seen	  on	  NP-­‐specific	  plasma	  cells	  at	  day	  16	  of	  
infection	  in	  both	  the	  spleen	  and	  bone	  marrow	  was	  not	  maintained	  to	  later	  time	  
points,	  when	  MHC	  II	  expression	  was	  similar	  to	  NP-­‐specific	  plasma	  cells	  in	  non-­‐
infected	  mice	  (fig	  6.7e).	  	  
Numbers	  of	  APRILhi	  cells	  did	  not	  change	  significantly	  in	  the	  bone	  marrow	  
throughout	  infection,	  although	  they	  were	  significantly	  elevated	  in	  the	  spleen	  at	  
day	  16.	  By	  day	  45,	  numbers	  had	  fallen	  in	  the	  spleen	  and	  were	  not	  significantly	  
different	  from	  non-­‐infected	  controls	  (fig	  6.7f).	  
We	  next	  looked	  at	  NP-­‐specific	  antibody	  levels	  in	  non-­‐infected	  versus	  infected	  
mice	  over	  the	  same	  time	  course	  of	  infection.	  For	  all	  IgG	  isotypes,	  the	  infected	  
group	  had	  significantly	  less	  circulating	  NP-­‐specific	  antibody.	  This	  was	  true	  at	  all	  
time	  points	  for	  most	  isotypes.	  Interestingly,	  following	  an	  initial	  drop	  in	  NP-­‐
specific	  IgM	  at	  day	  16,	  this	  recovered	  and	  by	  day	  75	  was	  significantly	  higher	  
than	  non-­‐infected	  controls,	  although	  differences	  were	  not	  large	  (fig	  6.8).	  
Differences	  in	  Salmonella-­‐mediated	  depletion	  of	  bone	  marrow	  plasma	  cells	  in	  
naïve	  mice	  or	  mice	  pre-­‐immunised	  with	  NP-­‐KLH	  is	  not	  due	  to	  differences	  in	  
plasma	  cell	  expression	  of	  FcϒRIIb	  
In	  figure	  6.5b,	  it	  was	  noted	  that	  mice	  immunised	  and	  boosted	  with	  NP-­‐KLH	  did	  
not	  exhibit	  as	  full	  a	  depletion	  of	  bone	  marrow	  plasma	  cells	  as	  mice	  that	  had	  not	  
received	  NP-­‐KLH	  before	  Salmonella	  infection.	  We	  therefore	  hypothesised	  that	  
there	  may	  be	  a	  difference	  in	  the	  expression	  of	  the	  plasma	  cell	  death	  receptor	  
FcϒRIIb	  on	  bone	  marrow	  plasma	  cells	  from	  naïve	  mice	  and	  those	  generated	  by	  
immunisation	  with	  NP-­‐KLH.	  NP-­‐specific	  plasma	  cells	  in	  non-­‐infected	  mice	  
expressed	  significantly	  greater	  levels	  of	  FcϒRIIb	  than	  non-­‐NP-­‐specific	  plasma	  
cells	  in	  both	  the	  spleen	  and	  bone	  marrow	  (splenic	  NP-­‐specific	  plasma	  cells:	  
3.44x102	  ±1.4x101,	  splenic	  non-­‐NP-­‐specific:	  2.74x102	  ±6.46x100;	  bone	  marrow	  
NP-­‐specific:	  4.55x102	  ±1.66x101,	  bone	  marrow	  non-­‐NP-­‐specific	  3.61x102	  
±4.54x100)	  (fig	  6.9a	  and	  b).	  Interestingly,	  at	  day	  16	  of	  infection,	  previously	  
established	  NP-­‐specific	  plasma	  cells	  further	  increased	  in	  FcϒRIIb	  expression	  
(this	  was	  significant	  in	  the	  spleen	  (p=0.0005),	  but	  not	  in	  the	  bone	  marrow	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(p=0.2367).	  Non-­‐NP-­‐specific	  plasma	  cells	  did	  not	  significantly	  increase	  in	  
expression	  of	  the	  death	  receptor	  in	  either	  spleen	  or	  bone	  marrow	  (fig	  6.9a	  and	  
b).	  
TNF-­‐α	  injection	  mediates	  reduced	  bone	  marrow	  cellularity,	  but	  not	  a	  specific	  
reduction	  in	  plasma	  cells	  	  
Inflammation	  has	  been	  shown	  to	  reduce	  the	  expression	  of	  the	  chemokine	  
CXCL12	  from	  bone	  marrow	  cells334.	  This	  was,	  at	  least	  in	  part,	  mediated	  by	  the	  
inflammatory	  cytokine	  TNF-­‐α,	  which	  is	  produced	  in	  large	  amounts	  during	  
infection	  with	  Salmonella335,336.	  In	  addition,	  CXCL12	  is	  the	  chemokine	  thought	  to	  
mediate	  the	  migration	  of	  plasma	  cells	  from	  secondary	  lymphoid	  organs	  to	  the	  
bone	  marrow	  (and	  also	  possibly	  their	  retention	  or	  survival	  there)85,194,201.	  We	  
therefore	  hypothesised	  that	  the	  depletion	  of	  bone	  marrow	  plasma	  cells	  seen	  in	  
infection	  may	  be	  due	  to	  increased	  levels	  of	  TNF-­‐α	  during	  infection.	  Mice	  were	  
given	  1μg	  of	  recombinant	  mouse	  TNF-­‐α	  I.V.	  on	  days	  1	  and	  2,	  and	  culled	  at	  day	  5.	  
Figure	  6.10a	  shows	  that	  injection	  of	  TNF-­‐α	  significantly	  reduced	  bone	  marrow	  
cellularity	  (2.52x107	  ±7.54x105	  to	  2.11x107	  ±5.03x105,	  p=0.002).	  While	  bone	  
marrow	  plasma	  cell	  numbers	  fell	  accordingly	  (4.75x104	  ±4.79x103	  to	  3.27x104	  
±3.85x103,	  p=0.043),	  there	  was	  no	  decrease	  in	  frequency	  within	  the	  
compartment	  (fig	  6.10b	  and	  d)	  (as	  was	  evident	  by	  day	  16	  of	  infection	  with	  
Salmonella,	  fig	  6.1).	  In	  agreement	  with	  data	  from	  Ueda	  et	  al,	  bone	  marrow	  B	  cell	  
frequencies	  were	  reduced	  to	  a	  far	  greater	  extent	  (26.04%	  ±1.38	  to	  11.95%	  
±1.20,	  p<0.0001)	  (fig	  6.10c)334.	  In	  contrast	  to	  these	  populations,	  CD11b+	  cells	  
increased	  in	  frequency	  (58.43%	  ±1.99	  to	  72.22%	  ±2.21,	  p=0.0027)	  (fig	  6.10e).	  
There	  was	  little	  change	  in	  numbers	  of	  most	  niche	  providing	  cells	  in	  the	  bone	  
marrow	  following	  TNF-­‐α	  injection,	  apart	  from	  APRILhi	  cells,	  which	  fell	  
significantly	  (5.39x105	  ±6.37x104	  to	  1.49x105	  ±1.64x104,	  p=0.0003).	  
Adjuvant	  depletes	  previously	  established	  bone	  marrow	  plasma	  cells,	  and	  
mediates	  a	  reduction	  in	  the	  establishment	  of	  newly	  generated	  plasma	  cells	  in	  the	  
bone	  marrow	  
It	  is	  thought	  that	  the	  bone	  marrow	  plasma	  cell	  pool	  is	  of	  limited	  size,	  and	  that	  
newly	  generated	  plasma	  cells	  must	  compete	  with	  previously	  generated	  ones	  for	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survival	  factors	  (or	  access	  to	  a	  survival	  niche)194,306.	  It	  has	  been	  documented	  
that,	  on	  vaccination	  with	  tetanus	  toxoid,	  mature	  plasma	  cells	  of	  other	  
specificities	  could	  be	  seen	  entering	  the	  blood.	  It	  was	  hypothesised	  that	  these	  are	  
likely	  to	  be	  ‘old’	  plasma	  cells	  being	  pushed	  out	  of	  their	  survival	  niches	  by	  newly	  
generated	  plasma	  cells249.	  We	  sought	  to	  test	  whether	  the	  depletion	  of	  plasma	  
cells	  seen	  during	  inflammatory	  episodes	  ‘created	  space’	  for	  newly	  generated	  
plasma	  cells.	  To	  test	  this	  we	  primed	  mice	  with	  two	  protein	  antigens;	  NP-­‐KLH	  
and	  FITC-­‐OVA.	  5-­‐weeks	  later,	  mice	  were	  boosted	  with	  NP-­‐KLH	  to	  generate	  a	  
population	  of	  NP-­‐specific	  plasma	  cells	  in	  the	  bone	  marrow.	  A	  further	  5-­‐weeks	  
later	  mice	  received	  either	  no	  further	  immunisation	  (NP-­‐only),	  a	  booster	  
immunisation	  with	  soluble	  FITC-­‐OVA	  (sol	  FITC-­‐OVA),	  or	  a	  booster	  
immunisation	  with	  alum-­‐precipitated	  FITC-­‐OVA	  with	  killed	  B.	  pertussis	  
(adjuvant/FITC-­‐OVA).	  	  
Figure	  6.11a	  shows	  that	  adjuvant/FITC-­‐OVA	  boosted	  mice	  produced	  the	  
greatest	  number	  of	  plasma	  cells	  in	  the	  spleen,	  and	  also	  exhibited	  a	  significantly	  
reduced	  number	  of	  plasma	  cells	  in	  the	  bone	  marrow	  at	  day	  5	  (splenic	  plasma	  
cells:	  2.98x106	  ±1.26x105	  in	  adjuvant/FITC-­‐OVA	  mice	  compared	  to	  1.07x105	  
±1.73x104	  in	  NP-­‐only	  mice.	  Bone	  marrow	  plasma	  cells:	  1.52x104	  ±1.29x103	  in	  
adjuvant/FITC-­‐OVA	  mice	  compared	  to	  2.76x104	  ±2.72x103	  in	  NP-­‐only	  mice).	  
This	  depletion	  in	  bone	  marrow	  plasma	  cells	  significantly	  reduced	  numbers	  of	  
the	  previously	  established	  NP-­‐specific	  bone	  marrow	  plasma	  cells,	  and	  these	  
continued	  to	  decline	  throughout	  the	  30-­‐day	  experiment	  (fig	  6.11c).	  However,	  
this	  did	  not	  mediate	  the	  establishment	  of	  increased	  numbers	  of	  newly	  
generated	  FITC-­‐OVA	  specific	  plasma	  cells.	  In	  fact,	  despite	  generating	  similar	  
numbers	  in	  the	  spleen	  compared	  to	  sol	  FITC-­‐OVA	  immunised	  mice	  at	  day	  5	  
(2.26x105	  ±9.05x104	  in	  sol	  FITC-­‐OVA	  and	  1.85x105	  ±2.7x104	  in	  adjuvant/FITC-­‐
OVA),	  only	  very	  few	  of	  these	  cells	  became	  established	  in	  the	  bone	  marrow	  
compartment	  by	  day	  12	  (1.03x104	  ±1.51x103	  in	  sol	  FITC-­‐OVA	  and	  7.23x102	  
±6.65x101)	  (fig	  6.11b).	  Interestingly,	  and	  despite	  the	  lack	  of	  entry	  of	  FITC-­‐OVA-­‐
specific	  plasma	  cells	  to	  the	  bone	  marrow,	  total	  bone	  marrow	  plasma	  cell	  
numbers	  had	  recovered	  by	  day	  12	  (fig	  6.11a).	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Boosting	  with	  sol	  FITC-­‐OVA	  generated	  similar	  numbers	  of	  FITC-­‐OVA-­‐specific	  
plasma	  cells	  in	  the	  spleen	  to	  adjuvant/FITC-­‐OVA	  (fig	  6.11b).	  These	  entered	  the	  
bone	  marrow	  by	  day	  5	  (5.82x103	  ±1.67x103),	  and	  peaked	  at	  day	  12	  (1.03x104	  
±1.51x103).	  Initially,	  no	  depletion	  in	  NP-­‐specific	  plasma	  cells	  was	  seen,	  and	  total	  
plasma	  cell	  numbers	  in	  the	  bone	  marrow	  increased	  (2.76x104	  ±2.73x103	  in	  NP-­‐
only	  mice	  and	  3.47x105	  ±2.57x103	  in	  sol	  FITC-­‐OVA	  mice	  at	  day	  12)	  (fig	  6.11a	  
and	  c).	  However,	  by	  day	  30,	  numbers	  of	  plasma	  cells	  in	  the	  bone	  marrow	  
returned	  to	  levels	  seen	  in	  control	  mice	  (NP-­‐only).	  This	  mediated	  a	  decline	  in	  
both	  NP-­‐specific	  and	  FITC-­‐OVA-­‐specific	  plasma	  cells,	  although	  numbers	  of	  both	  
specificities	  remained	  significantly	  higher	  than	  in	  alum/FITC-­‐OVA	  mice	  (NP-­‐
plasma	  cells:	  sol	  FITC-­‐OVA	  2.36x103	  ±9.6x101,	  adjuvant/FITC-­‐OVA	  2.84x102	  
±9.4x100.	  FITC-­‐OVA-­‐plasma	  cells:	  sol	  FITC-­‐OVA	  5.74x103	  ±2.52x102,	  
adjuvant/FITC-­‐OVA	  1.39x103	  ±6.1x101).	  	  
Boosting	  with	  adjuvant/FITC-­‐OVA	  generated	  far	  higher	  levels	  of	  FITC-­‐OVA-­‐
specific	  IgM	  in	  the	  serum	  than	  sol	  FITC-­‐OVA	  by	  day	  12	  (3.40x103	  ±0	  in	  
adjuvant/FITC-­‐OVA	  mice	  and	  4.16x102	  ±1.72x102	  in	  sol	  FITC-­‐OVA	  mice)	  (fig	  
6.11d).	  Interestingly,	  levels	  of	  NP-­‐specific	  IgM	  also	  increased	  significantly	  by	  
day	  12	  following	  adjuvant/FITC-­‐OVA	  boosting	  (from	  4.60x102	  ±5.36x101	  in	  NP-­‐
only	  mice	  to	  5.61x103	  ±8.11x102	  in	  adjuvant/FITC-­‐OVA	  mice)	  (fig	  6.11e).	  
Boosting	  with	  soluble	  FITC-­‐OVA	  did	  not	  increase	  FITC-­‐OVA	  specific	  IgM,	  and	  
reduced	  NP-­‐specific	  IgM	  (FITC-­‐OVA-­‐specific:	  from	  3.05x102	  ±0	  in	  NP-­‐only	  mice	  
to	  2.83x102	  ±0	  in	  sol	  FITC-­‐OVA	  mice	  at	  day	  30.	  NP-­‐specific:	  from	  4.60x102	  
±5.36x101	  in	  NP-­‐only	  mice	  to	  1.65x102	  ±2.68x101	  in	  sol	  FITC-­‐OVA	  mice	  at	  day	  
30).	  	  
NP-­‐specific	  IgG	  was	  not	  initially	  affected	  by	  either	  immunisation,	  although	  by	  
day	  30	  mice	  receiving	  adjuvant/FITC-­‐OVA	  had	  reduced	  levels	  (from	  8.67x103	  
±3.33x102	  in	  NP-­‐only	  mice	  to	  4.02x103	  ±5.90x102	  in	  adjuvant/FITC-­‐OVA	  mice	  
at	  day	  30)	  (fig	  6.11e).	  FITC-­‐OVA-­‐specific	  IgG	  peaked	  at	  day	  12	  in	  adjuvant/FITC-­‐
OVA	  boosted	  mice,	  and	  had	  declined	  by	  day	  30	  (4.28x104	  ±9.55x103	  at	  day	  12	  to	  
1.54x104	  ±2.77x103	  at	  day	  30)	  (fig	  6.11d).	  Mice	  receiving	  sol	  FITC-­‐OVA	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maintained	  elevated	  levels	  of	  FITC-­‐OVA-­‐specific	  IgG	  between	  day	  12	  and	  day	  30	  
(1.98x104	  ±	  2.44x103	  at	  day	  12	  and	  2.24x104	  ±3.10x103	  at	  day	  30).	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Discussion	  
In	  this	  chapter	  we	  show	  that	  bone	  marrow	  plasma	  cells,	  which	  maintain	  serum	  
antibody	  levels	  to	  prior	  infections	  and	  immunisations,	  are	  depleted	  during	  
inflammatory	  episodes.	  This	  causes	  a	  reduction	  in	  circulating	  antigen-­‐specific	  
serum.	  We	  look	  at	  the	  effects	  of	  this	  depletion	  on	  the	  establishment	  of	  newly	  
generated	  plasma	  cells.	  
Infection	  depletes	  bone	  marrow	  plasma	  cells	  
The	  upkeep	  of	  antibody	  levels	  specific	  for	  prior	  infections	  in	  the	  serum	  is	  
thought	  to	  be	  reliant	  on	  the	  maintenance	  of	  bone	  marrow	  plasma	  cell	  
numbers317.	  Unlike	  the	  majority	  of	  plasma	  cells	  in	  secondary	  lymphoid	  organs,	  
bone	  marrow	  plasma	  cells	  persist	  for	  long	  periods,	  maintaining	  a	  first	  line	  of	  
defence	  in	  case	  of	  reinfection.	  Under	  homeostatic	  conditions	  antigen-­‐specific	  
plasma	  cells	  in	  the	  bone	  marrow	  decline	  slowly,	  even	  when	  peripheral	  B	  cells	  
are	  depleted,	  indicating	  their	  long	  lifespan	  and	  independence	  of	  further	  
generation	  from	  the	  B	  cell	  pool	  for	  the	  maintenance	  of	  these	  
populations189,193,196,306.	  
Salmonella	  infection	  caused	  a	  dramatic	  depletion	  in	  bone	  marrow	  plasma	  cells	  
(fig	  6.1a	  and	  b),	  in	  part	  mediated	  by	  a	  drop	  in	  total	  bone	  marrow	  cellularity	  (fig	  
6.4a),	  but	  also	  a	  reduction	  in	  the	  frequency	  of	  bone	  marrow	  plasma	  cells	  within	  
the	  compartment	  (fig	  6.1b).	  This	  suggests	  a	  mechanism	  exists	  by	  which	  plasma	  
cells	  are	  specifically	  induced	  to	  exit	  the	  bone	  marrow	  during	  infection,	  or	  that	  
plasma	  cells	  are	  especially	  sensitive	  to	  changes	  in	  the	  cellular	  make-­‐up	  of	  the	  
compartment,	  as	  will	  be	  discussed	  later.	  	  
The	  infection	  of	  mice	  previously	  primed	  and	  boosted	  with	  NP-­‐KLH	  revealed	  that	  
previously	  generated	  populations	  of	  NP-­‐specific	  plasma	  cells	  in	  the	  bone	  
marrow	  were	  similarly	  depleted	  (fig	  6.5c	  and	  d),	  and	  this	  negatively	  affected	  
NP-­‐specific	  antibody	  in	  the	  serum	  (fig	  6.8).	  Despite	  total	  plasma	  cells	  returning	  
to	  numbers	  seen	  in	  non-­‐infected	  mice	  by	  day	  45	  following	  infection	  (fig	  6.7b),	  
NP-­‐specific	  plasma	  cells	  failed	  to	  recover,	  even	  by	  day	  75	  (fig	  6.7d),	  when	  
bacteria	  was	  cleared	  from	  these	  mice	  (fig	  6.8a).	  The	  recovery	  of	  plasma	  cells	  in	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the	  bone	  marrow	  may	  therefore	  represent	  the	  influx	  of	  plasma	  cells	  generated	  
by	  the	  Salmonella	  infection.	  	  
The	  bone	  marrow	  plasma	  cell	  pool,	  much	  like	  other	  memory	  pools,	  is	  of	  limited	  
size;	  immunisation	  does	  not	  dramatically	  expand	  this	  population	  (see	  fig	  3.1).	  
Odendahl	  et	  al	  have	  shown	  that	  vaccination	  of	  human	  patients	  with	  tetanus	  
toxoid	  (TT)	  mediates	  an	  increase	  in	  non	  TT-­‐specific,	  mature	  plasma	  cells	  in	  the	  
blood;	  speculated	  to	  be	  the	  egress	  of	  pre-­‐established	  plasma	  cells	  caused	  by	  the	  
influx	  of	  newly	  generated	  ones249.	  Commonly,	  the	  literature	  cites	  the	  “pushing	  
out”	  of	  old	  plasma	  cells	  (which	  are	  non-­‐migratory)	  by	  the	  migratory	  new	  
crop6,248,249,	  although	  the	  precise	  mechanism	  behind	  this	  is	  unclear.	  Our	  data	  
presented	  here	  may	  suggest	  that	  plasma	  cell	  competition	  is	  mediated	  by	  the	  
depletion	  of	  previously	  established	  plasma	  cells	  by	  inflammatory	  episodes.	  This	  
would	  appear	  to	  be	  a	  distinct	  event,	  occurring	  prior	  to	  the	  entry	  of	  newly	  
generated	  plasma	  cells.	  	  
Similarly	  to	  Salmonella	  infection,	  Schistosoma	  mansoni	  (a	  chronic,	  Th2	  infection)	  
caused	  a	  depletion	  in	  bone	  marrow	  plasma	  cells	  that	  was	  found	  to	  be	  dose	  
dependent	  (fig	  6.2a).	  The	  bone	  marrow	  plasma	  cell	  pool	  consists	  of	  mainly	  long-­‐
lived	  mature	  plasma	  cells,	  but	  also	  a	  short-­‐lived	  immature	  component	  (see	  
chapter	  3).	  It	  was	  seen	  that	  Schistosoma	  infection	  caused	  depletion	  of	  long-­‐lived,	  
and	  not	  of	  short-­‐lived	  plasma	  cells	  (fig	  6.2b).	  Similarly,	  the	  majority	  of	  
remaining	  plasma	  cells	  seen	  in	  the	  bone	  marrow	  following	  Salmonella	  infection	  
expressed	  high	  levels	  of	  MHC	  II.	  Mature	  plasma	  cells	  are	  non-­‐migratory201,	  and	  
may	  be	  more	  susceptible	  to	  depletion	  than	  immature	  plasmablasts.	  To	  test	  this,	  
a	  system	  using	  two	  different	  protein	  antigens	  (e.g.	  NP-­‐KLH	  and	  FITC-­‐OVA)	  could	  
be	  used	  to	  establish	  long-­‐lived	  plasma	  cells	  at	  different	  times	  (e.g.	  NP-­‐KLH	  at	  
day	  1,	  then	  FITC-­‐OVA	  at	  day	  35)	  followed	  by	  infection	  with	  Salmonella	  shortly	  
afterwards.	  It	  may	  be	  that	  the	  more	  mature,	  older,	  NP-­‐specific	  plasma	  cells	  
would	  undergo	  a	  greater	  depletion.	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Salmonella	  infection	  causes	  an	  increase	  in	  previously	  established	  NP-­‐specific	  
plasma	  cells	  in	  the	  spleen,	  and	  an	  increase	  in	  MHC	  II	  expression	  on	  all	  NP-­‐specific	  
plasma	  cells	  
We	  saw	  that	  Salmonella	  infection	  caused	  an	  increase	  of	  NP-­‐specific	  plasma	  cells	  
in	  the	  spleen	  (fig	  6.5g).	  These	  could	  potentially	  arise	  from	  two	  sources;	  firstly	  
new	  NP-­‐specific	  plasma	  cells	  may	  be	  generated	  in	  the	  spleen	  by	  the	  
restimulation	  of	  memory	  B	  cells	  through	  polyclonal	  stimulation188.	  However,	  
this	  seems	  unlikely,	  as	  the	  NP-­‐specific	  plasma	  cells	  had	  low	  turnover	  when	  
labelled	  with	  BrdU	  at	  days	  6-­‐8	  or	  days	  14-­‐16	  (fig	  6.6a).	  Similarly,	  it	  has	  been	  
shown	  that,	  in	  vivo,	  polyclonal	  stimulation	  alone	  is	  not	  sufficient	  to	  cause	  the	  
activation	  of	  memory	  B	  cells	  and	  their	  differentiation	  to	  plasma	  cells197.	  
Secondly,	  the	  reduction	  in	  NP-­‐specific	  bone	  marrow	  plasma	  cells	  could	  
represent	  a	  migration	  out	  of	  that	  organ	  to	  the	  secondary	  lymphoid	  organs.	  
Indeed,	  it	  is	  known	  that	  B	  cell	  precursors	  in	  the	  bone	  marrow	  migrate	  to	  the	  
spleen	  during	  inflammation	  due	  to	  reduced	  expression	  of	  CXCL12	  from	  bone	  
marrow	  cells334.	  We	  also	  observed	  this	  depletion	  in	  CD138	  expressing,	  BCRlo	  B	  
cell	  precursor	  cells	  from	  the	  bone	  marrow	  during	  Salmonella	  infection	  (fig	  6.1c,	  
e	  and	  f)337.	  It	  is	  possible	  that	  the	  same	  mechanism	  causes	  bone	  marrow	  plasma	  
cells	  to	  migrate	  to	  the	  spleen.	  CXCL12	  is	  the	  chemokine	  responsible	  for	  plasma	  
cell	  migration	  from	  the	  secondary	  lymphoid	  organs	  to	  the	  bone	  marrow,	  and	  
possibly	  plays	  a	  role	  in	  their	  close	  association	  with	  niche	  providing	  cells84,85.	  
However,	  the	  chemokine	  is	  also	  present	  in	  the	  splenic	  red	  pulp	  and	  other	  sites	  
of	  extrafollicular	  plasma	  cell	  responses78.	  It	  is	  possible	  that	  if	  CXCL12	  is	  reduced	  
from	  the	  bone	  marrow	  compartment	  during	  inflammation,	  plasma	  cells	  at	  this	  
site	  are	  attracted	  to	  migrate	  back	  to	  the	  secondary	  lymphoid	  organs.	  	  
It	  has	  been	  shown	  that	  mature	  bone	  marrow	  plasma	  cells	  are	  non-­‐migratory	  
and	  fail	  to	  respond	  to	  CXCL12,	  despite	  the	  continued	  expression	  of	  its	  receptor	  
CXCR4201.	  However,	  on	  infection,	  there	  was	  a	  highly	  significant	  up-­‐regulation	  of	  
MHC	  II	  on	  NP-­‐specific	  plasma	  cells	  remaining	  in	  the	  bone	  marrow,	  and	  those	  
appearing	  in	  the	  spleen	  (fig	  6.5e	  and	  h).	  Although	  these	  plasma	  cells	  did	  not	  
divide,	  this	  adoption	  of	  a	  more	  immature	  phenotype	  may	  allow	  for	  these	  cells	  to	  
Chapter	  6	  –	  Effects	  of	  inflammation	  on	  bone	  marrow	  plasma	  cells	  
	   197	  
once	  again	  become	  migratory	  in	  response	  to	  CXCL12.	  This	  could	  be	  tested	  by	  
assessing	  the	  migration	  of	  bone	  marrow	  plasma	  cells	  from	  NP-­‐only	  or	  
NP+Salmonella	  mice	  towards	  CXCL12.	  
There	  are	  other	  interesting	  connotations	  of	  the	  reversion	  to	  an	  immature,	  MHC	  
IIhi	  phenotype	  by	  antigen-­‐specific	  plasma	  cells	  during	  inflammation.	  Plasma	  
cells	  have	  been	  shown	  to	  be	  capable	  APC,	  as	  discussed	  previously267.	  While	  
untested,	  it	  would	  be	  a	  reasonable	  assumption	  that	  plasma	  cells	  expressing	  high	  
levels	  of	  MHC	  II	  would	  be	  more	  proficient	  at	  presenting	  antigen	  to	  CD4	  T	  cells.	  
As	  professional	  memory	  CD4	  T	  cells	  are	  also	  thought	  to	  reside	  in	  the	  bone	  
marrow312,	  it	  may	  be	  that	  bone	  marrow	  plasma	  cells	  are	  in	  a	  prime	  location	  to	  
activate	  these	  cells	  on	  re-­‐exposure	  to	  antigen.	  This	  could	  be	  tested	  by	  pulsing	  
sorted	  NP-­‐specific	  bone	  marrow	  plasma	  cells	  from	  NP-­‐only	  or	  NP+Salmonella	  
mice	  with	  NP-­‐KLH	  and	  assessing	  their	  ability	  to	  activate	  CD4	  T	  cells	  from	  NP-­‐
KLH-­‐immunised	  mice	  
The	  up-­‐regulation	  of	  MHC	  II	  on	  bone	  marrow	  plasma	  cells	  during	  Salmonella	  
infection	  was	  seen	  to	  be	  dependent	  on	  MyD88	  signalling	  (fig	  6.6d).	  However,	  it	  
would	  be	  interesting	  to	  know	  whether	  the	  increase	  was	  due	  to	  intrinsic	  MyD88	  
signalling	  in	  plasma	  cells,	  or	  an	  indirect	  pathway,	  for	  example	  from	  the	  
induction	  of	  inflammatory	  cytokines	  from	  other	  cell	  populations.	  The	  use	  of	  
chimeras	  in	  which	  only	  B	  cells	  were	  deficient	  in	  MyD88	  could	  help	  to	  determine	  
this.	  It	  is	  known	  that	  inflammatory	  cytokines,	  such	  as	  IFN-­‐α	  can	  enhance	  
immature	  plasma	  cell	  responses,	  and	  that	  IL-­‐6	  can	  support	  plasmablast	  
responses88,182,	  however	  whether	  these	  cytokines	  can	  cause	  mature	  plasma	  cells	  
to	  revert	  to	  an	  immature	  phenotype	  (at	  least	  in	  certain	  aspects),	  and	  the	  
potential	  effects	  of	  this	  remain	  untested.	  In	  addition,	  while	  plasma	  cells	  up	  
regulated	  MHC	  II,	  co-­‐stimulatory	  molecules	  involved	  in	  antigen	  presentation	  to	  
CD4	  T	  cells	  (CD80,	  CD86	  and	  CD40)	  were	  not	  up	  regulated,	  at	  least	  in	  the	  bone	  
marrow	  (fig	  6.6b	  and	  c).	  How	  efficient	  bone	  marrow	  plasma	  cells	  are	  at	  antigen	  
presentation	  remains	  to	  be	  seen.	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Neither	  the	  increase	  in	  MHC	  II	  seen	  on	  NP-­‐specific	  plasma	  cells,	  nor	  the	  
increased	  number	  of	  NP-­‐specific	  plasma	  cells	  in	  the	  spleen	  persisted	  as,	  by	  day	  
45	  of	  infection,	  these	  had	  returned	  to	  levels	  in	  non-­‐infected	  mice	  (fig	  6.7d	  and	  
e).	  This	  corresponded	  to	  the	  decline	  in	  bacterial	  loads	  in	  the	  spleen	  by	  day	  45	  
(fig	  6.7a)	  and,	  although	  not	  measured	  here,	  the	  likely	  decrease	  in	  TLR	  stimulus	  
and	  inflammatory	  cytokines.	  The	  decrease	  in	  splenic	  NP-­‐specific	  plasma	  cells	  
seen	  by	  day	  75	  of	  infection	  compared	  to	  non-­‐infected	  controls	  (fig	  6.7d)	  is	  likely	  
due	  to	  the	  increased	  competition	  faced	  by	  NP-­‐specific	  plasma	  cells	  for	  survival	  
factors	  (large	  numbers	  of	  splenic	  plasma	  cells	  generated	  by	  Salmonella	  infection	  
would	  likely	  decrease	  the	  availability	  of	  survival	  factors	  for	  NP-­‐specific	  plasma	  
cells).	  	  
Mechanism	  of	  Bone	  Marrow	  Plasma	  Cell	  Depletion	  
The	  mechanism	  by	  which	  plasma	  cells	  are	  depleted	  from	  the	  bone	  marrow	  is	  
not	  yet	  clear,	  although	  there	  are	  a	  number	  of	  possibilities,	  some	  of	  which	  have	  
been	  tested	  here.	  	  
Firstly,	  depletion	  caused	  a	  striking	  decrease	  in	  eosinophils	  from	  the	  bone	  
marrow	  compartment	  (fig	  6.3a	  and	  c).	  While	  in	  our	  own	  experiments,	  
eosinophils	  in	  the	  bone	  marrow	  did	  not	  secrete	  large	  amounts	  of	  APRIL	  (fig	  
6.2b),	  Chu	  et	  al	  have	  shown	  that	  these	  cells	  are	  vital	  for	  the	  maintenance	  of	  bone	  
marrow	  plasma	  cells151.	  Whether	  their	  depletion	  alone	  is	  sufficient	  to	  cause	  the	  
observed	  reduction	  is	  unknown,	  but	  could	  be	  tested	  by	  the	  injection	  of	  an	  anti-­‐
siglec-­‐F	  antibody,	  which	  causes	  the	  specific	  depletion	  of	  eosinophils151.	  Other	  
changes	  to	  the	  bone	  marrow	  compartment	  occur	  during	  infection,	  such	  as	  a	  
large	  increase	  in	  CD11b+	  cells	  (fig	  6.1c)	  and	  small	  increases	  in	  GR1hi	  and	  Gr1int	  
cells	  (fig	  6.3c).	  It	  is	  known	  that	  TLR	  signalling	  can	  cause	  the	  rapid	  egress	  of	  
monocytes	  from	  the	  bone	  marrow	  into	  the	  blood	  stream	  via	  changes	  in	  
gradients	  of	  CCR21.	  In	  another	  mechanism,	  neutrophils	  exit	  the	  bone	  marrow	  
during	  inflammation	  due	  to	  reduced	  CXCL12	  from	  the	  bone	  marrow,	  and	  
increased	  CXCL2	  from	  endothelial	  cells338.	  This	  altered	  environment	  in	  the	  bone	  
marrow	  compartment	  may	  reduce	  the	  availability	  of	  survival	  factors	  to	  plasma	  
cells,	  by	  disrupting	  their	  tight	  association	  with	  niche	  providing	  cells,	  or	  altering	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the	  availability	  of	  secreted	  factors.	  Both	  of	  these	  are	  thought	  to	  be	  important	  for	  
the	  maintenance	  of	  bone	  marrow	  plasma	  cell	  populations194,306,	  although	  to	  test	  
this	  definitively	  a	  greater	  understanding	  of	  the	  exact	  nature	  of	  the	  bone	  marrow	  
plasma	  cell	  niche	  would	  be	  required.	  
Secondly,	  we	  thought	  that	  TLR	  stimulation	  may	  cause	  the	  depletion	  in	  bone	  
marrow	  plasma	  cell	  numbers.	  This	  could	  be	  through	  direct	  stimulation	  of	  
plasma	  cells,	  or	  through	  changes	  to	  the	  bone	  marrow	  plasma	  cell	  compartment	  
mediated	  by	  altered	  secretion	  of	  survival	  factors	  from	  niche	  providing	  cells.	  B	  
cells	  respond	  to	  TLR	  stimulation	  by	  the	  up-­‐regulation	  of	  antigen	  presentation	  
machinery	  and	  cytokines31,339	  as	  well	  as	  differentiation	  to	  plasma	  cells58,59.	  
However,	  effects	  of	  TLR	  stimulation	  on	  bone	  marrow	  plasma	  cells	  are	  unknown;	  
little	  literature	  exists	  looking	  at	  this	  subject,	  although	  it	  is	  known	  that	  human	  
tonsillar	  plasma	  cells	  express	  TLRs	  at	  different	  levels	  to	  human	  B	  cells,	  and	  that	  
stimulation	  with	  TLR	  ligands	  leads	  to	  enhanced	  antibody	  secretion340.	  Here	  we	  
saw	  that	  TLR	  stimulation	  did	  not	  appear	  to	  control	  plasma	  cell	  migration	  from	  
the	  bone	  marrow,	  as	  MyD88-­‐/-­‐,	  TRIFF-­‐/-­‐	  and	  TLR4-­‐/-­‐	  all	  exhibited	  a	  greater	  fold-­‐
decrease	  in	  bone	  marrow	  plasma	  cell	  numbers	  (fig	  6.4d	  and	  e).	  In	  fact,	  this	  was	  
likely	  due	  to	  increased	  bacterial	  loads	  in	  the	  bone	  marrow	  of	  these	  mice	  (fig	  
6.4b)	  due	  to	  their	  reduced	  capacity	  to	  control	  the	  infection44.	  This	  could	  be	  
better	  tested	  by	  the	  infection	  of	  mice	  with	  various	  doses	  of	  Salmonella,	  although	  
a	  dose	  dependent	  effect	  was	  already	  seen	  in	  Schistosoma	  mansoni	  infected	  mice.	  
If	  not	  the	  action	  of	  TLR	  ligands	  on	  plasma	  cells,	  the	  likelihood	  exists	  that	  an	  
inflammatory	  cytokine,	  or	  chemokine	  up	  regulated	  during	  inflammation,	  causes	  
the	  depletion	  of	  bone	  marrow	  plasma	  cells.	  As	  previously	  mentioned,	  Ueda	  et	  al	  
have	  shown	  that	  CXCL12	  is	  reduced	  from	  the	  bone	  marrow	  during	  
inflammation,	  mediating	  a	  migration	  of	  early-­‐stage	  B	  cells	  from	  bone	  marrow	  to	  
spleen334.	  This	  decrease	  in	  CXCL12	  could	  be	  observed	  by	  a	  simple	  injection	  of	  
1ug	  of	  the	  inflammatory	  cytokine	  TNF-­‐α.	  As	  CXCL12	  controls	  plasma	  cell	  
migration	  to	  the	  bone	  marrow85,	  we	  performed	  similar	  experiments	  to	  see	  if	  
TNF-­‐α	  reduced	  bone	  marrow	  plasma	  cells.	  Despite	  observing	  a	  small,	  but	  
significant	  reduction	  in	  bone	  marrow	  plasma	  cells	  3	  days	  after	  the	  injection	  of	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TNF-­‐α,	  this	  was	  primarily	  mediated	  by	  the	  change	  in	  cellularity	  observed	  in	  the	  
bone	  marrow	  during	  inflammation	  (fig	  6.10a	  and	  b).	  That	  no	  change	  in	  
frequency	  of	  plasma	  cells	  within	  the	  bone	  marrow	  compartment	  was	  seen	  (fig	  
6.10d)	  implies	  that	  there	  may	  be	  multiple	  mechanisms	  that	  combine	  to	  generate	  
the	  substantial	  depletion	  in	  bone	  marrow	  plasma	  cell	  numbers	  and	  frequencies	  
seen	  during	  Salmonella	  infection.	  TNF-­‐α	  appears	  to	  mediate	  the	  reduction	  in	  
cellularity	  in	  the	  bone	  marrow,	  and	  this	  likely	  depletes	  plasma	  cells	  due	  to	  a	  
reduction	  of	  plasma	  cell	  survival	  factors	  or	  plasma	  cell	  niches,	  or	  due	  to	  a	  
reduction	  in	  CXCL12	  from	  bone	  marrow	  cells.	  We	  did	  not,	  however,	  see	  a	  
significant	  depletion	  in	  eosinophils	  or	  megakaryocytes	  following	  injection	  of	  
TNF-­‐α	  (fig	  6.10f),	  two	  populations	  that	  are	  known	  to	  be	  important	  in	  
maintaining	  bone	  marrow	  plasma	  cells,	  and	  that	  are	  depleted	  during	  Salmonella	  
infection.	  It	  would	  be	  interesting	  to	  extend	  the	  provision	  of	  TNF-­‐α	  from	  2	  days	  
to	  16	  days;	  it	  may	  be	  that	  high	  levels	  of	  TNF-­‐α	  over	  a	  sustained	  period	  (as	  is	  
likely	  the	  case	  in	  Salmonella	  infection)	  would	  generate	  a	  greater	  depletion	  in	  
bone	  marrow	  plasma	  cells.	  
It	  has	  been	  previously	  reported	  that	  subsequent	  ‘non-­‐specific’	  immunisation	  
leads	  to	  a	  reduction	  of	  antigen-­‐specific	  antibody	  levels	  to	  prior	  immunisations38.	  
This	  was	  thought	  to	  be	  mediated	  by	  the	  apoptosis	  of	  bone	  marrow	  plasma	  cells	  
caused	  by	  the	  cross-­‐linking	  of	  the	  Fc	  receptor	  FcγRIIb.	  It	  was	  observed	  that	  
autoimmune	  plasma	  cells	  in	  models	  of	  SLE	  were	  resistant	  to	  this	  mechanism	  of	  
death,	  as	  they	  did	  not	  express	  the	  Fc	  receptor.	  We	  observed	  that	  mice	  that	  were	  
primed	  and	  boosted	  with	  NP-­‐KLH	  exhibited	  a	  reduced	  depletion	  in	  bone	  
marrow	  plasma	  cells	  during	  Salmonella	  infection	  compared	  to	  those	  receiving	  
Salmonella	  alone	  (fig	  6.5c).	  We	  therefore	  hypothesised	  that	  the	  relatively	  
recently	  generated	  NP-­‐specific	  plasma	  cells	  may	  be	  somewhat	  resistant	  to	  
Salmonella-­‐mediated	  depletion,	  and	  this	  may	  be	  due	  to	  a	  reduced	  expression	  of	  
FcγRIIb.	  However,	  as	  shown	  in	  figure	  6.9,	  NP-­‐specific	  plasma	  cells	  expressed	  
greater	  levels	  of	  the	  receptor	  than	  non-­‐NP-­‐specific	  plasma	  cells	  in	  the	  same	  
host,	  in	  both	  spleen	  and	  bone	  marrow	  (fig	  6.9b).	  On	  infection,	  surviving	  NP-­‐
specific	  plasma	  cells	  in	  the	  spleen	  and	  bone	  marrow	  expressed	  elevated	  levels	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of	  this	  receptor.	  This	  implies	  that	  FcγRIIb	  may	  be	  induced	  on	  plasma	  cells	  in	  a	  
similar	  way	  to	  MHC	  II;	  it	  would	  be	  interesting	  to	  know	  whether	  this	  occurred	  in	  
MyD88-­‐/-­‐	  mice.	  It	  also	  implies	  that	  FcγRIIb	  does	  not	  control	  plasma	  cell	  death	  
following	  infection	  with	  Salmonella,	  as	  plasma	  cells	  with	  higher	  expression	  of	  
the	  receptor	  survive.	  Interestingly,	  non-­‐NP-­‐specific	  plasma	  cells	  in	  the	  spleens	  
of	  infected	  mice	  expressed	  low	  levels	  of	  the	  receptor	  (fig	  6.9b),	  this	  may	  help	  to	  
explain	  their	  extended	  survival	  in	  the	  spleen	  despite	  the	  abundance	  of	  antibody	  
that	  inevitably	  results	  from	  the	  high	  numbers	  of	  splenic	  plasma	  cells	  seen	  
throughout	  the	  first	  35	  days	  of	  Salmonella	  infection.	  
That	  NP-­‐specific	  plasma	  cells	  were	  depleted	  by	  the	  same	  amount	  as	  non-­‐NP-­‐
specific	  plasma	  cells	  in	  the	  bone	  marrow	  of	  NP+Salmonella	  mice	  means	  that	  
there	  is	  no	  inherent	  difference	  in	  the	  capacities	  of	  these	  cells	  to	  survive	  during	  
infection.	  The	  greater	  depletion	  of	  total	  bone	  marrow	  plasma	  cells	  in	  
Salmonella-­‐alone	  mice	  compared	  to	  NP+Salmonella	  mice	  is	  therefore	  likely	  due	  
to	  changes	  in	  the	  niche	  providing	  cells	  between	  these	  two	  groups;	  perhaps	  a	  
more	  stable	  compartment	  of	  these	  cells	  is	  generated	  during	  the	  NP-­‐KLH	  prime	  
and	  boost	  regime,	  and	  these	  are	  therefore	  less	  affected	  by	  subsequent	  infection	  
with	  Salmonella.	  A	  more	  detailed	  characterisation	  of	  these	  cells	  would	  be	  
required	  to	  fully	  understand	  this	  difference.	  
Competition	  between	  previously	  established	  and	  newly	  generated	  plasma	  cells	  in	  
the	  presence	  or	  absence	  of	  adjuvant	  
As	  we	  had	  witnessed	  the	  depletion	  of	  previously	  established	  bone	  marrow	  NP-­‐
specific	  plasma	  cells	  during	  Salmonella	  infection,	  followed	  by	  repopulation	  of	  
the	  bone	  marrow	  with	  non-­‐NP-­‐specific	  plasma	  cells	  (which	  are	  likely	  to	  be	  
specific	  for	  Salmonella	  antigens),	  we	  hypothesised	  that	  this	  depletion	  may	  
‘create	  space’	  in	  the	  limited	  bone	  marrow	  plasma	  cell	  pool,	  and	  allow	  for	  the	  
enhanced	  establishment	  of	  newly	  generated	  plasma	  cells	  entering	  from	  the	  
secondary	  lymphoid	  organs.	  To	  test	  this,	  mice	  were	  primed	  with	  two	  protein	  
antigens	  (NP-­‐KLH	  and	  FITC-­‐OVA),	  and	  subsequently	  boosted	  with	  soluble	  NP-­‐
KLH.	  5-­‐weeks	  later,	  mice	  were	  boosted	  with	  soluble,	  or	  alum-­‐precipitated	  FITC-­‐
OVA	  +	  killed	  B.	  pertussis	  (for	  schematic,	  see	  fig	  6.11f).	  	  
Chapter	  6	  –	  Effects	  of	  inflammation	  on	  bone	  marrow	  plasma	  cells	  
	   202	  
The	  group	  receiving	  adjuvant	  underwent	  a	  reduction	  in	  both	  total	  and	  NP-­‐
specific	  bone	  marrow	  plasma	  cell	  numbers	  by	  day	  5,	  similar	  to	  Salmonella	  
infection	  (fig	  6.11a	  and	  c).	  However,	  interestingly	  (and	  despite	  similar	  
generation	  of	  FITC-­‐OVA-­‐specific	  plasma	  cells	  in	  the	  spleens	  of	  mice	  receiving	  
soluble	  FITC-­‐OVA	  or	  adjuvant/FITC-­‐OVA,	  see	  fig	  6.11b),	  mice	  receiving	  adjuvant	  
failed	  to	  establish	  comparable	  populations	  of	  FITC-­‐OVA-­‐specific	  plasma	  cells	  in	  
the	  bone	  marrow	  even	  by	  30-­‐days	  after	  boosting	  (fig	  6.11b).	  This	  may	  be	  due	  to	  
the	  idea,	  discussed	  earlier,	  that	  inflammation	  (or	  specifically,	  TNF-­‐α)	  mediates	  a	  
reduction	  in	  CXCL12	  from	  bone	  marrow	  cells334.	  This	  may	  play	  a	  dual	  role,	  
firstly	  in	  depleting	  bone	  marrow	  plasma	  cells,	  but	  also	  by	  reducing	  the	  influx	  of	  
antigen-­‐specific	  plasma	  cells	  to	  the	  bone	  marrow,	  as	  CXCL12	  attracts	  plasma	  
cells	  to	  this	  site84,85.	  As	  previously	  observed	  (see	  chapter	  5),	  boosting	  with	  
soluble	  protein	  antigen	  led	  to	  the	  rapid	  seeding	  of	  large	  numbers	  of	  antigen-­‐
specific	  plasma	  cells	  in	  the	  bone	  marrow	  (fig	  6.11b).	  While	  boosting	  with	  
soluble	  antigen	  is	  common	  practise	  among	  immunologists,	  and	  has	  been	  used	  
extensively	  by	  groups	  examining	  the	  establishment	  of	  long-­‐lived	  bone	  marrow	  
plasma	  cells189,194,196,	  including	  ourselves,	  the	  response	  seen	  is	  surprising.	  As	  
shown	  in	  chapter	  5,	  by	  12-­‐days	  following	  booster	  immunisation,	  NP-­‐specific	  
plasma	  cells	  came	  to	  dominate	  the	  bone	  marrow	  plasma	  cell	  compartment	  as	  a	  
large	  ‘wave’	  of	  plasma	  cells	  migrated	  to	  the	  organ.	  Many	  of	  these	  cells	  survived,	  
and	  even	  45	  days	  after	  the	  secondary	  response,	  the	  frequency	  of	  NP-­‐specific	  
plasma	  cells	  within	  the	  bone	  marrow	  plasma	  cell	  compartment	  was	  around	  50	  
percent.	  This	  raises	  two	  points	  of	  interest:	  firstly,	  although	  common	  practise	  in	  
mouse	  experiments,	  booster	  vaccinations	  are	  often	  given	  with	  adjuvant.	  This	  
may	  lead	  to	  the	  reduced	  establishment	  of	  bone	  marrow	  plasma	  cells	  generated	  
during	  the	  recall	  response,	  and	  lower	  antibody	  levels.	  Secondly,	  if	  plasma	  cells	  
generated	  during	  the	  recall	  response	  came	  to	  dominate	  the	  bone	  marrow	  
plasma	  cell	  pool	  (as	  seen	  in	  these	  experiments),	  it	  may	  occur	  at	  the	  expense	  of	  
plasma	  cells	  and	  antibody	  specific	  for	  other	  prior	  infections,	  and	  significant	  
antibody	  levels	  could	  only	  be	  maintained	  against	  a	  few	  specificities.	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It	  is	  possible	  that	  inflammation,	  in	  this	  case	  mediated	  by	  adjuvant	  (but	  in	  
infections,	  mediated	  by	  TLR	  ligands	  present	  on	  many	  pathogens),	  reduces	  the	  
entry	  of	  plasma	  cells	  to	  the	  bone	  marrow,	  in	  order	  to	  prevent	  a	  single	  specificity	  
of	  plasma	  cell	  from	  dominating	  the	  compartment,	  and	  effectively	  reducing	  
circulating	  antibody	  to	  prior	  immune	  responses.	  This	  would	  allow	  (as	  seen	  
here)	  for	  high	  numbers	  of	  antigen-­‐specific	  plasma	  cells	  to	  be	  generated	  in	  the	  
spleen,	  creating	  large	  amounts	  of	  high	  affinity	  antibody.	  These	  plasma	  cells	  are	  
also	  supported	  in	  the	  spleen,	  for	  at	  least	  12	  days,	  likely	  by	  the	  induction	  of	  
APRIL	  producing	  cell	  populations	  (as	  discussed	  in	  chapter	  4),	  as	  they	  survived	  
in	  far	  greater	  numbers	  in	  mice	  receiving	  adjuvant/FITC-­‐OVA	  to	  those	  receiving	  
soluble	  FITC-­‐OVA	  (fig	  6.11b).	  However,	  rather	  than	  a	  mass-­‐migration	  to	  the	  
bone	  marrow,	  the	  vast	  majority	  of	  these	  plasma	  cells	  are	  allowed	  to	  die	  as	  
inflammation	  resolves	  and	  plasma	  cell	  survival	  factors	  are	  reduced.	  Only	  
relatively	  low	  numbers	  migrate	  to	  the	  bone	  marrow	  to	  become	  established	  as	  
long-­‐lived	  plasma	  cells.	  This	  may	  also	  be	  a	  means	  of	  allowing	  only	  the	  highest	  
affinity	  plasma	  cells	  to	  migrate	  to	  the	  bone	  marrow,	  as	  these	  are	  generated	  
during	  the	  latter	  stages	  of	  the	  immune	  response,	  when	  affinity	  maturation	  has	  
been	  occurring	  for	  some	  time.	  Inflammatory	  signals,	  which	  are	  high	  at	  early	  
stages	  of	  the	  immune	  response	  (and	  when	  the	  affinity	  of	  antibody	  secreted	  by	  
plasma	  cells	  is	  relatively	  low),	  drastically	  reduce	  the	  entry	  of	  plasma	  cells	  to	  the	  
bone	  marrow.	  As	  inflammation	  resolves,	  plasma	  cells	  of	  the	  very	  highest	  affinity	  
(generated	  during	  the	  later	  stages	  of	  the	  response)	  are	  allowed	  to	  enter	  the	  
bone	  marrow	  compartment.	  It	  would	  therefore	  be	  interesting	  to	  look	  at	  time	  
points	  beyond	  the	  30-­‐days	  examined	  here,	  to	  see	  if	  only	  very	  high	  affinity	  FITC-­‐
OVA-­‐specific	  plasma	  cells	  accumulated	  in	  the	  bone	  marrow	  of	  mice	  receiving	  
adjuvant/FITC-­‐OVA.	  	  
As	  can	  be	  seen	  in	  figure	  6.11d,	  early	  FITC-­‐OVA-­‐specific	  IgG	  was	  not	  impaired	  by	  
the	  reduced	  FITC-­‐OVA-­‐specific	  bone	  marrow	  plasma	  cells	  in	  mice	  receiving	  
adjuvant.	  This	  is	  likely	  due	  to	  high	  numbers	  persisting	  in	  the	  spleen.	  By	  day	  30,	  
FITC-­‐OVA-­‐specific	  IgG	  levels	  had	  begun	  to	  decline	  in	  this	  group	  (and	  were	  
already	  significantly	  lower	  than	  levels	  in	  mice	  receiving	  soluble	  FITC-­‐OVA),	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although	  whether	  they	  continue	  to	  decline	  is	  not	  yet	  known.	  Experiments	  
looking	  at	  later	  time	  points	  will	  be	  performed	  to	  determine	  this.	  IgG	  has	  a	  half-­‐
life	  of	  around	  3-­‐weeks,	  and	  so	  may	  take	  some	  time	  to	  decline	  even	  after	  the	  
majority	  of	  splenic	  FITC-­‐OVA-­‐specific	  plasma	  cells	  die.	  As	  seen	  previously,	  mice	  
receiving	  soluble	  FITC-­‐OVA	  maintained	  FITC-­‐OVA-­‐specific	  IgG	  for	  at	  least	  30	  
days,	  and	  previous	  experiments	  have	  shown	  that	  this	  persists	  for	  far	  longer	  (see	  
fig	  5.5).	  	  
Immunisation	  with	  soluble	  FITC-­‐OVA	  also	  showed	  interesting	  points.	  While	  
there	  was	  initially	  no	  depletion	  in	  the	  previously	  generated	  NP-­‐specific	  plasma	  
cells,	  despite	  the	  influx	  of	  large	  numbers	  of	  FITC-­‐OVA-­‐specific	  plasma	  cells,	  
these	  did	  decline	  by	  day	  30	  (fig	  6.11b	  and	  c).	  This	  reflects	  an	  increase	  in	  total	  
bone	  marrow	  plasma	  cells	  at	  day	  12	  (due	  to	  new	  FITC-­‐OVA-­‐specific	  plasma	  cells	  
entering	  the	  compartment).	  However	  these	  expanded	  numbers	  of	  plasma	  cells	  
could	  not	  be	  supported,	  presumably	  due	  to	  the	  limited	  amounts	  of	  survival	  
factors	  or	  niches	  available	  in	  the	  bone	  marrow,	  and	  declined	  to	  levels	  in	  control	  
mice	  by	  day	  30	  (fig	  6.11a).	  This	  mediated	  a	  similar	  decrease	  in	  both	  FITC-­‐OVA-­‐
specific	  and	  NP-­‐specific	  plasma	  cells	  (fig	  6.11ba	  and	  c).	  This	  is	  likely	  due	  to	  
competition	  between	  all	  bone	  marrow	  plasma	  cells	  for	  the	  available	  niches.	  
While	  it	  is	  thought	  that	  newly	  generated	  plasma	  cells	  have	  an	  advantage	  over	  
older,	  previously	  established	  plasma	  cells	  at	  accessing	  niches	  (due	  to	  their	  
ability	  to	  migrate	  towards	  CXCL1285,201),	  it	  is	  not	  known	  of	  the	  relative	  
importance	  of	  secreted	  survival	  factors	  (such	  as	  APRIL	  and	  IL-­‐6)	  and	  cognate	  
interactions	  between	  plasma	  cells	  and	  niche-­‐providing	  cells	  (data	  suggests	  that	  
plasma	  cells	  associate	  closely	  with	  ‘niche-­‐providing	  cells’	  and	  may	  receive	  
cognate	  signals	  through	  VLA-­‐4,	  LFA-­‐1,	  CD28	  and	  other	  molecules151,194,217,226).	  	  
Conclusion	  
Here	  we	  have	  documented	  a	  striking	  depletion	  of	  previously	  established	  bone	  
marrow	  plasma	  cells	  during	  infection	  with	  Salmonella	  or	  Schistosoma	  mansoni.	  
This	  reduced	  circulating	  antigen-­‐specific	  antibody	  levels.	  Interestingly,	  we	  also	  
observed	  a	  MyD88-­‐dependent	  increase	  in	  the	  expression	  of	  MHC	  II	  by	  surviving	  
plasma	  cells	  established	  during	  prior	  immune	  responses,	  and	  increased	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numbers	  of	  these	  cells	  appearing	  in	  the	  spleen.	  While	  these	  experiments	  do	  not	  
conclusively	  define	  the	  mechanism	  behind	  the	  depletion	  of	  bone	  marrow	  
plasma	  cells	  during	  inflammation,	  or	  the	  intriguing	  possibility	  that	  
inflammation	  may	  impede	  the	  entry	  of	  plasma	  cells	  to	  the	  bone	  marrow,	  they	  
provide	  evidence	  that	  inflammatory	  episodes	  play	  a	  role	  in	  both.	  To	  expand	  on	  
this	  data,	  it	  would	  be	  interesting	  to	  firstly	  pin	  down	  the	  mechanism,	  or	  multiple	  
mechanisms	  behind	  the	  depletion	  of	  plasma	  cells.	  Secondly,	  further	  
investigations	  into	  how	  boosting	  with	  antigens	  with	  or	  without	  adjuvants	  can	  
lead	  to	  a	  differing	  duration	  of	  humoral	  immunity	  could	  provide	  interesting	  data	  
which	  could	  have	  implications	  for	  booster	  vaccination	  protocols.	  Finally,	  we	  
have	  demonstrated	  that	  secondary	  immunisation	  with	  alum-­‐precipitated	  FITC-­‐
OVA	  with	  killed	  B.	  pertussis	  leads	  to	  the	  reduced	  generation	  of	  plasma	  cells	  that	  
persist	  in	  the	  bone	  marrow.	  This	  may	  be	  due	  to	  a	  failure	  to	  migrate	  to	  the	  organ,	  
as	  reduced	  levels	  of	  CXCL12	  secreted	  by	  bone	  marrow	  cells	  during	  times	  of	  
inflammation	  likely	  impair	  the	  ability	  of	  plasma	  cells	  to	  migrate	  there84,334.	  
Alternatively,	  the	  adjuvant	  used	  here	  contains	  a	  mixture	  of	  TLR-­‐ligands	  and	  
other	  innate	  signals	  that	  could	  influence	  the	  outcome	  of	  B	  cell	  responses	  and	  the	  
lifespan	  of	  the	  plasma	  cells	  produced.	  Autoantibody-­‐secreting	  plasma	  cells	  
generated	  during	  SLE	  secrete	  antibody	  against	  self-­‐DNA	  or	  self-­‐RNA.	  The	  B	  cells	  
that	  differentiate	  to	  these	  plasma	  cells	  are	  stimulated	  through	  different	  TLRs	  
(TLR7	  for	  RNA	  and	  TLR9	  for	  DNA).	  Interestingly	  anti-­‐DNA	  plasma	  cells	  are	  
short-­‐lived,	  while	  the	  anti-­‐RNA	  plasma	  cells	  may	  become	  long-­‐lived262.	  
Similarly,	  differing	  combinations	  of	  TLR	  ligands	  (e.g.	  TLR4	  +	  TLR7)	  can	  induce	  
greater	  levels	  of	  antibody	  in	  the	  serum,	  and	  more	  detectable	  long-­‐lived	  plasma	  
cells	  than	  single	  TLR	  ligands263.	  It	  would	  be	  interesting	  to	  see	  if	  differing	  innate	  
signals	  mediate	  the	  establishment	  of	  greater	  or	  fewer	  long-­‐lived	  plasma	  cells,	  
and	  to	  determine	  the	  mechanism	  behind	  these	  differences.	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Chapter	  7	  -­	  Final	  Discussion	  and	  Further	  Work	  
The	  studies	  here	  have	  investigated	  a	  number	  of	  areas	  of	  plasma	  cell	  biology.	  
Initially,	  we	  investigated	  the	  accumulation	  of	  plasma	  cells	  in	  the	  bone	  marrow	  
of	  naïve	  C57Bl/6	  mice	  over	  time.	  These	  studies	  arose	  from	  the	  surprising	  
finding	  that	  6-­‐week-­‐old	  naïve	  mice	  had	  similar	  turnover	  of	  plasma	  cells	  in	  the	  
spleen	  and	  bone	  marrow.	  While	  it	  has	  been	  shown	  that	  some	  plasma	  cells	  
survive	  for	  long	  periods	  in	  the	  spleen193,	  the	  majority	  of	  long-­‐lived	  plasma	  cells	  
reside	  in	  the	  bone	  marrow,	  where	  they	  persist	  for	  months	  or	  years	  without	  
cellular	  division	  and	  maintain	  serum	  antibody	  levels	  to	  prior	  infections	  and	  
vaccinations6,189,193,306,317.	  
We	  saw	  an	  accumulation	  of	  plasma	  cells	  in	  the	  bone	  marrow,	  but	  not	  the	  spleen	  
over	  time.	  These	  plasma	  cells	  did	  not	  divide	  in	  a	  10-­‐day	  BrdU	  pulse	  and	  
corresponded	  to	  a	  similar	  accumulation	  in	  serum	  antibody	  levels.	  This	  required	  
the	  expression	  of	  MHC	  II,	  CD40	  and	  a	  normal	  BCR	  repertoire	  as	  mice	  deficient	  in	  
MHC	  II	  and	  CD40,	  as	  well	  as	  MD4	  mice	  (expressing	  a	  BCR	  specific	  for	  HEL),	  did	  
not	  exhibit	  the	  same	  accumulation	  of	  plasma	  cells	  in	  the	  bone	  marrow.	  This	  data	  
indicates	  that	  CD4	  T	  cell	  activation	  is	  likely	  crucial	  for	  the	  generation	  of	  these	  
long-­‐lived	  bone	  marrow	  plasma	  cells,	  and	  this	  would	  be	  in	  agreement	  with	  the	  
literature6,246,303,306.	  Whether	  it	  is	  the	  activation	  of	  CD4	  T	  cells	  by	  professional	  
APC	  (and	  the	  subsequent	  production	  of	  cytokines),	  or	  the	  cognate	  interactions	  
between	  T	  and	  B	  cells	  that	  occur	  during	  the	  initiation	  of	  TD	  immune	  responses	  
is	  unclear.	  That	  long-­‐lived	  plasma	  cells	  are	  thought	  to	  arise	  from	  germinal	  
centre	  responses248	  (which	  require	  cognate	  interactions	  between	  activated	  CD4	  
T	  cells	  and	  B	  cells100)	  implies	  that	  germinal	  centre	  formation	  may	  be	  necessary	  
to	  generate	  long-­‐lived	  plasma	  cells	  in	  naïve	  mice.	  To	  confirm	  these	  hypotheses,	  
chimeric	  mice	  in	  which	  B	  cells	  do	  not	  express	  CD40	  or	  MHC	  II	  (allowing	  for	  the	  
priming	  of	  CD4	  T	  cells	  by	  professional	  APC,	  but	  not	  for	  cognate	  interactions	  with	  
B	  cells)	  could	  be	  used.	  Although	  it	  is	  already	  known	  that	  CD40	  expression	  on	  B	  
cells	  is	  essential	  for	  germinal	  centre	  formation341,	  it	  would	  be	  interesting	  to	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correlate	  germinal	  centre	  formation	  in	  these	  mice	  with	  a	  lack	  of	  long-­‐lived	  
plasma	  cell	  formation	  compared	  to	  wild	  type	  chimeras.	  
That	  these	  naive	  mice	  form	  germinal	  centres	  despite	  their	  housing	  in	  specific	  
pathogen-­‐free	  conditions	  is	  not	  surprising;	  they	  are	  not	  germ	  free	  mice	  and	  are	  
exposed	  to	  environmental	  antigens,	  and	  contain	  large	  amounts	  of	  microbial	  
flora	  in	  the	  gut.	  The	  comparison	  of	  these	  mice	  to	  germ-­‐free	  mice	  would	  be	  
interesting;	  from	  these	  experiments	  we	  cannot	  conclude	  what	  the	  accumulated	  
long-­‐lived	  plasma	  cells	  are	  specific	  for,	  and	  whether	  they	  would	  occur	  
independently	  of	  antigen.	  
As	  well	  as	  bone	  marrow	  plasma	  cells,	  we	  performed	  experiments	  looking	  at	  the	  
requirements	  for	  the	  extrafollicular	  plasma	  cell	  response	  to	  SRBC	  immunisation	  
and	  infection	  with	  Salmonella.	  From	  this,	  we	  observed	  that	  plasma	  cells	  
generated	  by	  SRBC	  were	  very	  short-­‐lived,	  dying	  within	  1-­‐3	  days	  following	  
immunisation.	  Those	  generated	  by	  Salmonella	  infection	  persisted	  for	  longer	  
periods	  with	  a	  half-­‐life	  of	  around	  6	  days.	  These	  were	  likely	  to	  be	  supported	  by	  
the	  local	  generation	  of	  large	  amounts	  of	  the	  plasma	  cell	  survival	  factor	  APRIL,	  
and	  the	  increased	  availability	  of	  splenic	  plasma	  cell	  niches	  due	  to	  the	  influx	  and	  
expansion	  of	  innate	  cell	  populations	  such	  as	  monocytes,	  macrophages	  and	  
dendritic	  cells.	  To	  conclusively	  show	  this,	  blocking	  antibodies	  to	  APRIL,	  or	  its	  
receptors	  TACI	  and	  BCMA,	  could	  be	  used;	  if	  plasma	  cell	  numbers	  fell,	  or	  the	  
turnover	  of	  plasma	  cells	  increased,	  it	  would	  be	  likely	  that	  APRIL	  is	  a	  key	  factor	  
in	  the	  support	  of	  these	  cells.	  
We	  also	  identified	  the	  key	  signalling	  required	  for	  IgM	  and	  IgG	  plasma	  cells	  seen	  
at	  day	  5	  of	  the	  response	  to	  SRBC	  and	  at	  days	  4	  and	  8	  of	  Salmonella	  infection.	  At	  
day	  5	  following	  SRBC	  immunisation,	  both	  IgM	  and	  IgG	  plasma	  cells	  were	  found	  
to	  be	  TD,	  requiring	  MHC	  II,	  CD40	  and	  ICOS	  expression.	  Surprisingly,	  the	  
expression	  of	  the	  TLR	  adaptor	  proteins	  MyD88/TRIF	  were	  also	  required	  for	  
optimal	  IgM	  and	  IgG	  responses.	  It	  remains	  unknown	  why	  TLR	  signalling	  would	  
be	  important	  in	  this	  immunisation;	  there	  are	  no	  known	  TLR	  ligands	  in	  SRBC.	  As	  
well	  as	  TLR	  signalling,	  MyD88	  plays	  a	  role	  in	  signalling	  through	  TACI149	  and	  the	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IL-­‐1	  receptor342;	  TACI	  is	  known	  to	  cause	  class	  switching,	  and	  IL-­‐1	  receptor	  
signalling	  causes	  the	  up-­‐regulation	  of	  CD40L	  on	  CD4	  T	  cells329.	  These	  effects	  
may	  impact	  both	  germinal	  centre	  and	  class	  switched	  plasma	  cell	  formation	  
following	  SRBC	  immunisation.	  
In	  Salmonella	  infection,	  two	  waves	  of	  extrafollicular	  plasma	  cells	  were	  observed.	  
An	  early	  IgM	  wave	  at	  day	  4	  that	  required	  MyD88/TRIF	  but	  not	  CD40,	  ICOS	  or	  
MHC	  II	  and	  a	  later	  IgG	  wave	  by	  day	  8	  that	  required	  CD40,	  ICOS	  and	  MHC	  II	  but	  
not	  MyD88/TRIF.	  As	  the	  mice	  used	  for	  these	  experiments	  were	  total	  knockouts,	  
we	  cannot	  conclude	  that	  cognate	  interactions	  between	  T	  and	  B	  cells	  are	  
required	  for	  the	  generation	  of	  these	  IgG	  plasma	  cells.	  However,	  CD4	  T	  cell	  
activation	  is	  certainly	  key,	  and	  it	  is	  known	  that	  TD	  extrafollicular	  plasma	  cell	  
responses	  require	  cognate	  interactions	  between	  T	  and	  B	  cells78.	  In	  addition,	  
Cunningham	  et	  al	  have	  shown	  that	  CD40L	  is	  required	  for	  IgG2c	  plasma	  cells	  in	  
Salmonella	  infection281.	  In	  addition,	  we	  observed	  that	  early	  TD	  Salmonella-­‐
specific	  IgG2c	  was	  dependent	  on	  TLR	  signalling,	  as	  MyD88/TRIF-­‐/-­‐	  mice	  
switched	  instead	  to	  the	  Th2	  associated	  isotype	  IgG1.	  
In	  contrast,	  the	  day	  4	  IgM	  plasma	  cell	  response	  did	  not	  require	  T	  cell	  help.	  While	  
Gil-­‐Cruz	  et	  al	  have	  shown	  that	  B1b	  cells	  contribute	  to	  the	  early	  plasma	  cell	  
response	  to	  Salmonella76;	  our	  data	  suggest	  that	  marginal	  zone	  B	  cells,	  too,	  play	  a	  
role.	  CD1d-­‐/-­‐	  mice,	  which	  lack	  the	  marginal	  zone	  B	  cell	  compartment,	  failed	  to	  
generate	  an	  IgM	  plasma	  cell	  response	  at	  day	  4.	  Indeed,	  the	  marginal	  zone	  B	  cell	  
compartment	  is	  thought	  to	  respond	  rapidly	  to	  systemic	  infections	  due	  to	  prime	  
location,	  and	  lower	  threshold	  of	  activation	  than	  follicular	  B	  cell	  types14,57,73,343.	  
Whether	  this	  is	  the	  case	  in	  Salmonella	  infection	  could	  be	  definitively	  tested	  
using	  chimeras	  that	  are	  reconstituted	  with	  both	  CD1d-­‐/-­‐	  and	  DS-­‐RED	  (which	  
express	  the	  modified	  red	  fluorescent	  protein	  ‘DS-­‐RED’	  ubiquitously)	  bone	  
marrow.	  In	  these	  mice,	  all	  marginal	  zone	  B	  cells	  would	  arise	  from	  the	  DS-­‐RED	  
bone	  marrow	  and	  would	  therefore	  be	  identifiable.	  If	  the	  majority	  of	  IgM	  plasma	  
cells	  arising	  at	  day	  4	  expressed	  the	  DS-­‐RED	  protein,	  they	  would	  likely	  arise	  from	  
the	  marginal	  zone	  compartment.	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Interestingly	  CD1d-­‐/-­‐	  mice	  also	  failed	  to	  generate	  a	  robust	  IgG	  plasma	  cell	  
response	  at	  day	  8.	  This	  may	  be	  due	  to	  a	  deficiency	  in	  NK	  T	  cells,	  which	  aid	  early	  
plasma	  cell	  responses	  to	  lipid	  antigens	  through	  both	  cognate	  interactions	  and	  
IL-­‐21	  secretion82,83,344.	  	  
That	  MD4	  mice	  failed	  to	  respond	  at	  day	  4	  could	  imply	  that	  BCR-­‐recognition	  of	  
antigen	  is	  essential	  for	  day	  4	  TI	  plasma	  cells,	  however,	  these	  mice	  responded	  at	  
day	  8,	  when	  the	  response	  was	  TD	  in	  wild	  type	  mice.	  Cognate	  interactions	  with	  
CD4	  T	  cells	  cannot	  occur	  without	  antigen-­‐specificity,	  as	  antigen	  presented	  on	  
MHC	  II	  molecules	  of	  B	  cells	  must	  be	  recognised	  by	  the	  BCR	  for	  uptake,	  and	  
subsequently	  by	  the	  TCR.	  Bystander	  activation,	  whereby	  the	  threshold	  of	  
activation	  is	  reduced	  by	  the	  presence	  of	  high	  levels	  of	  inflammatory	  cytokines,	  
may	  play	  a	  role	  in	  the	  activation	  of	  HEL-­‐specific	  B	  cells	  in	  MD4	  mice.	  In	  vitro,	  the	  
stimulation	  of	  follicular	  B	  cells	  with	  LPS	  alone	  is	  enough	  to	  induce	  suboptimal	  
differentiation	  to	  plasma	  cells	  and	  antibody	  secretion31,53,59.	  The	  specificity	  of	  
these	  B	  cells	  is,	  presumably,	  not	  towards	  LPS.	  Whether	  Salmonella	  infection	  is	  
sufficient	  to	  induce	  the	  polyclonal	  activation	  of	  follicular	  and	  marginal	  zone	  B	  
cells	  in	  wild	  type	  mice,	  irrelevant	  of	  BCR	  specificity,	  remains	  unknown.	  
This	  too	  could	  explain	  why	  we	  saw	  the	  expansion	  of	  NP-­‐specific	  plasma	  cells	  in	  
the	  spleens	  of	  Salmonella	  infected	  mice	  that	  were	  previously	  immunised	  and	  
boosted	  with	  NP-­‐KLH.	  While	  known	  not	  to	  occur	  following	  the	  injection	  of	  LPS	  
or	  CpG	  DNA	  alone,	  it	  is	  possible	  that	  inflammatory	  cytokines,	  and	  other	  
activatory	  signals	  (such	  as	  BLyS	  and	  APRIL)	  may	  be	  enough	  to	  stimulate	  the	  
differentiation	  of	  memory	  B	  cells	  to	  plasma	  cells.	  	  
In	  these	  experiments,	  we	  did	  not	  detect	  any	  turnover	  of	  NP-­‐specific	  plasma	  cells	  
in	  the	  spleen	  at	  day	  6-­‐8	  or	  day	  14-­‐16	  following	  infection	  with	  Salmonella.	  This	  
would	  imply	  that	  these	  cells	  were	  pre-­‐existing,	  although	  the	  possibility	  remains	  
that	  turnover	  occurred	  at	  other	  time	  points	  (i.e.	  not	  during	  our	  BrdU	  pulses).	  If	  
pre-­‐existing,	  these	  plasma	  cells	  may	  have	  migrated	  to	  the	  inflamed	  spleen	  from	  
the	  bone	  marrow	  due	  to	  altered	  chemokine	  expression	  in	  the	  inflamed	  spleen	  
Chapter	  7	  –	  Final	  discussion	  
	   210	  
(increased	  CXCL9,	  CXCL10,	  CXCL11	  and	  CXCL12201,345)	  and	  reduced	  CXCL12	  
from	  the	  bone	  marrow334.	  	  
This	  would	  be	  in	  accord	  with	  our	  data	  showing	  that	  inflammation	  depletes	  bone	  
marrow	  plasma	  cells.	  Although	  here	  we	  have	  not	  made	  estimates	  concerning	  
the	  total	  number	  of	  antigen-­‐specific	  plasma	  cells	  depleted	  from	  the	  bone	  
marrow	  during	  infection,	  and	  the	  increase	  in	  number	  seen	  in	  the	  spleen,	  the	  
kinetics	  of	  their	  appearance	  in	  the	  spleen	  is	  similar	  to	  their	  depletion	  from	  the	  
bone	  marrow.	  Experiments	  where	  mice	  were	  boosted	  with	  NP-­‐KLH	  and	  
provided	  with	  BrdU	  for	  a	  period	  of	  10-­‐20	  days	  (to	  label	  all	  NP-­‐specific	  plasma	  
cells	  generated	  by	  the	  secondary	  immunisation),	  and	  subsequently	  infected	  
with	  Salmonella,	  could	  be	  performed.	  If	  NP-­‐specific	  plasma	  cells	  appearing	  in	  
the	  spleen	  contained	  the	  BrdU	  label,	  it	  is	  likely	  that	  they	  have	  migrated	  there	  
from	  other	  organs	  such	  as	  the	  bone	  marrow.	  Similar	  experiments	  where	  NP-­‐
specific	  bone	  marrow	  plasma	  cells	  are	  transferred	  to	  naïve	  or	  Salmonella	  
infected	  hosts	  would	  allow	  the	  detection	  of	  altered	  migration.	  
Bone	  marrow	  plasma	  cells	  are	  thought	  to	  be	  non-­‐migratory,	  and	  this	  would	  
appear	  to	  confound	  these	  ideas201.	  However,	  that	  they	  up	  regulate	  certain	  other	  
markers	  of	  immaturity	  (such	  as	  MHC	  II)	  during	  Salmonella	  infection	  could	  mean	  
that	  they	  revert	  to	  a	  more	  immature	  state,	  and	  regain	  the	  ability	  to	  migrate.	  This	  
idea	  could	  be	  tested	  by	  sorting	  NP-­‐specific	  plasma	  cells	  from	  the	  bone	  marrow	  
of	  non-­‐infected	  or	  Salmonella	  infected	  mice	  and	  performing	  migration	  assays	  
towards	  chemokines	  such	  as	  CXCL12.	  The	  precise	  factor,	  or	  combination	  of	  
factors,	  that	  mediates	  the	  depletion	  of	  bone	  marrow	  plasma	  cells	  during	  
inflammatory	  episodes	  is	  yet	  to	  be	  identified,	  but	  studies	  looking	  at	  the	  levels	  of	  
various	  cytokines	  in	  the	  serum,	  or	  from	  cultured	  bone	  marrow	  cells	  from	  naïve	  
or	  Salmonella	  infected	  mice	  could	  help	  to	  identify	  candidates	  that	  are	  altered	  in	  
infected	  mice.	  By	  injecting	  candidate	  recombinant	  cytokines	  to	  naïve	  mice	  and	  
looking	  at	  the	  depletion	  of	  plasma	  cells,	  or	  by	  stopping	  the	  action	  of	  cytokines	  
with	  blocking	  antibodies,	  we	  may	  learn	  what	  factors	  are	  important	  to	  this	  
process.	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A	  similar	  mechanism	  may	  help	  to	  determine	  the	  observation	  that	  the	  formation	  
of	  bone	  marrow	  plasma	  cells	  is	  impaired	  during	  chronic	  inflammation.	  This	  was	  
observed	  in	  K/BxN	  mice	  undergoing	  a	  chronic	  autoimmune	  response,	  mice	  
infected	  with	  Salmonella,	  which	  exhibits	  high	  levels	  of	  inflammation	  over	  a	  long	  
period,	  and	  in	  mice	  receiving	  repeated	  immunisation	  with	  NP-­‐KLH	  over	  a	  
sustained	  period.	  While	  there	  are	  a	  number	  of	  possible	  mechanisms	  that	  could	  
explain	  these	  findings,	  reduced	  levels	  of	  CXCL12	  from	  the	  bone	  marrow	  caused	  
by	  inflammation334	  is	  a	  strong	  candidate,	  as	  CXCL12	  has	  been	  shown	  to	  mediate	  
migration	  of	  plasma	  cells	  to	  the	  bone	  marrow84.	  Furthermore,	  our	  data	  in	  which	  
mice	  were	  boosted	  either	  with	  soluble	  FITC-­‐OVA,	  or	  alum-­‐precipitated	  FITC-­‐
OVA	  with	  B.	  pertussis	  showed	  a	  reduced	  accumulation	  of	  FITC-­‐OVA-­‐specific	  
plasma	  cells	  in	  the	  bone	  marrow,	  at	  least	  in	  the	  first	  30-­‐days	  following	  
secondary	  immunisation.	  Whether	  these	  plasma	  cells	  accumulate	  at	  later	  time	  
points,	  and	  whether	  a	  reduced	  level	  of	  CXCL12	  from	  bone	  marrow	  cells	  can	  be	  
detected	  in	  mice	  receiving	  FITC-­‐OVA	  and	  adjuvant	  will	  be	  investigated	  in	  future	  
experiments.	  	  
Other	  possibilities	  exist,	  such	  as	  differential	  responsiveness	  of	  plasma	  cells	  to	  
chemokines	  when	  antigen	  is	  still	  present.	  Many	  plasma	  cells	  migrate	  towards	  
inflamed	  organs,	  thought	  to	  be	  mediated	  by	  CXCL9,	  CXCL10	  and	  CXCL11	  
through	  their	  expression	  of	  CXCR3201,345.	  It	  is	  possible	  that	  the	  persistence	  of	  
antigen	  alters	  the	  expression	  of	  CXCR4	  and	  CXCR3	  on	  plasma	  cells.	  In	  addition,	  
some	  plasma	  cells	  have	  been	  reported	  to	  be	  unresponsive	  towards	  CXCL12,	  
despite	  their	  continued	  expression	  of	  CXCR4333.	  
Whether	  the	  depletion	  of	  bone	  marrow	  plasma	  cells	  in	  infection	  is	  a	  mechanism	  
by	  which	  space	  is	  created	  for	  the	  establishment	  of	  new	  bone	  marrow	  plasma	  
cells	  is	  still	  unresolved.	  While	  we	  did	  not	  observe	  this	  during	  the	  first	  30-­‐days	  
following	  the	  injection	  of	  soluble	  or	  alum-­‐precipitated	  FITC-­‐OVA	  (with	  B.	  
pertussis),	  this	  may	  have	  been	  due	  to	  the	  reduced	  migration	  of	  plasma	  cells	  to	  
the	  bone	  marrow	  during	  inflammatory	  episodes.	  This	  will	  require	  longer	  time	  
course	  experiments.	  Additionally,	  the	  infection	  of	  mice	  with	  Salmonella	  
expressing	  the	  ovalbumin	  protein	  could	  allow	  for	  a	  greater	  understanding	  of	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when	  antigen-­‐specific	  plasma	  cells	  generated	  by	  live	  infection	  enter	  the	  bone	  
marrow.	  
Conclusion	  
While	  there	  is	  much	  work	  to	  do	  to	  dissect	  the	  mechanisms	  behind	  the	  
observations	  seen	  here,	  this	  thesis	  has	  expanded	  our	  knowledge	  on	  the	  factors	  
required	  for	  the	  formation	  and	  maintenance	  of	  extrafollicular	  plasma	  cell	  
responses	  in	  Salmonella	  infection	  as	  well	  as	  the	  TD	  response	  to	  SRBC.	  In	  
addition,	  we	  have	  noted	  the	  accumulation	  of	  bone	  marrow	  plasma	  cells	  in	  naïve	  
mice	  over	  time,	  and	  provided	  evidence	  that	  CD4	  T	  cell	  activation	  plays	  a	  key	  
role	  in	  their	  generation.	  Thirdly,	  we	  have	  shown	  that	  few	  bone	  marrow	  plasma	  
cells	  are	  formed	  during	  chronic	  inflammation	  compared	  to	  acutely	  immunised	  
mice.	  This	  may	  be	  due	  to	  reduced	  migration	  to	  the	  organ,	  or	  a	  failure	  to	  generate	  
plasma	  cells	  with	  the	  potential	  to	  survive	  for	  long	  periods.	  Similarly,	  we	  have	  
shown	  that	  adjuvant	  (in	  the	  form	  of	  alum-­‐precipitation	  and	  killed	  B.	  pertussis)	  
delays	  or	  reduces	  the	  number	  of	  bone	  marrow	  plasma	  cells	  formed	  in	  a	  
secondary	  immune	  response	  to	  protein	  antigen.	  Finally,	  we	  have	  shown	  that	  
inflammation	  reduces	  bone	  marrow	  plasma	  cell	  numbers.	  While	  these	  recover	  
following	  the	  resolution	  of	  inflammation,	  humoral	  immunity	  to	  prior	  
immunisation	  is	  reduced.	  Whether	  this	  mediates	  the	  establishment	  of	  increased	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